<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006924.pub2" GROUP_ID="AIRWAYS" ID="170407100911114246" MERGED_FROM="" MODIFIED="2013-05-24 14:38:46 +0100" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;23/5/12 - copyeditor request - please can you add 'date accessed' for exclu. study Novatis 2005 and additional study ICHE2a&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;CJC changes to PLS following Peer review. 2/5/2013&lt;/p&gt;&lt;p&gt;CJC accepted tracked changes and turned off totals in Forest plots. 15 March 2013&lt;/p&gt;&lt;p&gt;Emma notes 18/01/2012 - mostly brilliant, but a few picky things to consider:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Author initials are mainly CJC and TL in the methods. This was not the case for the update as TL was not an author, so can you revise please. Done and Marta added to acknowledgements&lt;/li&gt;&lt;li&gt;Can we delete the note against results of the search - I assume it's fixed now as there are 29 studies included Done&lt;/li&gt;&lt;li&gt;Do you want to acknowldege Liz or Emma J? Done and Marta too&lt;/li&gt;&lt;li&gt;SAEs non-fatal all cause - do you not want to include the pooled result of adults and children? Better kept separate I think, as this matches the other reviews and our effort to summarise adults and children separately in the overviews.&lt;/li&gt;&lt;li&gt;New Table of Mortality by cause of death added (to match LAB3 presentation as suggested by copy editor).&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;-------------------------&lt;/p&gt;&lt;p&gt;16/1/13 Changes from Stefanie and Montse incorporated by CJC. Also RoB added to match LAB3&lt;/p&gt;&lt;p&gt;++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;CJC to check references pending classification before submitting this one!!! Table 1 updated further and ongoing studies added and populated!&lt;/p&gt;&lt;p&gt;CJC added data from 2012 update studies to &lt;b&gt;first four&lt;/b&gt; forest plots and additional table updated. Meltzer data from Merck added for all cause SAEs, and hospital admissions for asthma. Now all studies added &lt;a link_type=&quot;STUDY&quot; href=&quot;Zangrilli 2011&quot; protected=&quot;true&quot;&gt;Zangrilli 2011&lt;/a&gt; shows rise in FEV1 on step down to run-in dose of ICS! SoF tables created for adults and children. Are the GRADE assessments correct?&lt;/p&gt;&lt;p&gt;CJC has now run spell check and accepted all changes 17th Dec. Pass on to other authors.&lt;/p&gt;&lt;p&gt;++++++++++++++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;FEb 16th Roman is happy with this and I have run spell checker. Ready for Publication. Additional Data from Sears Paper provided by AZ and added in discussion. RR 1.79 (0.80 to 4.00)&lt;/p&gt;&lt;p&gt;&amp;quot;The adjusted all-cause mortality in &lt;a link_type=&quot;REFERENCE&quot; href=&quot;Sears 2008&quot; protected=&quot;true&quot;&gt;Sears 2008&lt;/a&gt; is RR 1.79 (95% CI 0.80, 4.00) when studies with any baseline ICS are considered; the conditional logistic regression was adjusted for trial effect (data on file provided by AstraZeneca).&amp;quot;&lt;/p&gt;&lt;p&gt;Chris&lt;/p&gt;&lt;p&gt;Feb 9th&lt;/p&gt;&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;Peer Review Comments&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;Add call for more transparent reporting of SAEs to recommendations for further research. (CJC: This is already clear)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;Mention in the discussion the possibility that higher exacerbation rates on placebo could mask a real increase in SAEs on treatment. (CJC: I do not think this applies as the control arm all received ICS. This could have a bearing on asthma SAE data I suppose, but only if formoterol protected against SAE, and this is exactly what we are addressing in the review. No change suggested.)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;Second Peer Reviewer&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;Liked the all-cause and disease specific split.&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;Advised combinines FPS and BDF. Make clearer FPS is ongoing? (CJC: Final sentence added to background: A review comparing regular salmeterol randomised in combination with inhaled corticosteroids, (in a single inhaler or separate inhalers) and compared to inhaled corticosteroids alone is also currently ongoing.)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;Is there data on frequency of harm as continuous outcomes? (CJC: This data was not available to us)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;SAE data and severity of disease or dose of Rx do not seem to correlate (CJC: power and confounding are issues here. No dose effect seen in Sears or Formoterol only review. &amp;quot;The adjusted all-cause mortality in &lt;a link_type=&quot;REFERENCE&quot; href=&quot;Sears 2008&quot; protected=&quot;true&quot;&gt;Sears 2008&lt;/a&gt; is RR 1.39 (95% CI 0.71, 2.74) when studies with and without ICS at baseline are considered together, but no adjusted RR is presented for patients who were taking ICS at baseline. This information has been sought from the authors.&amp;quot; Added to Discussion on Mortality pending feedback from Roman).&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;p&gt;Results of observational studies could be mentioned in the discussion? (CJC: &amp;quot;Counfounding by severity was shown by &lt;a link_type=&quot;REFERENCE&quot; href=&quot;Sears 2008&quot; protected=&quot;true&quot;&gt;Sears 2008&lt;/a&gt; in data from the RELEIF study, where the rate of asthma-related SAEs was significantly higher in both arms of the study in patients taking ICS in comparison to those not taking ICS. This is a serious threat to any conclusions drawn from observational data when assessing the interaction between ICS and formoterol.&amp;quot; Sentence added to the background to emphasise the importance of RCT evidence.)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p&gt;Ask Roman for adjusted ICS all-cause mortality from Sears paper.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;January 12th Novartis FDA submission checked from Dec 10, but no trials that randomised ICS were reported for this submission.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;January 8th&lt;/p&gt;&lt;p&gt;Revised with OPTIMA 11 results (awaiting confirmation from Joe).&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;January 7th&lt;/p&gt;&lt;p&gt;Roman has signed off the review now so ready for Toby to look through. Then Peer Review? Search results error corrected and typos spotted by Toby.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;January 6th&lt;/p&gt;&lt;p&gt;Roman has pointed out that the Jenkins death had not been removed from RD and MH figures. Also 7 v 3 needs to be put in for 5 v 2 in figures 5,9,12. This is now done and text matches figures. Subtotals switched off for asthma deaths also.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;January 5th&lt;/p&gt;&lt;p&gt;Textual revisions after input from Roman. His changes have all been incorporated into this version. I have removed the TOTALS in Figure 13 and 14 as I agree that this could be misleading, but retained the figures to allow comparison between the results of the two reviews.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;Dec 15th OPTIMA data now agrees with Roman as patient who died also had non fatal SAE. I have added figures 13 and 14 to allow easier comparison of the results from the reviews with and without ICS. Combined mortality is not very reassuring!&lt;/p&gt;&lt;p&gt;For Roman to look over now and add conflicts of interest please. Aim to get out for peer review early in the New Year.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;Dec 1st&lt;/p&gt;&lt;p&gt;Jenkins death removed as it was at 17 weeks and 7 v 3 entered for pts with SAE. All risk differences and OR results will need to be rechecked...... Now done!&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;Nov 26th: I need Joe or Roman to indicate where the death was in FACET and what the cause was? Also was suicide on combined or separate inhalers in Zetterstrom and what about the OPTIMA discrepancy? Sears reports all cause mortality as 0.07% in formoterol, non-LABA and salmeterol randomised arms. In this review it is the lack of deaths on ICS that does not fit with this...... He reports 3 to 0 deaths on patients with known maintenance ICS and REGULAR formoterol. The is no total mortality data presented for this subset of people. Why not?&lt;/p&gt;&lt;p&gt;Nov 24th rogue version repaired by Jacob. This one has the table restored and is fine for Susan to add data. I have tidied up the sensitivity and subgroup analyses.&lt;/p&gt;&lt;p&gt;Nov 21st. Double data checking with Roman has revealed a mistake by Joe in the FACET asthma SAEs in the Bud 400 arm. It should have been five patients. Data checking with Toby fine and text modifications made.&lt;/p&gt;&lt;p&gt;#~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;Nov 17th&lt;/p&gt;&lt;p&gt;Will still need to ask Susan to enter all the additional references to included studies. I have described the included studies. Ready for risk of bias.&lt;/p&gt;&lt;p&gt;&amp;quot;A total of 7 patients in the budesonide/formoterol group had a serious adverse event requiring admission to hospital (asthma (5), larynx edema (1), pneumonia (1).&amp;quot; Deaths are not mentioned nor are any events in the budesonide group. Further clarification is being sought from the sponsors, but we have currently assumed no serious adverse events in the budesonide group (as none are recorded in the paper). Tal 2002&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;Nov 11 2009&lt;/p&gt;&lt;p&gt;First six included studies entered into RevMan and data checked against Roman's paper. Also complete set of excluded studies entered too.&lt;/p&gt;&lt;p&gt;Peto results and Mantel-Haenszel method given quite different looking results for all-cause mortality. What about exact methods?&lt;/p&gt;&lt;p&gt;Doses are widely variable here and may need some thought I guess.&lt;/p&gt;&lt;p&gt;TAL data needs to be referred back to Joe urgently. Done&lt;/p&gt;&lt;p&gt;Check that SAE non-fatal does not include the deaths......&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;CJC nov 9&lt;br&gt;Further amendments made following discussion with TL. SIT and AMD are included but not BDF for relief use only in randomisation. ICS remains the control arm for this review (so SIT v AMD would not be included for example).&lt;br&gt;Back to TL for checking.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;br&gt;CJC Nov 5&lt;br&gt;Thanks for amending this Toby. I am happy to publish the current version&lt;br&gt;~~~~~~~~~~~~~~~~~~~~~~&lt;br&gt;Will varying the exposure to LABA in intermittent/AMD studies confound the risk in control group? Given the emphasis on regular LABA use in the protocol we may need to give some thought as to whether control groups where there is exposure to LABAs are estimating a different treatment effect to something other than studies like FACET. I have restructured the Criteria for intervention section to reflect this.&lt;/p&gt;&lt;p&gt;----------------------------&lt;br&gt;Key differences in Red from the other Formoterol protocol. FACET may get left out in the cold here but the main focus is on REGULAR LABA use, so this is where I have drawn the line.&lt;br&gt;What do you think?&lt;br&gt;Chris&lt;/p&gt;" NOTES_MODIFIED="2013-05-24 14:29:04 +0100" NOTES_MODIFIED_BY="Emma Welsh" REVIEW_NO="LAB4-AST" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2013-05-24 14:38:46 +0100" MODIFIED_BY="Emma Welsh">
<TITLE>Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events</TITLE>
<CONTACT MODIFIED="2013-05-24 14:38:46 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="7270" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christopher</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Cates</LAST_NAME><SUFFIX>MD FRCGP</SUFFIX><POSITION>Senior Research Fellow</POSITION><EMAIL_1>ccates@sgul.ac.uk</EMAIL_1><URL>www.nntonline.net</URL><ADDRESS><DEPARTMENT>Population Health Sciences and Education</DEPARTMENT><ORGANISATION>St George's University of London</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><CITY>London</CITY><ZIP>SW17 0RE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 208 725 5412</PHONE_1><FAX_1>+44 208 725 3584</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-05-24 14:38:46 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="7270" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christopher</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Cates</LAST_NAME><SUFFIX>MD FRCGP</SUFFIX><POSITION>Senior Research Fellow</POSITION><EMAIL_1>ccates@sgul.ac.uk</EMAIL_1><URL>www.nntonline.net</URL><ADDRESS><DEPARTMENT>Population Health Sciences and Education</DEPARTMENT><ORGANISATION>St George's University of London</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><CITY>London</CITY><ZIP>SW17 0RE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 208 725 5412</PHONE_1><FAX_1>+44 208 725 3584</FAX_1></ADDRESS></PERSON><PERSON ID="18976" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roman</FIRST_NAME><LAST_NAME>Jaeschke</LAST_NAME><EMAIL_1>jaeschke@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine and Department of Clinical Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>301 James Street South</ADDRESS_1><CITY>Hamilton, Ontario</CITY><ZIP>L8P3B6</ZIP><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 521 6077</PHONE_1><FAX_1>+1 905 521 6068</FAX_1></ADDRESS></PERSON><PERSON ID="47914648483877848057120716150135" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Stefanie</FIRST_NAME><LAST_NAME>Schmidt</LAST_NAME><POSITION>Pre-doctoral researcher</POSITION><EMAIL_1>sschmidt@imim.es</EMAIL_1><ADDRESS><DEPARTMENT>Health Services Research Unit</DEPARTMENT><ORGANISATION>IMIM (Hospital del Mar Medical Research Institute)</ORGANISATION><ADDRESS_1>Doctor Aiguader 88</ADDRESS_1><CITY>Barcelona</CITY><ZIP>08003</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>0034-933160744</PHONE_1></ADDRESS></PERSON><PERSON ID="A334515682E26AA201F33AEF38D82AF3" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Montse</FIRST_NAME><LAST_NAME>Ferrer</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>mferrer@imim.es</EMAIL_1><ADDRESS><DEPARTMENT>Health Services Research Unit</DEPARTMENT><ORGANISATION>IMIM (Hospital del Mar Medical Research Institute)</ORGANISATION><ADDRESS_1>C/ Doctor Aiguader, 88</ADDRESS_1><CITY>Barcelona</CITY><ZIP>08003</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 933 160 763 - 740</PHONE_1><FAX_1>+34 933 160 797</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-10-22 15:52:00 +0100" MODIFIED_BY="Christopher Cates">
<UP_TO_DATE>
<DATE DAY="1" MONTH="8" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="8" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-12-17 16:38:31 +0000" MODIFIED_BY="Christopher J Cates">
<DATE DAY="29" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>With the addition of data from six new trials in adults, we have found a significant reduction in asthma-related serious adverse events on regular formoterol with inhaled corticosteroids, but this does not translate into a similar reduction in all-cause serious adverse events.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<DATE DAY="22" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>The 2012 update of this review includes six new trials, which recruited 2550 adults and adolescents given regular formoterol in combination with budesonide or mometasone (<LINK REF="STD-Brown-2012" TYPE="STUDY">Brown 2012</LINK>; <LINK REF="STD-Meltzer-2012" TYPE="STUDY">Meltzer 2012</LINK>; <LINK REF="STD-Nathan-2010" TYPE="STUDY">Nathan 2010</LINK>; <LINK REF="STD-Spector-2012" TYPE="STUDY">Spector 2012</LINK>; <LINK REF="STD-Weinstein-2010" TYPE="STUDY">Weinstein 2010</LINK>; <LINK REF="STD-Zangrilli-2011" TYPE="STUDY">Zangrilli 2011</LINK>).</P>
<P>There were no new studies in children, but two large ongoing studies have been identified in adults and adolescents, each intending to recruit 11,000 participants. They are expected to report in 2017 (<LINK REF="STD-NCT01444430" TYPE="STUDY">NCT01444430</LINK>; <LINK REF="STD-NCT01471340" TYPE="STUDY">NCT01471340</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2013-01-09 15:52:29 +0000" MODIFIED_BY="Christopher J Cates">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NHS R&amp;D</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-01-09 15:52:29 +0000" MODIFIED_BY="Christopher J Cates">
<SOURCE MODIFIED="2012-12-17 17:26:25 +0000" MODIFIED_BY="Christopher J Cates">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Programme Grant (10/4001/01)</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2013-01-09 15:52:29 +0000" MODIFIED_BY="Christopher J Cates">
<NAME>European Union (FP7) Health</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION>
<P>ASTROLAB project (EC HEALTH-F5-2011-282593)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-05-24 14:28:01 +0100" MODIFIED_BY="Christopher J Cates">
<SUMMARY MODIFIED="2013-05-24 14:27:37 +0100" MODIFIED_BY="Christopher J Cates">
<TITLE MODIFIED="2013-02-22 14:26:13 +0000" MODIFIED_BY="Christopher J Cates">Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events</TITLE>
<SUMMARY_BODY MODIFIED="2013-05-24 14:27:37 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Background</B>
<BR/>Asthma is a disease of the lungs. Symptoms include wheezing, breathlessness and chest tightness. Two main features of asthma have been identified: underlying inflammation, which can be treated with daily steroids, and bronchoconstriction (tightening of the muscles around small tubes in the lungs), which can be treated with a beta<SUB>2</SUB>-agonist to relax the muscles.</P>
<P>When asthma is not controlled by daily low-dose inhaled steroids, many asthma guidelines recommend additional daily long-acting beta<SUB>2</SUB>-agonists (such as formoterol). Although we know that long-acting beta<SUB>2</SUB>-agonists are beneficial for lung function, symptoms, quality of life, and exacerbations, long-standing controversy surrounds the safety of regular use of beta<SUB>2</SUB>-agonists in people with asthma. This is the topic we sought to explore in this review.</P>
<P>
<B>Review question</B>
<BR/>We assessed the risk of death and of non-fatal serious adverse events in clinical trials comparing regular formoterol and inhaled steroids with the same dose of inhaled steroids in adults and children with asthma.</P>
<P>
<B>Key results</B>
<BR/>We analysed data from 20 studies in adults and 7 in children; these studies included participants with a range of asthma severity, and most participants had been previously treated with regular inhaled steroids (over a wide range of doses). The number of children studied was insufficient to allow a solid conclusion. However, a large trial in children is now in progress.</P>
<P>Seven deaths were reported among 13,366 participants. Six of these deaths, including one related to asthma, were reported in adults taking formoterol and inhaled steroids, and one death occurred in a participant who was taking inhaled steroids alone. Because few deaths were reported in these trials, we cannot conclusively state whether taking formoterol and inhaled steroids reduces or increases the risk of death compared with taking inhaled steroids alone.</P>
<P>The number of people experiencing serious adverse events of any cause was very similar in adults with and without formoterol. A significant reduction in serious adverse events was noted in adult participants with asthma who were taking regular formoterol in combination with inhaled corticosteroids.</P>
<P>
<B>Quality of the evidence</B>
<BR/>The quality of the data was moderate for adults but low in children because data in children were insufficient. All trials were sponsored by drug manufacturers. We were therefore concerned that bias might have been introduced in the attribution of asthma as the cause of serious events, as this was not independently assessed. The trials were double-blind; however, formoterol can have a big impact on asthma symptoms, and those who decided on the cause of the events may have guessed which treatment was being given.<BR/>
</P>
<P>
<B>Bottom line</B>
<BR/>We are not able to confidently state that adding formoterol to inhaled steroids carries no risk of increasing the number of deaths in comparison with inhaled steroids alone. On the other hand, we found no conclusive evidence of serious harm, and only one asthma-related death was reported over 4200 patient-years of observation of those treated with formoterol. With the addition of new studies in 2012, we have found a lower risk of non-fatal serious adverse events attributed to asthma when formoterol is combined with inhaled steroids.</P>
<P>
<B>Glossary: serious adverse events:</B> events that are life threatening, require inpatient hospitalisation or prolongation of existing hospitalisation, or result in persistent or significant disability/incapacity or a birth defect.</P>
<P>This Cochrane plain language summary is current as of August 2012.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<ABS_BACKGROUND MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Epidemiological evidence has suggested a link between beta<SUB>2</SUB>-agonists and increases in asthma mortality. Much debate has surrounded possible causal links for this association and whether regular (daily) long-acting beta<SUB>2</SUB>-agonists are safe when used alone or in conjunction with inhaled corticosteroids. This is an updated Cochrane Review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-02-19 12:01:34 +0000" MODIFIED_BY="Christopher J Cates">
<P>To assess the risk of fatal and non-fatal serious adverse events in people with chronic asthma given regular formoterol with inhaled corticosteroids versus the same dose of inhaled corticosteroids alone.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of trials. Web sites of clinical trial registers were checked for unpublished trial data; Food and Drug Administration (FDA) submissions in relation to formoterol were also checked. The date of the most recent search was August 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-02-19 12:01:57 +0000" MODIFIED_BY="Christopher J Cates">
<P>Controlled clinical trials with a parallel design were included if they randomly allocated people of any age and severity of asthma to treatment with regular formoterol and inhaled corticosteroids for at least 12 weeks.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>We used standard methodological procedures expected by The Cochrane Collaboration. Unpublished data on mortality and serious adverse events were obtained from the sponsors. We assessed the quality of evidence using GRADE recommendations.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Following the 2012 update, we have included 20 studies on 10,578 adults and adolescents and seven studies on 2788 children and adolescents. We found data on all-cause fatal and non-fatal serious adverse events for all studies, and we judged the overall risk of bias to be low.</P>
<P>Six deaths occurred in participants taking regular formoterol with inhaled corticosteroids, and one in a participant administered regular inhaled corticosteroids alone. The difference was not statistically significant (Peto odds ratio (OR) 3.56, 95% confidence interval (CI) 0.79 to 16.03, low-quality evidence). All deaths were reported in adults, and one was believed to be asthma-related.</P>
<P>Non-fatal serious adverse events of any cause were very similar for each treatment in adults (Peto OR 0.98, 95% CI 0.76 to 1.27, moderate-quality evidence), and weak evidence suggested an increase in events in children on regular formoterol (Peto OR 1.62, 95% CI 0.80 to 3.28, moderate-quality evidence).</P>
<P>In contrast with all-cause serious adverse events, the addition of new trial data means that asthma-related serious adverse events associated with formoterol are now significantly fewer in adults taking regular formoterol with inhaled corticosteroids (Peto OR 0.49, 95% CI 0.28 to 0.88, moderate-quality evidence). Although a greater number of asthma-related events were reported in children receiving regular formoterol, this finding was not statistically significant (Peto OR 1.49, 95% CI 0.48 to 4.61, low-quality evidence).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>From the evidence in this review, it is not possible to reassure people with asthma that regular use of inhaled corticosteroids with formoterol carries no risk of increasing mortality in comparison with use of inhaled corticosteroids alone. On the other hand, we have found no conclusive evidence of serious harm, and only one asthma-related death was registered during more than 4200 patient-years of observation with formoterol.</P>
<P>In adults, no significant difference in all-cause non-fatal serious adverse events was noted with regular formoterol with inhaled corticosteroids, but a significant reduction in asthma-related serious adverse events was observed in comparison with inhaled corticosteroids alone.</P>
<P>In children the number of events was too small, and consequently the results too imprecise, to allow determination of whether the increased risk of all-cause non-fatal serious adverse events found in a previous meta-analysis on regular formoterol alone is abolished by the additional use of inhaled corticosteroids.</P>
<P>We await the results of large ongoing surveillance studies mandated by the Food and Drug Administration (FDA) for more information. Clinical decisions and information provided to patients regarding regular use of formoterol have to take into account the balance between known symptomatic benefits of formoterol and the degree of uncertainty associated with its potential harmful effects.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-05-24 14:28:01 +0100" MODIFIED_BY="Christopher J Cates">
<BACKGROUND MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>When asthma is not controlled by low-dose inhaled corticosteroids alone, many asthma guidelines recommend the use of additional long-acting beta<SUB>2</SUB>-agonists (LABA). Several Cochrane reviews have addressed the efficacy of long-acting beta<SUB>2</SUB>-agonists in addition to inhaled corticosteroids (<LINK REF="REF-Ni-Chroinin-2009a" TYPE="REFERENCE">Ni Chroinin 2009a</LINK>; <LINK REF="REF-Ni-Chroinin-2010" TYPE="REFERENCE">Ni Chroinin 2010</LINK>) in comparison with placebo (<LINK REF="REF-Walters-2007" TYPE="REFERENCE">Walters 2007</LINK>), short-acting beta<SUB>2</SUB>-agonists (<LINK REF="REF-Walters-2002" TYPE="REFERENCE">Walters 2002</LINK>) and leukotriene-receptor antagonists (<LINK REF="REF-Ducharme-2011a" TYPE="REFERENCE">Ducharme 2011a</LINK>) and have assessed their use against increased doses of inhaled corticosteroids (<LINK REF="REF-Ducharme-2010a" TYPE="REFERENCE">Ducharme 2010a</LINK>). The beneficial effects of long-acting beta<SUB>2</SUB>-agonists on lung function, symptoms, quality of life and exacerbations requiring oral steroids have been demonstrated.</P>
<P>However, long-standing controversy over the regular use of beta<SUB>2</SUB>-agonists in asthma is ongoing. <LINK REF="REF-Sears-1986" TYPE="REFERENCE">Sears 1986</LINK> suggested that excessive use of short-acting beta<SUB>2</SUB>-agonists might have contributed directly or indirectly to an increase in asthma deaths in New Zealand between 1960 and 1980. The authors comment that "most deaths were associated with poor assessment, underestimation of severity and inappropriate treatment (over-reliance on bronchodilators and under-use of systemic corticosteroids), and delays in obtaining help."</P>
<P>Concern remains that the symptomatic benefit derived from treatment with long-acting beta<SUB>2</SUB>-agonists might lead to underestimation of attack severity in acute asthma, and could lead to an increase in asthma-related deaths. Furthermore, regular treatment with beta<SUB>2</SUB>-agonists can lead to tolerance of their bronchodilator effects, and this phenomenon might be more marked with longer-acting as opposed to shorter-acting compounds (<LINK REF="REF-Lipworth-1997" TYPE="REFERENCE">Lipworth 1997</LINK>). A number of molecular mechanisms have been proposed to explain the possible detrimental effects of long-term beta<SUB>2</SUB>-agonists in patients with asthma, including receptor downregulation and desensitisation (<LINK REF="REF-Giembycz-2006" TYPE="REFERENCE">Giembycz 2006</LINK>).</P>
<P>Two long-acting beta<SUB>2</SUB>-agonists are currently available: salmeterol and formoterol (also known as eformoterol). These two drugs have shown differences in speed of onset and receptor activity and are used in different ways (e.g. salmeterol has a slower onset of action than salbutamol (<LINK REF="REF-Beach-1992" TYPE="REFERENCE">Beach 1992</LINK>) and therefore is unsuitable for use as a reliever). 'The Fenoterol Story' is a reminder that all beta<SUB>2</SUB>-agonists may not carry the same risks (<LINK REF="REF-Pearce-2007" TYPE="REFERENCE">Pearce 2007</LINK>), so in view of the potential differences in adverse effects between salmeterol and formoterol, we have considered the two drugs separately. Two recently updated systematic reviews have addressed the impact of long-acting beta<SUB>2</SUB>-agonists on all-cause mortality and serious adverse events: <LINK REF="REF-Cates-2008" TYPE="REFERENCE">Cates 2008</LINK> (salmeterol) and <LINK REF="REF-Cates-2012" TYPE="REFERENCE">Cates 2012</LINK> (formoterol). Both reviews considered long-acting beta<SUB>2</SUB>-agonists that were randomly assigned without additional inhaled corticosteroids and described increased risks of non-fatal serious adverse events.</P>
<P>Much debate has focused on the interaction between inhaled corticosteroids and long-acting beta<SUB>2</SUB>-agonists in relation to serious adverse events since the publication of <LINK REF="REF-SMART-2006" TYPE="REFERENCE">SMART 2006</LINK>. This study did not randomly assign participants to inhaled corticosteroids, but nevertheless a subgroup analysis of the results was carried out on the basis of inhaled corticosteroid use at baseline. It is tempting to find reassurance from the fact that no statistically significant increase in asthma-related mortality was observed in the subgroup using inhaled corticosteroids, but this is not the correct way to test for interaction (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>), and no assessment was carried out during the trial in relation to the actual use of inhaled corticosteroids during the course of the study.</P>
<P>Counfounding by severity has been shown by <LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> in data from the RELIEF study, where the rate of asthma-related SAEs was significantly higher in both arms of the study among participants taking ICS in comparison with those not taking ICS. This is a serious threat to any conclusions drawn from observational data when the interaction between ICS and formoterol is assessed. Therefore, there is a need to systematically review all available data from controlled trials that randomly assigned participants to regular formoterol in combination with inhaled corticosteroids, and to consider all serious adverse events (fatal and non-fatal), whether or not these are deemed by the investigators to be related to trial medication.</P>
<P>The focus of this review is therefore on regular formoterol randomly assigned in combination with inhaled corticosteroids (in a single inhaler or in separate inhalers) and compared with inhaled corticosteroids alone. Because of the difficulty involved in deciding whether adverse events are asthma-related, this review focusses on studies that capture mortality and serious adverse events and records both all-cause outcomes and those considered by trial investigators to be asthma-related events.</P>
<P>A review comparing regular salmeterol randomly assigned in combination with inhaled corticosteroids (in a single inhaler or in separate inhalers) versus inhaled corticosteroids alone is currently being updated (<LINK REF="REF-Cates-2009" TYPE="REFERENCE">Cates 2009</LINK>), and an overview of the safety of regular formoterol or salmeterol in children has been published (<LINK REF="REF-Cates-2012a" TYPE="REFERENCE">Cates 2012a</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>To assess the risks of mortality and non-fatal serious adverse events in trials that randomly assign participants with chronic asthma to regular formoterol and inhaled corticosteroid versus the same dose of inhaled corticosteroid.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-05-24 14:27:49 +0100" MODIFIED_BY="Christopher J Cates">
<SELECTION_CRITERIA MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<CRIT_STUDIES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Controlled parallel-design clinical trials, with or without blinding, in which formoterol and inhaled corticosteroid were randomly assigned to participants with chronic asthma for comparison with outcomes in those given the same dose of inhaled corticosteroid alone. Studies on acute asthma and exercise-induced bronchospasm have not been included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Dolores Matthews">
<P>Participants with a clinical diagnosis of asthma of any age group, unrestricted by disease severity or previous or current treatment.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Inhaled corticosteroids and formoterol given regularly once or twice daily for a period of at least 12 weeks at any dose and delivered by any single or separate devices (CFC-MDI, HFA-MDI, DPI). Studies that randomly assigned participants to formoterol and inhaled corticosteroids for intermittent use as a reliever have not been included in this review, and studies that compared different doses of formoterol or different delivery devices or propellants without a placebo arm were also not included. Studies in which formoterol was randomly assigned without an inhaled steroid have been considered in a separate review (<LINK REF="REF-Cates-2012" TYPE="REFERENCE">Cates 2012</LINK>). Studies that use comparison groups given the same dose and type of inhaled corticosteroid in the control arm will be included in this review, and co-intervention with leukotriene-receptor antagonists, cromones or theophylline will be allowed as long as they are not part of the randomly assigned intervention and therefore are not systematically different between groups. Studies comparing formoterol with salmeterol will be subject to another review and were not included in this review. We have also excluded from this review studies in which inhaled corticosteroids were used in all participants as background treatment (rather than as a randomised intervention).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<UL>
<LI>All-cause mortality.</LI>
<LI>All-cause non-fatal serious adverse events.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<UL>
<LI>Asthma-related mortality.</LI>
<LI>Asthma-related non-fatal serious adverse events.</LI>
<LI>Respiratory-related mortality.</LI>
<LI>Respiratory-related non-fatal serious adverse events.</LI>
<LI>Cardiovascular-related mortality.</LI>
<LI>Cardiovascular-related non-fatal serious adverse events.</LI>
<LI>Asthma-related non-fatal life-threatening events (intubation or admission to intensive care).</LI>
<LI>Respiratory-related non-fatal life-threatening events (intubation or admission to intensive care).</LI>
</UL>
<P>Outcomes were not subdivided according to whether the trial investigators considered them related to trial medication.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<ELECTRONIC_SEARCHES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO and from handsearching of respiratory journals and meeting abstracts (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for additional details). All records in the Specialised Register coded as 'asthma' were searched using the following terms:</P>
<P>(((beta* and agonist*) and (long-acting or "long acting")) or ((beta* and adrenergic*) and (long-acting or "long acting")) or (bronchodilat* and (long-acting or "long acting")) or (salmeterol or formoterol or eformoterol or advair or symbicort or serevent or seretide or oxis)) AND (serious or safety or surveillance or mortality or death or intubat* or adverse or toxicity or complications or tolerability)</P>
<P>Searches were conducted up to August 2012 with no restriction on language of publication.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Reference lists of all primary studies and review articles were checked for additional references. Web sites of clinical trial registers were checked for unpublished trial data; Food and Drug Administration (FDA) submissions in relation to formoterol were also checked.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-05-24 14:27:49 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Two review authors independently assessed studies identified in the literature searches by examining title, abstract and keywords fields. Studies that potentially fulfilled the inclusion criteria were obtained in full text. These were independently assessed for inclusion by CJC, with a second assessment by Toby Lasserson for the original review and by Marta Oleszczuk for the 2012 update. Disagreements were resolved by consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Data were extracted using a prepared checklist before they were entered into Rev Man 5.0 by one reviewer (CJC), and data extraction and entry were checked by a second reviewer (Toby Lasserson,MF or SS). Outcome data were independently extracted by the third reviewer (RJ, MF or SS) and discrepancies resolved by correspondence with the sponsors, when necessary. Data included characteristics of included studies (methods, participants, interventions, outcomes) and results of the included studies. Sponsors of included studies were contacted for unpublished adverse event data, and the sponsor's Web site was searched for further details of adverse events. All-cause serious adverse events (fatal and non-fatal) were recorded, and in view of the difficulty involved in deciding whether events were asthma related, details of the cause of death and of serious adverse events were noted when available. The definition of <I>serious adverse events</I> was recorded, and further information was sought if this was not clear (particularly in relation to hospital admissions and serious adverse events).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>One review author (CJC) assessed all included studies for bias protection (including sequence generation for randomisation, allocation concealment, blinding of participants and assessors, loss to follow-up and selective outcome reporting) with assistance from Susan Hansen for the original version of the review and from MF or SS for the 2012 update.</P>
</QUALITY_ASSESSMENT>
<UNIT_OF_ANALYSIS MODIFIED="2013-05-24 14:27:45 +0100" MODIFIED_BY="Christopher J Cates">
<P>We confined our analysis to participants with one or more serious adverse event, rather than focusing on the number of events that occurred (as the latter are not independent when one patient suffers multiple events).</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Heterogeneity was assessed using I<SUP>2 </SUP>to indicate how much of the total heterogeneity found was between, rather than within, studies.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The outcomes of this review were dichotomous, and we recorded the numbers of participants with at least one outcome event by allocated treated group. Pooled odds ratio (ORs) and risk difference (RDs) were calculated. The Peto OR provides advantages when events are rare as no adjustment for zero cells is required (<LINK REF="REF-Bradburn-2007" TYPE="REFERENCE">Bradburn 2007</LINK>). We considered this specific property to be more important than potential problems with unbalanced treatment arms and large effect sizes associated with this method in view of the low number of events and the high proportion of zero cells. The primary analysis of results for serious adverse event outcomes was conducted in RevMan 5.2 using the Peto method, and the Mantel-Haenszel method was used as a sensitivity analysis. Funnel plots were inspected for assessment of possible publication bias.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Subgroup analyses were conducted on the basis of participant age (adults vs children) and the dose of formoterol used (usual dose vs high dose). Subgroups were compared with the use of tests for interaction (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-05-24 14:27:49 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sensitivity analysis was carried out to assess the impact of the method used to combine study events (risk difference, Peto OR and Mantel-Haenszel OR). The degree of bias protection included in the study design was also included in the of sensitivity analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables</HEADING>
<P>We assessed the quality of the evidence for all-cause mortality, all-cause non-fatal serious adverse events and asthma-related serious adverse events. Assessments were conducted according to recommendations put forth by the <A HREF="http://www.gradeworkinggroup.org/">GRADE working group</A> and are presented in our reviews in separate Summary of Findings tables for adults and children.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-05-24 14:27:59 +0100" MODIFIED_BY="Christopher J Cates">
<STUDY_DESCRIPTION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<SEARCH_RESULTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>A total of 523 abstracts were found from the search of the Cochrane Airways Group Specialised Register of trials in October 2008. For this review, 59 abstracts were identified as potentially relevant, and of these, 48 were subsequently excluded (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>) and 11 were included in the review. Ten additional trials were identified primarily from the AstraZeneca register of controlled trials (<LINK REF="STD-Buhl-2003" TYPE="STUDY">Buhl 2003</LINK>; <LINK REF="STD-D5896C00001" TYPE="STUDY">D5896C00001</LINK>; <LINK REF="STD-Morice-2007" TYPE="STUDY">Morice 2007</LINK>; <LINK REF="STD-Morice-2008" TYPE="STUDY">Morice 2008</LINK>; <LINK REF="STD-Peters-2008" TYPE="STUDY">Peters 2008</LINK>; <LINK REF="STD-SD_x002d_039_x002d_0714" TYPE="STUDY">SD-039-0714</LINK>; <LINK REF="STD-SD_x002d_039_x002d_0718" TYPE="STUDY">SD-039-0718</LINK>; <LINK REF="STD-SD_x002d_039_x002d_0719" TYPE="STUDY">SD-039-0719</LINK>; <LINK REF="STD-SD_x002d_039_x002d_0725" TYPE="STUDY">SD-039-0725</LINK>; <LINK REF="STD-SD_x002d_039_x002d_0726" TYPE="STUDY">SD-039-0726</LINK>). No additional trials were found from the Novartis Website or the FDA Website. A submission from Novartis to the FDA in December 2008 indicated that no trials in the Novartis database were trials of Foradil in which participants had also been randomised to inhaled corticosteroids (<LINK REF="REF-Novartis-2008" TYPE="REFERENCE">Novartis 2008</LINK>).</P>
<P>The August 2012 search update found another 199 abstracts, from which 55 were identified as potentially relevant to this review. The full papers identified 25 reports of six new trials of 2550 adults and adolescents given regular formoterol in combination with budesonide or mometasone (<LINK REF="STD-Brown-2012" TYPE="STUDY">Brown 2012</LINK>; <LINK REF="STD-Meltzer-2012" TYPE="STUDY">Meltzer 2012</LINK>; <LINK REF="STD-Nathan-2010" TYPE="STUDY">Nathan 2010</LINK>; <LINK REF="STD-Spector-2012" TYPE="STUDY">Spector 2012</LINK>; <LINK REF="STD-Weinstein-2010" TYPE="STUDY">Weinstein 2010</LINK>; <LINK REF="STD-Zangrilli-2011" TYPE="STUDY">Zangrilli 2011</LINK>). Twelve additional citations were identified for six trials already included in the review (<LINK REF="STD-D5896C00001" TYPE="STUDY">D5896C00001</LINK>; <LINK REF="STD-Noonan-2006" TYPE="STUDY">Noonan 2006</LINK>; <LINK REF="STD-Peters-2008" TYPE="STUDY">Peters 2008</LINK>; <LINK REF="STD-SD_x002d_039_x002d_0718" TYPE="STUDY">SD-039-0718</LINK>; <LINK REF="STD-SD_x002d_039_x002d_0719" TYPE="STUDY">SD-039-0719</LINK>; <LINK REF="STD-SD_x002d_039_x002d_0725" TYPE="STUDY">SD-039-0725</LINK>). Twelve studies (with 18 reports) were excluded as documented in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>No new studies on children were identified.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The 27 trials included in this review are described in detail in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, and a summary of the daily dose of budesonide and formoterol that was used in each trial is provided in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). To avoid confusion, all delivered doses have been converted to an equivalent metered dose (so Symbicort 320/9 mcg is a delivered dose that is equivalent to a metered dose of budesonide 400 mcg and formoterol 12 mcg).</P>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> also indicates whether each study randomly assigned participants to once- or twice-daily formoterol, used combined or separate inhalers and delivered the medication using dry powder inhaler (DPI) or pressurised metered-dose inhalers (pMDIs). Some trials had more than two arms so featured more than one option in each of these cases. Because OPTIMA (<LINK REF="STD-O_x0027_Byrne-2001" TYPE="STUDY">O'Byrne 2001</LINK>; <LINK REF="STD-O_x0027_Byrne-2001a" TYPE="STUDY">O'Byrne 2001a</LINK>) and FACET (<LINK REF="STD-Pauwels-1997" TYPE="STUDY">Pauwels 1997</LINK>; <LINK REF="STD-Pauwels-1997a" TYPE="STUDY">Pauwels 1997a</LINK>) randomly assigned participants to higher and lower doses of budesonide, each has been considered as two separate comparisons and has been given two identifiers. The review therefore lists a total of 29 studies, drawn from the 27 trials that have been conducted.</P>
<P>All the trials on budesonide and formoterol have been sponsored or supported by AstraZeneca, and all the trials on mometasone and formoterol have been sponsored by Merck or Schering-Plough (<LINK REF="STD-Meltzer-2012" TYPE="STUDY">Meltzer 2012</LINK>; <LINK REF="STD-Nathan-2010" TYPE="STUDY">Nathan 2010</LINK>; <LINK REF="STD-Weinstein-2010" TYPE="STUDY">Weinstein 2010</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Adults</HEADING>
<P>After the 2012 update, a total of 10,578 adults and adolescents were randomly assigned in 13 trials enrolling participants over the age of 12 years (<LINK REF="STD-Brown-2012" TYPE="STUDY">Brown 2012</LINK>; <LINK REF="STD-Corren-2007" TYPE="STUDY">Corren 2007</LINK>; <LINK REF="STD-D5896C00001" TYPE="STUDY">D5896C00001</LINK>; <LINK REF="STD-Jenkins-2006" TYPE="STUDY">Jenkins 2006</LINK>; <LINK REF="STD-Meltzer-2012" TYPE="STUDY">Meltzer 2012</LINK>; <LINK REF="STD-Morice-2007" TYPE="STUDY">Morice 2007</LINK>; <LINK REF="STD-Nathan-2010" TYPE="STUDY">Nathan 2010</LINK>; <LINK REF="STD-Noonan-2006" TYPE="STUDY">Noonan 2006</LINK>; <LINK REF="STD-Peters-2008" TYPE="STUDY">Peters 2008</LINK>; <LINK REF="STD-Price-2002" TYPE="STUDY">Price 2002</LINK>; <LINK REF="STD-Spector-2012" TYPE="STUDY">Spector 2012</LINK>; <LINK REF="STD-Weinstein-2010" TYPE="STUDY">Weinstein 2010</LINK>; <LINK REF="STD-Zangrilli-2011" TYPE="STUDY">Zangrilli 2011</LINK>), a further six trials that enrolled adults over the age of 18 years (<LINK REF="STD-Buhl-2003" TYPE="STUDY">Buhl 2003</LINK>; <LINK REF="STD-Chuchalin-2002" TYPE="STUDY">Chuchalin 2002</LINK>; <LINK REF="STD-Kuna-2006" TYPE="STUDY">Kuna 2006</LINK>; <LINK REF="STD-O_x0027_Byrne-2001" TYPE="STUDY">O'Byrne 2001</LINK>; <LINK REF="STD-Pauwels-1997" TYPE="STUDY">Pauwels 1997</LINK>; <LINK REF="STD-Zetterstrom-2001" TYPE="STUDY">Zetterstrom 2001</LINK>) and a single trial that enrolled those older than 16 years of age (<LINK REF="STD-SD_x002d_039_x002d_0726" TYPE="STUDY">SD-039-0726</LINK>). All participants in these studies had a mean age of greater than 18 years.</P>
<P>The weighted mean duration of the adult and adolescent studies was 28 weeks. The daily metered dose of formoterol used was 12 to 24 mcg, with the exception of <LINK REF="STD-Jenkins-2006" TYPE="STUDY">Jenkins 2006</LINK> and <LINK REF="STD-Peters-2008" TYPE="STUDY">Peters 2008</LINK>, who used 48 mcg daily (which remains within the licensed daily dose range). The daily metered dose of budesonide ranged from 200 to 1600 mcg, and for mometasone from 200 to 800 mcg (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Children</HEADING>
<P>The seven trials in children included 2788 participants in the following age ranges: <LINK REF="STD-Morice-2008" TYPE="STUDY">Morice 2008</LINK>, 6 to 11 years old; <LINK REF="STD-Pohunek-2006" TYPE="STUDY">Pohunek 2006</LINK>, 4 to 11; <LINK REF="STD-SD_x002d_039_x002d_0714" TYPE="STUDY">SD-039-0714</LINK>, 11 to 17; <LINK REF="STD-SD_x002d_039_x002d_0718" TYPE="STUDY">SD-039-0718</LINK>, 6 to 15; <LINK REF="STD-SD_x002d_039_x002d_0719" TYPE="STUDY">SD-039-0719</LINK>, 6 to 11; <LINK REF="STD-SD_x002d_039_x002d_0725" TYPE="STUDY">SD-039-0725</LINK>, 6 to 15 and <LINK REF="STD-Tal-2002" TYPE="STUDY">Tal 2002</LINK> (4 to 17). In all studies, the mean age of participants was younger than 18 years.</P>
<P>The weighted mean duration of the studies of children and adolescents was 13 weeks. The daily metered dose of formoterol was 12 to 24 mcg. The daily metered dose of budesonide was 200 to 400 mcg (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-05-24 14:27:59 +0100" MODIFIED_BY="Christopher J Cates">
<P>An overview of the risk of bias in individual studies is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; individual judgements can be viewed in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<ALLOCATION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Very little information is available from the paper publications or from Web reports on sequence generation or allocation concealment, but this is unlikely to be a source of bias in view of the fact that all the studies are sponsored, and standard methodology is likely to have been used to minimise the risk of selection bias. We therefore regarded the risk of selection bias as low, although sequence generation and allocation concealment are marked as unclear in most studies in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-05-24 14:27:59 +0100" MODIFIED_BY="Christopher J Cates">
<P>All of the studies were double-blind with the exception of <LINK REF="STD-SD_x002d_039_x002d_0719" TYPE="STUDY">SD-039-0719</LINK>, which was an open study. We regard the overall risk of performance and detection bias as low for the all-cause events. We were concerned that bias might have been introduced in the attribution of asthma as the cause of serious events, as this was not independently assessed. Although the trials were double-blind, formoterol can have a big impact on asthma symptoms, and those who decided on the cause of the events may have guessed which treatment was being given.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The rate of withdrawals and dropouts was clearly reported and was generally less than 20% for randomly assigned participants; these rates were similar in the arms of each study. However, <LINK REF="STD-Spector-2012" TYPE="STUDY">Spector 2012</LINK> reported more withdrawals on budesonide alone (34% compared with 24% on combination treatment), so we judged this study to be at high risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Data have been found or provided from the sponsor for fatal and non-fatal serious adverse events by treatment group and causation for all studies, except for <LINK REF="STD-Brown-2012" TYPE="STUDY">Brown 2012</LINK>, which does not include details of asthma-related serious adverse events. We have therefore obtained data from all trials in relation to the primary outcomes of all-cause mortality and all-cause serious adverse events, and we regard the overall risk of reporting bias as low.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<SUBSECTION>
<HEADING LEVEL="3">Primary Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<P>No deaths were reported in the trials on children and adolescents (2788 participants). In the adult and adolescent studies (10,578 participants), seven deaths occurred. Six deaths were reported in 6163 participants taking formoterol with inhaled corticosteroids, and one death occurred out of 4415 participants taking inhaled corticosteroids alone. These trials were combined with the use of the Peto odds ratio (OR; as no continuity correction for zero cells is required). The increased odds of all-cause mortality with formoterol did not reach statistical significance (Peto OR 3.56, 95% confidence interval (CI) 0.79 to 16.03, P = 0.1) and I<SUP>2 </SUP>was zero (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). When analysed is performed with the use of risk differences (RD) with a fixed-effect model, the RD is 0.0009 (95% CI -0.0012 to 0.0030, P = 0.42) for adults and adolescents treated for an average of 28 weeks, and the RD is zero (95% CI -0.0042 to 0.0042, P = 1) in trials on children and adolescents treated for an average of 13 weeks (in which no deaths were reported).</P>
<P>Reports on the cause of each death are documented in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serious adverse events (non-fatal all-cause)</HEADING>
<P>A non-fatal serious adverse event is defined as an event that falls into any of the following categories:</P>
<UL>
<LI>Is life-threatening.</LI>
<LI>Requires inpatient hospitalisation or prolongation of existing hospitalisation.</LI>
<LI>Results in persistent or significant disability/incapacity.</LI>
<LI>Is a congenital anomaly/birth defect.</LI>
</UL>
<P>This is further explained in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>, and AstraZeneca has confirmed that this definition was used in its included trials (even though this often was not made explicit in the paper reports).</P>
<SUBSECTION>
<HEADING LEVEL="5">Adults and adolescents</HEADING>
<P>The number of participants experiencing one or more non-fatal serious adverse events was very similar when formoterol was randomly assigned with inhaled corticosteroids (ICS) in comparison with ICS alone. In 142 out of 6163 (2.3%) participants on regular formoterol with ICS and in 113 out of 4415 (2.6%) on ICS alone, such events occurred. The Peto OR was close to 1 (0.98, 95% CI 0.76 to 1.27, P = 0.87), and I<SUP>2 </SUP>was zero (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The pooled RD was -0.0005 (95% CI -0.0066 to 0.0056, P = 0.87) over an average of 28 weeks of treatment, and I<SUP>2 </SUP>was again zero.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Children and adolescents</HEADING>
<P>In trials of participants who were younger than 18 years of age, the results were more heterogeneous, and more non-fatal serious adverse events occurred with formoterol. A total of 25 such events were reported amongst young people out of 1719 (1.5%) on regular formoterol with ICS, and nine events occurred amongst 1069 (0.8%) participants taking ICS alone. The increased odds of serious adverse events with formoterol did not reach statistical significance: Peto OR: 1.62 (95% CI 0.80 to 3.28, P = 0.18); I<SUP>2</SUP>:<SUP> </SUP>32%. The pooled RD for children was 0.0058 (95% CI -0.0028 to 0.0144, P = 0.19). When <LINK REF="STD-Tal-2002" TYPE="STUDY">Tal 2002</LINK> is removed from the analysis, the I<SUP>2 </SUP>measurement is reduced to 0. In this study, events were reported in seven children on formoterol and in none on ICS alone.</P>
<P>The test for interaction between adults and children did not find a significant impact of age on treatment effect during analysis as Peto OR (test for subgroup differences: Chi = 1.72, df = 1, P = 0.19, I = 41.9%; see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality by cause of death</HEADING>
<P>None of the seven deaths in adults were reported as being due to asthma in the original trial reports, but the death in <LINK REF="STD-O_x0027_Byrne-2001" TYPE="STUDY">O'Byrne 2001</LINK> (OPTIMA) was subsequently attributed to status asthmaticus and septic shock in a recent meta-analysis (<LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK>). The full report on the cause of death provided by the sponsors stated, "One of the deaths occurred in a 35 year old female after an 8 day hospitalisation for a severe asthma attack leading to intubation, ventilation, and nosocomial pneumonia with septic shock." This is the only death that has been reported as related to asthma and it occurred in a patient taking budesonide/formoterol <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. Two deaths were reported as due to suicide, one as homicide, and one as cerebrovascular accident; one patient died of a uterine leiomyosarcoma and one from cardiac arrest (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serious adverse events related to asthma</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adults and adolescents</HEADING>
<P>The number of adults experiencing one or more asthma-related non-fatal serious adverse events was lower when formoterol was randomly assigned with ICSs in comparison with ICSs alone, and after the 2012 update, the difference reached statistical significance when both the Peto OR and the RD were used. A total of 17 out of 5981 (0.3%) participants on regular formoterol and ICS suffered an asthma-related serious adverse event, as well as 30 out of 4227 (0.7%) on ICS alone. The Peto OR was 0.49 (95% CI 0.28 to 0.88), and I<SUP>2 </SUP>was zero (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The pooled RD was -0.0034 (95% CI -0.0067 to -0.0001). This represents a reduction of three adults per thousand treated with combination therapy over 28 weeks, with a 95% CI of six fewer to less than one per thousand fewer.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Children and adolescents</HEADING>
<P>In trials in participants who were younger than 18 years of age, the results were again more heterogeneous. Nine young people out of 1719 (0.5%) on regular formoterol and ICS suffered an asthma-related serious adverse event (SAE), as did four out of 1069 (0.4%) on ICS alone. The increased odds of SAEs related to asthma was imprecise and was not statistically significant (Peto OR 1.49, 95% CI 0.48 to 4.61, P = 0.49), and I<SUP>2 </SUP>was 60% (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The pooled RD was 0.002 (95% CI -0.005 to 0.009).</P>
<P>The difference between children and adults was not statistically significant (test for subgroup differences: Chi = 2.94, df = 1, P = 0.09, I = 66.0%). The data retrieved were insufficient to allow assessment of the other proposed secondary outcomes (such as intensive care unit (ICU) admission and intubation). One intubation (ICS only group; <LINK REF="STD-O_x0027_Byrne-2001" TYPE="STUDY">O'Byrne 2001</LINK>) was reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Risk of bias</HEADING>
<P>No deaths occurred in children in the unblinded study (<LINK REF="STD-SD_x002d_039_x002d_0719" TYPE="STUDY">SD-039-0719</LINK>), so exclusion of this study resulted in no difference in mortality outcomes. When this study was excluded for non-fatal SAEs, the Peto OR for children was 1.69 (95% CI 0.81 to 3.54) and I<SUP>2 </SUP>was 45%. A funnel plot did not suggest obvious asymmetry related to publication bias (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Methods of analysis</HEADING>
<P>Primary outcomes were also analysed using Mantel-Haenszel fixed-effect and random-effects models. The result of a fixed-effect model for mortality was OR 1.95, 95% CI 0.56 to 6.82. This method uses a correction for zero cells, which means that the pooled OR is smaller than the Peto OR, because the addition of 0.5 to all cells when the arms have similar numbers randomly assigned will generate an OR of 3 when only one event is reported. When outcomes are very sparse (as for mortality), the results are entirely dependent on the size of the zero cell adjustment and whether the treatment arms are balanced. For all-cause SAEs in adults, the Mantel-Haenszel fixed-effect (OR 0.97, 95% CI 0.75 to 1.26) and random-effects models (OR 0.93, 95% CI 0.71 to 1.21) yielded results almost identical to those obtained by the Peto method. Similarly for asthma-related SAEs in adults, the fixed-effect (OR 0.52, 95% CI 0.30 to 0.90) and random-effects Mantel-Haenszel models (OR 0.53, 95% CI 0.30 to 0.95) provided very similar to results to those obtained when the Peto model was used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Dose of formoterol</HEADING>
<P>The dose of formoterol used in all studies was within the licensed daily dose, so no sensitivity analysis was required to exclude unlicensed doses.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<P>Mortality data were too sparse for any subgroup analyses to be carried out.</P>
<P>Although the results for adults and children showed opposite directions of effect for non-fatal SAEs (both all-cause and asthma-related), the test for interaction did not show a significant interaction of treatment effect and age.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-05-24 14:28:01 +0100" MODIFIED_BY="Christopher J Cates">
<SUMMARY_OF_RESULTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<P>The CIs for all-cause mortality in adults indicate that for every thousand patients treated with regular formoterol and ICS in comparison with ICS alone, we can expect something between three additional deaths and one less death in adults over 28 weeks of treatment, and at most four additional deaths to four fewer deaths in children over 13 weeks of treatment (the average duration of treatment in the respective trials). The pooled Peto OR for adults was 3.56 (95% CI 0.79 to 16.03) and could not be calculated for children because no deaths in children were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">All-cause non-fatal SAEs</HEADING>
<P>For non-fatal SAEs, the limits of the pooled CI are six more to seven fewer adults and ten more to three fewer children for every thousand treated over the period of time represented in the trials. The Peto OR was 0.98 (95% CI 0.76 to 1.27) for adults, and 1.62 (95% CI 0.80 to 3.28) for children, with heterogeneity noted in the results of studies in children.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Asthma-related mortality</HEADING>
<P>Only one death was attributed to asthma, so evidence was insufficient to allow assessment of impact on asthma-related mortality in adults or children.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Asthma-related non-fatal SAEs</HEADING>
<P>Since six new trials in adults were added, a significant reduction in asthma-related non-fatal events has been reported in adults (Peto OR 0.49, 95% CI 0.28 to 0.88). This represents a reduction of three adults per thousand treated with combination therapy over 28 weeks, with a 95% CI of six fewer to less than one per thousand fewer. The results in children do not show a significant difference (Peto OR 1.49, 95% CI 0.48 to 4.61), and although the direction of the effect in children contrasts with that in adults, the difference between results in children and those in adults is not significant (test for subgroup differences: Chi = 2.94, df = 1, P = 0.09, I = 66.0%).</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-05-24 14:28:01 +0100" MODIFIED_BY="Christopher J Cates">
<P>Two large studies have examined the use of regular salmeterol (<LINK REF="REF-SMART-2006" TYPE="REFERENCE">SMART 2006</LINK>, <LINK REF="REF-SNS-1993" TYPE="REFERENCE">SNS 1993</LINK>), but the only large surveillance study on formoterol (<LINK REF="STD-Pauwels-2003" TYPE="STUDY">Pauwels 2003</LINK>; RELIEF) investigated its use as a reliever rather than as maintenance therapy and therefore has not been included in this review. This means that data in this review are insufficient to allow investigation of the impact of formoterol on SAEs in comparison with our previous review on salmeterol (<LINK REF="REF-Cates-2008" TYPE="REFERENCE">Cates 2008</LINK>).</P>
<P>The small number of events in this review results in low precision of the estimates of relative risk between formoterol and control. However, outcome data for all-cause events were obtained from all included studies, and a funnel plot did not suggest publication bias (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>Two of the new trials included in the 2012 update focused on African American adults (<LINK REF="STD-Brown-2012" TYPE="STUDY">Brown 2012</LINK>; <LINK REF="STD-Spector-2012" TYPE="STUDY">Spector 2012</LINK>), and one studied Hispanic adults (<LINK REF="STD-Zangrilli-2011" TYPE="STUDY">Zangrilli 2011</LINK>), so the diversity of ethnic groups represented is now greater. However, there remains very little in the way of separate data on adolescent participants recruited in any of the adult or adolescent trials. Separate data on adolescents must be reported in large ongoing trials initiated by the FDA (<LINK REF="REF-Chowdhury-2011" TYPE="REFERENCE">Chowdhury 2011</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Risks of bias in the studies included in this review are thought to be low, as almost all of the studies were double-blind, and although allocation concealment was not well reported, it is likely to have been adequate, as all trials were sponsored or supported by product manufacturers. Because the trials were carried out for regulatory purposes, the collection of SAE data will have been assessed with the use of uniform definitions across studies.</P>
<P>Whilst we judged the risks of bias to be low in relation to all-cause fatal and non-fatal SAEs, this is not necessarily the case for asthma-related events. No independent assessment of the causation of events was undertaken, so bias may have been introduced if the investigators had a high threshold for classifying events as asthma-related. However, we would expect such a bias to decrease any differences observed in asthma-related events.</P>
<P>The level of heterogeneity within the subgroup of paediatric trials is significant (I<SUP>2 </SUP>= 60%), and cannot be explained easily. The CIs from two studies do not overlap (<LINK REF="STD-Morice-2008" TYPE="STUDY">Morice 2008</LINK>; <LINK REF="STD-Tal-2002" TYPE="STUDY">Tal 2002</LINK>), and observed results indicate protection (<LINK REF="STD-Morice-2008" TYPE="STUDY">Morice 2008</LINK>) and harm (<LINK REF="STD-Tal-2002" TYPE="STUDY">Tal 2002</LINK>).</P>
<P>The 2012 update of this review includes three new trials that are examining the combination of formoterol and mometasone in 1248 adults (<LINK REF="STD-Meltzer-2012" TYPE="STUDY">Meltzer 2012</LINK>; <LINK REF="STD-Nathan-2010" TYPE="STUDY">Nathan 2010</LINK>; <LINK REF="STD-Weinstein-2010" TYPE="STUDY">Weinstein 2010</LINK>). The number of participants is insufficient to allow investigators to compare and contrast the safety of this new combination versus the combination of formoterol and budesonide used in the other studies. However, a large ongoing trial on formoterol and mometasone is designed to recruit 11,000 adults and adolescents (<LINK REF="STD-NCT01471340" TYPE="STUDY">NCT01471340</LINK>) and will enable better safety comparison of various products in the future.</P>
<P>Despite the addition of new evidence to this updated review, we have downgraded the quality of evidence across a number of outcomes for imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The very low power of studies in children to detect any differences in SAEs means that we will have to await the results of the large ongoing study in children (<LINK REF="STD-NCT01471340" TYPE="STUDY">NCT01471340</LINK>) before we can determine whether the different directions of effect in asthma-related SAEs between children and adults are confounded or conflicting for another reason.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Selection of the best method to combine studies with rare events is contentious when event rates are low, not least because of the corrections required to calculate ORs with zero events (<LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>). It became apparent in the course of the review that the pooled ORs were heavily dependent on the zero adjustment used in the Mantel-Haenszel and inverse variance methods; therefore, we used the Peto OR and RDs to report results of this review. The imbalance between trial arms is never greater than two to one; therefore, the likely bias with use of the Peto OR is small (<LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>).</P>
<P>Similarly, the included studies were influenced by the decision to restrict the review to trials that randomly assigned participants to formoterol and ICS, but this decision reduces the risk of bias that arises when patients discontinue their usual inhaled steroid medication if they feel better while receiving the randomly assigned treatment. This presupposes a similar risk of SAEs when formoterol and budesonide are delivered via a single inhaler, and when formoterol is introduced to ICS therapy via a separate inhaler, when both are randomly assigned treatments in a controlled trial.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>Comparison of the results of this review with those of the review on regular formoterol without randomly assigned ICS (<LINK REF="REF-Cates-2012" TYPE="REFERENCE">Cates 2012</LINK>) indicates that nine out of 10 deaths in the trials comparing formoterol with placebo or comparing formoterol with ICS versus the same dose of ICS were performed in participants who were randomly assigned to formoterol (with or without ICS). This is a cause for concern because although it may seem that many of the deaths were not related to asthma, it is often difficult to be sure of the exact cause of death, and the classification of cause of death is not straightforward. For example, the participant who died during the OPTIMA trial (<LINK REF="STD-O_x0027_Byrne-2001" TYPE="STUDY">O'Byrne 2001</LINK>) was recorded by authors as dying from septic shock but was listed in <LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> as dying from status asthmaticus and septic shock, whereas the 13-year-old boy who died in <LINK REF="STD-Von-Berg-2003" TYPE="STUDY">Von Berg 2003</LINK> is listed in <LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> as dying of respiratory failure, although the article reported that the cause of death was subarachnoid haemorrhage. <LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> does not report all-cause mortality in the subgroup of trials in participants receiving regular formoterol and maintenance ICS; the primary analysis on all-cause mortality included the RELIEF study, which allowed regular long-acting beta<SUB>2</SUB>-agonists in both arms and therefore was not included in this review. The adjusted all-cause mortality in <LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> is relative risk (RR) 1.79 (95% CI 0.80 to 4.00) when studies with any baseline ICS are considered; the conditional logistic regression was adjusted for trial effect (data on file provided by AstraZeneca).</P>
<P>Only one asthma-related death was reported in this review, but the overview of <LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> identified two additional asthma-related deaths from the AstraZeneca database of trials in which participants were receiving maintenance ICS; all three deaths occurred amongst participants who had been randomly assigned to regular formoterol.</P>
<P>Six additional deaths were reported when formoterol and ICS were compared with higher doses of ICS&#65293;three deaths in each arm (<LINK REF="REF-Jaeschke-2008" TYPE="REFERENCE">Jaeschke 2008</LINK>).</P>
<P>We agree with the conclusion of <LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> that "the power is insufficient to conclude no increased mortality with formoterol" when regular formoterol is used in conjunction with ICS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">All-cause non-fatal SAEs</HEADING>
<P>
<LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> did not present data on all-cause SAEs, but <LINK REF="REF-Jaeschke-2008" TYPE="REFERENCE">Jaeschke 2008</LINK> reported that a reduction in asthma-related SAEs and in hospitalisations does not seem to translate into similar reductions in all-cause SAEs (which are about four times more common). <LINK REF="REF-Jaeschke-2008" TYPE="REFERENCE">Jaeschke 2008</LINK> and <LINK REF="REF-Jaeschke-2008a" TYPE="REFERENCE">Jaeschke 2008a</LINK> did not include trials in children. Information derived from trials in children in this review is insufficient to allow us to determine whether the increased risk of non-fatal SAEs found with formoterol alone in <LINK REF="REF-Cates-2012" TYPE="REFERENCE">Cates 2012</LINK> (Peto OR 2.48, 95% CI 1.27 to 4.83) is abolished by the addition of randomised ICS (Peto OR 1.62, 95% CI 0.80 to 3.28), as a large degree of overlap in CIs led to negative test findings for interaction (test for subgroup differences: Chi = 0.74, df = 1, P = 0.39, I = 0%) (see <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). This is discussed more fully in the overview of the safety of regular formoterol or salmeterol in children (<LINK REF="REF-Cates-2012a" TYPE="REFERENCE">Cates 2012a</LINK>) and is in agreement with the findings of <LINK REF="REF-McMahon-2011" TYPE="REFERENCE">McMahon 2011</LINK>, who reported a significant association between younger age and increased risk of formoterol or salmeterol monotherapy, but no significant age association with combination inhalers.</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<IMPLICATIONS_PRACTICE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>From the evidence provided in this review, it is not possible to reassure people with asthma that regular use of ICS with formoterol carries no risk of increasing mortality in comparison with ICS alone. On the other hand, we have found no conclusive evidence of harm, and only one asthma-related death was registered over more than 4200 patient-years of observation of individuals taking formoterol. In adults, the decrease in asthma-related SAEs seen amongst those receiving regular formoterol with ICS was not accompanied by a similar decrease in all-cause SAEs. In children, the number of events was too small to allow determination of whether the increase in all-cause non-fatal SAEs previously found among those taking regular formoterol alone is abolished by the additional use of ICS. Clinical decisions and information provided to patients regarding regular use of formoterol must take into account the balance between known symptomatic benefits of formoterol and the degree of uncertainty associated with its potential harmful effects.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Future research should clearly specify the number of patients with fatal and non-fatal SAEs by treatment group and cause. New large surveillance studies on combination therapies that are licensed in the United States have been mandated by the FDA; these aim to recruit 11,000 adults and adolescents to compare regular formoterol with budesonide against budesonide alone, and a similar number to compare regular formoterol with mometasone against mometasone alone, but trial investigators will not report results until 2017.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>We thank Susan Hansen, Elizabeth Stovold and Emma Jackson of the Cochrane Airways Group for assistance in searching for trials and obtaining the abstracts and full reports and for extracting data on trial characteristics. We also thank Toby Lasserson for his contribution to previous versions of the review. We acknowledge the assistance of Matthew Cates in relation to the physiology of beta-agonist receptors and co-writing of the protocol, and of Marta Oleszczuk for assessing studies for inclusion in the 2012 update. We thank Joe Gray, Finn Radner and Anders Ottosson of AstraZeneca, and Davis Gates from Merck, for obtaining data on file for SAEs in these studies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>None known for CJC. RJ received on one occasion honorarium and travel support from GlaxoSmtihKline for a lecture related to the topic of this review and is a deputy editor of a medical journal that is financed in part by advertising of drugs, including medications for asthma.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-05-23 10:54:07 +0100" MODIFIED_BY="Christopher J Cates">
<P>CJC: Conception of the idea and co-writing of protocol with MJC. Trial selection, data extraction and co-writing the original review and the 2012 update.</P>
<P>RJ: Trial selection, data extraction and co-writing the review.</P>
<P>MF &amp; SS: Data-extraction and co-writing the 2012 update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Peto OR was used for primary meta-analysis of ORs, as otherwise the results are largely dependent on the zero correction adopted. Single-inhaler therapy and adjustable maintenance dosing were not included in the review, nor was comparison with higher-dose ICS. This was done because we decided to restrict our attention to the question of regular use of formoterol, in addition to the same ICS regimen, in both active and control arms. Subgroup analysis was not attempted on the basis of asthma severity or dose of ICS.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-05-24 14:29:04 +0100" MODIFIED_BY="Christopher J Cates">
<STUDIES MODIFIED="2013-05-24 14:29:04 +0100" MODIFIED_BY="Christopher J Cates">
<INCLUDED_STUDIES MODIFIED="2013-05-24 14:29:04 +0100" MODIFIED_BY="Christopher J Cates">
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2012" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Brown 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma</TI>
<SO>http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D5896C00022</SO>
<YR>(accessed 15 October 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 09:55:07 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Brown, Randall W&lt;br&gt;O'Brien, Christopher D&lt;br&gt;Martin, Ubaldo J&lt;br&gt;Uryniak, Tom&lt;br&gt;Lampl, Kathy L&lt;br&gt;J Allergy Clin Immunol. 2012 Aug;130(2):362-7.e9. Epub 2012 Apr 25.&lt;/p&gt;" NOTES_MODIFIED="2013-01-22 09:55:07 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown RW, O'Brien CD, Martin UJ, Uryniak T, Lampl KL</AU>
<TI>Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2012</YR>
<VL>130</VL>
<NO>2</NO>
<PG>362-7 e9</PG>
<EN>2012/05/01</EN>
<MD>Research Support, Non-U.S. Gov't</MD>
<IDENTIFIERS MODIFIED="2012-10-15 14:44:11 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER MODIFIED="2012-10-15 14:44:11 +0100" MODIFIED_BY="Christopher J Cates" OTHERTYPE="1097-6825" TYPE="OTHER" VALUE="(Electronic)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;3/11&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Brown RW, Uryniak T, Lampl KL</AU>
<TI>Long-term safety of budesonide/formoterol pressurized metered-dose inhaler (PMDI) and budesonide PMDI In African-American patients with asthma: asthma exacerbations and adverse events [Abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<NO>Meeting Abstracts</NO>
<PG>A1294</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buhl-2003" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Buhl 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>Symbicort high dose once daily in mild to moderate asthmatic patients (SD-039-0666)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0666.pdf (accessed 26 November 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-17 09:17:16 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Buhl, R" NOTES_MODIFIED="2008-11-17 09:17:16 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T</AU>
<TI>Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>4</NO>
<PG>323-30</PG>
<EN>2003/04/16</EN>
<IDENTIFIERS MODIFIED="2008-11-11 13:13:33 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="0954-6111" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-26 15:23:05 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buhl R, Creemers JPHM, Vondra V, Martelli NA</AU>
<TI>Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler in mild-to-moderate persistent asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>21s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-26 15:23:05 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buhl R, Creemers JPHM, Vondra V, Martelli NA</AU>
<TI>Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate-persistent asthma</TI>
<SO>Thorax</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>Suppl 3</NO>
<PG>iii62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buhl R, Creemers JPHM, Vondra V, Martelli NA</AU>
<TI>Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>21s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Buhl R, Creemers JPHM, Vondra V, Martelli NA</AU>
<TI>Symbicort budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma</TI>
<SO>Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA</SO>
<YR>2001</YR>
<PG>D31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chuchalin-2002" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Chuchalin 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-26 15:23:27 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chuchalin A G, Svensson K, Stahl E, Ovcharenko S I, Goriachkina L A, Sidorenko I V et al</AU>
<TI>A health-related quality-of-life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia</TI>
<SO>Respiration</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>5</NO>
<PG>427-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 09:56:21 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chuchalin A, Stahl E, Svensson K, Ovcharenko S, Goriachkina L, Sidorenko I et al</AU>
<TI>Formoterol (oxis(r)) turbuhaler(r) plus budesonide turbuhaler(r) and budesonide alone improve health-related quality of life vs non-steroid therapy in mild to moderate asthma in Russia [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>5 Suppl</NO>
<PG>A506</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Chuchalin AG, Ovcharenko SI, Goriachkina LA, Sidorenko IV, Tsoi AN, Epoch Study G</AU>
<TI>The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>1</NO>
<PG>15-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chuchalin AG, Ovcharenko SI, Goriachkina LA, Sidorenko IV, Tsoi AN</AU>
<TI>Formoterol Oxis Turbuhaler plus budesonide turbuhaler is more effective than current non-steroid therapy and budesonide alone in mild to moderate asthma in Russia</TI>
<SO>Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA.</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corren-2007" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Corren 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>SD-039-0716. A twelve-week, randomized, double-blind, double-dummy, placebo-controlled trial of SYMBICORT pMDI (80/4.5 &#956;g) versus its monoproducts (budesonide andformoterol) in children (&#8805;6 years of age) and adults with asthma&#65293;SPRUCE 80/4.5</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0716.pdf</SO>
<YR>(accessed November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-17 09:13:54 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS</AU>
<TI>Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma</TI>
<SO>Clinical Therapeutics</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>5</NO>
<PG>823-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="Record Number: 2220" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L</AU>
<TI>Patient satisfaction with budesonide and formoterol in one pressurized metered-dose inhaler in adults with mild to moderate persistent asthma [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 18-23, 2007; San Francisco, California, USA. Poster #928.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-06 15:38:54 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Record Number: 14690" NOTES_MODIFIED="2009-01-06 15:38:54 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L</AU>
<TI>The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>3</NO>
<PG>879-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D5896C00001" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="D5896C00001" YEAR="2008">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A randomized, double-blind, active-controlled, parallel-group, single dummy, multicenter, 12 week study to assess the efficacy and safety of SYMBICORT pMDI 160/4.5 &#956;g  2 actuations once-daily (qd) compared to SYMBICORT pMDI 80/4.5 &#956;g  2 actuations qd, SYMBICORT pMDI80/4.5 &#956;g  2 actuations twice-daily (bid) and to budesonide pMDI 160 &#956;g  2 actuations qd in asthmatic subjects 12 years of age and older.</TI>
<TO>D5896C00001</TO>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/D5896C00001.pdf</SO>
<YR>(accessed 11 November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerwin EM, Oppenheimer JJ, LaForce C, Miller CJ, O'Dowd L, Goldman M</AU>
<TI>Effects on pulmonary function of once-daily (qd) budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice-daily (bid) budesonide/formoterol pMDI</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2 Suppl 1</NO>
<PG>S152-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LaForce C, Kerwin EM, Oppenheimer JJ, Miller CJ, Vervaet P, O'Dowd L et al</AU>
<TI>Safety of once-daily (qd) budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) in adults and adolescents with asthma previously stable With twice-daily (bid) budesonide/formoterol pMDI</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2 Suppl 1</NO>
<PG>S153</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oppenheimer JJ, Kerwin EM, LaForce C, Miller CJ, O'Dowd L, Goldman M</AU>
<TI>Asthma control with once-daily (qd) budesonide/formoterol pressurized metered-dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice-daily (bid) budesonide/formoterol pMDI</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2 Suppl 1</NO>
<PG>S8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenkins-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Jenkins 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>Efficacy and safety of Symbicort (budesonide/ formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis (formoterol) 36 mcg delivered dose all delivered via Turbuhaler in steroid-using asthmatic adolescents and adults: a double-blind, double-dummy, randomized, parallel group, phase III, multicentre study. (SD-039-0689)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0689.pdfs (accessed 26 November 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 09:57:55 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Record Number: 606710" NOTES_MODIFIED="2013-01-22 09:57:55 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W et al</AU>
<TI>Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma</TI>
<SO>Respirology</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>3</NO>
<PG>276-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 10:16:58 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W, et al</AU>
<SO>Symbicort turbuhaler offers an effective and well tolerated treatment for patients with moderate to severe asthma [abstract] American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle</SO>
<YR>2003</YR>
<PG>D034 Poster C37</PG>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuna-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Kuna 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>Symbicort low dose once daily in mild to moderate asthmatic patients (SD-039-0665)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0665.pdf (accessed 26 November 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 09:58:13 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuna P, Chuchalin A, Ringdal N, De la Padilla EA, Black P, Lindqvist A et al</AU>
<TI>Low-dose single-inhaler budesonide/formoterol administered once daily is effective in mild-persistent asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>158s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 09:58:26 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Record Number: 12840" NOTES_MODIFIED="2013-01-22 09:58:26 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Kuna P, Creemers J, Vondra V, Black PN, Lindqvist A, Nihlen U et al</AU>
<TI>Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>2006</YR>
<VL>100</VL>
<NO>12</NO>
<PG>2151-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2012" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Meltzer 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/10&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: [copy of abstract saved locally in M:\Electronic papers\ERS 2010 conference abstracts]&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Meltzer E, Nolte H, LaForce C</AU>
<TI>Efficacy and safety of combined mometasone furoate/formoterol 100/10?g twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids [Abstract]</TI>
<SO>European Respiratory Society Annual Congress; September 18-22, 2010; Barcelona, Spain. Poster 1203</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: C. Laforce, RaleighNCUnited States&lt;br&gt;Author, Monographic: 70254954&lt;br&gt;Author Role: English&lt;br&gt;3/10 //INHC-AST_Nov 2010// //HOM-AST//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Meltzer E, Nolte H, Laforce C</AU>
<TI>Low-dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma [Abstract]</TI>
<SO>Annals of Allergy, Asthma, and Immunology</SO>
<YR>2009</YR>
<PG>A66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 09:58:57 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Meltzer, E O&lt;br&gt;Kuna, P&lt;br&gt;Nolte, H&lt;br&gt;Nayak, A S&lt;br&gt;Laforce, C&lt;br&gt;P04073 Study Investigators&lt;br&gt;Switzerland&lt;br&gt;Eur Respir J. 2012 Feb;39(2):279-89. Epub 2011 Aug 4.&lt;/p&gt;" NOTES_MODIFIED="2013-01-22 09:58:57 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C</AU>
<TI>Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function</TI>
<SO>European Respiratory Journal</SO>
<YR>2012</YR>
<VL>39</VL>
<NO>2</NO>
<PG>279-89</PG>
<EN>2011/08/11</EN>
<MD>Multicenter Study</MD>
<IDENTIFIERS MODIFIED="2012-10-15 15:14:32 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="1399-3003" TYPE="OTHER" VALUE="(Electronic)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;2/10 //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Meltzer EO, Nolte H, LaForce C</AU>
<TI>Treatment of moderate asthma with mometasone furoate and formoterol (MF/F) 100/10 1/4g twice-daily administered via a pressurized metered-dose inhaler: efficacy and safety characteristics in subjects 12 years of age and older [Abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<NO>Meeting Abstracts</NO>
<PG>A5661</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morice-2007" MODIFIED="2013-05-23 10:47:43 +0100" MODIFIED_BY="Christopher J Cates" NAME="Morice 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-05-23 10:47:43 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 160/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 200 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 160/4.5 mcg 2 inhalations b.i.d., delivered dose) in adolescents and adults with asthma.</TI>
<SO>http://www.astrazenecaclinicaltrials.com/search/?itemId=8574676</SO>
<YR>(accessed 26 November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-12 10:42:57 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Morice AH, Hochmuth L, Puterman A, Artheden L, Beckman O</AU>
<TI>Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>2 Suppl</NO>
<PG>S3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-17 09:17:50 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Morice, A H" NOTES_MODIFIED="2008-11-17 09:17:50 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Morice AH, Peterson S, Beckman O, Osmanliev D</AU>
<TI>Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2007</YR>
<VL>61</VL>
<NO>11</NO>
<PG>1874-83</PG>
<EN>2007/09/25</EN>
<IDENTIFIERS MODIFIED="2008-11-12 10:42:47 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="1368-5031" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morice-2008" MODIFIED="2008-11-26 15:24:51 +0000" MODIFIED_BY="Christopher J Cates" NAME="Morice 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-11-26 15:24:51 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A 12-week randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 80/4.5 g 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 100 g 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 80/4.5 g 2 actuations b.i.d., delivered dose) in children with asthma (SD-039-0682)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0682.pdf (accessed 26 November 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-17 09:18:16 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Morice, Alyn H" NOTES_MODIFIED="2008-11-17 09:18:16 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Morice AH, Peterson S, Beckman O, Kukova Z</AU>
<TI>Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study</TI>
<SO>Pulmonary Pharmacology and Therapeutics</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>1</NO>
<PG>152-9</PG>
<EN>2007/03/23</EN>
<IDENTIFIERS MODIFIED="2008-11-14 10:11:29 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="1094-5539" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nathan-2010" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Nathan 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<TI>Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00383240</SO>
<YR>(accessed 15 October 15 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>FDA</AU>
<TI>Clinical review of Dulera (NDA 22-518)</TI>
<SO>http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224593.pdf</SO>
<YR>(accessed 3 October 2012)</YR>
<PG>1-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-15 16:35:05 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;2/10 //CCC-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 16:35:05 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Nathan R, Pearlman D, Nayak A, Nolte H</AU>
<TI>Safety and tolerability of medium-dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium-dose inhaled corticosteroids (alone or with long-acting beta2-agonist)</TI>
<SO>Chest</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>4</NO>
<PG>8S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;3/10 //CCC-AST_Aug 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Nathan R, Pearlman D, Nolte H, Nayak A</AU>
<TI>Efficacy and safety of combined medium-dose mometasone furoate/formoterol (MF/F) in persistent asthmatics [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2010</YR>
<VL>125</VL>
<NO>2 Suppl 1</NO>
<PG>AB195</PG>
<IDENTIFIERS MODIFIED="2012-10-15 16:35:00 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER TYPE="OTHER" VALUE="0091-6749"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-15 16:35:26 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/10&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: [copy of abstract saved locally in M:\Electronic papers\ERS 2010 conference abstracts]&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 16:35:26 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Nathan R, Pearlman D, Nolte H, Nayak A</AU>
<TI>Efficacy and safety of combined mometasone furoate/formoterol 200/10mcg in persistent asthmatics [Abstract]</TI>
<SO>European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22</SO>
<YR>2010</YR>
<PG>[E5489]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: R. Nathan, Colorado SpringsCOUnited States&lt;br&gt;Author, Monographic: 70254923&lt;br&gt;Author Role: English&lt;br&gt;3/10 //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Nathan R, Pearlman D, Nolte H, Nayak A</AU>
<TI>Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium-dose inhaled corticosteroids (alone or with a long-acting beta2-agonist) [Abstract]</TI>
<SO>Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009; Miami, FL, USA</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-15 16:41:05 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: R. A. Nathan, Asthma and Allergy Associates and Research Center, 2709 North Tejon Street, Colorado Springs, CO 80907, United States. E-mail: drrnathan@aol.com&lt;br&gt;Author, Monographic: 2010482202&lt;br&gt;Author Role: English&lt;br&gt;3/10 //CCP-AST// //INHC-AST_Nov 2010// //PTR-AST_2011 update//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Article&lt;br&gt;Call Number: NCT00383240/ClinicalTrials.gov&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 16:41:05 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Nathan RA, Nolte H, Pearlman DS</AU>
<TI>Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 mug combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids</TI>
<SO>Allergy and Asthma Proceedings</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>4</NO>
<PG>269-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;2/10 //CCC-AST_Aug 2010// //INHC-AST_Nov 2010// //HOM-AST//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Nathan RA, Pearlman D, Nolte H, Nayak A</AU>
<TI>Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice-daily administered via a pressurized metered-dose inhaler in subjects 12 years of age and older with moderate-to-severe asthma [Abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<NO>Meeting Abstracts</NO>
<PG>A5412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-15 16:35:05 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: R.A. Nathan, Colorado SpringsCOUnited States&lt;br&gt;Author, Monographic: 70452847&lt;br&gt;Author Role: English&lt;br&gt;3/11&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract [2010 Annual Meeting of the American College of Allergy, Asthma and Immunology Phoenix, Arizona United States]&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 16:35:05 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Nathan RA, Weinstein SF, Nolte H</AU>
<TI>Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metered-dose inhaler [Abstract]</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>5 Suppl</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noonan-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Noonan 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A twelve-week, randomized, double-blind, double-dummy, placebo-controlled trial of SYMBICORT (160/4.5 mcg) versus its mono-products (budesonide and formoterol) in adolescents (&gt; 12 years of age) and adults with asthma, international (SD-039-0717)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0717.pdf (accessed 26 November 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-26 15:25:04 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker J, Martin P, Parasuraman B</AU>
<TI>Patient satisfaction with budesonide and formoterol in one pressurized metered-dose inhaler in patients with asthma</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>4</NO>
<PG>509b-510</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L</AU>
<TI>Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial</TI>
<SO>Drugs</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>17</NO>
<PG>2235-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/08 //SING-AST// //CCC-AST// //LAB1-AST// //LAB2-AST// //LAB3-AST// //DAY-AST// //ILA-AST// //REG-AST// //INCS-AST// //SPAR-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Noonan MJ, Eid NS, Uryniak T, O'Brien CD</AU>
<TI>Safety of once daily (qd) budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children and adolescents with asthma previously stable on twice daily (bid) BUD/FM pMDI [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 16-21, 2008; Toronto, Ontario, Canada. Abstract 711 [#K71].</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 10:26:19 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/08 //CIBA-AST// //SING-AST// //CCC-AST// //LAB1-AST// //LAB2-AST// //LAB3-AST// //CER-AST// //STER-ST// //DAY-AST// //ILA-AST// //REG-AST// //SPAR-AST// //CER-AST// //STER-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 10:26:19 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Rosenwasser LJ, Noonan MJ, Martin P, O'Dowd L, O'Brien CD</AU>
<TI>Safety of budesonide and formoterol administered via one pressurized metered dose inhaler (budesonide/formoterol pMDI) in patients (&gt;12 years) with moderate to severe persistent asthma [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>1 Suppl</NO>
<PG>S5 [17]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Byrne-2001" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="O'Byrne 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes PJ, O'Byrne PM, Rodriguez Roisin R, Runnerstrom E, Sandstrom T, Svensson K et al</AU>
<TI>Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol</TI>
<SO>Thorax</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>Suppl 3</NO>
<PG>A4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grosser D, Smith B</AU>
<TI>Low-dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid-treated patients</TI>
<SO>ACP Journal Club.</SO>
<YR>2002</YR>
<VL>137</VL>
<NO>1</NO>
<PG>19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jnsson BG, Berggren FE, Svensson K, O'Byrne PM</AU>
<TI>Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide&#65293;a cost-effectiveness analysis</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>517s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-26 15:25:31 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jnsson BG, Berggren FE, Svensson K, O'Byrne PM</AU>
<TI>Economic results of adding formoterol to budesonide in mild persistent asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>331s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-26 15:25:31 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonsson B, Berggren F, Svensson K, O'Byrne PM</AU>
<TI>An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>11</NO>
<PG>1146-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom EVA, Sandstrom T, Svensson K et al</AU>
<TI>Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>164</VL>
<NO>8</NO>
<PG>1392-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-26 15:25:31 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Sandtrm T, Tattersfield AE, Runnerstrm EM et al</AU>
<TI>Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Supp 33</NO>
<PG>330s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Byrne-2001a" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="O'Byrne 2001a" YEAR="2001">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom EVA, Sandstrom T, Svensson K, et al</AU>
<TI>Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>164</VL>
<NO>8</NO>
<PG>1392-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauwels-1997" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Pauwels 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-01-22 10:02:12 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Lofdahl CGA et al</AU>
<TI>Asthma quality of life during 1 year of treatment with budesonide with or without formoterol</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>5</NO>
<PG>1038-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pauwels R</AU>
<TI>Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]</TI>
<SO>Allergy</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>42 Suppl</NO>
<PG>20-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-17 09:19:43 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Pauwels, R A" NOTES_MODIFIED="2008-11-17 09:19:43 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al</AU>
<TI>Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>20</NO>
<PG>1405-11</PG>
<EN>1997/11/14</EN>
<IDENTIFIERS MODIFIED="2008-11-12 14:54:53 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="0028-4793" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-27 14:09:35 +0000" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, et al</AU>
<TI>Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<NO>2</NO>
<PG>594-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauwels-1997a" MODIFIED="2013-01-22 10:03:27 +0000" MODIFIED_BY="Christopher J Cates" NAME="Pauwels 1997a" YEAR="1997">
<REFERENCE MODIFIED="2013-01-22 10:03:27 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ et al</AU>
<TI>Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group</TI>
<TO>New England Journal of Medicine</TO>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>20</NO>
<PG>1405-11</PG>
<EN>1997/11/14</EN>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="0028-4793" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Peters-2008" MODIFIED="2013-05-24 14:29:04 +0100" MODIFIED_BY="Christopher J Cates" NAME="Peters 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A 52-week, randomized, double-blind, single-dummy, parallel-group, multicenter Phase III study comparing the long-term safety of SYMBICORT pMDI 160/4.5 mcg  4 actuations twice daily to SYMBICORT pMDI 160/4.5 mcg  2 actuations twice daily and budesonide HFA pMDI 160 mcg  4 actuations twice daily in adult and adolescent subjects with asthma (SD-039-0728)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD_039_0728.pdf (accessed 26 November 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;3/08 //LAB4-AST// //INHC-AST// //CIBA-AST// //SING-AST// //CCC-AST// //LAB1-AST// //LAB2-AST// //LAB3-AST// //CER-AST// //STER-ST// //DAY-AST// //ILA-AST// //REG-AST// //SPAR-AST// //CER-AST// //STER-AST// //CCC-AST_Aug 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Lawrance R, Ambrose H, Goldman M</AU>
<TI>Effect of gly16arg beta2-adrenergic receptor variation on the long-term safety of formoterol (FM) in combination with budesonide (BUD) and of BUD alone, delivered via one pressurized metered-dose inhaler (pMDI) in patients with moderate to severe asthma [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #420.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>O'Brien CD, Peters SP, Prenner BM, Martin P</AU>
<TI>Long-term safety of budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI) in asthma patients: adverse events and asthma exacerbations [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #L57.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>O'Brien CD, Peters SP, Prenner BM, Martin P</AU>
<TI>Resource use with budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI) versus BUD pMDI in asthma patients [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #L58.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Peters SP, Prenner BM, Martin P, O'Brien CD</AU>
<TI>Long-term effects on lung function of budesonide (BUD) and formoterol (FM) in one pressurized metered-dose inhaler (BUD/FM pMDI) and BUD pMDI in patients with asthma [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #K5.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-17 09:20:05 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peters SP, Prenner BM, Mezzanotte WS, Martin P, O'Brien CD</AU>
<TI>Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurised metered-dose inhaler in asthma</TI>
<SO>Alllergy and Asthma Proceedings</SO>
<YR>2008</YR>
<VL>29</VL>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-24 14:29:04 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Prenner BM, Peters SP, Martin P, O'Brien CD</AU>
<TI>Long-term control of asthma symptoms with budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI) versus BUD pMDI [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #L67</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Prenner BM, Peters SP, Martin P, O'Brien CD</AU>
<TI>Safety pharmacodynamics (PD) of budesonide/formoterol (BUD/FM) pMDI in asthma patients [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #L66</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pohunek-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Pohunek 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>Efficacy and safety of Symbicort (budesonide/formoterol 80/4.5 g, 2 inhalations b.i.d.) compared to Pulmicort (budesonide 100 mcg, 2 inhalations b.i.d.) and Pulmicort (budesonide 100 g, 2 inhalations b.i.d.) plus Oxis (formoterol 4.5 g, 2 inhalations b.i.d.) all delivered via Turbuhaler in steroid using asthmatic children: a double-blind, double-dummy, randomised, parallel-group, phase III, multicentre 12-week study (SD-039-0688)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0688.pdf (accessed 26 November 2008).</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-26 15:26:30 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pohunek P, Kuna P, De Boeck K</AU>
<TI>Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>Suppl 48</NO>
<PG>379s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 10:06:21 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Record Number: 13390" NOTES_MODIFIED="2013-01-22 10:06:21 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Pohunek P, Kuna P, Jorup C, De Boeck K</AU>
<TI>Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma</TI>
<SO>Pediatric Allergy &amp; Immunology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>6</NO>
<PG>458-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 10:05:59 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T</AU>
<TI>Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma</TI>
<SO>Pediatric Allergy &amp; Immunology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>1</NO>
<PG>32-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-2002" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Price 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-17 09:20:19 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Price, D" NOTES_MODIFIED="2008-11-17 09:20:19 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Price D, Dutchman D, Mawson A, Bodalia B, Duggan S, Todd P</AU>
<TI>Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>9</NO>
<PG>791-8</PG>
<EN>2002/08/30</EN>
<IDENTIFIERS MODIFIED="2008-11-14 11:45:53 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="0040-6376" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-26 15:26:40 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price MJ, Briggs AH</AU>
<TI>Development of an economic model to assess the cost effectiveness of asthma management strategies</TI>
<SO>Pharmacoeconomics.</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>3</NO>
<PG>183-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Price MJ, Sondhi S, Yan S, Nyth A, House K</AU>
<TI>Salmeterol/fluticasone propionate combination inhaler is more cost effective than fluticasone propionate in patients with asthma</TI>
<SO>European Respiratory Society; Oct 9-13, 1999; Madrid, Spain. Poster #2459.</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SD_x002d_039_x002d_0714" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="SD-039-0714" YEAR="2003">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>Efficacy and safety of budesonide/formoterol Turbuhaler (160/4.5 mg b.i.d.delivered dose) compared to budesonide Turbuhaler (200 mg b.i.d. metered dose) in steroid-using asthmatic adolescent patients: a double-blind, double dummy,randomised, parallel group, phase III, multicentre study. (ATTAINSTUDY)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0714.pdf</SO>
<YR>(accessed 14 November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SD_x002d_039_x002d_0718" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="SD-039-0718" YEAR="2004">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A twelve-week, randomized, double-blind, double-dummy trial of Symbicort (40/4.5 mcg) versus its mono-products (budesonide and formoterol) in asthmatic children aged six to fifteen years</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0718.pdf</SO>
<YR>(accessed 14 November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/08 //SING-AST// //CCC-AST// //LAB1-AST// //LAB2-AST// //LAB3-AST// //DAY-AST// //ILA-AST// //REG-AST// //SPAR-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Pearlman DS, Murphy KR, Uryniak T, O'Brien CD, Mezzanotte WS, Denver M</AU>
<TI>Safety of budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children with asthma previously treated with inhaled corticosteroids (ICSs) [Abstract]</TI>
<SO>American Thoracic Society International Conference; May 16-21, 2008; Toronto, Ontario, Canada. Abstract #A710 (#K67).</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SD_x002d_039_x002d_0719" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="SD-039-0719" YEAR="2005">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A six-month, randomized, open-label safety study of SYMBICORT (160/4.5 &#956;g) compared to PULMICORT Turbuhaler in asthmatic children aged 6 to 11 years</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0719.pdf</SO>
<YR>(accessed 14 November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: W. E. Berger, Allergy and Asthma Associates, 27800 Medical Center Road, Mission Viejo, CA 92691, United States. E-mail: weberger@uci.edu&lt;br&gt;Author, Monographic: 2010095923&lt;br&gt;Author Role: English&lt;br&gt;1/10 //ADJ-AST// //VIRL-AST// //CCC-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010// //VIRL-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Article&lt;br&gt;Call Number: NCT00652392/ClinicalTrials.gov&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Berger WE, Bleecker ER, O'Dowd L, Miller CJ, Mezzanotte W</AU>
<TI>Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once- and twice-daily dosing in patients with asthma</TI>
<SO>Allergy and Asthma Proceedings</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>1</NO>
<PG>49-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 10:07:09 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: W. E. Berger, Allergy and Asthma Associates of Southern California, 27800 Medical Center Road, Number 244, Mission Viejo, CA 29691-6410, United States. E-mail: Weberger@uci.edu&lt;br&gt;Author, Monographic: 2010095921&lt;br&gt;Author Role: English&lt;br&gt;1/10 //CCC-AST// //CCC-AST_Aug 2010// //PAR-AST// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Article&lt;br&gt;Call Number: NCT00646529/ClinicalTrials.gov&lt;/p&gt;" NOTES_MODIFIED="2013-01-22 10:07:09 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Berger WE, Leflein JG, Geller DE, Parasuraman B, Miller CJ, O'Brien CD et al</AU>
<TI>The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children</TI>
<SO>Allergy and Asthma Proceedings</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>1</NO>
<PG>26-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berger WE, Leflein JG, Uryniak T, O'Brien CD, O'Dowd L</AU>
<TI>Long-term efficacy and resource utilization after treatment with budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2 Suppl 1</NO>
<PG>S8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leflein JG, Berger WE, Uryniak T, Vervaet P, O'Dowd L, O'Brien CD</AU>
<TI>Long-term safety and systemic effects of budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) in children with asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2 Suppl 1</NO>
<PG>S155</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Dowd L, Berger WE, Leflein JG, Uryniak T, Parasuraman B, O'Brien CD</AU>
<TI>Health-related quality of life (HRQL) and asthma control after long-term treatment with budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2 Suppl 1</NO>
<PG>S152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SD_x002d_039_x002d_0725" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="SD-039-0725" YEAR="2005">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A twelve-week, randomized, double-blind, double-dummy, active-controlled study of SYMBICORT pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD_039_0725.pdf</SO>
<YR>(accessed 18 November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-30 13:28:09 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: N. S. Eid, Pediatric Pulmonary Medicine, Childhood Asthma Care and Education Center, Cystic Fibrosis Center, 571 S Floyd St, Louisville, KY 40202, United States. E-mail: nseid@louisville.edu&lt;br&gt;Author, Monographic: 2010480687&lt;br&gt;Author Role: English&lt;br&gt;3/10 //NED-AST_Oct 2010// //CCP-AST// //INHC-AST_Nov 2010// //VIRL-AST_Nov 2010// //HOM-AST// //SCH-AST// //PTR-AST_2011 update// //EDER-AST// //OXY-AST_June 2011//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Article&lt;br&gt;Call Number: NCT00646321/ClinicalTrials.gov&lt;/p&gt;" NOTES_MODIFIED="2012-10-30 13:28:09 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Eid NS, Noonan MJ, Chipps B, Parasuraman B, Miller CJ, O'Brien CD</AU>
<TI>Once- vs twice-daily budesonide/formoterol in 6- to 15-year-old patients with stable asthma</TI>
<SO>Pediatrics</SO>
<YR>2010</YR>
<VL>126</VL>
<NO>3</NO>
<PG>e565-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SD_x002d_039_x002d_0726" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" NAME="SD-039-0726" YEAR="2005">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A twelve-week, randomized, double-blind, double-dummy, placebo- and active-controlled study of SYMBICORT pMDI administered once daily in adults and adolescents with asthma</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0726.pdf</SO>
<YR>(accessed 14 November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spector-2012" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Spector 2012" YEAR="2010">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A 12-week, randomized, double-blind, double-dummy, multi-center,phase IV study comparing the efficacy and safety of SYMBICORT pMDI160/4.5 &#956;g  2 actuations twice daily versus budesonide inhalation powderDPI 180 &#956;g  2 inhalations twice daily, in adult and adolescent (&#8805;12 years) African American subjects with asthma</TI>
<SO>http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D589BL00003</SO>
<YR>(accessed 19 October 2012)</YR>
<IDENTIFIERS MODIFIED="2012-10-19 15:09:43 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER MODIFIED="2012-10-19 15:09:43 +0100" MODIFIED_BY="Christopher J Cates" TYPE="OTHER" VALUE="D589BL00003"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-03 16:59:07 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;1/11&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2012-10-03 16:59:07 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Spector SL, CD OB, Uryniak T, Martin UJ</AU>
<TI>Safety and tolerability of a budesonide/formoterol (BUD/FM) pressurized metered-dose inhaler (pMDI) in black adolescents and adults with moderate to severe persistent asthma [Abstract]</TI>
<SO>Chest</SO>
<YR>2010</YR>
<VL>138</VL>
<NO>4</NO>
<PG>705A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-04 16:44:13 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Spector, Sheldon L&lt;br&gt;Martin, Ubaldo J&lt;br&gt;Uryniak, Tom&lt;br&gt;O'Brien, Christopher D&lt;br&gt;England&lt;br&gt;J Asthma. 2012 Feb;49(1):70-7. Epub 2011 Dec 1.&lt;/p&gt;" NOTES_MODIFIED="2012-10-04 16:44:13 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Spector SL, Martin UJ, Uryniak T, O'Brien CD</AU>
<TI>Budesonide/formoterol pressurized metered-dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma</TI>
<SO>J Asthma</SO>
<YR>2012</YR>
<VL>49</VL>
<NO>1</NO>
<PG>70-7</PG>
<EN>2011/12/03</EN>
<MD>Clinical Trial, Phase IV</MD>
<IDENTIFIERS MODIFIED="2012-10-04 16:43:39 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="1532-4303" TYPE="OTHER" VALUE="(Electronic)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-19 15:06:35 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: S.L. Spector, Los AngelesCAUnited States&lt;br&gt;Author, Monographic: 70452838&lt;br&gt;Author Role: English&lt;br&gt;3/11&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract [2010 Annual Meeting of the American College of Allergy, Asthma and Immunology Phoenix, Arizona United States]&lt;/p&gt;" NOTES_MODIFIED="2012-10-19 15:06:35 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Spector SL, Martin UJ, Uryniak T, O'Brien CD</AU>
<TI>Effect of budesonide/formoterol pressurized metered-dose inhaler versus budesonide dry powder inhaler on asthma control in black adolescents and adults with moderate to severe persistent asthma [Abstract]</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>5 Suppl</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tal-2002" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Tal 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-26 15:27:15 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>Efficacy and safety of budesonide/formoterol Turbuhaler in a fixed combination in steroid-using asthmatic children - COMIC (SD-039-0353)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0353.pdf (accessed 26 November 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 10:07:58 +0000" MODIFIED_BY="Christopher J Cates" NOTES="Record Number: 570" NOTES_MODIFIED="2013-01-22 10:07:58 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML et al</AU>
<TI>Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>5</NO>
<PG>342-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 10:08:13 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML et al</AU>
<TI>Rapid and sustained improvements in lung function and symptom control with budesonide/ formoterol in adolescent asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>494s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML et al</AU>
<TI>Symbicort budesonide and formoterol in a single inhaler is more effective that budesonide alone in children with asthma</TI>
<SO>International Paediatric Respiratory and Allergy Congress; April 1-4, 2001; Prague. Poster 84-5.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tal A, Simon G, Vermeulen JH, Vit P, Cobos N, Everard ML et al</AU>
<TI>The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>384s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Tal A, Simon G, Vermeulen JH</AU>
<TI>Symbicort Budesonide and formoterol in a single inhaler is effective and well tolerated in children with asthma</TI>
<SO>Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA, USA. Poster D29.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Vermeulen JH, Simon G, Tal A</AU>
<TI>Symbicort Budesonide and formoterol in a single inhaler improves lung function in asthmatic children aged 4-17 years</TI>
<SO>Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA, USA. Poster D29.</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinstein-2010" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Weinstein 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Schering-Plough</AU>
<TI>Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04431AM2) (COMPLETED)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00381485</SO>
<YR>(accessed 19 October 2012)</YR>
<IDENTIFIERS MODIFIED="2012-10-19 15:46:26 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER MODIFIED="2012-10-19 15:46:26 +0100" MODIFIED_BY="Christopher J Cates" TYPE="OTHER" VALUE="NCT00381485"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;3/10 //CCC-AST_Aug 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Weinstein S, Murphy K, Corren J, Nolte H, White M</AU>
<TI>Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2010</YR>
<VL>125</VL>
<NO>2 Suppl 1</NO>
<PG>AB196</PG>
<IDENTIFIERS MODIFIED="2012-10-19 15:42:09 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER TYPE="OTHER" VALUE="0091-6749"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/10&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: [copy of abstract saved locally in M:\Electronic papers\ERS 2010 conference abstracts]&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Weinstein S, Murphy K, Corren J, Nolte H, White M</AU>
<TI>Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma</TI>
<SO>European Respiratory Society Annual Congress; September 18-22, 2010; Barcelona, Spain. Poster E5482.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: K. Murphy, OmahaNEUnited States&lt;br&gt;Author, Monographic: 70254950&lt;br&gt;Author Role: English&lt;br&gt;3/10 //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Weinstein S, Murphy K, White M, Nolte H, Corren J</AU>
<TI>The safety and tolerability of high and medium doses of mometasone furoate/formoterol combination treatment in subjects with severe persistent asthma [Abstract]</TI>
<SO>Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009; Miami, FL, USA</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;2/10 //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Weinstein S, Murphy K, White M, Nolte H, Corren J</AU>
<TI>Treatment of severe asthma with a new mometasone furoate and formoterol (MF/F) combination administered with a pressurized metered-dose inhaler device</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>181</VL>
<NO>Meeting Abstracts</NO>
<PG>A5411</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;2/10 //CCC-AST// //CCC-AST_Aug 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Weinstein S, White M, Corren J, Nolte H</AU>
<TI>Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients [Abstract]</TI>
<SO>European Respiratory Society Annual Congress; September 12-16, 2009; Vienna, Austria. Poster E280</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-19 15:39:43 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: S. F. Weinstein, Allergy and Asthma Specialists Medical Group, 17742 Beach Boulevard, Huntington Beach, CA 92647, United States. E-mail: sfw@ocallergy.com&lt;br&gt;Author, Monographic: 2010482203&lt;br&gt;Author Role: English&lt;br&gt;3/10 //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Article&lt;/p&gt;" NOTES_MODIFIED="2012-10-19 15:39:43 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Weinstein SF, Corren J, Murphy K, Nolte H, White M</AU>
<TI>Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 mug and 400/10 mug combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids</TI>
<SO>Allergy and Asthma Proceedings</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>4</NO>
<PG>280-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/09 //HVL-AST// //SPAR-AST// //CIBA-AST// //CCC-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Weinstein SF, White M, Corren J, Nolte H</AU>
<TI>Safety and tolerability of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment administered via a metered-dose inhaler (MDI), in severe asthma patients previously treated with high-dose inhaled corticosteroids (ICS)</TI>
<SO>American Thoracic Society International Conference; May 15-20, 2009; San Diego, CA, USA. Poster #J53.</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zangrilli-2011" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Zangrilli 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>An efficacy study comparing SYMBICORT pressurised metered dose inhaler (pMDI) with budesonide jydrofluoroalkanes (HFA) pMDI, in Hispanic subjects with ICS dependent asthma</TI>
<SO>http://clinicaltrials.gov/ct2/show/study/NCT00419757?sect=X3015</SO>
<YR>(accessed 22 October 2012)</YR>
<IDENTIFIERS MODIFIED="2012-10-22 11:12:22 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER MODIFIED="2012-10-22 11:12:19 +0100" MODIFIED_BY="Christopher J Cates" TYPE="OTHER" VALUE="NCT00419757"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: J. Zangrilli, AstraZeneca LP, 1800 Concord Pike, Wilmington, DE 19803, United States. E-mail: James.Zangrilli@astrazeneca.com&lt;br&gt;Author Role: English&lt;br&gt;Size: AST//&lt;br&gt;3/11 //STER-AST_Nov 2011// //CER-AST_Nov 2011// //VIRL-AST_Nov 2011//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Article&lt;br&gt;Call Number: NCT00419757&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Zangrilli J, Mansfield LE, Uryniak T, O'Brien CD</AU>
<TI>Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial</TI>
<SO>Annals of Allergy, Asthma, and Immunology</SO>
<YR>2011</YR>
<VL>107</VL>
<PG>258-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zetterstrom-2001" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Zetterstrom 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-11-26 15:27:31 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler in inhaled steroid-using asthmatic adults. (SD-039-0349)</TI>
<SO>http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0349.pdf (accessed 26 November 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buhl R, Zetterstrom O, Mellem H, Perpina M, Hedman J, O'Neill S et al</AU>
<TI>Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>48s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zetterstrm O, Buhl R, Mellem H, Perpi M, Hedman J, O'Neill S et al</AU>
<TI>Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>455s. Abstract P3198</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zetterstrm O, Buhl R, Mellem H, Perpi M, Hedman J, O'Neill S et al</AU>
<TI>The new single inhaler product containing both budesonide/formoterol improves asthma control in adults</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Supp 31</NO>
<PG>455s. Abstract P3199</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="Record Number: 2050" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="YES" TYPE="OTHER">
<AU>Zetterstrom O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S et al</AU>
<TI>Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>2</NO>
<PG>262-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zetterstrom O, Buhl R, Mellem H</AU>
<TI>Efficacy and safety of Symbicort budesonide and formoterol in a single inhaler in adults with asthma</TI>
<SO>Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-05-24 14:17:17 +0100" MODIFIED_BY="Christopher J Cates">
<STUDY DATA_SOURCE="PUB" ID="STD-Ankerst-2003" MODIFIED="2008-11-26 14:26:07 +0000" MODIFIED_BY="Christopher J Cates" NAME="Ankerst 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-26 14:26:07 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Ankerst J, Persson G, Weibull E</AU>
<TI>Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma</TI>
<SO>Pulmonary Pharmacology &amp; Therapeutics</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>3</NO>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2005" MODIFIED="2008-11-26 14:26:45 +0000" MODIFIED_BY="Christopher J Cates" NAME="AstraZeneca 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-26 14:26:45 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>Efficacy &amp; safety of Symbicort Turbuhaler 160/4.5 g twice daily &amp; Pulmicort Turbuhaler 200 g twice daily + Theolong tablet 200 mg twice daily in Japanese asthmatic patients</TI>
<SO>clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2005a" MODIFIED="2008-11-26 14:26:12 +0000" MODIFIED_BY="Christopher J Cates" NAME="AstraZeneca 2005a" YEAR="2005">
<REFERENCE MODIFIED="2008-11-26 14:26:12 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>SHARE - symbicort and health economics in a real life evaluation</TI>
<SO>clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2005b" MODIFIED="2008-11-26 14:26:15 +0000" MODIFIED_BY="Christopher J Cates" NAME="AstraZeneca 2005b" YEAR="2005">
<REFERENCE MODIFIED="2008-11-26 14:26:15 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>SOLO-symbicort in the treatment of persistent asthma in adolescents &amp; adults</TI>
<SO>clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2005c" MODIFIED="2008-11-26 14:26:19 +0000" MODIFIED_BY="Christopher J Cates" NAME="AstraZeneca 2005c" YEAR="2005">
<REFERENCE MODIFIED="2008-11-26 14:26:19 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>STYLE - symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma</TI>
<SO>clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2005d" MODIFIED="2008-11-26 14:26:22 +0000" MODIFIED_BY="Christopher J Cates" NAME="AstraZeneca 2005d" YEAR="2005">
<REFERENCE MODIFIED="2008-11-26 14:26:22 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>SYMPHONIE -a comparison of symbicort single inhaler and conventional best practice for the treatment of persistent asthma in adolescents and adults</TI>
<SO>clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2006" MODIFIED="2008-11-26 14:26:49 +0000" MODIFIED_BY="Christopher J Cates" NAME="AstraZeneca 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-26 14:26:49 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A comparison of the control of asthma inflammation provided by Symbicort turbuhaler 160/4.5 mcg/inhalation bid plus as-needed versus symbicort turbuhaler 320/9 ug/inhalation bid plus pulmicort turbuhaler 400mcg/dose bid plus terbutaline turbuhaler 0.4mg/inhalation as-needed</TI>
<SO>clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2006a" MODIFIED="2008-11-26 14:26:26 +0000" MODIFIED_BY="Christopher J Cates" NAME="AstraZeneca 2006a" YEAR="2006">
<REFERENCE MODIFIED="2008-11-26 14:26:26 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults</TI>
<SO>clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2006b" MODIFIED="2008-11-26 14:26:29 +0000" MODIFIED_BY="Christopher J Cates" NAME="AstraZeneca 2006b" YEAR="2006">
<REFERENCE MODIFIED="2008-11-26 14:26:29 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>SALTO - symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma</TI>
<SO>clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balanag-2006" MODIFIED="2008-11-26 14:26:53 +0000" MODIFIED_BY="Christopher J Cates" NAME="Balanag 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-26 14:26:53 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Balanag VM, Yunus F, Yang PC, Jorup C</AU>
<TI>Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma</TI>
<SO>Pulmonary Pharmacology &amp; Therapeutics</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>2</NO>
<PG>139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bateman-2003" MODIFIED="2013-01-22 10:13:48 +0000" MODIFIED_BY="Christopher J Cates" NAME="Bateman 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-22 10:13:48 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Bateman ED, Bantje TA, Gomes MJ, Toumbis MG, Huber RM, Naya I et al</AU>
<TI>Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma</TI>
<SO>American Journal of Respiratory Medicine</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>3</NO>
<PG>275-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bateman-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Bateman 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Bateman ED, Fairall L, Lombardi DM, English R</AU>
<TI>Budenoside/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol</TI>
<SO>Respiratory Research</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bodzenta_x002d_Lukaszyk-2011" MODIFIED="2013-01-22 10:13:57 +0000" MODIFIED_BY="Christopher J Cates" NAME="Bodzenta-Lukaszyk 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-22 10:13:57 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: A. Bodzenta-Lukaszyk, Department of Allergology and Internal Medicine, Medical University of Bialystok, M.Sklodowskiej-Curie 24 A, 15-276 Bialystok, Poland. E-mail: abodzentalukaszyk@gmail.com&lt;br&gt;Author, Monographic: 2011165274&lt;br&gt;Author Role: English&lt;br&gt;1/11&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Article&lt;br&gt;Call Number: NCT00734318/ClinicalTrials.gov&lt;/p&gt;" NOTES_MODIFIED="2013-01-22 10:13:57 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Bodzenta-Lukaszyk A, Pulka G, Dymek A, Bumbacea D, McIver T, Schwab B et al</AU>
<TI>Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler</TI>
<SO>Respiratory Medicine</SO>
<YR>2011</YR>
<VL>105</VL>
<NO>5</NO>
<PG>674-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bouros-1999" MODIFIED="2013-01-22 10:14:14 +0000" MODIFIED_BY="Christopher J Cates" NAME="Bouros 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-01-22 10:14:14 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Bouros D, Bachlitzanakis N, Kottakis J, Pfister P, Polychronopoulos V, Papadakis E et al</AU>
<TI>Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>3</NO>
<PG>627-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buhl-2004" MODIFIED="2013-01-22 10:14:30 +0000" MODIFIED_BY="Christopher J Cates" NAME="Buhl 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-22 10:14:30 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Bruggenjurgen B, Willich SN et al</AU>
<TI>The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>8</NO>
<PG>1209-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bumbacea-2010" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Bumbacea 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: D. Bumbacea, Department of Pulmonology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania&lt;br&gt;Author, Monographic: 70325873&lt;br&gt;Author Role: English&lt;br&gt;1/11&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract [British Thoracic Society Winter Meeting 2010 London United Kingdom]&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Bumbacea D, Dymek A, Mansikka H</AU>
<TI>Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently: a randomised controlled trial [Abstract]</TI>
<SO>Thorax</SO>
<YR>2010</YR>
<VL>65</VL>
<NO>Suppl 4</NO>
<PG>P16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgess-1998" MODIFIED="2008-11-26 14:27:11 +0000" MODIFIED_BY="Christopher J Cates" NAME="Burgess 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-11-26 14:27:11 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD</AU>
<TI>The extrapulmonary effects of increasing doses of formoterol in patients with asthma</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>54</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canonica-2004" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Canonica 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Canonica GW, Castellani P, Cazzola M, Fabbri LM, Fogliani V, Mangrella M et al</AU>
<TI>Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing</TI>
<SO>Pulmonary Pharmacology &amp; Therapeutics</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>4</NO>
<PG>239-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceylan-2004" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Ceylan 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Ceylan E, Mehmet G, Sahin A</AU>
<TI>Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control</TI>
<SO>Respiration</SO>
<YR>2004</YR>
<VL>71</VL>
<NO>6</NO>
<PG>594-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dhillon-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Dhillon 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Dhillon S, Keating GM</AU>
<TI>Beclometasone dipropionate/formoterol in an HFA-propelled pressurised metered-dose inhaler</TI>
<SO>Drugs</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>11</NO>
<PG>1475-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FitzGerald-1999" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="FitzGerald 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD et al</AU>
<TI>Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1999</YR>
<VL>103</VL>
<NO>3 I</NO>
<PG>427-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FitzGerald-2003" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="FitzGerald 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>FitzGerald JM, Sears MR, Boulet LP, Becker AB, McIvor AR, Ernst P et al</AU>
<TI>Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study</TI>
<SO>Canadian Respiratory Journal</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>8</NO>
<PG>427-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haahtela-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Haahtela 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Haahtela T, Tamminen K, Malmberg LP, Zetterstrom O, Karjalainen J, Yla-Outinen H et al</AU>
<TI>Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study</TI>
<SO>European Respiratory Journal</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>4</NO>
<PG>748-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ind-2004" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Ind 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Ind PW, Haughney J, Price D, Rosen JP, Kennelly J</AU>
<TI>Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study</TI>
<SO>Respiratory Medicine</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>5</NO>
<PG>464-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jakopovic-2009" MODIFIED="2013-01-22 10:19:29 +0000" MODIFIED_BY="Christopher J Cates" NAME="Jakopovic 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-22 10:19:29 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: University Hospital for Lung Diseases Jordanovac, Zagreb, Croatia. marko.jakopovic@klinika-jordanovac.hr&lt;br&gt;Connective Phrase: 19662783&lt;br&gt;Author Role: English&lt;br&gt;4/09 //HVL-AST// //CER-AST// //STER-AST// //CCC-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: CCT&lt;br&gt;Notes: PUBLICATION TYPE: Controlled Clinical Trial PUBLICATION TYPE: Journal Article&lt;/p&gt;" NOTES_MODIFIED="2013-01-22 10:19:29 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Jakopovic M, Pavicic F, Redzepi G, Plestina S, Jankovic M, Franic Z et al</AU>
<TI>Efficacy and safety of budesonide/formeterol combination therapy in asthma patients</TI>
<SO>Collegium Antropologicum</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>2</NO>
<PG>587-91</PG>
<IDENTIFIERS MODIFIED="2012-10-30 13:42:43 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER TYPE="OTHER" VALUE="0350-6134"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kozlik_x002d_Feldmann-1996" MODIFIED="2008-11-26 14:27:35 +0000" MODIFIED_BY="Christopher J Cates" NAME="Kozlik-Feldmann 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-26 14:27:35 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Kozlik-Feldmann R, von Berg A, Berdel D, Reinhardt D</AU>
<TI>Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma</TI>
<SO>European Journal of Medical Research</SO>
<YR>1996</YR>
<VL>1</VL>
<NO>10</NO>
<PG>465-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lalloo-2003" MODIFIED="2013-01-22 10:19:49 +0000" MODIFIED_BY="Christopher J Cates" NAME="Lalloo 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-22 10:19:49 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B et al</AU>
<TI>Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>123</VL>
<NO>5</NO>
<PG>1480-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemanske-2010" MODIFIED="2013-01-22 10:31:41 +0000" MODIFIED_BY="Christopher J Cates" NAME="Lemanske 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-22 10:31:41 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;(CARE)&lt;br&gt;Author Affiliation: University of Wisconsin School of Medicine and Public Health, Madison, USA. rfl@medicine.wisc.edu&lt;br&gt;Connective Phrase: 20197425&lt;br&gt;Author Role: English&lt;br&gt;1/10 //EDU-AST// //CCC-AST// //EDER-AST// //ALE-AST_June 2010// //CULT-AST// //EDUC-AST_july 2010// //CCC-AST_Aug 2010// //IVO-AST// //ALE-AST_Sept 2010// //HOM-AST// //SCH-AST// //ACHO-AST_June 2011// //CBB-AST_2011 update// //ALE2-AST_2011 update//&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: PUBLICATION TYPE: Journal Article PUBLICATION TYPE: Multicenter Study PUBLICATION TYPE: Randomized Controlled Trial PUBLICATION TYPE: Research Support, N.I.H., Extramural&lt;/p&gt;" NOTES_MODIFIED="2013-01-22 10:31:41 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Lemanske RF, Jr., Mauger DT, Sorkness CA, Pharm D, Jackson DJ, Boehmer SJ et al</AU>
<TI>Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>362</VL>
<NO>11</NO>
<PG>975-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leuppi-2003" MODIFIED="2013-01-22 10:32:27 +0000" MODIFIED_BY="Christopher J Cates" NAME="Leuppi 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-22 10:32:27 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Leuppi FD, Salzberg M, Meyer L, Bucher SE, Nief M, Brutsche MH et al</AU>
<TI>An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2003</YR>
<VL>133</VL>
<NO>21-22</NO>
<PG>302-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lotvall" MODIFIED="2013-02-19 15:19:14 +0000" MODIFIED_BY="Christopher J Cates" NAME="Lotvall" YEAR="">
<REFERENCE MODIFIED="2013-02-19 15:19:14 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Ltvall J, Langley S, Woodcock A</AU>
<TI>Inhaled steroid/long-acting beta2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients</TI>
<SO>Respiratory Research</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>110</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundborg-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Lundborg 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G et al</AU>
<TI>Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>5</NO>
<PG>809-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maspero-2010" MODIFIED="2012-12-17 17:20:26 +0000" MODIFIED_BY="Christopher J Cates" NAME="Maspero 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-12-17 17:20:26 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: J. F. Maspero, Fundacion CIDEA, AllergyRespiratory Research, Allergy and Respiratory Research Unit, Buenos Aires, Argentina. E-mail: maspero@ciudad.com.ar&lt;br&gt;Author, Monographic: 2010641203&lt;br&gt;Author Role: English&lt;br&gt;4/10&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Article&lt;/p&gt;" NOTES_MODIFIED="2012-12-17 17:20:26 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Maspero JF, Nolte H, Cherrez-Ojeda I</AU>
<TI>Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma</TI>
<SO>Journal of Asthma</SO>
<YR>2010</YR>
<VL>47</VL>
<NO>10</NO>
<PG>1106-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-2003" MODIFIED="2013-01-22 10:44:55 +0000" MODIFIED_BY="Christopher J Cates" NAME="Mitchell 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-22 10:44:55 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Mitchell C, Jenkins C, Scicchitano R, Rubinfeld A, Kottakis J</AU>
<TI>Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma</TI>
<SO>Pulmonary Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>5</NO>
<PG>299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molimard-2001" MODIFIED="2013-01-22 10:45:05 +0000" MODIFIED_BY="Christopher J Cates" NAME="Molimard 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-01-22 10:45:05 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P et al</AU>
<TI>Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>1</NO>
<PG>64-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nayak-2010" MODIFIED="2012-10-30 14:28:53 +0000" MODIFIED_BY="Christopher J Cates" NAME="Nayak 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-30 14:28:53 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: A. Nayak, NormalILUnited States&lt;br&gt;Author, Monographic: 70452853&lt;br&gt;Author Role: English&lt;br&gt;3/11&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract [2010 Annual Meeting of the American College of Allergy, Asthma and Immunology Phoenix, Arizona United States]&lt;/p&gt;" NOTES_MODIFIED="2012-10-30 14:28:53 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nayak A, LaForce C, Nathan RA, Nolte H, Weinstein SF</AU>
<TI>Mometasone furoate/formoterol administered via a pressurized metered-dose inhaler improves proportions of saba-free days and nights in subjects with persistent asthma [Abstract]</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2010</YR>
<VL>105</VL>
<PG>5 Suppl</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novartis-2005" MODIFIED="2013-05-24 14:17:17 +0100" MODIFIED_BY="Christopher J Cates" NAME="Novartis 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-24 14:17:17 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Novartis</AU>
<TI>A 12-month multicenter, randomized, double-blind, double-dummy trial to examine the long-term tolerability of formoterol 10g via the multiple dose dry powder inhaler (MDDPI), both as twice daily maintenance therapy and as on-demand use in addition to maintenance in patients with persistent asthma</TI>
<SO>http://pharma.us.novartis.com/</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Byrne-2005" MODIFIED="2013-01-22 10:52:54 +0000" MODIFIED_BY="Christopher J Cates" NAME="O'Byrne 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-22 10:52:54 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y et al</AU>
<TI>Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.[see comment]</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>2005</YR>
<VL>171</VL>
<NO>2</NO>
<PG>129-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohta-2008" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Ohta 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;1/09 //SING-AST// //CCC-AST// //LAB1-AST// //LAB2-AST// //LAB3-AST// //DAY-AST// //ILA-AST// //REG-AST// //BVT-AST// //CCC-AST_Aug 2010// //BVT-AST_Nov 10//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Ohta K, Adachi M</AU>
<TI>Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma [Abstract]</TI>
<SO>European Respiratory Society Annual Congress; October 4-8, 2008; Berlin, Germany. Poster 3626.</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overbeek-2005" MODIFIED="2013-01-22 11:01:34 +0000" MODIFIED_BY="Christopher J Cates" NAME="Overbeek 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-22 11:01:34 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overbeek SE, Mulder PG, Baelemans SM, Hoogsteden HC, Prins JB</AU>
<TI>Formoterol added to low dose budesonide has no additional anti-inflammatory effect in asthmatic patients</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>128</VL>
<PG>1121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papi-2007" MODIFIED="2013-01-22 11:01:50 +0000" MODIFIED_BY="Christopher J Cates" NAME="Papi 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-22 11:01:50 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM, Zarkovic J et al</AU>
<TI>Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>4</NO>
<PG>682-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauwels-2003" MODIFIED="2013-01-22 11:02:02 +0000" MODIFIED_BY="Christopher J Cates" NAME="Pauwels 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-22 11:02:02 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A et al</AU>
<TI>Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>5</NO>
<PG>787-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-2008a" MODIFIED="2012-10-30 13:42:48 +0000" MODIFIED_BY="Christopher J Cates" NAME="Peters 2008a" YEAR="2008">
<REFERENCE MODIFIED="2012-10-30 13:42:48 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/08 //SING-AST// //CCC-AST// //LAB1-AST// //LAB2-AST// //LAB3-AST// //DAY-AST// //ILA-AST// //REG-AST// //SPAR-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2012-10-30 13:42:48 +0000" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Peters SP, Rosenwasser LJ, Vervaet P, O'Brien CD</AU>
<TI>Cardiac safety of budesonide (BUD)/formoterol (FM) pressurized metered dose inhaler (pMDI) pooled data from clinical studies of children, adolescents and adults with asthma [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2 Suppl 1</NO>
<PG>S155 [595]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pleskow-2003" MODIFIED="2013-01-22 11:02:45 +0000" MODIFIED_BY="Christopher J Cates" NAME="Pleskow 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-22 11:02:45 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G</AU>
<TI>Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial</TI>
<SO>Journal of Asthma</SO>
<YR>2003</YR>
<VL>40</VL>
<NO>5</NO>
<PG>505-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pohl-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Pohl 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Pohl WR, Vetter N, Zwick H, Hrubos W</AU>
<TI>Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study</TI>
<SO>Respiratory Medicine</SO>
<YR>2006</YR>
<VL>100</VL>
<NO>3</NO>
<PG>551-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabe-2006" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Rabe 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T et al</AU>
<TI>Budisonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>2</NO>
<PG>246-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenhall-2002" MODIFIED="2008-11-26 14:24:50 +0000" MODIFIED_BY="Christopher J Cates" NAME="Rosenhall 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-26 14:24:50 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Rosenhall L, Heinig JH, Lindqvist A, Leegaard J, Stahl E, Bergqvist PB</AU>
<TI>Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma</TI>
<SO>International Journal of Clinical Practice.</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>6</NO>
<PG>427-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenhall-2003" MODIFIED="2008-11-26 14:24:46 +0000" MODIFIED_BY="Christopher J Cates" NAME="Rosenhall 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-26 14:24:46 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Rosenhall L, Borg S, Andersson HF, Ericsson K</AU>
<TI>Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>8</NO>
<PG>662-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenhall-2003a" MODIFIED="2008-11-26 14:24:42 +0000" MODIFIED_BY="Christopher J Cates" NAME="Rosenhall 2003a" YEAR="2003">
<REFERENCE MODIFIED="2008-11-26 14:24:42 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Stahl E, et al</AU>
<TI>One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>6</NO>
<PG>702-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenwasser-2008" MODIFIED="2013-05-23 10:29:40 +0100" MODIFIED_BY="Christopher J Cates" NAME="Rosenwasser 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-23 10:29:40 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/08 //SING-AST// //CCC-AST// //LAB1-AST// //LAB2-AST// //LAB3-AST// //DAY-AST// //ILA-AST// //REG-AST// //SPAR-AST// //CCC-AST_Aug 2010// //INHC-AST_Nov 2010//&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 10:29:40 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Rosenwasser LJ, Peters SP, Vervaet P, O'Brien CD</AU>
<TI>Tolerability of budesonide (BUD)/formoterol (FM) pressurized metered dose inhaler (pMDI) pooled adverse event (AE) data from clinical studies of children, adolescents and adults with asthma [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2 Suppl 1</NO>
<PG>S154 [591]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-2011" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Saito 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;3/11&lt;br&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saito T, Hasunuma T</AU>
<TI>Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler in Japanese patients with asthma: phase III study results.</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<NO>Meeting Abstracts</NO>
<PG>A4489</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scicchitano-2004" MODIFIED="2013-01-22 11:04:28 +0000" MODIFIED_BY="Christopher J Cates" NAME="Scicchitano 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-22 11:04:28 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centann S et al</AU>
<TI>Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>9</NO>
<PG>1403-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stelmach-2007" MODIFIED="2013-01-22 11:04:48 +0000" MODIFIED_BY="Christopher J Cates" NAME="Stelmach 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-22 11:04:48 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P</AU>
<TI>A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma</TI>
<SO>Pulmonary Pharmacology and Therapeutics</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>6</NO>
<PG>691-700</PG>
<EN>2006/10/19</EN>
<IDENTIFIERS MODIFIED="2008-11-14 12:10:03 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="1094-5539" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Molen-1997" MODIFIED="2013-01-22 11:04:58 +0000" MODIFIED_BY="Christopher J Cates" NAME="van der Molen 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-01-22 11:04:58 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>van der Molen T, Postma DS, Turner MO, Jong BM, Malo JL, Chapman K et al</AU>
<TI>Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>6</NO>
<PG>535-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villa-2002" MODIFIED="2013-05-23 10:36:24 +0100" MODIFIED_BY="Christopher J Cates" NAME="Villa 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-05-23 10:36:24 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Villa J, Kuna P, Egner J, Brander R</AU>
<TI>A 6-month comparison of the safety profiles of formoterol (Oxis) turbuhaler as needed and terbutaline (Bricanyl) turbuhaler as needed in asthmatic children on anti-inflammatory medication [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>8 Suppl</NO>
<PG>A746</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Berg-2003" MODIFIED="2008-11-26 14:23:55 +0000" MODIFIED_BY="Christopher J Cates" NAME="Von Berg 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-26 14:23:55 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ</AU>
<TI>Efficacy and tolerability of formoterol turbuhaler in children</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>10</NO>
<PG>852-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinstein-2010a" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Weinstein 2010a" YEAR="2010">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: S. Weinstein, Allergy and Asthma Specialists Medical Group, Huntington Beach, CA, United States&lt;br&gt;Author, Monographic: 70313321&lt;br&gt;Author Role: English&lt;br&gt;4/10&lt;br&gt;CODEN: RCT/pooled-analysis&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Weinstein S, Nathan RA, Meltzer E, Nolte H, Maspero J</AU>
<TI>Treatment of persistent asthma with mometasone furoate/formoterol combination therapy is associated with a low incidence of oral candidiasis and dysphonia [Abstract]</TI>
<SO>Congress of the Asian Pacific Society of Respirology; 2010; Manila, Philippines</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-2010" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="White 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Author Affiliation: M. White, WheatonMDUnited States&lt;br&gt;Author, Monographic: 70452850&lt;br&gt;Author Role: English&lt;br&gt;3/11&lt;br&gt;CODEN: RCT&lt;br&gt;Notes: Publication Type: Journal: Conference Abstract [ 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology Phoenix, Arizona United States]&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>White M, Meltzer EO, Nathan RA, Nolte H</AU>
<TI>Improved asthma control with mometasone furoate/formoterol: a new combination treatment for persistent asthma [Abstract]</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>5 Suppl</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Worth-2005" MODIFIED="2013-02-19 15:24:58 +0000" MODIFIED_BY="Christopher J Cates" NAME="Worth 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-02-19 15:24:58 +0000" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Worth H</AU>
<TI>DESOLO - SiT Peri-Launch: a comparison of symbicort single inhaler therapy and conventional best practice for the treatment of persistent asthma in adults</TI>
<SO>clinicaltrials.gov</SO>
<YR>(accessed 3rd September 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zetterstr_x00f6_m-2000" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Zetterstrm 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Zetterstrm O, Buhl R, Mellem H, Perpi M, Hedman J, O'Neill S et al</AU>
<TI>Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>455s. Abstract P3198</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zetterstrom-2001a" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Zetterstrom 2001a" YEAR="2001">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Zetterstrom O, Buhl R, Mellem H</AU>
<TI>Efficacy and safety of symbicort budesonide and formoterol in a single inhaler in adults with asthma</TI>
<SO>Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA, USA.</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-10-30 14:21:26 +0000" MODIFIED_BY="Christopher J Cates"/>
<ONGOING_STUDIES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01444430" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="NCT01444430" YEAR="2012 (accessed June 2012)">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2012 (accessed June 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01471340" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="NCT01471340" YEAR="2012 (accessed June 2012)">
<REFERENCE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" PRIMARY="NO" TYPE="OTHER">
<AU>Merck</AU>
<TI>A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241 AM3) (SPIRO)</TI>
<SO>ClinicalTrials.gov</SO>
<YR>(accessed June 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-05-24 14:17:26 +0100" MODIFIED_BY="Christopher J Cates">
<ADDITIONAL_REFERENCES MODIFIED="2013-05-24 14:17:26 +0100" MODIFIED_BY="Christopher J Cates">
<REFERENCE ID="REF-Altman-2003" MODIFIED="2008-11-11 15:20:28 +0000" MODIFIED_BY="Christopher J Cates" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Statistics Notes: Interaction revisited: the difference between two estimates</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7382</NO>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2006" MODIFIED="2008-11-18 12:58:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Anderson 2006" TYPE="OTHER">
<AU>Anderson GP</AU>
<TI>Current issues with beta(2)-adrenoceptor agonists - Pharmacology and molecular and cellular mechanisms</TI>
<SO>Clinical Reviews in Allergy &amp; Immunology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>2-3</NO>
<PG>119-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnold-1985" MODIFIED="2013-01-22 11:15:13 +0000" MODIFIED_BY="Christopher J Cates" NAME="Arnold 1985" TYPE="OTHER">
<AU>Arnold JMO, O'Connor PC, Riddell JG, Harron DWG, Shanks RG, McDevitt DG</AU>
<TI>Effects of the beta-2-adrenoceptor antagonist ici-118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1985</YR>
<VL>19</VL>
<NO>5</NO>
<PG>619-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1993" MODIFIED="2008-11-18 12:58:08 +0000" MODIFIED_BY="Christopher J Cates" NAME="Barnes 1993" TYPE="OTHER">
<AU>Barnes PJ</AU>
<TI>Beta-adrenoceptors on smooth-muscle, nerves and inflammatory cells</TI>
<SO>Life Sciences</SO>
<YR>1993</YR>
<VL>52</VL>
<NO>26</NO>
<PG>2101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1995" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Barnes 1995" TYPE="OTHER">
<AU>Barnes PJ</AU>
<TI>Beta-adrenergic receptors and their regulation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>3</NO>
<PG>838-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beach-1992" MODIFIED="2013-01-22 11:15:46 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Beach 1992" TYPE="JOURNAL_ARTICLE">
<AU>Beach JR, Young CL, Stenton SC, Avery AJ, Walters EH, Hendrick DJ</AU>
<TI>A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction</TI>
<SO>Pulmonary Pharmacology</SO>
<YR>1992</YR>
<VL>5</VL>
<NO>2</NO>
<PG>133-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bennett-1994" MODIFIED="2008-11-18 13:04:00 +0000" MODIFIED_BY="Christopher J Cates" NAME="Bennett 1994" TYPE="OTHER">
<AU>Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE</AU>
<TI>Systemic effects of salbutamol and salmeterol in patients with asthma</TI>
<SO>Thorax</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>8</NO>
<PG>771-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradburn-2007" MODIFIED="2012-10-30 13:15:34 +0000" MODIFIED_BY="Christopher J Cates" NAME="Bradburn 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A</AU>
<TI>Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events</TI>
<SO>Statistics in Medicine</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>1</NO>
<PG>53-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1983" MODIFIED="2008-11-18 13:04:00 +0000" MODIFIED_BY="Christopher J Cates" NAME="Brown 1983" TYPE="OTHER">
<AU>Brown MJ, Brown DC, Murphy MB</AU>
<TI>Hypokalemia from beta-2-receptor stimulation by circulating epinephrine</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>23</NO>
<PG>1414-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burgess-1991" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Burgess 1991" TYPE="OTHER">
<AU>Burgess CD, Windom HH, Pearce N, Marshall S, Beasley R, Siebers RWL et al</AU>
<TI>Lack of evidence for beta-2 receptor selectivity&#65293;a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1991</YR>
<VL>143</VL>
<NO>2</NO>
<PG>444-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burggraaf-2001" MODIFIED="2013-01-22 11:16:26 +0000" MODIFIED_BY="Christopher J Cates" NAME="Burggraaf 2001" TYPE="OTHER">
<AU>Burggraaf J, Westendorp RGJ, in't Veen J, Schoemaker RC, Sterk PJ, Cohen AF et al</AU>
<TI>Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients</TI>
<SO>Thorax</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>7</NO>
<PG>567-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2008" MODIFIED="2013-02-19 16:19:09 +0000" MODIFIED_BY="Christopher J Cates" NAME="Cates 2008" TYPE="COCHRANE_REVIEW">
<AU>Cates CJ, Cates MJ</AU>
<TI>Regular treatment with salmeterol for chronic asthma: serious adverse events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006363.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cates-2009" MODIFIED="2013-02-19 16:18:47 +0000" MODIFIED_BY="Christopher J Cates" NAME="Cates 2009" TYPE="COCHRANE_REVIEW">
<AU>Cates CJ, Lasserson TJ, Jaeschke R</AU>
<TI>Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-10-29 15:52:00 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER MODIFIED="2012-10-29 15:52:00 +0000" MODIFIED_BY="Christopher J Cates" TYPE="DOI" VALUE="10.1002/14651858.CD006902.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cates-2012" MODIFIED="2012-10-29 15:53:19 +0000" MODIFIED_BY="Christopher J Cates" NAME="Cates 2012" TYPE="COCHRANE_REVIEW">
<AU>Cates CJ, Cates MJ, Lasserson TJ</AU>
<TI>Regular treatment with formoterol for chronic asthma: serious adverse events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006923.pub3"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD006923"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cates-2012a" MODIFIED="2013-01-18 16:13:13 +0000" MODIFIED_BY="Christopher J Cates" NAME="Cates 2012a" TYPE="OTHER">
<AU>Cates CJ, Oleszczuk M, Stovold E, Wieland LS</AU>
<TI>Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>10</NO>
<PG>Art. No.: CD010005.</PG>
<IDENTIFIERS MODIFIED="2012-10-22 15:46:45 +0100" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER MODIFIED="2012-10-22 15:46:45 +0100" MODIFIED_BY="Christopher J Cates" TYPE="DOI" VALUE="10.1002/14651858.CD010005.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chowdhury-2011" MODIFIED="2012-10-30 13:07:29 +0000" MODIFIED_BY="Christopher J Cates" NAME="Chowdhury 2011" TYPE="JOURNAL_ARTICLE">
<AU>Chowdhury BA, Seymour SM, Levenson MS</AU>
<TI>Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>364</VL>
<NO>26</NO>
<PG>2473-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cockcroft-1993" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Cockcroft 1993" TYPE="OTHER">
<AU>Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC</AU>
<TI>Regular inhaled salbutamol and airway responsiveness to allergen</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<NO>8875</NO>
<PG>833-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1969" MODIFIED="2013-01-22 11:26:21 +0000" MODIFIED_BY="Christopher J Cates" NAME="Collins 1969" TYPE="OTHER">
<AU>Collins JM, McDevitt DG, Shanks RG, Swanton JG</AU>
<TI>Cardio-toxicity of isoprenaline during hypoxia</TI>
<SO>British Journal of Pharmacology</SO>
<YR>1969</YR>
<VL>36</VL>
<NO>1</NO>
<PG>35-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crane-1989" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Crane 1989" TYPE="OTHER">
<AU>Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T et al</AU>
<TI>Prescribed fenoterol and death from asthma in New Zealand, 1981-83&#65293;case-control study</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8644</NO>
<PG>917-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ducharme-2010a" MODIFIED="2013-02-19 16:18:17 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Ducharme 2010a" TYPE="COCHRANE_REVIEW">
<AU>Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ</AU>
<TI>Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-01-30 12:57:14 +0000" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2013-01-30 12:57:14 +0000" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD005533.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ducharme-2011a" MODIFIED="2013-02-19 15:12:31 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Ducharme 2011a" TYPE="COCHRANE_REVIEW">
<AU>Ducharme FM, Lasserson TJ, Cates CJ</AU>
<TI>Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2013-01-30 12:44:53 +0000" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2013-01-30 12:44:53 +0000" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD003137.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Giembycz-2006" MODIFIED="2013-01-22 11:28:40 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Giembycz 2006" TYPE="JOURNAL_ARTICLE">
<AU>Giembycz MA, Newton R</AU>
<TI>Beyond the dogma: novel 2-adrenoceptor signalling in the airways</TI>
<SO>European Respiratory Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>6</NO>
<PG>1286-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grainger-1991" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Grainger 1991" TYPE="OTHER">
<AU>Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A et al</AU>
<TI>Prescribed fenoterol and death from asthma in New Zealand, 1981-7&#65293;a further case-control study</TI>
<SO>Thorax</SO>
<YR>1991</YR>
<VL>46</VL>
<NO>2</NO>
<PG>105-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guhan-2000" MODIFIED="2008-11-18 13:04:00 +0000" MODIFIED_BY="Christopher J Cates" NAME="Guhan 2000" TYPE="OTHER">
<AU>Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE</AU>
<TI>Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects</TI>
<SO>Thorax</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>8</NO>
<PG>650-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-1989" MODIFIED="2008-11-18 13:02:03 +0000" MODIFIED_BY="Christopher J Cates" NAME="Hall 1989" TYPE="OTHER">
<AU>Hall JA, Petch MC, Brown MJ</AU>
<TI>Intracoronary injections of salbutamol demonstrate the presence of functional beta-2-adrenoceptors in the human-heart</TI>
<SO>Circulation Research</SO>
<YR>1989</YR>
<VL>65</VL>
<NO>3</NO>
<PG>546-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hanania-2002" MODIFIED="2008-11-18 12:59:20 +0000" MODIFIED_BY="Christopher J Cates" NAME="Hanania 2002" TYPE="OTHER">
<AU>Hanania NA, Sharfkhaneh A, Barber R, Dickey BF</AU>
<TI>beta-agonist intrinsic efficacy - Measurement and clinical significance</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>10</NO>
<PG>1353-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hanania-2007" MODIFIED="2008-11-18 13:07:56 +0000" MODIFIED_BY="Christopher J Cates" NAME="Hanania 2007" TYPE="OTHER">
<AU>Hanania NA, Moore RH, Zimmerman JL, Miller CT, Bag R, Sharafkhaneh A, et al</AU>
<TI>The role of intrinsic efficacy in determining response to beta(2)-agonist in acute severe asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>5</NO>
<PG>1007-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hancox-1999" MODIFIED="2013-01-22 11:30:24 +0000" MODIFIED_BY="Christopher J Cates" NAME="Hancox 1999" TYPE="OTHER">
<AU>Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR et al</AU>
<TI>Tolerance to beta-agonists during acute bronchoconstriction</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>2</NO>
<PG>283-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hancox-2006" MODIFIED="2013-01-22 11:30:49 +0000" MODIFIED_BY="Christopher J Cates" NAME="Hancox 2006" TYPE="OTHER">
<AU>Hancox RJ</AU>
<TI>Interactions between corticosteroids and beta2-agonists</TI>
<SO>Clinical Reviews in Allergy and Immunology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>2-3</NO>
<PG>231-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haney-2006" MODIFIED="2013-01-22 11:31:22 +0000" MODIFIED_BY="Christopher J Cates" NAME="Haney 2006" TYPE="OTHER">
<AU>Haney S, Hancox RJ</AU>
<TI>Recovery from bronchoconstriction and bronchodilator tolerance</TI>
<SO>Clinical Reviews in Allergy and Immunology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>2-3</NO>
<PG>181-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harvey-1982" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Harvey 1982" TYPE="OTHER">
<AU>Harvey JE, Tattersfield AE</AU>
<TI>Airway response to salbutamol - effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects</TI>
<SO>Thorax</SO>
<YR>1982</YR>
<VL>37</VL>
<NO>4</NO>
<PG>280-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICHE2a-1995" MODIFIED="2013-05-24 14:17:26 +0100" MODIFIED_BY="Christopher J Cates" NAME="ICHE2a 1995" TYPE="OTHER">
<AU>Expert Working Group (Efficacy) of theInternational Conference on Harmonisation of Technical Requirements for Registrationof Pharmaceuticals for Human Use (ICH)</AU>
<TI>Clinical safety data management: Definitions and standards for expedited reporting</TI>
<SO>www.fda.gov/cder/guidance/iche2a.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaeschke-2008" MODIFIED="2013-05-23 10:42:25 +0100" MODIFIED_BY="Christopher J Cates" NAME="Jaeschke 2008" TYPE="OTHER">
<AU>Jaeschke R, O'Byrne PM, Nair P, Mejza F, Le&#347;niak W, Brozek J, et al</AU>
<TI>The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis.</TI>
<SO>Polskie Archiwum Medycyny Wewnetrznej</SO>
<YR>2008</YR>
<VL>118</VL>
<NO>11</NO>
<PG>627-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaeschke-2008a" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Jaeschke 2008a" TYPE="OTHER">
<AU>Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J et al</AU>
<TI>The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis</TI>
<SO>America Journal of Respiratory and Critical Care Medicine</SO>
<YR>2008</YR>
<VL>178</VL>
<NO>10</NO>
<PG>1009-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2001" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Jones 2001" TYPE="OTHER">
<AU>Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR</AU>
<TI>Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>3</NO>
<PG>368-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2003" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Lee 2003" TYPE="OTHER">
<AU>Lee DKC, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ</AU>
<TI>Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2003</YR>
<VL>56</VL>
<NO>5</NO>
<PG>494-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipworth-1989" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Lipworth 1989" TYPE="OTHER">
<AU>Lipworth BJ, Struthers AD, McDevitt DG</AU>
<TI>Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high-dose inhaled salbutamol in asthmatics</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1989</YR>
<VL>140</VL>
<NO>3</NO>
<PG>586-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipworth-1992" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Lipworth 1992" TYPE="OTHER">
<AU>Lipworth BJ, McDevitt DG</AU>
<TI>Inhaled beta-2-adrenoceptor agonists in asthma&#65293;help or hindrance</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1992</YR>
<VL>33</VL>
<NO>2</NO>
<PG>129-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipworth-1997" MODIFIED="2008-10-01 15:22:47 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Lipworth 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lipworth BJ</AU>
<TI>Airway sub-sensitivity with long-acting beta 2-agonists: Is there cause for concern?</TI>
<SO>Drug Safety</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>5</NO>
<PG>295-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipworth-2000" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Lipworth 2000" TYPE="OTHER">
<AU>Lipworth BJ, Aziz I</AU>
<TI>Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<NO>1</NO>
<PG>156-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDevitt-1974" MODIFIED="2008-11-18 13:04:00 +0000" MODIFIED_BY="Christopher J Cates" NAME="McDevitt 1974" TYPE="OTHER">
<AU>McDevitt DG, Shanks RG, Swanton JG</AU>
<TI>Further observations on cardiotoxicity of isoprenaline during hypoxia</TI>
<SO>British Journal of Pharmacology</SO>
<YR>1974</YR>
<VL>50</VL>
<NO>3</NO>
<PG>335-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McMahon-2011" MODIFIED="2012-10-30 13:10:40 +0000" MODIFIED_BY="Christopher J Cates" NAME="McMahon 2011" TYPE="JOURNAL_ARTICLE">
<AU>McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D</AU>
<TI>Age and risks of FDA&#8211;approved long-acting &#946;2-adrenergic receptor agonists</TI>
<SO>Pediatrics</SO>
<YR>2011</YR>
<VL>128</VL>
<NO>5</NO>
<PG>e1147-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morrison-1993" MODIFIED="2008-11-18 12:58:24 +0000" MODIFIED_BY="Christopher J Cates" NAME="Morrison 1993" TYPE="OTHER">
<AU>Morrison KJ, Gao Y, Vanhoutte PM</AU>
<TI>Beta-adrenoceptors and the epithelial layer in airways</TI>
<SO>Life Sciences</SO>
<YR>1993</YR>
<VL>52</VL>
<NO>26</NO>
<PG>2123-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1977" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Nelson 1977" TYPE="OTHER">
<AU>Nelson HS, Raine D, Doner HC, Posey WC</AU>
<TI>Subsensitivity to bronchodilator action of albuterol produced by chronic administration</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1977</YR>
<VL>116</VL>
<NO>5</NO>
<PG>871-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ni-Chroinin-2009a" MODIFIED="2013-02-19 16:17:10 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Ni Chroinin 2009a" TYPE="COCHRANE_REVIEW">
<AU>Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM</AU>
<TI>Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-01-30 12:17:33 +0000" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2013-01-30 12:17:33 +0000" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD005307.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ni-Chroinin-2010" MODIFIED="2013-02-19 15:14:43 +0000" MODIFIED_BY="Christopher J Cates" NAME="Ni Chroinin 2010" TYPE="COCHRANE_REVIEW">
<AU>Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ</AU>
<TI>Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2013-01-30 12:20:40 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER MODIFIED="2013-01-30 12:20:40 +0000" MODIFIED_BY="Christopher J Cates" TYPE="DOI" VALUE="10.1002/14651858.CD005535"/>
<IDENTIFIER MODIFIED="2013-01-30 12:19:00 +0000" MODIFIED_BY="Christopher J Cates" TYPE="OTHER" VALUE="CD005535"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Novartis-2008" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Novartis 2008" TYPE="OTHER">
<AU>Novartis</AU>
<TI>Foradil (formoterol fumarate inhalation powder). FDA Advisory Committee Meeting for the safety of long-acting beta<SUB>2</SUB>-agonists for the treatment of asthma in adults and children (December 10-11, 2008)</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-02-Novartis.pdf</SO>
<YR>(accessed 8 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmqvist-1999" MODIFIED="2008-11-18 12:59:07 +0000" MODIFIED_BY="Christopher J Cates" NAME="Palmqvist 1999" TYPE="OTHER">
<AU>Palmqvist M, Ibsen T, Mellen A, Lotvall J</AU>
<TI>Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<NO>1</NO>
<PG>244-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pearce-1990" MODIFIED="2013-01-22 11:33:12 +0000" MODIFIED_BY="Christopher J Cates" NAME="Pearce 1990" TYPE="OTHER">
<AU>Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C et al</AU>
<TI>Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81</TI>
<SO>Thorax</SO>
<YR>1990</YR>
<VL>45</VL>
<NO>3</NO>
<PG>170-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pearce-2007" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Pearce 2007" TYPE="BOOK">
<AU>Pearce N</AU>
<SO>Adverse Reactions: The Fenoterol Story</SO>
<YR>2007</YR>
<PG>215</PG>
<EN>1</EN>
<PB>Auckland University Press</PB>
<CY>Auckland</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="9781869403744"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sears-1986" MODIFIED="2013-01-22 11:33:29 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Sears 1986" TYPE="JOURNAL_ARTICLE">
<AU>Sears M, Rea H, Rothwell R, O'Donnell T, Holst P, Gillies A et al</AU>
<TI>Asthma mortality: comparison between New Zealand and England</TI>
<SO>British Medical Journal</SO>
<YR>1986</YR>
<VL>293</VL>
<NO>6558</NO>
<PG>1342-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sears-1990" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Sears 1990" TYPE="OTHER">
<AU>Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al</AU>
<TI>Regular inhaled beta-agonist treatment in bronchial-asthma</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8728</NO>
<PG>1391-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sears-2008" MODIFIED="2008-11-24 14:11:27 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Sears 2008" TYPE="OTHER">
<AU>Sears MR, Ottosson A, Radner F, Suissa S</AU>
<TI>Long-acting {beta}-agonists: A review of formoterol safety data from asthma clinical trials</TI>
<SO>European Respiratory Journal</SO>
<YR>2008</YR>
<PG>09031936.00145006</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SMART-2006" MODIFIED="2008-10-01 15:22:25 +0100" MODIFIED_BY="Toby J Lasserson" NAME="SMART 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group</AU>
<TI>The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<PG>15-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SNS-1993" MODIFIED="2009-01-05 16:03:11 +0000" MODIFIED_BY="Christopher J Cates" NAME="SNS 1993" TYPE="JOURNAL_ARTICLE">
<AU>Castle W, Fuller R, Hall J</AU>
<TI>Serevent nationwide surveillance study:Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment</TI>
<SO>British Medical Journal</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>1034-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Speizer-1968" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Speizer 1968" TYPE="OTHER">
<AU>Speizer FE, Doll R, Heaf P</AU>
<TI>Observations on recent increase in mortality from asthma</TI>
<SO>British Medical Journal</SO>
<YR>1968</YR>
<VL>1</VL>
<NO>5588</NO>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sweeting-2004" MODIFIED="2008-11-26 13:52:15 +0000" MODIFIED_BY="Christopher J Cates" NAME="Sweeting 2004" TYPE="OTHER">
<AU>Sweeting MJ, Sutton AJ, Lambert PC</AU>
<TI>What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</TI>
<SO>Stat Med</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1351-75</PG>
<EN>2004/04/30</EN>
<IDENTIFIERS MODIFIED="2008-11-26 13:52:05 +0000" MODIFIED_BY="Christopher J Cates">
<IDENTIFIER OTHERTYPE="0277-6715" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-der-Woude-2001" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="van der Woude 2001" TYPE="OTHER">
<AU>van der Woude HJ, Winter TH, Aalbers R</AU>
<TI>Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta(2) agonists</TI>
<SO>Thorax</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>7</NO>
<PG>529-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-vanNoord-1996" MODIFIED="2008-11-18 12:58:56 +0000" MODIFIED_BY="Christopher J Cates" NAME="vanNoord 1996" TYPE="OTHER">
<AU>vanNoord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV</AU>
<TI>Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1684-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-2002" MODIFIED="2008-11-21 16:22:14 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Walters 2002" TYPE="COCHRANE_REVIEW">
<AU>Walters EH, Walters JAE, Gibson PW</AU>
<TI>Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-11-21 16:22:14 +0000" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2008-11-21 16:22:11 +0000" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD003901"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walters-2007" MODIFIED="2012-10-30 13:56:10 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Walters 2007" TYPE="COCHRANE_REVIEW">
<AU>Walters EH, Gibson PG, Lasserson TJ, Walters JAE</AU>
<TI>Long-acting beta2-agonists for stable chronic asthma (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-10-30 13:56:10 +0000" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2012-10-30 13:56:10 +0000" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD001385.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weber-1982" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Weber 1982" TYPE="OTHER">
<AU>Weber RW, Smith JA, Nelson HS</AU>
<TI>Aerosolized terbutaline in asthmatics&#65293;development of subsensitivity with long-term administration</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1982</YR>
<VL>70</VL>
<NO>6</NO>
<PG>417-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1981" MODIFIED="2008-11-18 13:04:00 +0000" MODIFIED_BY="Christopher J Cates" NAME="Wilson 1981" TYPE="OTHER">
<AU>Wilson JD, Sutherland DC, Thomas AC</AU>
<TI>Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>8232</NO>
<PG>1235-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-1990" MODIFIED="2008-11-18 13:04:00 +0000" MODIFIED_BY="Christopher J Cates" NAME="Wong 1990" TYPE="OTHER">
<AU>Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE</AU>
<TI>Bronchodilator, cardiovascular, and hypokalemic effects of fenoterol, salbutamol, and terbutaline in asthma</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8728</NO>
<PG>1396-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yates-1996" MODIFIED="2008-11-18 13:06:36 +0000" MODIFIED_BY="Christopher J Cates" NAME="Yates 1996" TYPE="OTHER">
<AU>Yates DH, Kharitonov SA, Barnes PJ</AU>
<TI>An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta(2)-agonist</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1996</YR>
<VL>154</VL>
<NO>6</NO>
<PG>1603-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-01-24 13:51:27 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cates-2009a" MODIFIED="2013-01-24 13:51:27 +0000" MODIFIED_BY="[Empty name]" NAME="Cates 2009a" TYPE="COCHRANE_REVIEW">
<AU>Cates CJ, Lasserson TJ, Jaeschke R</AU>
<TI>Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-01-24 13:51:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-24 13:51:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006924.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-10-30 13:15:34 +0000" MODIFIED_BY="Christopher J Cates">
<REFERENCE ID="REF-Anderson-2008" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Anderson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Anderson GP</AU>
<TI>Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9643</NO>
<PG>1107-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boushey-1980" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Boushey 1980" TYPE="JOURNAL_ARTICLE">
<AU>Boushey HA, Holtzman MJ, Sheller JR, Nadel JA</AU>
<TI>Bronchial hyperreactivity</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1980</YR>
<VL>121</VL>
<NO>2</NO>
<PG>389-413</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1997" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Bucher 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Guyatt GH, Griffith LE, Walter SD</AU>
<TI>The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6</NO>
<PG>683-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castle-1993" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Castle 1993" TYPE="JOURNAL_ARTICLE">
<AU>Castle W, Fuller R, Hall J, Palmer J</AU>
<TI>Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<NO>6884</NO>
<PG>1034-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2011" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Cates 2011" TYPE="JOURNAL_ARTICLE">
<AU>Cates CJ</AU>
<TI>Safety of tiotropium</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d2970</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan A-W, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004a" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Chan 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Chan A-W, Krleza-Jeric K, Schmid I, Altman DG</AU>
<TI>Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2004</YR>
<VL>171</VL>
<NO>7</NO>
<PG>735-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cockcroft-2006" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Cockcroft 2006" TYPE="JOURNAL_ARTICLE">
<AU>Cockcroft D</AU>
<TI>Airway hyper-responsiveness as a determinant of the early asthmatic response to inhaled allergen</TI>
<SO>Journal of Asthma</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>3</NO>
<PG>175-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ducharme-2010" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Ducharme 2010" TYPE="OTHER">
<AU>Ducharme Francine M, Ni Chroinin M, Greenstone I, Lasserson Toby J</AU>
<TI>Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>5</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005535.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ducharme-2011" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Ducharme 2011" TYPE="OTHER">
<AU>Ducharme Francine M, Lasserson Toby J, Cates Christopher J</AU>
<TI>Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>5</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003137.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GINA-2011" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="GINA 2011" TYPE="OTHER">
<AU>Global Initiative for Asthma (GINA)</AU>
<TI>Global Strategy for Asthma Management and Prevention</TI>
<SO>Available from: http://www.ginasthma.org/.</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH-E2A-1995" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="ICH E2A 1995" TYPE="OTHER">
<AU>Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).</AU>
<TI>Clinical safety data management: definitions and standards for expedited reporting</TI>
<SO>www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073087.pdf (accessed July 2012).</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2001" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Ioannidis 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Lau J</AU>
<TI>Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>4</NO>
<PG>437-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JPA, Evans SJW, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al; CONSORT Group</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<NO>10</NO>
<PG>781-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2010" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Li 2010" TYPE="JOURNAL_ARTICLE">
<AU>Li JS, Qaqundah PY, Weinstein SF, LaForce CF, Ellsworth AV, Ortega HG, et al</AU>
<TI>Fluticasone propionate/salmeterol combination in children with asthma: Key cardiac and overall safety results</TI>
<SO>Clinical Research and Regulatory Affairs</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>3</NO>
<PG>87-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lougheed-2010" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Lougheed 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lougheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al</AU>
<TI>Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada</TI>
<SO>Canadian Respiratory Journal</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>2</NO>
<PG>57-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2006" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Nelson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group</AU>
<TI>The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>1</NO>
<PG>15-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ni-Chroinin-2009" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Ni Chroinin 2009" TYPE="OTHER">
<AU>Ni Chroinin M, Lasserson Toby J, Greenstone I, Ducharme Francine M</AU>
<TI>Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD007949"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Phillips-1990" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Phillips 1990" TYPE="JOURNAL_ARTICLE">
<AU>Phillips GD, Finnerty JP, Holgate ST</AU>
<TI>Comparative protective effect of the inhaled beta-2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1990</YR>
<VL>85</VL>
<NO>4</NO>
<PG>755-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="RevMan 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salpeter-2006" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Salpeter 2006" TYPE="JOURNAL_ARTICLE">
<AU>Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE</AU>
<TI>Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2006</YR>
<VL>144</VL>
<NO>12</NO>
<PG>904-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senn-1997" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Senn 1997" TYPE="BOOK_SECTION">
<AU>Senn SJ, Lillienthal J, Patalano F, Till D</AU>
<TI>An incomplete blocks cross-over in asthma: a case study in collaboration</TI>
<SO>Cross-over Clinical Trials</SO>
<YR>1997</YR>
<PG>3-26</PG>
<ED>Vollmar J, Hothorn LA</ED>
<PB>Fischer</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shea-2007" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Shea 2007" TYPE="JOURNAL_ARTICLE">
<AU>Shea B, Grimshaw J, Wells G, Boers M, Andersson N, Hamel C, et al</AU>
<TI>Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1186/1471-2288-7-10"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SIGN_x002f_BTS-2012" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="SIGN/BTS 2012" TYPE="BOOK">
<AU>Scottish Intercollegiate Guidelines Network/British Thoracic Society</AU>
<SO>British guideline on the management of asthma: a national clinical guideline</SO>
<YR>2008 (revised 2012)</YR>
<PB>Scottish Intercollegiate Guidelines Network</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tattersfield-2006" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Tattersfield 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tattersfield AE</AU>
<TI>Current issues with beta2-adrenoceptor agonists: historical background</TI>
<SO>Clinical Reviews in Allergy and Immunology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>2-3</NO>
<PG>107-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Noord-1996" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Van Noord 1996" TYPE="JOURNAL_ARTICLE">
<AU>Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV</AU>
<TI>Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1684-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Visual-Rx-2012" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Visual Rx 2012" TYPE="OTHER">
<TI>Visual Rx</TI>
<SO>www.nntonline.net/visualrx/</SO>
<YR>Accessed June 2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinberger-2006" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Weinberger 2006" TYPE="JOURNAL_ARTICLE">
<AU>Weinberger M, Abu-Hasan M</AU>
<TI>Life threatening asthma during treatment with salmeterol</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>852-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whittington-2004" MODIFIED="2012-10-22 15:37:34 +0100" MODIFIED_BY="Christopher J Cates" NAME="Whittington 2004" TYPE="JOURNAL_ARTICLE">
<AU>Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E</AU>
<TI>Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9418</NO>
<PG>1341-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-05-24 14:28:21 +0100" MODIFIED_BY="Christopher J Cates">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-05-24 14:28:16 +0100" MODIFIED_BY="Christopher J Cates" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Brown-2012">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, parallel-group study over 52 weeks in 122 centers in America, between February 2007 and November 2009. Two-week single-blind run-in on budesonide 320 g BD.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 742 African American adults (aged 12 years or older) with asthma (ATS definition).</P>
<P>
<B>Baseline Characteristics</B>: mean age 37 years. FEV<SUB>1</SUB> 78% predicted. Concomitant ICS used by 100% of participants (with or without LABA).</P>
<P>
<B>Inclusion Criteria</B>: stable asthma for at least 6 months. FEV<SUB>1</SUB> % predicted ri at least 50%, bronchodilator reversibility at least 12% in FEV<SUB>1</SUB> or 0.2 litres.</P>
<P>
<B>Exclusion Criteria</B>: smoking history of greater than 10 pack-years, use of oral corticosteroids within 30 days or beta-blockers (including eye drops) during the study. Pregnancy, breast-feeding or malignancy in the past five years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 160/9 g BD.</LI>
<LI>Budesonide 160 g BD. </LI>
</UL>
<P>Delivery was pMDI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Safety variables included asthma exacerbations (oral/systemic corticosteroid use or an asthma-related hospitalisation or emergency room/urgent care visit) and adverse events (AEs).</P>
<P>No published data found on asthma-related non-fatal SAEs, so we used hospitalisation for asthma exacerbation as a proxy measure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-24 14:28:04 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;I have used the data from Roman's paper here. 2 SAE on BDF and 2 SAE on bud and one death on BDF. One SAE on BDF was entered as asthma related.&lt;/p&gt;&lt;p&gt;&amp;quot;A: According to my old letter from AZ it was death on combination treatment (classified as cardiac death / cardiac arrest). Also, asthma SAE on combination. Also, numbers confirmed using Sears paper AZ sent to me (Table 3).&amp;quot; Nov 27th. Data checked and cause entered in characteristics of studies. Not clear if the death was on once or twice daily BDF?&lt;/p&gt;" NOTES_MODIFIED="2013-05-24 14:28:04 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Buhl-2003">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, active-controlled, multi-centre, parallel-group study over 12 weeks from October 1999 to June 2000 at 56 centres in 9 countries: Argentina (5), Belgium (5), the Czech Republic (14), Germany (6), Mexico (4), Russia (6), Spain (5), the Netherlands (7) and the United Kingdom (4). Run-in 2 weeks (budesonide 200 mcg twice daily).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-24 14:28:04 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 523 adults (18 to 78 years) with moderate persistent asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 44 years. FEV<SUB>1</SUB> 77% predicted. Concomitant ICS used by 100% of participants (400-1000 mcg/day), and condition not fully controlled on this dose.</P>
<P>
<B>Inclusion Criteria</B>:outpatients aged 18 years and older with perennial asthma (ATS) with a minimum duration of 6 months. Used any ICS at a constant daily dose of 400 to 1000 g for at least 30 days before entry and still had sub-optimal asthma control. FEV<SUB>1</SUB> % predicted between 60% and 90%, bronchodilator reversibility by an increase of at least 12% in FEV<SUB>1</SUB> over baseline at 15 minutes after inhalation of a short-acting beta2-agonist.</P>
<P>
<B>Exclusion Criteria</B>: use of oral, parenteral or rectal GCS within 30 days before visit 1; seasonal asthma, significant respiratory infection within 30 days of visit 1, severe cardiovascular disorder or any other significant disease or disorder, pregnant or planning a pregnancy, breast-feeding, not using acceptable contraceptives, not surgically sterile, hypersensitivity to study drugs and tobacco smokers or previous smokers if greater than 10 pack-years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 320/9 g daily.</LI>
<LI>Budesonide/formoterol 160/4.5 g twice daily.</LI>
<LI>Budesonide 400 g daily (equivalent daily dose of budesonide).</LI>
</UL>
<P>Delivery was DPI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary efficacy variable was morning peak expiratory flow (am PEF, L/min).</P>
<P>Paper reports five SAEs: one in the once-daily BDF group and two each in the other groups. One death due to cardiac arrest and four other events were reported. (No details given by treatment group in article or in Web report.)</P>
<P>
<LINK REF="REF-Jaeschke-2008" TYPE="REFERENCE">Jaeschke 2008</LINK> reports one death on combined treatment and two participants with non-fatal SAE on combined treatment and two on budesonide. One SAE on BDF was asthma-related.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Why does Roman report 3 SAE or admissions in Budesonide group? Error on his part agreed. 0/2 entered for this review&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Chuchalin-2002">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, parallel-group study over 12 weeks in Russia. Run-in 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 338 adults (18 to 66 years) with mild to moderate asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 45 years. FEV<SUB>1</SUB> unknown % predicted. Concomitant ICS used by 0% of participants.</P>
<P>
<B>Inclusion Criteria</B>: diagnosed at least 6 months. FEV<SUB>1</SUB> % predicted between 50% and 85%, bronchodilator reversibility at least 15% in FEV<SUB>1</SUB> over baseline after inhalation of terbutaline. Female participants to be postmenopausal or surgically sterile or using medically approved contraceptive measures.</P>
<P>
<B>Exclusion Criteria</B>: smoking history of greater than 10 pack-years, current or recent users of inhaled, oral or parenteral corticosteroids, oral leukotriene antagonists, nedocromil sodium or sodium cromoglycate, beta-blockers (including eye drops).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide and formoterol 200 and 9 g BD.</LI>
<LI>Budesonide 200 g BD. </LI>
</UL>
<P>Delivery was DPI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary efficacy variable was change in peak expiratory flow (PEF) in the morning before any study medication was taken.</P>
<P>Article reports no deaths and two serious adverse events (aggravated asthma and hypertension) in the budesonide-only group that required hospitalisation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Supported by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Jaeschke says 2/2 SAE for Corren and this is not correct according to the web report. Need to check. 2/0 is correct, this was an error in Roman's table.&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Corren-2007">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Randomised, double-blind, double-dummy, multi-centre, placebo-controlled study over 12 weeks at 56 US centres from July 2002 to September 2003. Run-in 7 to 21 days, in which usual asthma therapy was withdrawn.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 480 adolescents and adults (12 to 78 years) with mild to moderate persistent asthma. 123 randomly assigned to BDF and 121 to budesonide. The Web report also includes 13 children in these treatment groups aged 6 to 11 years, but they were not separately analysed.</P>
<P>
<B>Baseline Characteristics</B>: mean age 36 years. FEV<SUB>1</SUB> 75% predicted. Concomitant ICS used by 100% of participants at baseline but withdrawn for the formoterol and placebo arms of this study.</P>
<P>
<B>Inclusion Criteria</B>: mild to moderate persistent asthma for at least 6 months, treated with ICS for at least 4 weeks before screening, FEV<SUB>1</SUB> between 60% and 90% predicted on ICS at screening and between 50% and 85% predicted after discontinuation of ICS during the run-in period. Bronchodilator reversibility of at least 12% and 0.20 L in FEV<SUB>1 </SUB>over baseline within 15 to 30 minutes after administration of albuterol pMDI (2 to 4 inhalations [90 g per inhalation]).</P>
<P>
<B>Exclusion Criteria</B>: reasons for exclusion from the study included severe: </P>
<P>asthma (as judged by the investigator), asthma requiring hospitalisation once or emergency treatment more than once within the 6 months before the study or requiring treatment with systemic corticosteroids within the 4 weeks before screening, and/or a &gt; 10-pack-year smoking history at screening. Pregnant or breast-feeding.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide<B>/f</B>ormoterol 160/9 g (DPI) twice daily.</LI>
<LI>Budesonide 160<B> </B>g (DPI) twice daily.</LI>
</UL>
<P>The Symbicort and budesonide arms of this study are included in this review.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The co-primary efficacy variables were changes from baseline in morning predose FEV<SUB>1 </SUB>and 12-hour mean FEV<SUB>1</SUB> (from serial spirometry) after administration of the morning dose of study medication.</P>
<P>Two serious adverse events in the BDF group (lobar pneumonia and facial bone fracture) were reported in the article. No cardiac-related SAEs were reported in any group. No deaths occurred in any group (Website data).</P>
<P>
<LINK REF="REF-Jaeschke-2008" TYPE="REFERENCE">Jaeschke 2008</LINK> reports no asthma-related SAEs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-26 15:38:39 +0000" MODIFIED_BY="Christopher J Cates">
<P>Study sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;No asthma SAE data found. Roman does not seem to have data on this one!&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-D5896C00001">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, single-dummy, active-controlled, multi-centre, parallel-group study over 12 weeks from October 2003 to February 2005 at 143 centres in the United States. Run-in 4 to 5<I> </I>weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 619 adolescents and adults (12 to 79 years) with asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 35 years. FEV<SUB>1</SUB> 76% predicted. Concomitant ICS used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>: 12 years of age and older, had a documented clinical diagnosis of asthma for at least 6 months before screening and were in stable condition. Should have received maintenance asthma treatment with IICS for at least 4 weeks before the screening visit. FEV<SUB>1</SUB> % predicted between 60% and 90% measured at least 24 hours<B> </B>after the last dose of long-acting beta<SUB>2</SUB>-agonist and 6 hours after the last dose of short-acting<B> </B>beta<SUB>2</SUB>-agonist.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 160/4.5 g 2 QD pMDI.</LI>
<LI>Budesonide/Formoterol 80/4.5 g 2 QD pMDI(data from this arm not used).</LI>
<LI>Budesonide/formoterol 80/4.5 g 2 BD pMDI.</LI>
<LI>Budesonide 160 g 2 QD pMDI.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Primary variable: evening predose FEV<SUB>1</SUB>.</P>
<P>No full paper publication for this study. Web report indicated 2 SAEs on BDF 160/4.5 twice daily with a participant who had had a myocardial infarction on the day after the treatment was discontinued. No deaths occurred. No data on asthma SAEs were found in the original review, but 2012 update includes report by Kerwin (no asthma-related SAEs in the arms included in this review).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Was LABA withdrawn during run-in I wonder? Roman states 7/3 for SAE so asked to recheck this. Data provided from AZ below so review changed to reflect these numbers. Also the death was at 17 weeks and therefore not in the randomised period when there was a LABA control arm. REMOVED!&lt;/p&gt;&lt;p&gt;&amp;quot;SD-039-0689 is a tricky study since it involved re-randomization of the Pulmicort arm (but not the two other arms) after 3 months and we therefore only use the data for the first 3 months, since the last 3 months do not have a non-LABA comparator arm.&lt;/p&gt;&lt;p&gt;The results in the table below show the SAEs with onset before day 90 in the trial, and give 7 vs 3 patients with SAE. (one Pulmicort patient reported two different SAEs).&amp;quot;&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;CENTER&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;PAT&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;DRUG_NAME&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;DOSE&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;SAE&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;MDRA_PT&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;ONSET_DAY&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;308&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;195&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;PULMICORT_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Metrorrhagia&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;308&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;195&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;PULMICORT_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Haemorrhoids&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;309&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;256&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;PULMICORT_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Cervical dysplasia&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;402&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;284&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;PULMICORT_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Cardiac failure&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;3 patients&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;203&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;119&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;SYMBICORT_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280/36&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Abdominal pain&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;301&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;184&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;SYMBICORT_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280/36&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Cerebral ischaemia&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;305&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;557&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;SYMBICORT_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280/36&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Pharyngeal oedema&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;507&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;519&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;SYMBICORT_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280/36&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Uterine leiomyoma&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;112&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;45&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;PULMICORT_OXIS_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280/36&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Umbilical hernia&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;306&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;192&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;PULMICORT_OXIS_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280/36&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Abdominal pain&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;407&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;306&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;PULMICORT_OXIS_TBH&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;1280/36&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Y&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;Pneumonitis&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot;&gt;&lt;p&gt;7 patients&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Jenkins-2006">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design:</B> a randomised, double-blind, double-dummy, reference-controlled, multi-centre, parallel-group study over 24 weeks from July 2001 to June 2002 at 54 centres in 6 countries: Australia (11), Austria (6) Czech Republic (15), France (9), Poland (8) and Spain (5). Run-in 2 weeks (on usual ICS).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 456 adolescents and adults (12 to 79 years) with persistent symptomatic asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 46 years. FEV<SUB>1</SUB> 66% predicted. Concomitant ICS used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>: outpatients aged 12 years and older with a diagnosis of asthma (minimum duration 6 months), FEV<SUB>1</SUB> % predicted between 40% and 85% and bronchodilator reversibility by an increase of at least 15% in FEV<SUB>1</SUB> over baseline after inhalation of a bronchodilator. For patients aged 18 years and older, an increase in baseline FEV<SUB>1</SUB> of at least 200 mL 15 to 30 minutes post bronchodilator was required at study entry (visit 1). All participants had used ICS for at least 4 months at a constant daily dose of at least 750 mcg for at least 4 weeks before study entry. </P>
<P>
<B>Exclusion Criteria</B>: if asthma deteriorated, resulting in a change in asthma therapy. Total asthma symptom score had to be &gt; 1 on a scale of 0 to 6 for at least 4 of the last 7 days of run-in. The total asthma symptom score was the sum of daytime and night-time asthma symptom scores, each measured on a scale of 0 to 3 (where 0 = no symptoms and 3 = unable to perform usual activities (or to sleep because of asthma).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 320/9 g two inhalations BD + Placebo BD.</LI>
<LI>Budesonide 400 g two inhalations BD + Formoterol 9 g two inhalationsBD + Placebo BD.</LI>
<LI>Budesonide 400 g two inhalations BD + Placebo BD.<B> </B>
</LI>
</UL>
<P>This was the treatment for the first 12 weeks, then group three was split between the first two treatments. DPI delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary efficacy variable was morning peak expiratory flow (PEF) as registered daily on diary cards.</P>
<P>Article reports five participants with SAE on BDF and two on budesonide. One death occurred in the BDF group from pulmonary embolism, but as this was after 17 weeks, when there was no budesonide control arm, this has not been included in the meta-analysis.</P>
<P>Data from AstraZeneca show 7 participants with SAE on BDF and 3 on budesonide in the first 12 weeks of the study. This has been used in the meta-analysis. It is not clear why the article reports different numbers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Check with Roman whether he has data on patients rather than events for 1/2 in asthma and 3/4 total SAEs. Confirmed Dec 1st&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Kuna-2006">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study design:</B> a randomised, double-blind, double-dummy, active-controlled, multi-centre, parallel-group study over 12 weeks from November 1999 to July 2000 at 60 centres in 8 countries: Finland (5), Germany (17), Mexico (4), New Zealand (3), Norway (6), Poland (7), Russia (5) and Sweden (13). Run-in 2 weeks in which all participants received budesonide 200 mcg daily (half the previous average dose).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 616 adults (18 to 80 years) with mild to moderate persistent asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 45 years. FEV<SUB>1</SUB> 78.5% predicted. Concomitant inhaled corticosteroids used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>: 18 years of age and older, a diagnosis of asthma (minimum duration 6 months) that was not optimally controlled despite a daily ICS dose of 200 to 500 mg for at least 30 days before study entry. FEV<SUB>1</SUB> % predicted of 60% to 90%, bronchodilator reversibility by an increase of at least 12% in FEV<SUB>1</SUB> over baseline after inhalation of either 1 mg of terbutaline or salbutamol 0.4 mg.</P>
<P>
<B>Exclusion Criteria</B>: used any systemic corticosteroids within the previous 30 days; seasonal asthma (defined as asthma exacerbated by seasonal increases in aero allergens); respiratory infection in the 4 weeks before study entry; a severe cardiovascular disorder or any other significant disease; used beta-blocker therapy (including eye drops) or had a history of heavy smoking (10 pack-years), women of child-bearing potential who were pregnant or who failed to use acceptable contraceptive measures.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 80/4.5 g 2 QD.</LI>
<LI>Budesonide/formoterol 80/4.5 g BD.</LI>
<LI>Budesonide 200 g QD.</LI>
</UL>
<P>Delivery was DPI, and all arms received equivalent delivered dose of 160 mcg budesonide daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary variable was morning PEF.</P>
<P>"Seven serious adverse events were reported: two in the once-daily BDF group, one in the twice-daily BDF group and four in the budesonide group." Although the three asthma SAEs were not described by treatment group in the article or the Web report, <LINK REF="REF-Jaeschke-2008" TYPE="REFERENCE">Jaeschke 2008</LINK> indicates one on BDF and two events on budesonide, with one hospitalisation for asthma in each group. No mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-24 14:28:05 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Meltzer-2012">
<CHAR_METHODS MODIFIED="2013-05-24 14:28:05 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: randomised, multi-centre, double-blind, double-dummy, placebo-controlled, parallel-group study over 26 weeks at 172 sites worldwide. Run-in two weeks mometasone fumarate (MF) 100 mcg twice daily.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 370 adults (in the arms that were eligible for this review) who were aged 12 years or older with asthma (generally moderate uncontrolled asthma).</P>
<P>
<B>Baseline Characteristics</B>: mean age 38 years. FEV<SUB>1</SUB> 75% predicted. Concomitant inhaled corticosteroids used by 100% of participants for at least 12 weeks (with or without LABA).</P>
<P>
<B>Inclusion Criteria</B>: asthma for at least 12 months and on a stable ICS regimen for at least 12 weeks. FEV<SUB>1</SUB> 60% to 85% predicted, bronchodilator reversibility at least 12% in FEV<SUB>1</SUB> or 0.2 litres; alternatively PEF variability over 20%.</P>
<P>
<B>Exclusion Criteria</B>: unstable asthma, smoking history greater than 10 pack-years, past history or present evidence of oropharyngeal candidiasis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Mometasone furoate/formoterol (MF/F) 100/10 mcg twice daily.</LI>
<LI>Mometasone furoate (MF)100 mcg twice daily.</LI>
</UL>
<P>Delivery was pMDI (the placebo and formoterol arms in this trial were not considered for this review).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>All-cause SAE data not reported by treatment group in article but data kindly provided by the authors, four adults with SAE on MF/F and 5 with SAE on MF (one on formoterol and one on placebo). No hospital admissions for asthma exacerbation, so no asthma-related SAEs (confirmed by authors).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by Merck Sharp &amp; Dohme.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;This study was excluded on its abstract but included from full paper and AZ trial register.&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Morice-2007">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, parallel-group study over 12 weeks from April </P>
<P>2002 to February 2003 at 62 centres in Brazil (7), Bulgaria (5), Canada (9), Hungary (9), Mexico (7), the Philippines (6), Thailand (5) and UK (14). Run-in 2<I> </I>weeks on pre-study ICS, but LABA was withdrawn from the 15% previously treated with LABA and ICS.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 680 adolescents and adults (12 to 79 years) with asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 40 years. FEV<SUB>1</SUB>70% predicted. Concomitant ICS used previously by 100% of participants (mean dose 770 mcg/day).</P>
<P>
<B>Inclusion Criteria</B>: 12 years of age and older with asthma for at least 6 months, who were inadequately controlled on ICS alone, FEV1 % predicted between 50% and 90%, bronchodilator reversibility by an increase of at least 12% in FEV<SUB>1 </SUB>after inhalation of terbutaline 1 mg, a history of daily ICS use (stable dose of 500 to 1600 mcg/day within 30 days before enrolment) for at least 3 months.Symptoms must have been present on at least 4 of the last 7 days of run-in.</P>
<P>
<B>Exclusion Criteria</B>: not defined.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide 200 g 2 BD pMDI (CFC propellant).</LI>
<LI>Budesonide/formoterol 160/4.5 g 2 BD DPI.</LI>
<LI>Budesonide/formoterol 160/4.5 g 2 BD pMDI (HFA propellant).</LI>
</UL>
<P>All delivered the same daily dose of budesonide.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary efficacy endpoint was the change in morning peak expiratory flow (PEF) from baseline (mean of the last 10 days of run-in) to the mean value over the 12-week treatment period.</P>
<P>Article reports: "No deaths occurred. Four participants experienced serious adverse events, two in the budesonide group (joint dislocation, asthma) and two in BDF pMDI (menorrhagia, increased liver enzymes)."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 10:53:31 +0000" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;Children's data so not included by Roman. Dose 200 per day.&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Morice-2008">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, parallel-group study over 12 weeks from June 2002 to May 2003 at 53 centres in Argentina (4), Brazil (6), Denmark (14), Hong Kong (1), Mexico (6), Poland (4), Slovakia (12) and Taiwan (6).</P>
<P>Run-in 2<I> </I>weeks on previous ICS dose (but previous LABA may have been withdrawn; not made clear in the article).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>
<B>Population</B>: 622 children (6 to 11 years) with symptomatic asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 8 years. FEV<SUB>1</SUB>82% predicted. Concomitant ICS used by 100% of participants (375 to 100 mcg daily).</P>
<P>
<B>Inclusion Criteria</B>: paediatric outpatients (6 to 11 years) with asthma and a history of clinically important exercise-induced bronchoconstriction, daily use of 375 to 1000 g of inhaled<B> </B>glucocorticosteroids (GCSs), peak expiratory flow (PEF) at least 50% of predicted<B> </B>normal value (pre-bronchodilator). Had to have a total asthma symptom score (night-time plus daytime) of at least 1 on at least 4 of the last 7 days of the run-in period and a mean morning PEF (mPEF) during the last 7 days of the run-in period of 50% to 85%<B> </B>of post bronchodilatory PEF, measured at Visit 1 (enrolment).</P>
<P>
<B>Exclusion Criteria</B>: inability to use DPI and peak flow meter.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide 100 g 2 BD pMDI.</LI>
<LI>Budesonide/formoterol 80/4.5 g 2 BD DPI.</LI>
<LI>Budesonide/formoterol 80/4.5 g 2 BD pMDI,</LI>
</UL>
<P>Dose of budesonide was equivalent in each arm (100 metered dose equivalent to 160 delivered doses).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary efficacy endpoint was the change in morning peak expiratory flow (PEF) from baseline (mean of the last 10 days of run-in) to the mean value over the 12-week treatment period.</P>
<P>Article reports: "Five patients reported serious adverse events: 3 in budesonide group (asthma aggravation (2), nervousness), 2 BDF DPI (acute sinusitis, migraine). No deaths were reported."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Nathan-2010">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: randomised, multi-centre, double-blind, double-dummy, placebo-controlled, parallel-group study over 26 weeks at 152 sites worldwide. Run-in two or three weeks mometasone fumarate (MF) 200 mcg twice daily.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 383 adults (in the arms that were eligible for this review) who were aged 12 years or older) with asthma (generally moderate uncontrolled asthma).</P>
<P>
<B>Baseline Characteristics</B>: mean age 42 years. FEV<SUB>1</SUB> 73% predicted. Concomitant inhaled corticosteroids used by 100% of participants for at least 12 weeks (with or without LABA).</P>
<P>
<B>Inclusion Criteria</B>: asthma for at least 12 months and on a stable medium dose ICS regimen for at least 12 weeks. FEV<SUB>1</SUB> 60% to 85% predicted, bronchodilator reversibility at least 12% in FEV<SUB>1</SUB> or 0.2 litres; alternatively PEF variability over 20%.</P>
<P>
<B>Exclusion Criteria</B>: unstable asthma, smoking history greater than 10 pack-years, past history or present evidence of oropharyngeal candidiasis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Mometasone furoate/formoterol (MF/F) 200/10 mcg twice daily.</LI>
<LI>Mometasone furoate (MF)200 mcg twice daily.</LI>
</UL>
<P>Delivery was pMDI (the placebo and formoterol arms in this trial were not considered for this review).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>To evaluate the safety and tolerability of the study drugs, clinical assessment and review of laboratory data included monitoring of adverse events (AEs) and serious AEs (SAEs).</P>
<P>We found no specific reporting of deaths in trial reports, but the FDA report detailed that "in P04334, a 53-year-old female (Patient 0012/Site 12) on MF/F 200/10 BID died from metastatic uterine leiomyosarcoma"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by Merck &amp; Co.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;This one appears to be missing from Roman's review. He excluded due to loss to follow-up. Prespecified. Data matches Sears supplementary but totals higher in Sears as they included the placebo and formoterol only arms....&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Noonan-2006">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Randomised, double-blind, double-dummy, multi-centre, placebo-controlled study over 12 weeks from July 2002 to January 2004 at 84 US centres (respiratory or allergy speciality clinical practice). Run-in 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 596 adolescents and adults(12 to 87 years) with moderate to severe persistent asthma.BDF 124 participants, BD + F 115 participants, budesonide 109 participants.</P>
<P>
<B>Baseline Characteristics</B>: mean age 41 years. FEV<SUB>1</SUB> 67% predicted. Concomitant ICS used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>:moderate to severe persistent asthma treated long term with a medium to high dose of ICS, FEV<SUB>1</SUB> % predicted within the entrance range of 45% to 85%, bronchodilator reversibility of FEV<SUB>1</SUB> of at least 12% and 0.20 L from the pre-albuterol baseline value within 15 to 30 min after administration of a standard dose of salbutamol.</P>
<P>
<B>Exclusion Criteria</B>: requiring hospitalisation once or emergency treatment more than once in the preceding 6 months, greater than 10-pack-per-year smoking history.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide 160 mcg twice daily.</LI>
<LI>Budesonide/formoterol 160/9 mcg pMDI twice daily.</LI>
<LI>Budesonide pMDI and formoterol DPI 160/9 mcg twice daily.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The co-primary efficacy variables were baseline adjusted average 12-hour FEV<SUB>I</SUB> and predose FEV<SUB>I</SUB>.</P>
<P>"Nine subjects had SAEs during double-blind treatment: 4 on BDF pMDI (asthma -2, urti and ECG T wave inversion), 2 in the formoterol group and 3 in the budesonide + formoterol group (small intestine obstruction, abdominal injury, pneumonia)."</P>
<P>Web data found on AZ clinical trials Website SD-039-0717.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca. <LINK REF="REF-Jaeschke-2008" TYPE="REFERENCE">Jaeschke 2008</LINK> excluded this study as it included more than 20% dropouts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;OPTIMA but data entered as from Susan's sheet. Roman to check this and the group and cause of death in the single patient. &lt;a link_type=&quot;REFERENCE&quot; href=&quot;Sears 2008&quot; protected=&quot;true&quot;&gt;Sears 2008&lt;/a&gt; indicates that the death was also related to status asthmaticus and was in a patient taking budesonide/formoterol combination treatment.&lt;/p&gt;&lt;p&gt;&amp;quot;2. OPTIMA (O&amp;#8217;Byrne 2001) study, &amp;#8220;total SAE&amp;#8221;.&lt;/p&gt;&lt;p&gt;When calculated from the AZ safety database the answer is 33 vs 40, while the CSR states 35 vs 42. I&amp;#8217;m not sure how to explain this, possible some events may have been downgraded in the safety database after the report was written. I suppose it is best to go with the CSR data. Sorry for the confusion.&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;3. OPTIMA &amp;#8220;For asthma-related SAE: 6 vs 11 or 7 vs 10 or 7 vs 11. If it is different than 7 vs 10, please confirm the distribution within subgroups&amp;#8221;.&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;7 vs 11&lt;/p&gt;&lt;p&gt;BUD+F: 3 on low, 4 on high&lt;/p&gt;&lt;p&gt;BUD: 4 on low, 7 on high *******(BUT JOE HAS RECORDED THIS AS 6 ON HIGH)******** He will check. No change in data as yet.....&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;I have no idea regarding the different numbers, 7 vs 11 is the ratio used in the Sears online supplement (you can always use that to confirm the numbers). We have enclosed that tocument for your and Dr Cates convenience.&amp;quot;&lt;/p&gt;&lt;p&gt;&amp;quot;One of the deaths occurred in a 35 year old female after an 8 day hospitalization for a severe asthma attack leading to intubation, ventilation, and nosocomial pneumonia with septic shock.&amp;quot;&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-O_x0027_Byrne-2001">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study design: </B>A randomised, double-blind, parallel-group study over 12 months from January 1998 to February 2000 at 198 centres in 17 countries. Run-in 1 month.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 1970 adults (18 to 76 years) with mild asthma (Group A 698) and mild to moderate asthma (Group B 1272).</P>
<P>
<B>Baseline Characteristics</B>:</P>
<P>(Group A) Mean age 31 years. FEV<SUB>1</SUB> 90% predicted. Concomitant ICS used by 0% of participants.</P>
<P>(Group B) Mean age 37 years. FEV<SUB>1</SUB> 87% predicted. Concomitant ICS used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>: 12 years of age and older. Diagnosis of stable asthma, according to the American Thoracic Society (ATS).</P>
<P>(Group A) had used no inhaled corticosteroid for at least3 months, pre-bronchodilator FEV<SUB>1</SUB> % predicted at least 70% at visit 1. 15 min post bronchodilator FEV<SUB>1</SUB> % predicted of at least 80% at visit 1 (2  0.5 mg Bricanyl Turbuhaler).</P>
<P>(Group B) taking no more than 400 g of inhaled budesonide or its equivalent</P>
<P>for at least 3 months, pre-bronchodilator FEV<SUB>1</SUB> % predicted at least 50% at visit 1. 15 minutes post bronchodilator FEV<SUB>1</SUB> % predicted at least 70% at visit 1 (2 x 0.5 mg Bricanyl Turbuhaler).</P>
<P>
<B>Exclusion Criteria</B>: use of oral GCS within 3 months before visit 1, beta-blocker therapy (eyedrops included). Pregnant and/or lactating women or women not using acceptable contraceptives as judged by the investigator, participants with a history of smoking greater than 15 pack-years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>THIS REPORT RELATES TO PATIENTS GIVEN <B>200 mcg budesonide twice daily:</B>
</P>
<P>(Group A)</P>
<UL>
<LI>
<B> Budesonide 200 g.</B>
</LI>
<LI>
<B>Budesonide and formoterol 200 and 4.5 g.</B>
</LI>
</UL>
<P>Placebo arm from Group A was not included in this review.</P>
<P>(Group B)</P>
<UL>
<LI>
<B> Budesonide 200 g.</B>
</LI>
<LI>
<B> Budesonide and formoterol 200 and 4.5 g.</B>
</LI>
<LI>Budesonide 400 g.</LI>
<LI>Budesonide and formoterol 400 and 4.5 g.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Primary variable was time to first severe asthma exacerbation, expressed as the risk for a first severe exacerbation, and rate (proportion) of poorly controlled days.</P>
<P>Serious adverse events are not mentioned at all in the article publication and the Web report (SD-037-0345) gives only total numbers of participants with SAEs for Groups A and B (with no indication of treatment group).</P>
<P>AstraZeneca has provided a breakdown of all-cause SAE and asthma-related SAE (AstraZeneca Data on file 2008).</P>
<P>One death was not reported in the article but was mentioned in the Web report as probably due to 'septic shock' in group A. <LINK REF="REF-Sears-2008" TYPE="REFERENCE">Sears 2008</LINK> indicates that the death was also related to status asthmaticus and occurred in a participant who was taking budesonide/formoterol combination treatment. The full report of the death from the sponsors is as follows: "One of the deaths occurred in a 35 year old female after an 8-day hospitalisation for a severe asthma attack leading to intubation, ventilation, and nosocomial pneumonia with septic shock."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Use this for the 200 mcg ICS data from Optima. The 6 on Bud 200mcg has been revised to 7 after lenghty correspondence with AZ. There was one patient listed as pneumonia in the trial report but who also had asthma in the study database. &lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;Group A&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Group A&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Group A&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Placebo&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Budesonide 100?g bid&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Budesonide 100?g bid&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;+ formoterol 4.5?g bid&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;(n=239)&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;(n=228)&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;(n=231)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;Number of patients &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&lt;b&gt;with one or more &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;8&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;SAEs of any cause &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;Number of patients &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&lt;b&gt;with one or more &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;asthma SAEs &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&amp;#160;Group B Budesonide 100?g bid (n=322)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Group B Budesonide 100?g bid + formoterol 4.5?g bid (n=323)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Group B Budesonide 200?g bid (n=312)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Group B Budesonide 200?g bid + formoterol 4.5?g bid (n=315)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&lt;b&gt;Number of patients with one or more SAEs of any cause &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;12&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&lt;b&gt;Number of patients with one or more asthma SAEs &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;(6)&lt;b&gt;7&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-O_x0027_Byrne-2001a">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study design: </B>a randomised, double-blind, parallel-group study over 12 months from January 1998 to February 2000 at 198 centres in 17 countries. Run-in 1 month.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 1970 adults (18 to 76 years) with mild asthma. (Group A 698) and mild to moderate asthma (Group B 1272).</P>
<P>
<B>Baseline Characteristics</B>:</P>
<P>(Group A) Mean age 31 years. FEV<SUB>1</SUB> 90% predicted. Concomitant ICS used by 0% of participants.</P>
<P>(Group B) Mean age 37 years. FEV<SUB>1</SUB> 87% predicted. Concomitant ICS used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>: 12 years of age and older. Diagnosis of stable asthma, according to the American Thoracic Society (ATS).</P>
<P>(Group A) had used no inhaled corticosteroid for at least 3 months, pre-bronchodilator FEV<SUB>1</SUB> % predicted at least 70% at visit 1. 15 min post bronchodilator FEV<SUB>1</SUB> % predicted at least 80% at visit 1 (2 0.5 mg Bricanyl Turbuhaler).</P>
<P>(Group B) taking no more than 400 g of inhaled budesonide or its equivalent</P>
<P>for at least 3 months, pre-bronchodilator FEV<SUB>1</SUB> % predicted at least 50% at visit 1. 15 minutes post bronchodilator FEV<SUB>1</SUB> % predicted of at least 70% at visit 1 (2  0.5 mg Bricanyl Turbuhaler).</P>
<P>
<B>Exclusion Criteria</B>: use of oral GCS within 3 months before visit 1, beta-blocker therapy (eye drops included).pregnant and/or lactating women or women not using acceptable contraceptives as judged by the investigator, participants with a history of smoking greater than 15 pack-years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>THIS REPORT RELATES TO PATIENTS GIVEN 400 mcg budesonide twice daily.</P>
<P>(Group A)</P>
<UL>
<LI>Budesonide 200 g.</LI>
<LI>Budesonide and formoterol 200 and 4.5 g.</LI>
</UL>
<P>Placebo arm from Group A was not included in this review.</P>
<P>(Group B)</P>
<UL>
<LI>Budesonide 200 g.</LI>
<LI>Budesonide and formoterol 200 and 4.5 g.</LI>
<LI>
<B>Budesonide 400 g.</B>
</LI>
<LI>
<B>Budesonide and formoterol 400 and 4.5 g.</B>
</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary variable was time to first severe asthma exacerbation, expressed as the risk for a first severe exacerbation, and rate (proportion) of poorly controlled days.</P>
<P>SAEs are not mentioned at all in the paper publication, and the Web report (SD-037-0345) gives only total numbers of participants with SAEs for Groups A and B (with no indication of treatment group).</P>
<P>AstraZeneca has provided a breakdown of all-cause SAE and asthma-related SAE that was used in the meta-analysis. (AstraZeneca Data on file 2008)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Pauwels-1997">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, multi-centre, parallel-group study over 12 months at 71 centres in 9 countries. (Belgium, Canada, the Netherlands, Israel, Italy, Luxembourg, Norway, Spain and the United Kingdom). Run-in 4 weeks on 800 mcg twice daily.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, multi-centre, parallel-group study over 12 months at 71 centres in 9 countries. (Belgium, Canada, the Netherlands, Israel, Italy, Luxembourg, Norway, Spain and the United Kingdom). Run-in 4 weeks on 800 mcg twice daily.</P>
<P>
<B>Population</B>: 852 adults (18 to 70 years) with persistent symptomatic asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 42 years. FEV<SUB>1</SUB> 76% predicted. Concomitant inhaled corticosteroids used by 100% of participants (mean dose 820 mcg/day). </P>
<P>
<B>Inclusion Criteria</B>: 18 to 70 years old, who had had asthma for at least six months and had been treated with an inhaled glucocorticoid for at least three months. FEV<SUB>1</SUB> % predicted at least 50%, bronchodilator reversibility by an increase of at least 15% in FEV<SUB>1</SUB> over baseline after inhalation of 1 mg of terbutaline. Stable asthma during run-in and compliant with treatment.</P>
<P>
<B>Exclusion Criteria</B>: three or more courses of oral glucocorticoids or had been hospitalised for asthma during the previous six months. Taking more than 2000 mcg of beclomethasone or 1600 mcg of budesonide daily by pressurised metered dose inhaler, 800 mcg of budesonide daily by Turbuhaler dry-powder inhaler or 800 mcg of fluticasone daily.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Budesonide 100 g BD + Placebo.</B>
</P>
<P>
<B>Budesonide100 g + Formoterol 12 g BD(9 g delivered dose).</B>
</P>
<P>Budesonide 400 g BD + Placebo.</P>
<P>Budesonide 400 g + Formoterol 12 g BD (9 g delivered dose).</P>
<P>Delivery was DPI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Two primary outcome variables, the rate of severe exacerbations and the rate of mild exacerbations, according to treatment group.</P>
<P>SAE data (all-cause and asthma-related) provided by AstraZeneca from Data on file 2008.</P>
<P>No SAE data given in the paper publication, except asthma admissions, but the sponsors have provided data on file for the numbers of participants with all-cause and asthma-related SAEs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Check 4 or 5 and where is the single death. IT was FIVE - mistake by Joe GRAY. Joe also confirms that the single death was on the higher dose Budesonide plus formoterol. Cause awaited. The table now reads 15 and 10 for all cause SAE on BD and F and 3/8 for &lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Pauwels-1997a">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, multi-centre, parallel-group study over 12 months at 71 centres in 9 countries (Belgium, Canada, the Netherlands, Israel, Italy, Luxembourg, Norway, Spain and the United Kingdom). Run-in 4 weeks on 800 mcg twice daily.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, multi-centre, parallel-group study over 12 months at 71 centres in 9 countries (Belgium, Canada, the Netherlands, Israel, Italy, Luxembourg, Norway, Spain and the United Kingdom). Run-in 4 weeks on 800 mcg twice daily.</P>
<P>
<B>Population</B>: 852 adults (18 to 70 years) with persistent symptomatic asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 42 years. FEV<SUB>1</SUB> 76% predicted. Concomitant ICS used by 100% of participants (mean dose 820 mcg/day). </P>
<P>
<B>Inclusion Criteria</B>: 18 to 70 years old, who had asthma for at least six months and had been treated with an inhaled glucocorticoid for at least three months. FEV<SUB>1</SUB> % predicted at least 50%, bronchodilator reversibility by an increase of at least 15% in FEV<SUB>1</SUB> over baseline after inhalation of 1 mg of terbutaline. Stable asthma during run-in and compliant with treatment.</P>
<P>
<B>Exclusion Criteria</B>: three or more courses of oral glucocorticoids or had been hospitalised for asthma during the previous six months. Taking more than 2000 mcg of beclomethasone or 1600 mcg of budesonide daily by pressurised metered dose inhaler, 800 mcg of budesonide daily by Turbuhaler dry-powder inhaler or 800 mcg of fluticasone daily.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>This report deals with patients on 800 mcg budesonide daily.</P>
<P>Budesonide 100 g BD + Placebo.</P>
<P>Budesonide100 g + Formoterol 12 g BD(9 g delivered dose).</P>
<P>
<B>Budesonide 400 g BD + Placebo.</B>
</P>
<P>
<B>Budesonide 400 g + Formoterol 12 g BD (9 g delivered dose).</B>
</P>
<P>Delivery was DPI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Two primary outcome variables, the rate of severe exacerbations and the rate of mild exacerbations, according to treatment group.</P>
<P>SAE data (all-cause and asthma-related) provided by AstraZeneca from Data on file 2008.</P>
<P>No SAE data given in the paper publication, except asthma admissions, but the sponsors have provided data on file for the number of participants with all-cause and asthma-related SAEs. One death (unrelated to asthma) occurred in a participant on budesonide 400 and formoterol 12 twice daily.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Zero Asthma SAE on Bud also needs to be run by Joe! Too recent for Roman's paper.&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Peters-2008">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, single-dummy, multi-centre, phase III, parallel-group study over 52 weeks from August 2003 to February 2005 at 77 centres in the United States.</P>
<P>Run-in 2 weeks on budesonide 320 mcg bd (LABA discontinued).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 708 adults and adolescents (12 to 81 years) with moderate to severe persistent asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 40 years. FEV<SUB>1</SUB> 72% predicted. Concomitant ICS used by 100% of participants (mean daily dose around 500 mcg).</P>
<P>
<B>Inclusion Criteria</B>: 12 years of age and older with a documented clinical diagnosis of moderate to severe asthma for at least 6 months before screening, received maintenance asthma treatment with a stable dose of ICS for at least 4 weeks before the screening visit. FEV<SUB>1</SUB> % predicted ofat least 45%, bronchodilator reversibility by an increase of at least 12% in FEV<SUB>1</SUB> and at least 0.20 L from baseline within 15 to 30 minutes after administration of a fast-acting beta<SUB>2</SUB>-agonist or have a documented history of this level of reversibility after administration of a fast-acting beta<SUB>2</SUB>-agonist while using ICS within 1 year of screening.To require two asthma controller medications or to have had a history of at least two asthma-related night-time awakenings or at least three uses of rescue medication within the week before screening. Required to be nonsmokers, with a less than 20-pack-year smoking history.</P>
<P>
<B>Exclusion Criteria</B>: had a significant disease or disorder (e.g. cardiovascular,<B> </B>pulmonary [other than asthma], hepatic, renal)<B> </B>that, in the opinion of the investigator, may put the<B> </B>participant at risk or influence the results of the study. In<B> </B>addition, those treated with systemic corticosteroids<B> </B>within 30 days before screening or during the period between screening and randomisation were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 640/18 g BD.</LI>
<LI>Budesonide/formoterol 320/9 g BD (this arm was not used in the analysis for this review).</LI>
<LI>Budesonide 640 g BD.</LI>
</UL>
<P>Delivery was pMDI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Because this study was a safety study, no single variable was considered primary. However, spirometry (predose and 2-hour post-dose FEV<SUB>1</SUB>) was conducted at each study visit to detect any untoward decreases in lung function over the 52-week period.</P>
<P>Web report indicates 21 participants with SAE on BDF 640/18 bd and 5 on budesonide 640 bd. No deaths in the study.</P>
<P>Article reports one asthma SAE in the BDF 640/18 bd group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca (SD-039-0728).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pohunek-2006">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, active-controlled, multi-centre, parallel-group study over 12 weeks from March 2002 to March 2003 at 80 centres in 8 countries: Austria (5), Belgium (11), Czech Republic (14), France (11), Hungary (12), Poland (17), Spain (8) and Switzerland (2).</P>
<P>Run-in 2 weeks on previous dose of ICS, but LABA appears to have been withdrawn from the 40% previously taking LABA?</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>
<B>Population</B>: 630 children (4 to 11 years) with asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 8 years. FEV<SUB>1</SUB> 92% predicted. Concomitant ICS used by 100% of participants (mean 450 mcg/day), and around 40% had previously being taking LABA.</P>
<P>
<B>Inclusion Criteria</B>:outpatients aged 4 to 11 years who had been diagnosed with asthma (as defined by the American Thoracic Society) for a minimum period of 6 months, to have a pre-bronchodilator PEF at least 50% of predicted normal and to havereceived treatment with an ICS (any brand) for at least 3 months before entry into the study, with the dose remaining constant (375 to1000 g/day) during the 30 days immediately before enrolment, had to have a history of an average of more than 1 clinically important exercise-induced bronchoconstriction per week during the 3 months leading up to the study.</P>
<P>
<B>Exclusion Criteria</B>: used oral, parenteral, or rectal corticosteroids within 30 days of inclusion in the study; any respiratory infection affecting asthma control within the 30 days before enrolment; any significant disease or concomitant disorder; known or suspected hypersensitivity to the study medication or inhaled lactose. Use of inhaled anticholinergics, beta-blockers (including eye drops), xanthines, and other anti-asthma products was not permitted during the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 80/4.5 g 2 BD.</LI>
<LI>Budesonide 100 g 2 BD.</LI>
<LI>Budesonide 100 g 2 BD + Formoterol 4.5 g 2 BD (separate inhalers).</LI>
</UL>
<P>Equivalent budesonide in each arm (400 mcg metered dose). DPI delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary efficacy variable was the change from baseline to treatment (average of the 12-week treatment period) in morning peak expiratory flow (PEF).</P>
<P>Article reports: "Serious adverse events were experienced by a total of 11 participants: 3 BDF (fracture, laryngitis, torticollis), 5 with budesonide and formoterol in separate inhalers (appendicitis (2), vomiting, laryngitis, pneumonia) and 3 with budesonide (gastroenteritis (2) and fracture). No deaths were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Data from Roman's paper: 2/3 SAE and 0/2 asthma SAE. No deaths. 250/255&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Price-2002">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, multi-centre, parallel-group study in 152 general practices in the UK and the Republic of Ireland comprising two parts (4 weeks and 24 weeks). Run-in 7 to 14 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 663 adolescents and adults (12+ years) with mild to moderate asthma (part 1). <B>505 continued to part 2.</B>
</P>
<P>
<B>Baseline Characteristics</B>: mean age 38 years. Concomitant ICS used by 67% of participants.</P>
<P>
<B>Inclusion Criteria</B>:12 years and older with a diagnosis of asthma confirmed in the clinical record for at least 3 months. Current treatment had to include a short-acting beta<SUB>2</SUB>-agonist alone or with an ICS (&lt;400 mg/day beclomethasone dipropionate or budesonide via pressurised metered dose inhaler, or &lt;200 mg/day fluticasone or budesonide via Turbohaler) at a constant dose for &gt;4 weeks. Were required to have experienced asthma symptoms (chest tightness, cough, wheeze or shortness of breath) on a minimum of 3 days in the week before enrolment into the study. Either reversibility of peak expiratory flow (PEF)/forced expiratory volume in 1 second (FEV<SUB>1</SUB>) of &gt; 12% (or &gt; 9% of predicted normal), or a diurnal variation of &gt; 20% on at least one day during the run in period.</P>
<P>
<B>Exclusion Criteria</B>: more severe or recently unstable asthma, PEF &lt; 50% predicted; currently receiving (during 4 weeks before enrolment) nebulised therapy, oral corticosteroids, leukotriene antagonist, or long-acting beta<SUB>2</SUB>-agonist; a clinically relevant upper respiratory tract infection in the 4 weeks leading up to enrolment, irreversible chronic airways disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<UL>
<LI>Budesonide 400 g BD + Eformoterol 9 g BD.</LI>
<LI>Budesonide 400 g BD + placebo.</LI>
</UL>
<P>Data from part 2 used after 4 weeks stabilisation of participants on the same treatments in part 1. DPI delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>In part 2, the primary outcome measure was time to the first mild asthma exacerbation.</P>
<P>SAE data not reported in article but obtained from <LINK REF="REF-Jaeschke-2008" TYPE="REFERENCE">Jaeschke 2008</LINK>.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Supported by grant from AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-SD_x002d_039_x002d_0714">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A randomised, double-blind, multi-centre, parallel-group study over 12 weeks from August 2001 to September 2002 at 122 centres in the United Kingdom (119 general practice centres and 3 hospital centres). Run-in 2 weeks on budesonide 200 mcg twice daily.</P>
<P>Efficacy and safety of budesonide/formoterol Turbuhaler (160/4.5 mg bid delivered dose) compared with budesonide Turbuhaler (200 mg bid metered dose) in steroid-using asthmatic adolescent participants. A double-blind, double-dummy, randomised, parallel-group, phase III, multicentre study (ATTAIN study).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 271 steroid-using asthmatic adolescents (11 to 17) years.</P>
<P>
<B>Baseline Characteristics</B>: mean age 14 years. FEV<SUB>1</SUB> 75% predicted. Concomitant ICS used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>: 12 to 17 years old. FEV<SUB>1</SUB> % predicted 40% to 90%,bronchodilator reversibility of at least 12% in FEV<SUB>1 </SUB>and experiencing asthma symptoms. Receiving an ICS for perennial asthma, dose of ICS within or equal to 375 to 1000 mg daily dose within the licensed dose for participants&#8217; age,</P>
<P>
<B>Exclusion Criteria</B>: not obvious.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 160/4.5 g BD.</LI>
<LI>Budesonide 200 g BD.</LI>
</UL>
<P>Delivery was DPI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>am PEF as recorded in diary daily by participants..</P>
<P>Web report indicates no deaths and one SAE in each group (overdose on BDF and bronchospasm on budesonide).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-SD_x002d_039_x002d_0718">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, active-controlledstudy over 12 weeks from July 2002 to October 2003 at 52 centres in the United States. Run-in 2 weeks on 100 mcg budesonide twice daily.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>
<B>Population</B>: 411 children (6 to15 years) with mild to moderate asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 10 years. FEV<SUB>1</SUB> 82% predicted. Concomitant inhaled corticosteroids used by 100% of participants (mean 235 mcg/day).</P>
<P>
<B>Inclusion Criteria</B>: 6 to 15 years of age, treated long term with a low to medium dose of ICS, FEV<SUB>1</SUB> % predicted at least 50% on ICS therapy, older than 12 years, bronchodilator reversibility of at least 12% in FEV<SUB>1 </SUB>and at least 0.20 L from the pre-albuterol value within 15 to 30 minutes after administration of a standard dose of a fast-acting beta<SUB>2</SUB>-agonist (albuterol pMDI, 2 to 4 actuations [90 g per actuation], with or without a spacer) or after administration of up to 2.5 mg nebulized albuterol. Younger than 12 years needed to show only reversibility of at least 12%. Alternatively, reversibility of PEF of at least 15%, but not more than 50%, could be used by any subject to meet the reversibility criterion.</P>
<P>
<B>Exclusion Criteria</B>: not obvious.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 40/4.5 g 2 BD pMDI delivery.</LI>
<LI>Budesonide 40 g 2 BD pMDI delivery.</LI>
<LI>Formoterol 4.5 g 2 BD DPI delivery.</LI>
</UL>
<P>Arm three not used in this review.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Primary efficacy variable: morning peak expiratory flow (PEF).</P>
<P>Web report lists no deaths and no participants with SAE in groups one or two.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-SD_x002d_039_x002d_0719">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, open-label, safety study over 26 weeksfrom July 2002 to October 2003 at 29 centers in the United States. Run-in 1 week.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 187 children (6 to 11 years) with ICS-dependent asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 9 years. FEV<SUB>1</SUB> 84% predicted. Concomitant ICS used by 100% of participants. </P>
<P>
<B>Inclusion Criteria</B>: 6 to under 12 years of age with ICS-dependent asthma. FEV<SUB>1</SUB> % predicted at least 50%, documented historic peak expiratory flow (PEF) or FEV<SUB>1</SUB> reversibility at least 12% from a pre-albuterol value within 15 to 30 min after administration of a standard dose of fast-acting beta<SUB>2</SUB>-agonist. Participants without a documented history of reversibility must have demonstrated FEV<SUB>1</SUB> reversibility as above at any time before visit 2. </P>
<P>
<B>Exclusion Criteria</B>: not obvious.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 160/4.5 g 2 BD pMDI delivery.</LI>
<LI>Budesonide 160 g 2 BD TBH delivery.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-22 10:25:10 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Outcome</B>: No single variable was considered to be primary. The primary objective of the study was to assess long-term safety.</P>
<P>Web report indicates no deaths. Two SAEs in BDF group (asthma and pneumonia) and one on budesonide (sickle cell anaemia).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Only SAEs that occured during the double blind treatment period are included here. See table.&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-SD_x002d_039_x002d_0725">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, multi-centre, active-controlled, parallel-group study over 12 weeks from January 2003 to August 2004 at 128 centres in the United States. Run-in 4 to 5 weeks, single-blind (participants had to be stable on budesonide/formoterol 40/4.5 mcg two puffs twice daily).</P>
<P>A 12--week, randomised, double-blind, double-dummy, active-controlled study of SYMBICORT pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 522 children and adolescents (6 to15 years) with asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 10 years. FEV<SUB>1</SUB> 78% predicted. Concomitant ICS previously used by 100% of participants (mean 245 mcg/day).</P>
<P>
<B>Inclusion Criteria</B>: 6 to 15 years with a documented clinical diagnosis of asthma for at least 6 months before screening, and in stable condition. Should have received maintenance asthma treatment with ICS for at least 4 weeks before the screening visit. FEV<SUB>1</SUB> % predicted of between 60% and 90%, as measured approximately 24 hours after the last dose of long-acting beta<SUB>2</SUB>-<SUB> </SUB>agonist and 6 hours after the last dose of short-acting beta<SUB>2</SUB>-agonist. Participants with an FEV<SUB>1</SUB> predicted between 90% and 95% predicted could be included if they had an FEV<SUB>1</SUB>/FVC ratio measured on screening spirometry ofless than 80%. Bronchodilator reversibility of at least 12% in FEV<SUB>1 </SUB>and at least 0.20 L from baseline within 15 to 30 minutes after administration of a standard dose of fast-acting beta2-agonist, except for participants younger than 11 years of age, who were required to show reversibility of at least 12% but not also a change of at least 0.20 L. </P>
<P>
<B>Exclusion Criteria</B>: Not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 80/4.5 g 2 QD.</LI>
<LI>Budesonide/formoterol 40/4.5 g 2 BD.</LI>
<LI>Budesonide 80 g 2 QD.</LI>
</UL>
<P>Delivery was pMDI. All groups had 160 mcg budesonide daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Primary variable: evening PEF (from daily diary).</P>
<P>"There were no deaths at any time during the study."</P>
<P>"6 subjects had an SAE during the double blind treatment period: 2 on BDF 40 bd (abdominal pain, asthma), 3 in BDF 80 qd group (influenza, asthma 2) and one in the budesonide group (asthma)."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-24 14:28:16 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-SD_x002d_039_x002d_0726">
<CHAR_METHODS MODIFIED="2013-05-24 14:28:16 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, multi-centre, parallel-group, placebo- and active-controlled<B> </B>study over 12 weeks from April 2003 to June 2004 at 151 centers in the United States. Run-in 4- to 5-week single-blind.</P>
<P>A twelve-week, randomised, double-blind, double-dummy, placebo- and active-controlled study of SYMBICORT pMDI administered once daily in adults and adolescents with asthma.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 752 adolescents and adults (16 to 79 years) with asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 38 years. FEV<SUB>1</SUB> 75% predicted. Concomitant ICS used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>: 16 years of age and older, with a documented clinical diagnosis of asthma for at least 6 months before screening, and in stable condition. Received maintenance asthma treatment with a low to medium dose of ICS for at least 4 weeks before the screening visit.</P>
<P>FEV<SUB>1</SUB> % predicted of between 60% and 90%, measured at least 24 hours after the last dose of long-acting beta<SUB>2</SUB>-agonist and 6 hours after the last dose of short-acting beta<SUB>2</SUB>-agonist.</P>
<P>
<B>Exclusion Criteria</B>: not obvious.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 160/4.5 g 2 QD.</LI>
<LI>Budesonide/formoterol 80/4.5 g 2 QD. </LI>
<LI>Budesonide/formoterol 80/4.5 g 2 BD.</LI>
<LI>Budesonide 160 g 2 QD.</LI>
</UL>
<P>Placebo arm and arm two not used in this analysis. MDI delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Primary variable: evening PEF (from daily diary).</P>
<P>SAE data obtained from Web report. Five participants suffered an SAE: three on BDF 80 bd (breast cancer in situ, road traffic accident, musculoskeletal chest pain), one on BDF 160 daily (prostate cancer), and one on budesonide (tension headache). No deaths were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Spector-2012">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design: </B>This was a 12-week, randomised, double-blind, double-dummy, phase IV study comparing the efficacy and safety of SYMBICORT pressurized metered dose inhaler (pMDI) 160/4.5 &#956;g  2 actuations twice daily (BID) with budesonide inhalation powder dry powder inhaler (DPI) 180 &#956;g  2 inhalations BID in adult and adolescent (&#8805; 12 years) African American (self-reported) participants with asthma who required a medium to high dose of ICS therapy. Randomisation was stratified by asthma severity, based on daily dosage of ICS at screening (visit 1).</P>
<P>Conducted in 46 US centres from June 2008 to September 2009. Two-week run-in on budesonide DPI 90 mcg (two puffs twice daily) and enrolled if symptomatic on three or more of seven consecutive days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 301 adolescents and adults(12+ years old) with moderate to severe persistent asthma.BDF 156 participants, budesonide 155 participants.</P>
<P>
<B>Baseline Characteristics</B>: mean age 39 years. FEV<SUB>1</SUB> 66% predicted. Concomitant ICS used by 100% of participants.</P>
<P>
<B>Inclusion Criteria</B>:moderate to severe persistent asthma treated long term with a medium to high dose of ICS, FEV<SUB>1</SUB> % predicted within the entrance range of 45% to 85%, bronchodilator reversibility of FEV<SUB>1</SUB> of at least 12% and 0.20 L from the pre-albuterol baseline value within 15 to 30 minutes after administration of a standard dose of salbutamol.</P>
<P>
<B>Exclusion Criteria</B>: requiring hospitalisation once in the preceding 6 months or emergency treatment more than once in the previous 3 months, or systemic corticosteroids in previous 30 days or omalizumab in previous 90 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 160/9 mcg pMDI two inhalations twice daily.</LI>
<LI>Budesonide DPI 180 mcg two inhalations twice daily.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Primary efficacy variable was pre-dose FEV<SUB>1</SUB>. SAEs were those that were immediately life threatening, or resulted in death, significant disability or hospitalisation. No deaths and no SAEs were reported in the article by treatment group and causation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Data entered as described with zero entries for Budesonide group This has now been confirmed by Joe.&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Tal-2002">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, active-controlled, multi-centre, parallel-group study over 12 weeks from November 1998 to June 1999 at 48 centres in 7 countries: Hungary (6), the Czech Republic (7), the United Kingdom (11), Spain (7), Belgium (4), Israel (4) and South Africa (4).</P>
<P>Run-in 2 to 4 weeks on budesonide 400 mcg daily (unclear if previous LABA withdrawn).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 286 children (4 to 17 years) with asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 11 years. FEV<SUB>1</SUB> 75% predicted. Concomitant ICS used by 100% of participants (mean 548 mcg/day), previous LABA use not reported.</P>
<P>
<B>Inclusion Criteria</B>: between 4 and 17 years of age with a diagnosis of asthma (minimum duration 6 months), FEV<SUB>1</SUB> % predicted of 40% to 90%, bronchodilator reversibility by an increase of at least 15% in FEV<SUB>1</SUB> over baseline within 15 minutes of inhalation of a short-acting beta2-agonist.</P>
<P>
<B>Exclusion Criteria</B>: unstable asthma (defined as the use of oral, parenteral, or rectal corticosteroids within 30 days of study commencement), any respiratory infection affecting disease control within the previous 4 weeks, and known hypersensitivity to study medication or inhaled lactose.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 80/4.5 g 2 BD.</LI>
<LI>Budesonide 100 g 2 BD.</LI>
</UL>
<P>Delivery was DPI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary efficacy variable was the change in morning PEF from baseline to end of treatment.</P>
<P>"A total of 7 patients in the budesonide/formoterol group had a serious adverse event requiring admission to hospital (asthma (5), larynx edema (1), pneumonia (1)." Deaths are not mentioned, nor are any events in the budesonide group. Further clarification was sought from the sponsors, who have confirmed no SAEs in the budesonide group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Weinstein-2010">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: randomised, multi-centre, double-blind, double-dummy, placebo-controlled, parallel-group study over 12 weeks at 115 sites worldwide. Run-in two weeks mometasone fumarate (MF) 400 mcg twice daily (pMDI).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 495 adults (in the arms that were eligible for this review) who were 12 years of age or older) with severe asthma.</P>
<P>
<B>Baseline Characteristics</B>: mean age 48 years. FEV<SUB>1</SUB> 66% predicted. Concomitant ICS used at high dose by 100% of participants for at least 12 weeks (with or without LABA) .</P>
<P>
<B>Inclusion Criteria</B>: asthma for at least 12 months (with a history of deterioration requiring oral steroids in the previous 2 to 12 months) and on a high-dose ICS regimen (with or without LABA) for at least 12 weeks. FEV<SUB>1</SUB> 50% to 85% predicted, bronchodilator reversibility at least 12% in FEV<SUB>1</SUB> or 0.2 litres; alternatively, PEF variability over 20%.</P>
<P>
<B>Exclusion Criteria</B>: unstable asthma between screening and baseline, smoking history more than 10 pack-years (or current smoking), past history of pregnancy or clinically significant abnormality in electrocardiogram.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Mometasone furoate/formoterol (MF/F) 400/10 mcg twice daily.</LI>
<LI>Mometasone furoate (MF)400 mcg twice daily.</LI>
<LI>MF/F 200/10 mcg twice daily (not used in this review).</LI>
</UL>
<P>Delivery was pMDI (the placebo and formoterol arms in this trial were not considered for this review).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Primary outcome mean change from baseline in FEV<SUB>1</SUB> (AUC<SUB>0-12h</SUB>) up to week 12. SAEs were those that were immediately life threatening or that resulted in death, significant disability or hospitalisation. No deaths and no SAEs were reported with causation on the clinicaltrials.gov Website.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by Schering-Plough.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Zangrilli-2011">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study design: </B>a 12-week, randomised, double-blind, active-controlled, multi-centre, phase IIIB study comparing the efficacy and safety of SYMBICORT pMDI 160/4.5 mg  2 actuations twice daily versus budesonide HFA pMDI 160 mg  2 actuations twice daily, in adult/adolescent (&gt; 12 yrs) Hispanic subjects with asthma.</P>
<P>Carried out in 39 US centres between January 2007 and June 2008.</P>
<P>Two-week run-in on BUD pMDI 160 mcg twice daily.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 250 adults and adolescents (over 12 years of age) with moderate to severe asthma based on historical daily dosing of medium- to high-dose ICS alone or in combination with LABA for 30 days or longer before enrolment.</P>
<P>
<B>Baseline characteristics: </B>mean age 38 years. FEV<SUB>1</SUB> 68% predicted. Concomitant ICS reported by 91% of participants at a mean dose of 600 mcg per day, but FEV<SUB>1</SUB> rose to 72% predicted after step-down to BUD 160 mcg twice daily during run-in.</P>
<P>
<B>Inclusion Criteria</B>:</P>
<UL>
<LI>Male or female, Hispanic (self-reported), &gt; 12 years of age.</LI>
<LI>Moderate to severe asthma requiring treatment with an ICS.</LI>
<LI>Diagnosis of asthma for at least 6 months.</LI>
<LI>Participants had pre-bronchodilator forced expiratory volume in 1 second (FEV<SUB>1</SUB>) of 45% to 85% of predicted normal and reversibility of 12% or greater and 0.20 L or greater.</LI>
<LI>Randomly assigned participants had documented daytime or night-time asthma symptom scores greater than 0 on 3 or more days within 7 consecutive days during a 2-week run-in period on BUD pMDI 160 &#956;g twice daily.</LI>
</UL>
<P>
<B>Exclusion Criteria</B>:</P>
<UL>
<LI>Participants requiring treatment with systemic corticosteroids (e.g. oral, parenteral, ocular).</LI>
<LI>Participants who had required hospitalisation once or emergency treatment more than once in the preceding 6 months, used systemic corticosteroids within the previous 30 days, or had a smoking history of 10 or more pack-years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 160/9 mcg pMDI twice daily.</LI>
<LI>Budesonide 160 mcg HFA pMDI twice daily.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Primary outcome: </B>mean change from baseline in morning peak expiratory flow.</P>
<P>SAEs were those that were immediately life threatening, or that resulted in death, significant disability or hospitalisation, or required intervention to prevent one of these outcomes. No deaths and no SAEs were reported in the article by treatment group and causation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Data confirmed by Roman's paper/ 1 to zero deaths, 3/1 SAE and none related to asthma. 238/124 totals Care needed not to include deaths in non-fatal arm. Sponsors have confirmed death on Symbicort inhaler.&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Zetterstrom-2001">
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Study Design</B>: a randomised, double-blind, double-dummy, active-controlled, parallel-group study over 12 weeks at 63 centres<I> </I>in 6 countries: Finland (7), Germany (12), Ireland (6), Norway (12), Spain (11) and Sweden (15).</P>
<P>Run-in 2 weeks receiving usual ICS (no mention of continuing previous LABA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>
<B>Population</B>: 362 adults (18 to 78 years) with asthma not controlled with inhaled corticosteroids alone.</P>
<P>
<B>Baseline Characteristics</B>: mean age 47 years. FEV<SUB>1</SUB> 74% predicted. Concomitant ICS used by 100% of participants (mean dose 960 mcg/day).</P>
<P>
<B>Inclusion Criteria</B>: 18 years and older, using inhaled glucocorticosteroids at a constant daily dose of at least 500 g for at least 30 days before entry, FEV<SUB>1</SUB> % predicted of 50% to 90%, bronchodilator reversibility by an increase of at least 15% in FEV<SUB>1</SUB> over baseline after inhalation of terbutaline sulphate 1 mg (Bricanyl Turbuhaler) or salbutamol 0.4 mg.</P>
<P>
<B>Exclusion Criteria</B>: use of oral, parenteral, or rectal glucocorticosteroids within 30 days before study entry; respiratory infection; seasonal asthma; severe cardiovascular disorder; beta-blocker therapy; a history of heavy smoking (greater than10 pack-years); pregnancy or failure to use acceptable contraceptives in women of child-bearing potential.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Budesonide/formoterol 160/4.5 g 2 BD.</LI>
<LI>Budesonide 200 g<B> </B>+ Formoterol 4.5 g 2 BD.</LI>
<LI>Budesonide 200 g 2 BD.</LI>
</UL>
<P>Delivery was DPI, equivalent to budesonide 400 mcg bd metered dose in all arms.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>The primary efficacy variable was change in average morning PEF from baseline to study end.</P>
<P>Article reports: "There were five serious adverse events in the single inhaler therapy group and one in the budesonide alone group. There was one death by suicide and four hospital admissions (due to pneumonia, liver cysts, ischaemic stroke and intervertebral disc prolapse)." The sponsors have confirmed that the death occurred in a participant who was using a combined budesonide/formoterol inhaler.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Sponsored by AstraZeneca.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-05-24 14:28:21 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Ankerst-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Short-term cross-over study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-AstraZeneca-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison with budesonide and theophylline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-AstraZeneca-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Ongoing study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-AstraZeneca-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison of single-inhaler therapy with current best practice.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-AstraZeneca-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison of single-inhaler therapy with current best practice.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-AstraZeneca-2005d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison of single-inhaler therapy with current best practice.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-AstraZeneca-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison of single-inhaler therapy with ICS and terbutaline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-AstraZeneca-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison of single-inhaler therapy with current best practice.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-AstraZeneca-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison of single-inhaler therapy with current best practice.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Balanag-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison with salbutamol in acute asthma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Bateman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>BDF compared with higher-dose fluticasone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Bateman-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Acute asthma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Bodzenta_x002d_Lukaszyk-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Eight-week duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Bouros-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Formoterol and beclomethasone compared with higher-dose beclomethasone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Buhl-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Adjustable versus fixed-dose BDF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Bumbacea-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Eight-week duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Burgess-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Short-term cross-over study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Canonica-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Adjustable versus fixed-dose BDF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Ceylan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Formoterol in comparison with montelukast in addition to low-dose ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Dhillon-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Review of beclomethasone/formoterol treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-FitzGerald-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>No randomisation to ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-FitzGerald-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Adjustable versus fixed-dose BDF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Haahtela-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Formoterol used as needed (with or without budesonide).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Ind-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Adjustable versus fixed-dose BDF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Jakopovic-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Uncontrolled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Kozlik_x002d_Feldmann-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>No randomisation to ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Lalloo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>BDF compared with higher-dose ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Lemanske-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Cross-over design without same-dose ICS comparator group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Leuppi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Adjustable versus fixed-dose BDF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Lotvall">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Short-term comparison of bronchodilation following FPS and BDF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Lundborg-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Cost-effectiveness of single-inhaler therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Maspero-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>No arm with same-dose ICS comparator.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Mitchell-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Comparison with higher-dose ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Molimard-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Not randomly assigned to ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Nayak-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Combined results of other studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Novartis-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>No random assignment to ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-O_x0027_Byrne-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>BDF as single-inhaler therapy or fixed-dose treatment compared with higher-dose budesonide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Ohta-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Eight-week duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Overbeek-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Duration of less than 12 weeks on each dose of budesonide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Papi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Delivery device comparison for beclomethasone/formoterol combination inhalers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pauwels-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Comparison of formoterol with salbutamol as relief medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Peters-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Overview.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Pleskow-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Not randomly assigned to ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Pohl-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Adjustable maintenance dosing study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Rabe-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>BDF single-inhaler therapy compared with higher-dose budesonide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Rosenhall-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Combined BDF inhaler compared with both medications given together in separate inhalers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Rosenhall-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Combined BDF inhaler compared with both medications given together in separate inhalers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Rosenhall-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Combined BDF inhaler compared with both medications given together in separate inhalers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Rosenwasser-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Combined results of other studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Saito-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Cross-over study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Scicchitano-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>BDF single-inhaler therapy compared with higher-dose budesonide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Stelmach-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>4-Week study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-24 14:28:21 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-van-der-Molen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-24 14:28:21 +0100" MODIFIED_BY="Christopher J Cates">
<P>No random assignment to ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Villa-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Formoterol as needed compared with terbutaline as needed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Von-Berg-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>No random assignment to ICS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Weinstein-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Overview.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-White-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Combined results of other studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Worth-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Single-inhaler therapy compared with current best practice.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Zetterstrom-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Single-inhaler therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-Zetterstr_x00f6_m-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Single-inhaler therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-10-30 14:21:26 +0000" MODIFIED_BY="Christopher J Cates" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-05-24 14:28:21 +0100" MODIFIED_BY="Christopher J Cates" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-NCT01444430">
<CHAR_STUDY_NAME MODIFIED="2012-12-17 17:11:10 +0000" MODIFIED_BY="Christopher J Cates">
<P>D5896C00027</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>A 26-week, randomised, double-blind, parallel-group, active-controlled, multi-centre, multi-national safety study evaluating the risk of serious asthma-related events during treatment with Symbicort, a fixed combination of inhaled Corticosteroid (ICS) (budesonide) and a long-acting beta2-agonist (LABA) (formoterol) as compared with treatment with ICS (budesonide) alone in adult and adolescent (&#8805; 12 years of age) patients with asthma</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Male or female, &#8805; 12 years of age.</LI>
<LI>Documented clinical diagnosis of asthma for at least 1 year before visit 2.</LI>
<LI>Patient must have history of at least 1 asthma exacerbation, including one of the following: requiring treatment with systemic corticosteroids, asthma-related hospitalisation between 4 weeks and 12 months before randomisation.</LI>
<LI>Current asthma therapy: Participants must be appropriately using one of the treatments for asthma listed in the protocol combined with achieving certain results when an asthma control questionnaire is completed.</LI>
<LI>Estimated enrolment 11,700.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Symbicort pMDI80/4.5 &#956;g 2 actuations bid (morning and evening), for oral inhalation, 26-week treatment.</LI>
<LI>Symbicort pMDI160/4.5 &#956;g 2 actuations bid (morning and evening), for oral inhalation, 26-week treatment.</LI>
<LI>budesonide pMDI80 &#956;g 2 actuations bid (morning and evening), for oral inhalation, 26-week treatment.</LI>
<LI>budesonide pMDI160 &#956;g 2 actuations bid (morning and evening), for oral inhalation, 26-week treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Time to first event in composite endpoint (asthma-related death, asthma-related intubation or asthma-related hospitalisation) [timeframe:up to 27 weeks].</LI>
<LI>Time to first event included in the definition of asthma exacerbation [timeframe:up to 26 weeks]; asthma exacerbation defined as deterioration of asthma requiring systemic corticosteroids for at least 3 days or an inpatient hospitalisation or emergency room visit as a result of asthma that required systemic corticosteroids.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>December 2011.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>AstraZeneca.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-10-22 16:23:28 +0100" MODIFIED_BY="Christopher J Cates"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-05-24 14:28:21 +0100" MODIFIED_BY="Christopher J Cates" STUDY_ID="STD-NCT01471340">
<CHAR_STUDY_NAME MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>P06241.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-05-24 14:28:21 +0100" MODIFIED_BY="Christopher J Cates">
<P>A 26-week randomised, double-blinded, active-controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed-dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (Protocol No. P06241, also known as P202).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Male or female, &#8805; 12 years of age.</LI>
<LI>Persistent asthma for at least 1 year.</LI>
<LI>Must use a daily asthma controller medication for at least 4 weeks before randomisation, including an ICS with or without a long-acting beta-agonist (LABA) or other adjunctive asthma therapy OR must be using a leukotriene receptor antagonist (LTRA), xanthine or a short-acting beta-agonist (SABA) as monotherapy.</LI>
<LI>Must be able to discontinue current asthma medication.</LI>
<LI>Must have a history of at least one asthma exacerbation in previous 4 to 52 weeks.</LI>
<LI>Estimated enrolment 11,664.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<UL>
<LI>Mometasone furoate/formoterol MDI 100/5 mcg two inhalations twice daily (BID); Dulera/Zenhale.</LI>
<LI>Drug: mometasone furoate/formoterol MDI 200/5 mcg two inhalations BID; Dulera/Zenhale.</LI>
<LI>Drug: mometasone furoate MDI 100 mcg two inhalations BID.</LI>
<LI>Drug: mometasone furoate MDI 200 mcg two inhalations BID.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Primary outcome measures: time to first serious asthma outcomes (a composite endpoint defined as asthma-related: hospitalisations, intubations, and deaths) [Timeframe:baseline up to 26 weeks].<BR/>
<BR/>Secondary outcome measures: time-to-first asthma exacerbation [timeframe:baseline up to 26 weeks].</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>January 2012.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<P>Merck.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-10-22 16:30:00 +0100" MODIFIED_BY="Christopher J Cates"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-05-24 14:28:16 +0100" MODIFIED_BY="Christopher J Cates">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-05-24 14:28:16 +0100" MODIFIED_BY="Christopher J Cates" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Brown-2012">
<DESCRIPTION>
<P>Randomisation occurred with the use of computer-generated sequential allocation; approximately equal distribution of participants per treatment group at each site was ensured by the use of balanced blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Buhl-2003">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Chuchalin-2002">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Corren-2007">
<DESCRIPTION>
<P>By study site, computer-generated allocation schedule using balanced blocks of four.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-D5896C00001">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Jenkins-2006">
<DESCRIPTION>
<P>Individual treatment codes were computer generated in balanced blocks of eight at AstraZeneca R&amp;D, Lund, Sweden.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Kuna-2006">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2012">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2007">
<DESCRIPTION>
<P>Participants were randomly assigned sequentially in blocks of six using a computer-generated randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2008">
<DESCRIPTION>
<P>Participants were randomly assigned sequentially in blocks of six using a computer-generated randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Nathan-2010">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Noonan-2006">
<DESCRIPTION>
<P>Computer-generated allocation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001a">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997">
<DESCRIPTION>
<P>Computer-generated randomisation schedule (<LINK REF="REF-Ni-Chroinin-2010" TYPE="REFERENCE">Ni Chroinin 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997a">
<DESCRIPTION>
<P>Computer-generated randomisation schedule (<LINK REF="REF-Ni-Chroinin-2010" TYPE="REFERENCE">Ni Chroinin 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-24 14:28:16 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Peters-2008">
<DESCRIPTION>
<P>Randomly assigned using a 3:1:1 overall randomisation scheme and a computer-generated allocation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Pohunek-2006">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Price-2002">
<DESCRIPTION>
<P>Computer-generated random numbers (<LINK REF="REF-Ni-Chroinin-2010" TYPE="REFERENCE">Ni Chroinin 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0714">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0718">
<DESCRIPTION>
<P>Randomisation was stratified by age group (children younger than 8 years of age vs children 8 years and older). Participants were randomly assigned to 1 of the 3 treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0719">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0725">
<DESCRIPTION>
<P>Randomisation was stratified by age (6 to 11 years of age vs 12 to 15 years of age) at the time of screening, to ensure an approximately uniform distribution of participants across treatment groups within each of these 2 strata.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0726">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Spector-2012">
<DESCRIPTION>
<P>Randomisation was generated by computer-derived sequential allocation and stratification by asthma severity using balanced blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Tal-2002">
<DESCRIPTION>
<P>Computer-generated block randomisation list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-17 17:10:50 +0000" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Weinstein-2010">
<DESCRIPTION>
<P>&#8220;Randomization was performed in blocks using random numbers generated by SAS.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-17 17:11:02 +0000" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zangrilli-2011">
<DESCRIPTION>
<P>"Randomization used a computer-generated allocation schedule."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zetterstrom-2001">
<DESCRIPTION>
<P>Computerised randomisation occurred on a per country basis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Brown-2012">
<DESCRIPTION>
<P>Allocation concealment was maintained by packaging the study medications identically, with the exception of the computer-generated randomisation number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Buhl-2003">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Chuchalin-2002">
<DESCRIPTION>
<P>"Allocated a randomised number (identifying which of the three treatments they would receive) in consecutive order, per centre, at the second visit."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Corren-2007">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-D5896C00001">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Jenkins-2006">
<DESCRIPTION>
<P>Codes were then assigned to participants and were kept in sealed envelopes until data analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Kuna-2006">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2012">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2007">
<DESCRIPTION>
<P>Eligible participants were consecutively allocated the lowest available randomisation code. In view of double-dummy design, this is considered satisfactory.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Morice-2008">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Nathan-2010">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Noonan-2006">
<DESCRIPTION>
<P>Identical packages shipped to centres.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001">
<DESCRIPTION>
<P>Opaque consecutive numbered envelopes containing assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001a">
<DESCRIPTION>
<P>Opaque consecutive numbered envelopes containing assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997">
<DESCRIPTION>
<P>Participants were randomly assigned to treatment groups in balanced blocks of four at each centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997a">
<DESCRIPTION>
<P>Participants were randomly assigned to treatment groups in balanced blocks of four at each centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Peters-2008">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Pohunek-2006">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Price-2002">
<DESCRIPTION>
<P>Numbered coded solutions supplied by pharmacy<I> </I>(<LINK REF="REF-Ni-Chroinin-2010" TYPE="REFERENCE">Ni Chroinin 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0714">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0718">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0719">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0725">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-SD_x002d_039_x002d_0726">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Spector-2012">
<DESCRIPTION>
<P>Randomisation was generated by computer-derived sequential allocation and stratification by asthma severity using balanced blocks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Tal-2002">
<DESCRIPTION>
<P>Individual treatment code envelopes provided for each participant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Weinstein-2010">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Zangrilli-2011">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zetterstrom-2001">
<DESCRIPTION>
<P>Individual treatment codes were kept in sealed envelopes until data analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Brown-2012">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Buhl-2003">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Chuchalin-2002">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Corren-2007">
<DESCRIPTION>
<P>Double-dummy. Participants received both a pMDI and a DPI containing active treatment or placebo of the alternative active treatment as appropriate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-D5896C00001">
<DESCRIPTION>
<P>Double-blind. To maintain blinding with the twice-daily dosing regimen, all participants randomly assigned to receive once-daily dosing were to take the active treatment in the evening and a matched placebo device in the morning.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Jenkins-2006">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Kuna-2006">
<DESCRIPTION>
<P>To ensure treatment blinding, a double-dummy design was used so that participants received four successively numbered Turbuhalers, with the corresponding placebo inhalers identical in appearance to those containing active medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Meltzer-2012">
<DESCRIPTION>
<P>Double-blind, double-dummy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-12 10:55:27 +0000" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2007">
<DESCRIPTION>
<P>Double-blind, double-dummy. To maintain blinding, each patient also received a placebo device.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2008">
<DESCRIPTION>
<P>Double-blind (all participants used a placebo inhaler and an active inhaler).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Nathan-2010">
<DESCRIPTION>
<P>Double-blind, double-dummy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Noonan-2006">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001">
<DESCRIPTION>
<P>Double-blind. Identical placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001a">
<DESCRIPTION>
<P>Double-blind. Identical placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997a">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Peters-2008">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pohunek-2006">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Price-2002">
<DESCRIPTION>
<P>Double blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0714">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0718">
<DESCRIPTION>
<P>Double-blind. Treatments were given in double-dummy fashion because of the differences in devices.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-SD_x002d_039_x002d_0719">
<DESCRIPTION>
<P>Open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0725">
<DESCRIPTION>
<P>Double-blind. To maintain blinding with the twice-daily dosing regimen, all participants randomly assigned to receive once-daily dosing were to receive the active treatment in the evening and placebo treatment with a matched device in the morning.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0726">
<DESCRIPTION>
<P>Double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Spector-2012">
<DESCRIPTION>
<P>Double-blind, double-dummy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Tal-2002">
<DESCRIPTION>
<P>Double-blind, double-dummy technique.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Weinstein-2010">
<DESCRIPTION>
<P>"Double-blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zangrilli-2011">
<DESCRIPTION>
<P>"Double-blind (subject, caregiver, investigator, outcomes assessor)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zetterstrom-2001">
<DESCRIPTION>
<P>Double-blind; participants successively used three numbered inhalers (identical in appearance to the corresponding placebo) each morning and evening.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="9">
<NAME>Independent Assessment of causation (detection bias)</NAME>
<DESCRIPTION>
<P>Bias due to possible under assessment of asthma as a cause of SAE in all participants</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1" REF_IDS="CMP-001.04">
<NAME>Asthma-related events</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Brown-2012">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Buhl-2003">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Chuchalin-2002">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Corren-2007">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-D5896C00001">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Jenkins-2006">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Kuna-2006">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Meltzer-2012">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Morice-2007">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Morice-2008">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Nathan-2010">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Noonan-2006">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-O_x0027_Byrne-2001">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-O_x0027_Byrne-2001a">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Pauwels-1997">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Pauwels-1997a">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Peters-2008">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Pohunek-2006">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Price-2002">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-SD_x002d_039_x002d_0714">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-SD_x002d_039_x002d_0718">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-SD_x002d_039_x002d_0719">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-SD_x002d_039_x002d_0725">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-SD_x002d_039_x002d_0726">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Spector-2012">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Tal-2002">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Weinstein-2010">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Zangrilli-2011">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed,</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Zetterstrom-2001">
<DESCRIPTION>
<P>Causation of SAEs not independently assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2012">
<DESCRIPTION>
<P>Number of reported withdrawals reasonably balanced, but high proportions of total:</P>
<UL>
<LI>149/377 (intervention group).</LI>
<LI>125/365 (control group).</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Buhl-2003">
<DESCRIPTION>
<P>480 of 523 (92%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Chuchalin-2002">
<DESCRIPTION>
<P>316 of 338 (93%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Corren-2007">
<DESCRIPTION>
<P>18 of 123 discontinued on BDF and 18 of 121 on budesonide.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-D5896C00001">
<DESCRIPTION>
<P>12% dropout in each arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Jenkins-2006">
<DESCRIPTION>
<P>400 of 456 (88%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Kuna-2006">
<DESCRIPTION>
<P>555 of 616 (90%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2012">
<DESCRIPTION>
<P>36 of 182 discontinued on combination and 41/188 on MF alone, but imbalance was noted for treatment failure (2% and 7%, respectively).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2007">
<DESCRIPTION>
<P>600 of 680 (88%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2008">
<DESCRIPTION>
<P>583 of 622 (94%) completed the study,</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Nathan-2010">
<DESCRIPTION>
<P>18% and 17% withdrawals on combination and MF.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Noonan-2006">
<DESCRIPTION>
<P>23% withdrawals in combined arms and 28% in budesonide arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001">
<DESCRIPTION>
<P>81% in Group A and 87% in Group B completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001a">
<DESCRIPTION>
<P>81% in Group A and 87% in Group B completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997">
<DESCRIPTION>
<P>694 of 852 (81%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997a">
<DESCRIPTION>
<P>694 of 852 (81%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Peters-2008">
<DESCRIPTION>
<P>579 of 708 (82%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pohunek-2006">
<DESCRIPTION>
<P>592 of 630 (94%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Price-2002">
<DESCRIPTION>
<P>400 of 505 (79%) completed part 2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0714">
<DESCRIPTION>
<P>219 of 271 (81%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0718">
<DESCRIPTION>
<P>28% dropout on BDF and 35% on budesonide (all randomly assigned participants in safety analysis and no events reported!).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0719">
<DESCRIPTION>
<P>87% completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0725">
<DESCRIPTION>
<P>499 of 521 (96%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0726">
<DESCRIPTION>
<P>707 of 751 (94%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="NO" STUDY_ID="STD-Spector-2012">
<DESCRIPTION>
<P>38 of 156 withdrawals on combination treatment and 53 of 155 on budesonide alone (high rate and unbalanced).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Tal-2002">
<DESCRIPTION>
<P>268 of 286 (94%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Weinstein-2010">
<DESCRIPTION>
<P>33 of 240 withdrawals on combination and 27 of 255 on MF.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zangrilli-2011">
<DESCRIPTION>
<P>18 of 127 and 21 of 123 withdrawals given combination and budesonide, respectively.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zetterstrom-2001">
<DESCRIPTION>
<P>309 of 362 (85%) completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2012">
<DESCRIPTION>
<P>No reporting of asthma-related SAEs, so there may be high risk for this outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Buhl-2003">
<DESCRIPTION>
<P>SAE data not attributable to treatment groups in article but obtained from Jaeschke 2008.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Chuchalin-2002">
<DESCRIPTION>
<P>SAE data reported in the article.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Corren-2007">
<DESCRIPTION>
<P>SAEs reported in paper publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-11 16:22:17 +0000" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-D5896C00001">
<DESCRIPTION>
<P>No asthma-related SAE data found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Jenkins-2006">
<DESCRIPTION>
<P>SAE data in article, but they did not match final data from sponsors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Kuna-2006">
<DESCRIPTION>
<P>SAEs reported in paper by treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Meltzer-2012">
<DESCRIPTION>
<P>SAE details obtained from authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2007">
<DESCRIPTION>
<P>Full SAE data available from article by treatment group and cause.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Morice-2008">
<DESCRIPTION>
<P>SAEs reported by treatment group and cause in paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Nathan-2010">
<DESCRIPTION>
<P>Full SAE data obtained from publications and FDA report,</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Noonan-2006">
<DESCRIPTION>
<P>Full SAE data on Website.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001">
<DESCRIPTION>
<P>SAE data provided by sponsors and found from other sources.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-2001a">
<DESCRIPTION>
<P>SAE data provided by sponsors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997">
<DESCRIPTION>
<P>SAE data provided by sponsors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pauwels-1997a">
<DESCRIPTION>
<P>SAE data provided by sponsors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Peters-2008">
<DESCRIPTION>
<P>SAE data available from paper and Web report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Pohunek-2006">
<DESCRIPTION>
<P>SAEs reported by treatment group and event type in article.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Price-2002">
<DESCRIPTION>
<P>Data on SAEs from Jaeschke 2008.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0714">
<DESCRIPTION>
<P>SAE data in Web report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0718">
<DESCRIPTION>
<P>SAE data on Web report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0719">
<DESCRIPTION>
<P>SAE reported fully.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0725">
<DESCRIPTION>
<P>SAEs reported by treatment group and cause.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-SD_x002d_039_x002d_0726">
<DESCRIPTION>
<P>SAE data on Web report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Spector-2012">
<DESCRIPTION>
<P>SAE data fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Tal-2002">
<DESCRIPTION>
<P>SAEs appear to be fully reported in the article.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Weinstein-2010">
<DESCRIPTION>
<P>Full SAE data obtained from report of NCT00381485 and from article.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zangrilli-2011">
<DESCRIPTION>
<P>Full report of SAEs in published article and at clinicaltrials.gov.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Zetterstrom-2001">
<DESCRIPTION>
<P>SAE by treatment group in article.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-01-16 15:38:58 +0000" MODIFIED_BY="Christopher J Cates" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-10-30 12:33:27 +0000" MODIFIED_BY="Grade Profiler">Regular formoterol and ICS compared to ICS in adults with asthma</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Regular formoterol and ICS compared to ICS in adults with asthma</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with asthma<BR/>
<B>Settings:</B> community<BR/>
<B>Intervention:</B> regular formoterol and ICS<BR/>
<B>Comparison: </B>same dose ICS</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Same dose ICS</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Regular formoterol and ICS</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>All-cause mortality </B>
<BR/>Follow-up: mean 28 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1 per 1000</B>
<BR/>(0 to 4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 3.56 </B>
<BR/>(0.79 to 16.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>10578<BR/>(22 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>All-cause non-fatal serious adverse events </B>
<BR/>Follow-up: mean 28 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
<BR/>(20 to 32)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.98 </B>
<BR/>(0.76 to 1.27)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>10578<BR/>(22 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Asthma-related non-fatal serious adverse events</B>
<BR/>Follow-up: mean 28 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>3 per 1000</B>
<BR/>(2 to 6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.49 </B>
<BR/>(0.28 to 0.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>10208<BR/>(21 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the mean control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Imprecision (-2): very wide confidence interval.<BR/>
<SUP>2</SUP> Imprecision (-1): wide confidence interval.<BR/>
<SUP>3</SUP> Risk of bias (-1): no independent assessment of causation of SAEs.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-10-30 12:59:26 +0000" MODIFIED_BY="Grade Profiler">Regular formoterol and ICS compared to ICS in children with asthma</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Regular formoterol and ICS compared to ICS in children with asthma</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> children with asthma<BR/>
<B>Settings:</B> community<BR/>
<B>Intervention:</B> regular formoterol and ICS<BR/>
<B>Comparison: </B>same dose ICS</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Same dose ICS</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Regular formoterol and ICS</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
<BR/>Follow-up: mean 13 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2788<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>There were no deaths in children</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>All-cause non-fatal serious adverse events </B>Follow-up: mean 13 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>14 per 1000</B>
<BR/>(7 to 27)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.62 </B>
<BR/>(0.8 to 3.28)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2788<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Asthma-related non-fatal serious adverse events </B>Follow-up: mean 13 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 1000</B>
<BR/>(2 to 17)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.49 </B>
<BR/>(0.48 to 4.61)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2788<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the mean control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No deaths in children were reported.<BR/>
<SUP>2</SUP>Imprecision (-1): wide confidence interval.<BR/>
<SUP>3</SUP>Risk of bias (-1): no independent assessment of causation of SAEs.<BR/>
<SUP>4</SUP>Unexplained heterogeneity between trial results.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-12-17 17:11:56 +0000" MODIFIED_BY="Christopher J Cates" NO="1">
<TITLE MODIFIED="2008-11-25 16:40:02 +0000" MODIFIED_BY="Christopher J Cates">Dose and delivery of budesonide and formoterol</TITLE>
<TABLE COLS="13" ROWS="30">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Age (Years</P>
</TH>
<TH>
<P>N on F&amp;ICS</P>
</TH>
<TH>
<P>N on ICS Alone</P>
</TH>
<TH>
<P>Daily dose of budesonide or mometasone (mcg metered dose)</P>
</TH>
<TH>
<P>Daily Dose of Formoterol (mcg metered dose)</P>
</TH>
<TH>
<P>Once daily</P>
</TH>
<TH>
<P>Twice daily</P>
</TH>
<TH>
<P>Combined inhalers</P>
</TH>
<TH>
<P>Separate inhalers</P>
</TH>
<TH>
<P>DPI</P>
</TH>
<TH>
<P>pMDI</P>
</TH>
<TH>
<P>Duration weeks</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brown-2012" TYPE="STUDY">Brown 2012</LINK>
</P>
</TD>
<TD>
<P>12+</P>
</TD>
<TD>
<P>377</P>
</TD>
<TD>
<P>364</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Buhl-2003" TYPE="STUDY">Buhl 2003</LINK>
</P>
</TD>
<TD>
<P>18+</P>
</TD>
<TD>
<P>352</P>
</TD>
<TD>
<P>171</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chuchalin-2002" TYPE="STUDY">Chuchalin 2002</LINK>
</P>
</TD>
<TD>
<P>18+</P>
</TD>
<TD>
<P>111</P>
</TD>
<TD>
<P>114</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Corren-2007" TYPE="STUDY">Corren 2007</LINK>
</P>
</TD>
<TD>
<P>12+</P>
</TD>
<TD>
<P>123</P>
</TD>
<TD>
<P>121</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-D5896C00001" TYPE="STUDY">D5896C00001</LINK>
</P>
</TD>
<TD>
<P>12+</P>
</TD>
<TD>
<P>312</P>
</TD>
<TD>
<P>153</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>12/24</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jenkins-2006" TYPE="STUDY">Jenkins 2006</LINK>
</P>
</TD>
<TD>
<P>12+</P>
</TD>
<TD>
<P>341</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>1600</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>24</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kuna-2006" TYPE="STUDY">Kuna 2006</LINK>
</P>
</TD>
<TD>
<P>18+</P>
</TD>
<TD>
<P>409</P>
</TD>
<TD>
<P>207</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Meltzer-2012" TYPE="STUDY">Meltzer 2012</LINK>
</P>
</TD>
<TD>
<P/>
<P>12+</P>
</TD>
<TD>
<P>182</P>
</TD>
<TD>
<P>188</P>
</TD>
<TD>
<P>200 (mometasone)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morice-2007" TYPE="STUDY">Morice 2007</LINK>
</P>
</TD>
<TD>
<P>12+</P>
</TD>
<TD>
<P>462</P>
</TD>
<TD>
<P>217</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morice-2008" TYPE="STUDY">Morice 2008</LINK>
</P>
</TD>
<TD>
<P>6 to 11</P>
</TD>
<TD>
<P>415</P>
</TD>
<TD>
<P>207</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nathan-2010" TYPE="STUDY">Nathan 2010</LINK>
</P>
</TD>
<TD>
<P/>
<P>12+</P>
</TD>
<TD>
<P>191</P>
</TD>
<TD>
<P>192</P>
</TD>
<TD>
<P>400 (mometasone)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Noonan-2006" TYPE="STUDY">Noonan 2006</LINK>
</P>
</TD>
<TD>
<P>12+</P>
</TD>
<TD>
<P>239</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Byrne-2001" TYPE="STUDY">O'Byrne 2001</LINK>
</P>
</TD>
<TD>
<P>18+</P>
</TD>
<TD>
<P>554</P>
</TD>
<TD>
<P>550</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Byrne-2001a" TYPE="STUDY">O'Byrne 2001a</LINK>
</P>
</TD>
<TD>
<P>18+</P>
</TD>
<TD>
<P>315</P>
</TD>
<TD>
<P>312</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pauwels-1997" TYPE="STUDY">Pauwels 1997</LINK>
</P>
</TD>
<TD>
<P>18+</P>
</TD>
<TD>
<P>210</P>
</TD>
<TD>
<P>213</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pauwels-1997a" TYPE="STUDY">Pauwels 1997a</LINK>
</P>
</TD>
<TD>
<P>18+</P>
</TD>
<TD>
<P>215</P>
</TD>
<TD>
<P>214</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Peters-2008" TYPE="STUDY">Peters 2008</LINK>
</P>
</TD>
<TD>
<P>12+</P>
</TD>
<TD>
<P>443</P>
</TD>
<TD>
<P>133</P>
</TD>
<TD>
<P>1600</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pohunek-2006" TYPE="STUDY">Pohunek 2006</LINK>
</P>
</TD>
<TD>
<P>4 to 11</P>
</TD>
<TD>
<P>417</P>
</TD>
<TD>
<P>213</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Price-2002" TYPE="STUDY">Price 2002</LINK>
</P>
</TD>
<TD>
<P>12+</P>
</TD>
<TD>
<P>250</P>
</TD>
<TD>
<P>255</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>24</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SD_x002d_039_x002d_0714" TYPE="STUDY">SD-039-0714</LINK>
</P>
</TD>
<TD>
<P>11 to 17</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>134</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SD_x002d_039_x002d_0718" TYPE="STUDY">SD-039-0718</LINK>
</P>
</TD>
<TD>
<P>6 to 15</P>
</TD>
<TD>
<P>128</P>
</TD>
<TD>
<P>145</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SD_x002d_039_x002d_0719" TYPE="STUDY">SD-039-0719</LINK>
</P>
</TD>
<TD>
<P>6 to 11</P>
</TD>
<TD>
<P>123</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>26</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SD_x002d_039_x002d_0725" TYPE="STUDY">SD-039-0725</LINK>
</P>
</TD>
<TD>
<P>6 to 15</P>
</TD>
<TD>
<P>352</P>
</TD>
<TD>
<P>169</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>12/24</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-SD_x002d_039_x002d_0726" TYPE="STUDY">SD-039-0726</LINK>
</P>
</TD>
<TD>
<P>16+</P>
</TD>
<TD>
<P>301</P>
</TD>
<TD>
<P>145</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>12/24</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Spector-2012" TYPE="STUDY">Spector 2012</LINK>
</P>
</TD>
<TD>
<P/>
<P>12+</P>
</TD>
<TD>
<P>156</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tal-2002" TYPE="STUDY">Tal 2002</LINK>
</P>
</TD>
<TD>
<P>4 to 17</P>
</TD>
<TD>
<P>148</P>
</TD>
<TD>
<P>138</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Weinstein-2010" TYPE="STUDY">Weinstein 2010</LINK>
</P>
</TD>
<TD>
<P/>
<P>12+</P>
</TD>
<TD>
<P>255</P>
</TD>
<TD>
<P>240</P>
</TD>
<TD>
<P>800 (mometasone)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zangrilli-2011" TYPE="STUDY">Zangrilli 2011</LINK>
</P>
</TD>
<TD>
<P/>
<P>12+</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>123</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zetterstrom-2001" TYPE="STUDY">Zetterstrom 2001</LINK>
</P>
</TD>
<TD>
<P>18+</P>
</TD>
<TD>
<P>238</P>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P>&#10003;</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="2">
<TITLE MODIFIED="2013-02-19 14:43:34 +0000" MODIFIED_BY="Christopher J Cates">Mortality by cause of death</TITLE>
<TABLE COLS="3" ROWS="9">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Treatment given</P>
</TH>
<TH>
<P>Cause of death</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Buhl-2003" TYPE="STUDY">Buhl 2003</LINK>
</P>
</TD>
<TD>
<P>Formoterol and budesonide</P>
</TD>
<TD>
<P>Cardiac arrest</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Byrne-2001" TYPE="STUDY">O'Byrne 2001</LINK>
</P>
</TD>
<TD>
<P>Formoterol and budesonide (separate inhalers)</P>
</TD>
<TD>
<P>Status asthmaticus, followed by septic shock</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pauwels-1997a" TYPE="STUDY">Pauwels 1997a</LINK>
</P>
</TD>
<TD>
<P>Formoterol and budesonide (separate inhalers)</P>
</TD>
<TD>
<P>Suicide</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zetterstrom-2001" TYPE="STUDY">Zetterstrom 2001</LINK>
</P>
</TD>
<TD>
<P>Formoterol and budesonide</P>
</TD>
<TD>
<P>Suicide</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brown-2012" TYPE="STUDY">Brown 2012</LINK>
</P>
</TD>
<TD>
<P>Formoterol and budesonide</P>
</TD>
<TD>
<P>Cerebrovascular accident</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brown-2012" TYPE="STUDY">Brown 2012</LINK>
</P>
</TD>
<TD>
<P>Budesonide</P>
</TD>
<TD>
<P>Homicide</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nathan-2010" TYPE="STUDY">Nathan 2010</LINK>
</P>
</TD>
<TD>
<P>Formoterol and mometasone</P>
</TD>
<TD>
<P>Uterine leiomyosarcoma</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jenkins-2006" TYPE="STUDY">Jenkins 2006</LINK>
</P>
</TD>
<TD>
<P>Formoterol and budesonide</P>
</TD>
<TD>
<P>Pulmonary embolus (but the death occurred after the control budesonide arm was discontinued so was not included in the meta-analysis)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates">
<COMPARISON ID="CMP-001" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NO="1">
<NAME>Formoterol and ICS versus same dose ICS</NAME>
<DICH_OUTCOME CHI2="1.2720003772180806" CI_END="16.03424195820441" CI_START="0.789259624570082" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.557411950870783" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.2050484328549942" LOG_CI_START="-0.1027801134304343" LOG_EFFECT_SIZE="0.55113415971228" METHOD="PETO" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.9377862813652983" P_Q="1.0" P_Z="0.09855427836321076" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7882" TOTAL_2="5484" WEIGHT="100.0" Z="1.6519032357167478">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Formoterol and ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Same Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Formoterol &amp; ICS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours same dose ICS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2720003772180806" CI_END="16.03424195820441" CI_START="0.789259624570082" DF="5" EFFECT_SIZE="3.557411950870783" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="1.2050484328549942" LOG_CI_START="-0.1027801134304343" LOG_EFFECT_SIZE="0.55113415971228" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.9377862813652983" P_Z="0.09855427836321076" STUDIES="22" TAU2="0.0" TOTAL_1="6163" TOTAL_2="4415" WEIGHT="100.0" Z="1.6519032357167478">
<NAME>Adults and Adolescents</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:35:03 +0000" MODIFIED_BY="Christopher J Cates" ORDER="69" O_E="0.0" SE="0.0" STUDY_ID="STD-Pauwels-1997" TOTAL_1="210" TOTAL_2="213" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="370.66083605007884" CI_START="0.1459356100631718" EFFECT_SIZE="7.354768197264519" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.568976700985388" LOG_CI_START="-0.8358387220412485" LOG_EFFECT_SIZE="0.8665689894720698" MODIFIED="2008-11-26 14:14:18 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Where was the single death???? Wait for response from Joe Gray. 400 Bd and F group is the answer.&lt;/p&gt;" NOTES_MODIFIED="2008-11-26 14:14:18 +0000" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="70" O_E="0.4988344988344988" SE="2.00000543359401" STUDY_ID="STD-Pauwels-1997a" TOTAL_1="215" TOTAL_2="214" VAR="0.24999864160703322" WEIGHT="14.754159635615503"/>
<DICH_DATA CI_END="284.59801699898463" CI_START="0.07360363166197464" EFFECT_SIZE="4.576838167875467" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4542318697138352" LOG_CI_START="-1.1331007566972204" LOG_EFFECT_SIZE="0.6605655565083073" MODIFIED="2008-11-14 16:35:05 +0000" MODIFIED_BY="Christopher J Cates" ORDER="66" O_E="0.3425414364640884" SE="2.1072169423367453" STUDY_ID="STD-Zetterstrom-2001" TOTAL_1="238" TOTAL_2="124" VAR="0.2252068007692073" WEIGHT="13.291020576016049"/>
<DICH_DATA CI_END="369.71538582937444" CI_START="0.14555897975641185" EFFECT_SIZE="7.33589765206494" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5678675242592264" LOG_CI_START="-0.8369609971069162" LOG_EFFECT_SIZE="0.8654532635761552" MODIFIED="2008-11-14 16:35:01 +0000" MODIFIED_BY="Christopher J Cates" ORDER="61" O_E="0.49818840579710144" SE="2.0000131276234736" STUDY_ID="STD-O_x0027_Byrne-2001" TOTAL_1="554" TOTAL_2="550" VAR="0.24999671812644406" WEIGHT="14.754046117640021"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:35:01 +0000" MODIFIED_BY="Christopher J Cates" ORDER="65" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Byrne-2001a" TOTAL_1="315" TOTAL_2="312" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:34:58 +0000" MODIFIED_BY="Christopher J Cates" ORDER="3271" O_E="0.0" SE="0.0" STUDY_ID="STD-Chuchalin-2002" TOTAL_1="111" TOTAL_2="114" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:35:04 +0000" MODIFIED_BY="Christopher J Cates" ORDER="57" O_E="0.0" SE="0.0" STUDY_ID="STD-Price-2002" TOTAL_1="250" TOTAL_2="255" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="288.2737322189992" CI_START="0.06772366666177597" EFFECT_SIZE="4.418478714234751" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4598050708582857" LOG_CI_START="-1.1692595365662364" LOG_EFFECT_SIZE="0.6452727671460248" MODIFIED="2008-11-14 16:34:57 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1645" O_E="0.32695984703632885" SE="2.1317305145606933" STUDY_ID="STD-Buhl-2003" TOTAL_1="352" TOTAL_2="171" VAR="0.22005710546230928" WEIGHT="12.987101218117363"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-18 14:15:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="78" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0726" TOTAL_1="301" TOTAL_2="145" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:34:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="23" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuna-2006" TOTAL_1="409" TOTAL_2="207" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-01 11:12:42 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Death removed as it was at 17 weeks when there was no Bud control arm.&lt;/p&gt;" NOTES_MODIFIED="2008-12-01 11:12:42 +0000" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="3415" O_E="0.0" SE="0.0" STUDY_ID="STD-Jenkins-2006" TOTAL_1="341" TOTAL_2="115" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:35:00 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1640" O_E="0.0" SE="0.0" STUDY_ID="STD-Noonan-2006" TOTAL_1="239" TOTAL_2="109" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:35:00 +0000" MODIFIED_BY="Christopher J Cates" ORDER="27" O_E="0.0" SE="0.0" STUDY_ID="STD-Morice-2007" TOTAL_1="462" TOTAL_2="217" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:34:58 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1643" O_E="0.0" SE="0.0" STUDY_ID="STD-Corren-2007" TOTAL_1="123" TOTAL_2="121" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-18 14:15:43 +0000" MODIFIED_BY="Christopher J Cates" ORDER="70" O_E="0.0" SE="0.0" STUDY_ID="STD-Peters-2008" TOTAL_1="443" TOTAL_2="133" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:35:02 +0000" MODIFIED_BY="Christopher J Cates" ORDER="3412" O_E="0.0" SE="0.0" STUDY_ID="STD-D5896C00001" TOTAL_1="312" TOTAL_2="153" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="374.3446632753178" CI_START="0.14738519748166456" EFFECT_SIZE="7.427843706153216" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5732716461281377" LOG_CI_START="-0.8315461323171904" LOG_EFFECT_SIZE="0.8708627569054737" MODIFIED="2012-10-03 17:58:57 +0100" MODIFIED_BY="Christopher J Cates" ORDER="376" O_E="0.5013054830287207" SE="2.0000068171786087" STUDY_ID="STD-Nathan-2010" TOTAL_1="191" TOTAL_2="192" VAR="0.2499982957140617" WEIGHT="14.75413922206411"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-04 16:58:19 +0100" MODIFIED_BY="Christopher J Cates" ORDER="378" O_E="0.0" SE="0.0" STUDY_ID="STD-Weinstein-2010" TOTAL_1="255" TOTAL_2="240" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-04 16:45:33 +0100" MODIFIED_BY="Christopher J Cates" ORDER="377" O_E="0.0" SE="0.0" STUDY_ID="STD-Spector-2012" TOTAL_1="156" TOTAL_2="155" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-04 17:05:58 +0100" MODIFIED_BY="Christopher J Cates" ORDER="379" O_E="0.0" SE="0.0" STUDY_ID="STD-Zangrilli-2011" TOTAL_1="127" TOTAL_2="123" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.470938452495165" CI_START="0.06024984019086862" EFFECT_SIZE="0.9654644319526213" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1895166583909436" LOG_CI_START="-1.2200441006919482" LOG_EFFECT_SIZE="-0.015263721150502283" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;One cva on bdf, and one homicide on ICS&lt;/p&gt;" NOTES_MODIFIED="2013-05-02 16:52:43 +0100" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="374" O_E="-0.01754385964912286" SE="1.4153879174034127" STUDY_ID="STD-Brown-2012" TOTAL_1="377" TOTAL_2="364" VAR="0.49917063878282725" WEIGHT="29.459533230546963"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-03 17:26:27 +0100" MODIFIED_BY="Christopher J Cates" ORDER="375" O_E="0.0" SE="0.0" STUDY_ID="STD-Meltzer-2012" TOTAL_1="182" TOTAL_2="188" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-11-18 14:17:08 +0000" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="7" TAU2="0.0" TOTAL_1="1719" TOTAL_2="1069" WEIGHT="0.0" Z="0.0">
<NAME>Children and Adolescents</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 12:35:18 +0000" MODIFIED_BY="Christopher J Cates" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Tal-2002" TOTAL_1="148" TOTAL_2="138" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 15:20:00 +0000" MODIFIED_BY="Christopher J Cates" ORDER="74" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0714" TOTAL_1="136" TOTAL_2="134" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:52:29 +0000" MODIFIED_BY="Christopher J Cates" ORDER="84" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0718" TOTAL_1="128" TOTAL_2="145" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-18 14:17:06 +0000" MODIFIED_BY="Christopher J Cates" ORDER="89" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0725" TOTAL_1="352" TOTAL_2="169" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 16:55:25 +0000" MODIFIED_BY="Christopher J Cates" ORDER="88" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0719" TOTAL_1="123" TOTAL_2="63" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 11:39:04 +0000" MODIFIED_BY="Christopher J Cates" ORDER="53" O_E="0.0" SE="0.0" STUDY_ID="STD-Pohunek-2006" TOTAL_1="417" TOTAL_2="213" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-18 14:17:08 +0000" MODIFIED_BY="Christopher J Cates" ORDER="47" O_E="0.0" SE="0.0" STUDY_ID="STD-Morice-2008" TOTAL_1="415" TOTAL_2="207" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.143421228056418" CI_END="1.3227609040860278" CI_START="0.8159407842086239" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0388910286456716" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="122" I2="4.062836635215238" I2_Q="41.91730072469231" ID="CMP-001.02" LOG_CI_END="0.1214813502947187" LOG_CI_START="-0.08834135843315483" LOG_EFFECT_SIZE="0.016569995930781903" METHOD="PETO" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="0.40360759784403566" P_Q="0.18947663882235344" P_Z="0.756893865088476" Q="1.7216830699621484" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7882" TOTAL_2="5484" WEIGHT="200.0" Z="0.3095622532490311">
<NAME>All-cause non-fatal serious adverse events</NAME>
<GROUP_LABEL_1>Formoterol and ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Same Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Formoterol &amp; ICS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours same dose ICS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.027278032994992" CI_END="1.2666305303754604" CI_START="0.7574588378565561" DF="21" EFFECT_SIZE="0.9795001222724934" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="113" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.10264995188472696" LOG_CI_START="-0.12064096279592547" LOG_EFFECT_SIZE="-0.008995505455599248" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.58339031340874" P_Z="0.8745211361727795" STUDIES="22" TAU2="0.0" TOTAL_1="6163" TOTAL_2="4415" WEIGHT="100.0" Z="0.15791835275450847">
<NAME>Adults and Adolescents</NAME>
<DICH_DATA CI_END="2.84029371254217" CI_START="0.451872163702912" EFFECT_SIZE="1.1328943752346055" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.45336325242055187" LOG_CI_START="-0.3449844113188826" LOG_EFFECT_SIZE="0.0541894205508346" MODIFIED="2008-11-12 15:42:27 +0000" MODIFIED_BY="Christopher J Cates" ORDER="73" O_E="0.5673758865248235" SE="0.46895336956521444" STUDY_ID="STD-Pauwels-1997" TOTAL_1="210" TOTAL_2="213" VAR="4.547164634313502" WEIGHT="7.8227236438545065"/>
<DICH_DATA CI_END="2.745707151546142" CI_START="0.5788142953977106" EFFECT_SIZE="1.2606563966008482" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.4386542148928181" LOG_CI_START="-0.23746075133379688" LOG_EFFECT_SIZE="0.10059673177951058" MODIFIED="2008-11-17 11:18:32 +0000" MODIFIED_BY="Christopher J Cates" ORDER="74" O_E="1.4685314685314683" SE="0.39715327798457334" STUDY_ID="STD-Pauwels-1997a" TOTAL_1="215" TOTAL_2="214" VAR="6.339918822436305" WEIGHT="10.906891845994986"/>
<DICH_DATA CI_END="1.5406837731623217" CI_START="0.387043538862628" EFFECT_SIZE="0.7722122116575024" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.18771350850180757" LOG_CI_START="-0.4122401780709582" LOG_EFFECT_SIZE="-0.11226333478457533" MODIFIED="2008-11-12 14:37:33 +0000" MODIFIED_BY="Christopher J Cates" ORDER="67" O_E="-2.081339712918659" SE="0.35241576531148777" STUDY_ID="STD-O_x0027_Byrne-2001a" TOTAL_1="315" TOTAL_2="312" VAR="8.05173259836984" WEIGHT="13.851814050443123"/>
<DICH_DATA CI_END="1.5791877876055629" CI_START="0.4666863178058678" EFFECT_SIZE="0.8584784992774338" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.19843377679211247" LOG_CI_START="-0.3309749314664953" LOG_EFFECT_SIZE="-0.06627057733719144" MODIFIED="2008-12-15 10:05:17 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Data does not exactly match Roman's figures. Will ask him to recheck. Also split into 200 and 400 mcg Bud daily He has 33/40 and we have 34/42 after the death has been removed. For Asthma he has 7/11 and we have 7/10. After further correspondence with AZ will go with 35/42 as the patient who died later also had non fatal SAE it appears. This is 20/554 and 23/550.&lt;/p&gt;" NOTES_MODIFIED="2008-12-15 10:05:17 +0000" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="63" O_E="-1.5778985507246368" SE="0.3109772958464768" STUDY_ID="STD-O_x0027_Byrne-2001" TOTAL_1="554" TOTAL_2="550" VAR="10.340526084390532" WEIGHT="17.789344436715876"/>
<DICH_DATA CI_END="12.037539067042108" CI_START="0.1902706113544937" EFFECT_SIZE="1.5134034219234818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.0805377096090836" LOG_CI_START="-0.7206282863961977" LOG_EFFECT_SIZE="0.17995471160644297" MODIFIED="2008-11-24 16:11:39 +0000" MODIFIED_BY="Toby J Lasserson" ORDER="68" O_E="0.37016574585635365" SE="1.0580138219689765" STUDY_ID="STD-Zetterstrom-2001" TOTAL_1="238" TOTAL_2="124" VAR="0.8933411044363015" WEIGHT="1.536861130332926"/>
<DICH_DATA CI_END="2.216052960242662" CI_START="0.008558782824312088" EFFECT_SIZE="0.1377197008923954" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.34558013514768726" LOG_CI_START="-2.0675879935320705" LOG_EFFECT_SIZE="-0.8610039291921915" MODIFIED="2008-11-24 16:19:46 +0000" MODIFIED_BY="Christopher J Cates" ORDER="3272" O_E="-0.9866666666666667" SE="1.417506904161379" STUDY_ID="STD-Chuchalin-2002" TOTAL_1="111" TOTAL_2="114" VAR="0.49767936507936505" WEIGHT="0.8561836769414918"/>
<DICH_DATA CI_END="3.962409861200107" CI_START="0.11725470507098179" EFFECT_SIZE="0.6816239429812956" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5979593957990166" LOG_CI_START="-0.9308697213602872" LOG_EFFECT_SIZE="-0.16645516278063527" MODIFIED="2008-11-24 16:21:55 +0000" MODIFIED_BY="Christopher J Cates" ORDER="58" O_E="-0.4752475247524752" SE="0.8980417912455574" STUDY_ID="STD-Price-2002" TOTAL_1="250" TOTAL_2="255" VAR="1.2399578005891114" WEIGHT="2.1331638469506804"/>
<DICH_DATA CI_END="3.684737125329129" CI_START="0.055800417713759765" EFFECT_SIZE="0.45344224633216934" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5664065100807565" LOG_CI_START="-1.2533625499853267" LOG_EFFECT_SIZE="-0.34347801995228516" MODIFIED="2008-11-24 16:08:37 +0000" MODIFIED_BY="Toby J Lasserson" ORDER="1646" O_E="-0.6921606118546846" SE="1.0689413538849437" STUDY_ID="STD-Buhl-2003" TOTAL_1="352" TOTAL_2="171" VAR="0.8751696378156208" WEIGHT="1.5055998119050804"/>
<DICH_DATA CI_END="11.647528699903194" CI_START="0.27135406509736537" EFFECT_SIZE="1.777808837039844" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.0662337892378144" LOG_CI_START="-0.5664636679627796" LOG_EFFECT_SIZE="0.24988506063751742" MODIFIED="2008-11-24 16:11:29 +0000" MODIFIED_BY="Toby J Lasserson" ORDER="79" O_E="0.6255605381165918" SE="0.9590545683423866" STUDY_ID="STD-SD_x002d_039_x002d_0726" TOTAL_1="301" TOTAL_2="145" VAR="1.0872098120125686" WEIGHT="1.870383543644302"/>
<DICH_DATA CI_END="22.040959360353103" CI_START="0.8785093504508752" EFFECT_SIZE="4.400362359053848" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.3432304938022466" LOG_CI_START="-0.05625361171267323" LOG_EFFECT_SIZE="0.6434884410447868" MODIFIED="2008-11-24 16:10:20 +0000" MODIFIED_BY="Toby J Lasserson" ORDER="1641" O_E="2.192528735632184" SE="0.8220638911375125" STUDY_ID="STD-Noonan-2006" TOTAL_1="239" TOTAL_2="109" VAR="1.4797517260035722" WEIGHT="2.5456937993163895"/>
<DICH_DATA CI_END="1.6663240803053898" CI_START="0.07125993784603576" EFFECT_SIZE="0.3445898292084588" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.22175947042052482" LOG_CI_START="-1.1471545607828628" LOG_EFFECT_SIZE="-0.4626975451811689" MODIFIED="2008-11-24 16:09:46 +0000" MODIFIED_BY="Toby J Lasserson" ORDER="25" O_E="-1.6477272727272725" SE="0.80410687816261" STUDY_ID="STD-Kuna-2006" TOTAL_1="409" TOTAL_2="207" VAR="1.5465802005644025" WEIGHT="2.6606622972864797"/>
<DICH_DATA CI_END="3.263905454666281" CI_START="0.18265705947421085" EFFECT_SIZE="0.772123936134077" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.5137375700844532" LOG_CI_START="-0.7383635381717598" LOG_EFFECT_SIZE="-0.11231298404365321" MODIFIED="2008-12-01 11:14:55 +0000" MODIFIED_BY="Christopher J Cates" ORDER="3416" O_E="-0.47807017543859676" SE="0.7354903889901454" STUDY_ID="STD-Jenkins-2006" TOTAL_1="341" TOTAL_2="115" VAR="1.8486129713622792" WEIGHT="3.1802649700179773"/>
<DICH_DATA CI_END="3.5710037688149154" CI_START="0.052889162124646144" EFFECT_SIZE="0.4345887680055416" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5527903085446882" LOG_CI_START="-1.2766333130627896" LOG_EFFECT_SIZE="-0.36192150225905073" MODIFIED="2008-11-24 16:21:20 +0000" MODIFIED_BY="Christopher J Cates" ORDER="29" O_E="-0.7216494845360826" SE="1.0746124911252095" STUDY_ID="STD-Morice-2007" TOTAL_1="462" TOTAL_2="217" VAR="0.8659568084407981" WEIGHT="1.4897505027260423"/>
<DICH_DATA CI_END="117.86725575607588" CI_START="0.45580744831811715" EFFECT_SIZE="7.329718486165472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0713931721895893" LOG_CI_START="-0.34121858232144386" LOG_EFFECT_SIZE="0.8650872949340728" MODIFIED="2008-11-24 16:19:53 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1644" O_E="0.9918032786885247" SE="1.417180087220574" STUDY_ID="STD-Corren-2007" TOTAL_1="123" TOTAL_2="121" VAR="0.4979089319544394" WEIGHT="0.8565786127676412"/>
<DICH_DATA CI_END="49.9179935837739" CI_START="0.3998329128779371" EFFECT_SIZE="4.46753363497383" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6982571208849584" LOG_CI_START="-0.3981214591099885" LOG_EFFECT_SIZE="0.6500678308874849" MODIFIED="2008-11-12 11:10:47 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;This includes the DAE who had an MI the day after discontinuation of treatment.&lt;/p&gt;" NOTES_MODIFIED="2008-11-12 11:10:47 +0000" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="3413" O_E="0.9870967741935486" SE="1.2314231551303647" STUDY_ID="STD-D5896C00001" TOTAL_1="312" TOTAL_2="153" VAR="0.6594553087660124" WEIGHT="1.1344952406211015"/>
<DICH_DATA CI_END="3.1894177736800122" CI_START="0.493901539028354" EFFECT_SIZE="1.2550929634990966" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.5037114100928881" LOG_CI_START="-0.30635962054733973" LOG_EFFECT_SIZE="0.09867589477277422" MODIFIED="2008-11-14 14:47:24 +0000" MODIFIED_BY="Christopher J Cates" ORDER="71" O_E="1.0034722222222214" SE="0.47583973331434254" STUDY_ID="STD-Peters-2008" TOTAL_1="443" TOTAL_2="133" VAR="4.416503644155931" WEIGHT="7.597940751825047"/>
<DICH_DATA CI_END="4.9186985470502425" CI_START="0.05244477449030903" EFFECT_SIZE="0.5078976630049212" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6918502067096897" LOG_CI_START="-1.2802977776912103" LOG_EFFECT_SIZE="-0.2942237854907604" MODIFIED="2012-10-04 16:46:07 +0100" MODIFIED_BY="Christopher J Cates" ORDER="377" O_E="-0.504823151125402" SE="1.1584494883270557" STUDY_ID="STD-Spector-2012" TOTAL_1="156" TOTAL_2="155" VAR="0.7451535860878196" WEIGHT="1.2819264409748385"/>
<DICH_DATA CI_END="5.983189994544777" CI_START="0.30185992144060264" EFFECT_SIZE="1.3439067161516403" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7769327939622664" LOG_CI_START="-0.52019454531624" LOG_EFFECT_SIZE="0.12836912432301315" MODIFIED="2012-10-15 17:02:30 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;4/191 and 3/192 because there was also one death on combination treatment. CJC&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 17:02:30 +0100" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="385" O_E="0.5091383812010446" SE="0.7619390199760788" STUDY_ID="STD-Nathan-2010" TOTAL_1="191" TOTAL_2="192" VAR="1.722501346385891" WEIGHT="2.963308587347517"/>
<DICH_DATA CI_END="3.655385756799588" CI_START="0.10798235291088004" EFFECT_SIZE="0.6282651946559967" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5629332152772412" LOG_CI_START="-0.966647213583812" LOG_EFFECT_SIZE="-0.2018569991532854" MODIFIED="2012-10-04 16:58:58 +0100" MODIFIED_BY="Christopher J Cates" ORDER="378" O_E="-0.5757575757575757" SE="0.8984831154582179" STUDY_ID="STD-Weinstein-2010" TOTAL_1="255" TOTAL_2="240" VAR="1.238739994720856" WEIGHT="2.1310687922241947"/>
<DICH_DATA CI_END="52.701362046438575" CI_START="1.0205879314944706" EFFECT_SIZE="7.333919421285997" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7218218395314913" LOG_CI_START="0.00885042847167281" LOG_EFFECT_SIZE="0.8653361340015819" MODIFIED="2012-10-04 17:06:29 +0100" MODIFIED_BY="Christopher J Cates" ORDER="379" O_E="1.968" SE="1.0062078862017751" STUDY_ID="STD-Zangrilli-2011" TOTAL_1="127" TOTAL_2="123" VAR="0.9876988915662651" WEIGHT="1.699189735458259"/>
<DICH_DATA CI_END="3.0869032393011624" CI_START="0.2197506529472178" EFFECT_SIZE="0.823619452430133" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4895230164933766" LOG_CI_START="-0.6580698258289237" LOG_EFFECT_SIZE="-0.08427340466777357" MODIFIED="2012-10-19 11:40:11 +0100" MODIFIED_BY="Christopher J Cates" ORDER="375" O_E="-0.42702702702702666" SE="0.6741017162563054" STUDY_ID="STD-Meltzer-2012" TOTAL_1="182" TOTAL_2="188" VAR="2.2006406670348664" WEIGHT="3.7858765103279355"/>
<DICH_DATA CI_END="1.6698659132949412" CI_START="0.33907448634436965" EFFECT_SIZE="0.7524685553659063" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.2226815996182185" LOG_CI_START="-0.46970488747557565" LOG_EFFECT_SIZE="-0.12351164392867853" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Web report says 11 and 14 respectively, with one fatality in each group as well. No reporting of asthma-related SAE, so used admissions for asthma exacerbation as proxy!&lt;/p&gt;" NOTES_MODIFIED="2013-05-02 16:52:43 +0100" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="374" O_E="-1.7192982456140342" SE="0.4067112498872817" STUDY_ID="STD-Brown-2012" TOTAL_1="377" TOTAL_2="364" VAR="6.045436017735187" WEIGHT="10.4002777723236"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.394460125099277" CI_END="3.2827531184273444" CI_START="0.7994740305306517" DF="5" EFFECT_SIZE="1.6200234155178668" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" I2="32.38181130995185" ID="CMP-001.02.02" LOG_CI_END="0.5162382225598806" LOG_CI_START="-0.09719563896016441" LOG_EFFECT_SIZE="0.20952129179985812" MODIFIED="2013-02-19 17:10:53 +0000" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="0.1929175596057111" P_Z="0.18061290325660206" STUDIES="7" TAU2="0.0" TOTAL_1="1719" TOTAL_2="1069" WEIGHT="100.0" Z="1.3388702896330429">
<NAME>Children and Adolescents</NAME>
<DICH_DATA CI_END="32.21222984602999" CI_START="1.6090340805391266" EFFECT_SIZE="7.199345500281389" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.5080207892812607" LOG_CI_START="0.20656524287673858" LOG_EFFECT_SIZE="0.8572930160789997" MODIFIED="2013-02-19 17:10:53 +0000" MODIFIED_BY="Christopher J Cates" ORDER="64" O_E="3.3776223776223775" SE="0.7644814302668712" STUDY_ID="STD-Tal-2002" TOTAL_1="148" TOTAL_2="138" VAR="1.7110634672651603" WEIGHT="22.216559981768455"/>
<DICH_DATA CI_END="15.834314607973708" CI_START="0.0613033238051652" EFFECT_SIZE="0.9852391159741222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1995992695761308" LOG_CI_START="-1.2125159778289158" LOG_EFFECT_SIZE="-0.006458354126392451" MODIFIED="2008-11-14 15:20:55 +0000" MODIFIED_BY="Christopher J Cates" ORDER="75" O_E="-0.007407407407407307" SE="1.4168884364887677" STUDY_ID="STD-SD_x002d_039_x002d_0714" TOTAL_1="136" TOTAL_2="134" VAR="0.4981139310865319" WEIGHT="6.467543863481645"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0718" TOTAL_1="128" TOTAL_2="145" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.520123202354366" CI_START="0.3712500434284612" EFFECT_SIZE="2.068053732177982" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.061457123689324" LOG_CI_START="-0.43033348687139134" LOG_EFFECT_SIZE="0.3155618184089663" MODIFIED="2008-11-17 09:42:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="91" O_E="0.9462571976967373" SE="0.8762851891259819" STUDY_ID="STD-SD_x002d_039_x002d_0725" TOTAL_1="352" TOTAL_2="169" VAR="1.3022940528512643" WEIGHT="16.909071166900695"/>
<DICH_DATA CI_END="11.339411847772608" CI_START="0.09257338668297033" EFFECT_SIZE="1.024562227364111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0545905291696647" LOG_CI_START="-1.0335138478530683" LOG_EFFECT_SIZE="0.01053834065829812" MODIFIED="2008-12-01 15:14:20 +0000" MODIFIED_BY="Christopher J Cates" ORDER="90" O_E="0.016129032258064502" SE="1.2265628473465209" STUDY_ID="STD-SD_x002d_039_x002d_0719" TOTAL_1="123" TOTAL_2="63" VAR="0.6646919031414348" WEIGHT="8.630403148715624"/>
<DICH_DATA CI_END="4.740181311451506" CI_START="0.3819600893012355" EFFECT_SIZE="1.3455705395950317" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6757949537114117" LOG_CI_START="-0.4179820137944853" LOG_EFFECT_SIZE="0.1289064699584632" MODIFIED="2008-11-14 11:40:00 +0000" MODIFIED_BY="Christopher J Cates" ORDER="56" O_E="0.7190476190476192" SE="0.6424900049962735" STUDY_ID="STD-Pohunek-2006" TOTAL_1="417" TOTAL_2="213" VAR="2.4225193140319194" WEIGHT="31.45414923340323"/>
<DICH_DATA CI_END="1.9250885882842166" CI_START="0.046081858479800356" EFFECT_SIZE="0.297845026626922" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.2844507195680275" LOG_CI_START="-1.3364700141498163" LOG_EFFECT_SIZE="-0.5260096472908945" MODIFIED="2008-11-14 10:28:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="49" O_E="-1.3360128617363345" SE="0.9521368626728978" STUDY_ID="STD-Morice-2008" TOTAL_1="415" TOTAL_2="207" VAR="1.1030653460296453" WEIGHT="14.322272605730348"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2013-03-15 07:57:56 +0000" MODIFIED_BY="Christopher J Cates" NO="3" NOTES="&lt;p&gt;Subtotals switched off as pooled estimate from one study is not appropriate. I agree with Roman.&lt;/p&gt;" NOTES_MODIFIED="2013-03-15 07:57:56 +0000" NOTES_MODIFIED_BY="Christopher J Cates" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7882" TOTAL_2="5484" WEIGHT="0.0" Z="0.0">
<NAME>Asthma mortality</NAME>
<GROUP_LABEL_1>Formoterol and ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Same Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Formoterol &amp; ICS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours same dose ICS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-10-04 17:06:08 +0100" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="22" TAU2="0.0" TOTAL_1="6163" TOTAL_2="4415" WEIGHT="0.0" Z="0.0">
<NAME>Adults and Adolescents</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="71" O_E="0.0" SE="0.0" STUDY_ID="STD-Pauwels-1997" TOTAL_1="210" TOTAL_2="213" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-12 15:41:49 +0000" MODIFIED_BY="Christopher J Cates" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Pauwels-1997a" TOTAL_1="215" TOTAL_2="214" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67" O_E="0.0" SE="0.0" STUDY_ID="STD-Zetterstrom-2001" TOTAL_1="238" TOTAL_2="124" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="369.71538582937444" CI_START="0.14555897975641185" EFFECT_SIZE="7.33589765206494" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5678675242592264" LOG_CI_START="-0.8369609971069162" LOG_EFFECT_SIZE="0.8654532635761552" MODIFIED="2008-11-26 14:19:55 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;Web report says septic shock but Roman has the death as asthma related????? So does Sears who reports status asthmaticus too.&lt;/p&gt;" NOTES_MODIFIED="2008-11-26 14:19:55 +0000" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="62" O_E="0.49818840579710144" SE="2.0000131276234736" STUDY_ID="STD-O_x0027_Byrne-2001" TOTAL_1="554" TOTAL_2="550" VAR="0.24999671812644406" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="66" O_E="0.0" SE="0.0" STUDY_ID="STD-O_x0027_Byrne-2001a" TOTAL_1="315" TOTAL_2="312" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="60" O_E="0.0" SE="0.0" STUDY_ID="STD-Price-2002" TOTAL_1="250" TOTAL_2="255" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3273" O_E="0.0" SE="0.0" STUDY_ID="STD-Chuchalin-2002" TOTAL_1="111" TOTAL_2="114" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-11 13:48:27 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1650" O_E="0.0" SE="0.0" STUDY_ID="STD-Buhl-2003" TOTAL_1="352" TOTAL_2="171" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0726" TOTAL_1="301" TOTAL_2="145" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuna-2006" TOTAL_1="409" TOTAL_2="207" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="52" O_E="0.0" SE="0.0" STUDY_ID="STD-Jenkins-2006" TOTAL_1="341" TOTAL_2="115" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1649" O_E="0.0" SE="0.0" STUDY_ID="STD-Noonan-2006" TOTAL_1="239" TOTAL_2="109" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28" O_E="0.0" SE="0.0" STUDY_ID="STD-Morice-2007" TOTAL_1="462" TOTAL_2="217" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1651" O_E="0.0" SE="0.0" STUDY_ID="STD-Corren-2007" TOTAL_1="123" TOTAL_2="121" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3414" O_E="0.0" SE="0.0" STUDY_ID="STD-D5896C00001" TOTAL_1="312" TOTAL_2="153" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Peters-2008" TOTAL_1="443" TOTAL_2="133" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-04 16:58:23 +0100" MODIFIED_BY="Christopher J Cates" ORDER="378" O_E="0.0" SE="0.0" STUDY_ID="STD-Weinstein-2010" TOTAL_1="255" TOTAL_2="240" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-04 16:45:41 +0100" MODIFIED_BY="Christopher J Cates" ORDER="377" O_E="0.0" SE="0.0" STUDY_ID="STD-Spector-2012" TOTAL_1="156" TOTAL_2="155" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-03 17:59:24 +0100" MODIFIED_BY="Christopher J Cates" ORDER="376" O_E="0.0" SE="0.0" STUDY_ID="STD-Nathan-2010" TOTAL_1="191" TOTAL_2="192" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-04 17:06:08 +0100" MODIFIED_BY="Christopher J Cates" ORDER="379" O_E="0.0" SE="0.0" STUDY_ID="STD-Zangrilli-2011" TOTAL_1="127" TOTAL_2="123" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-03 17:12:24 +0100" MODIFIED_BY="Christopher J Cates" ORDER="374" O_E="0.0" SE="0.0" STUDY_ID="STD-Brown-2012" TOTAL_1="377" TOTAL_2="364" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-10-03 17:26:34 +0100" MODIFIED_BY="Christopher J Cates" ORDER="375" O_E="0.0" SE="0.0" STUDY_ID="STD-Meltzer-2012" TOTAL_1="182" TOTAL_2="188" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-11-18 13:18:33 +0000" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="7" TAU2="0.0" TOTAL_1="1719" TOTAL_2="1069" WEIGHT="0.0" Z="0.0">
<NAME>Children and Adolescents</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="63" O_E="0.0" SE="0.0" STUDY_ID="STD-Tal-2002" TOTAL_1="148" TOTAL_2="138" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0714" TOTAL_1="136" TOTAL_2="134" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="87" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0718" TOTAL_1="128" TOTAL_2="145" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="90" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0725" TOTAL_1="352" TOTAL_2="169" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="89" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0719" TOTAL_1="123" TOTAL_2="63" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="54" O_E="0.0" SE="0.0" STUDY_ID="STD-Pohunek-2006" TOTAL_1="417" TOTAL_2="213" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" O_E="0.0" SE="0.0" STUDY_ID="STD-Morice-2008" TOTAL_1="415" TOTAL_2="207" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.74413108269526" CI_END="1.0409851283628453" CI_START="0.37041113248983604" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6209609329917293" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" I2="22.312390595914746" I2_Q="66.01128753569196" ID="CMP-001.04" LOG_CI_END="0.017444525172315598" LOG_CI_START="-0.43131596932743677" LOG_EFFECT_SIZE="-0.20693572207756056" METHOD="PETO" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NO="4" P_CHI2="0.17442980736744595" P_Q="0.0862957873925756" P_Z="0.07067098044769345" Q="2.9421532252806344" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7700" TOTAL_2="5296" WEIGHT="199.99999999999997" Z="1.8075858608674062">
<NAME>Asthma-related non-fatal serious adverse events</NAME>
<GROUP_LABEL_1>Formoterol and ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Same Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Formoterol &amp; ICS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours same dose ICS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.914028546403843" CI_END="0.8796132594891806" CI_START="0.27507265598788455" DF="15" EFFECT_SIZE="0.4918918128306764" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="30" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.055708232608676606" LOG_CI_START="-0.5605525791624757" LOG_EFFECT_SIZE="-0.30813040588557616" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.6089383754796271" P_Z="0.016733224465964397" STUDIES="21" TAU2="0.0" TOTAL_1="5981" TOTAL_2="4227" WEIGHT="99.99999999999997" Z="2.392517623303049">
<NAME>Adults and Adolescents</NAME>
<DICH_DATA CI_END="2.64876535037628" CI_START="0.051821953357366515" EFFECT_SIZE="0.3704918277665625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4230434865907325" LOG_CI_START="-1.2854862209075675" LOG_EFFECT_SIZE="-0.43122136715841747" MODIFIED="2008-11-12 15:44:11 +0000" MODIFIED_BY="Christopher J Cates" ORDER="76" O_E="-0.9858156028368794" SE="1.003598807542952" STUDY_ID="STD-Pauwels-1997" TOTAL_1="210" TOTAL_2="213" VAR="0.9928410535577682" WEIGHT="8.731119357694052"/>
<DICH_DATA CI_END="1.855270082926298" CI_START="0.09384077609264" EFFECT_SIZE="0.41725290225864264" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2684071414370067" LOG_CI_START="-1.027608409126146" LOG_EFFECT_SIZE="-0.37960063384456955" MODIFIED="2008-11-21 12:06:05 +0000" MODIFIED_BY="Christopher J Cates" ORDER="75" O_E="-1.508158508158508" SE="0.761285949781237" STUDY_ID="STD-Pauwels-1997a" TOTAL_1="215" TOTAL_2="214" VAR="1.725457914269103" WEIGHT="15.173807471172228"/>
<DICH_DATA CI_END="3.29064182225189" CI_START="0.16860166434122384" EFFECT_SIZE="0.7448541387295278" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5172806130494346" LOG_CI_START="-0.7731381425781692" LOG_EFFECT_SIZE="-0.12792876476436715" MODIFIED="2008-11-12 14:35:25 +0000" MODIFIED_BY="Christopher J Cates" ORDER="64" O_E="-0.51268115942029" SE="0.7579983647315139" STUDY_ID="STD-O_x0027_Byrne-2001" TOTAL_1="554" TOTAL_2="550" VAR="1.7404576595584442" WEIGHT="15.305716366344265"/>
<DICH_DATA CI_END="1.872780399576232" CI_START="0.17281768204806078" EFFECT_SIZE="0.5689020721001159" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2724868554085433" LOG_CI_START="-0.7624118242238266" LOG_EFFECT_SIZE="-0.24496248440764165" MODIFIED="2009-01-08 16:13:31 +0000" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;This is the disputed OPTIMA line where Roman has 7 and Joe Gray has extracted 6 for the BUD arm. If we use 7 the pooled confidence interval will shrink down to 0.53 (0.28 to 1.00). This version has used the 7 result.....&lt;/p&gt;" NOTES_MODIFIED="2009-01-08 16:13:31 +0000" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="68" O_E="-1.526315789473684" SE="0.6079046072471381" STUDY_ID="STD-O_x0027_Byrne-2001a" TOTAL_1="315" TOTAL_2="312" VAR="2.706008336799625" WEIGHT="23.796842089525853"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="69" O_E="0.0" SE="0.0" STUDY_ID="STD-Zetterstrom-2001" TOTAL_1="238" TOTAL_2="124" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.004776286791366" CI_START="0.002756039305573203" EFFECT_SIZE="0.13894401308852464" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8453942696769695" LOG_CI_START="-2.559714592979279" LOG_EFFECT_SIZE="-0.857160161651155" MODIFIED="2008-11-11 14:23:55 +0000" MODIFIED_BY="Christopher J Cates" ORDER="3274" O_E="-0.49333333333333335" SE="2.000177801484994" STUDY_ID="STD-Chuchalin-2002" TOTAL_1="111" TOTAL_2="114" VAR="0.24995555555555554" WEIGHT="2.198128070806351"/>
<DICH_DATA CI_END="6.956858175335876" CI_START="0.002738041830253125" EFFECT_SIZE="0.13801510312718696" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8424131497861598" LOG_CI_START="-2.5625599212460983" LOG_EFFECT_SIZE="-0.8600733857299693" MODIFIED="2008-11-14 12:03:23 +0000" MODIFIED_BY="Christopher J Cates" ORDER="61" O_E="-0.49504950495049505" SE="2.000098036812882" STUDY_ID="STD-Price-2002" TOTAL_1="250" TOTAL_2="255" VAR="0.24997549259876484" WEIGHT="2.1983033986730587"/>
<DICH_DATA CI_END="288.2737322189992" CI_START="0.06772366666177597" EFFECT_SIZE="4.418478714234751" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4598050708582857" LOG_CI_START="-1.1692595365662364" LOG_EFFECT_SIZE="0.6452727671460248" MODIFIED="2008-11-11 13:43:17 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1647" O_E="0.32695984703632885" SE="2.1317305145606933" STUDY_ID="STD-Buhl-2003" TOTAL_1="352" TOTAL_2="171" VAR="0.22005710546230928" WEIGHT="1.9351988381373848"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0726" TOTAL_1="301" TOTAL_2="145" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.4914117186721354" CI_START="0.020522407063312247" EFFECT_SIZE="0.22611891883010574" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.39644550287660607" LOG_CI_START="-1.687771702380593" LOG_EFFECT_SIZE="-0.6456630997519933" MODIFIED="2008-11-12 10:28:37 +0000" MODIFIED_BY="Christopher J Cates" ORDER="26" O_E="-0.9918831168831168" SE="1.2242795034096356" STUDY_ID="STD-Kuna-2006" TOTAL_1="409" TOTAL_2="207" VAR="0.6671735840576909" WEIGHT="5.867174986201644"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-14 10:56:52 +0000" MODIFIED_BY="Christopher J Cates" ORDER="51" O_E="0.0" SE="0.0" STUDY_ID="STD-Jenkins-2006" TOTAL_1="341" TOTAL_2="115" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="85.86056999149186" CI_START="0.2160653786337206" EFFECT_SIZE="4.307144827483603" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9337937672477523" LOG_CI_START="-0.6654148169802824" LOG_EFFECT_SIZE="0.6341894751337349" MODIFIED="2008-11-11 12:27:50 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1642" O_E="0.6264367816091954" SE="1.5267879886655442" STUDY_ID="STD-Noonan-2006" TOTAL_1="239" TOTAL_2="109" VAR="0.42898541868222534" WEIGHT="3.77253023512986"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-11 13:44:20 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1648" O_E="0.0" SE="0.0" STUDY_ID="STD-Corren-2007" TOTAL_1="123" TOTAL_2="121" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.927185827023039" CI_START="6.541943960423383E-4" EFFECT_SIZE="0.04376012527647778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.46645029369753593" LOG_CI_START="-3.184293180446918" LOG_EFFECT_SIZE="-1.358921443374691" MODIFIED="2008-11-12 10:59:15 +0000" MODIFIED_BY="Christopher J Cates" ORDER="30" O_E="-0.6804123711340206" SE="2.144464788184102" STUDY_ID="STD-Morice-2007" TOTAL_1="462" TOTAL_2="217" VAR="0.21745137634180042" WEIGHT="1.912283859064495"/>
<DICH_DATA CI_END="384.20981666476" CI_START="0.035058494760182086" EFFECT_SIZE="3.6701250447841702" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5845684570089413" LOG_CI_START="-1.4552067343169635" LOG_EFFECT_SIZE="0.5646808613459889" MODIFIED="2008-11-14 14:48:43 +0000" MODIFIED_BY="Christopher J Cates" ORDER="73" O_E="0.2309027777777778" SE="2.3729839445945444" STUDY_ID="STD-Peters-2008" TOTAL_1="443" TOTAL_2="133" VAR="0.17758668499228394" WEIGHT="1.5617107465979991"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3418" O_E="0.0" SE="0.0" STUDY_ID="STD-D5896C00001" TOTAL_1="312" TOTAL_2="153" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.856174710537491" CI_START="0.0026993804448553734" EFFECT_SIZE="0.13604199329669078" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8360818758427399" LOG_CI_START="-2.5687359026025884" LOG_EFFECT_SIZE="-0.8663270133799242" MODIFIED="2012-10-03 17:39:47 +0100" MODIFIED_BY="Christopher J Cates" ORDER="385" O_E="-0.49869451697127937" SE="2.0000068171786087" STUDY_ID="STD-Nathan-2010" TOTAL_1="191" TOTAL_2="192" VAR="0.2499982957140617" WEIGHT="2.1985039309945926"/>
<DICH_DATA CI_END="6.776743117802312" CI_START="0.0026680701818322817" EFFECT_SIZE="0.13446496288083928" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8310210233948732" LOG_CI_START="-2.573802750774374" LOG_EFFECT_SIZE="-0.8713908636897504" MODIFIED="2012-10-04 16:46:30 +0100" MODIFIED_BY="Christopher J Cates" ORDER="377" O_E="-0.5016077170418006" SE="2.000010339096518" STUDY_ID="STD-Spector-2012" TOTAL_1="156" TOTAL_2="155" VAR="0.24999741524591348" WEIGHT="2.198496188091068"/>
<DICH_DATA CI_END="351.74464197956524" CI_START="0.13799297205843722" EFFECT_SIZE="6.9669425541187815" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.546227490679828" LOG_CI_START="-0.8601430315260262" LOG_EFFECT_SIZE="0.8430422295769007" MODIFIED="2012-10-04 16:59:30 +0100" MODIFIED_BY="Christopher J Cates" ORDER="378" O_E="0.48484848484848486" SE="2.0009189065497472" STUDY_ID="STD-Weinstein-2010" TOTAL_1="255" TOTAL_2="240" VAR="0.2497704315886134" WEIGHT="2.196500076631906"/>
<DICH_DATA CI_END="361.0201425178772" CI_START="0.1420003325887984" EFFECT_SIZE="7.159956725343665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5575314333193067" LOG_CI_START="-0.8477106384246144" LOG_EFFECT_SIZE="0.8549103974473461" MODIFIED="2012-10-04 17:07:02 +0100" MODIFIED_BY="Christopher J Cates" ORDER="379" O_E="0.492" SE="2.000256049162488" STUDY_ID="STD-Zangrilli-2011" TOTAL_1="127" TOTAL_2="123" VAR="0.249936" WEIGHT="2.1979560977709394"/>
<DICH_DATA CI_END="0.9233476517003797" CI_START="0.018165118507996892" EFFECT_SIZE="0.12950953446452515" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.034634750991405006" LOG_CI_START="-1.740761764484381" LOG_EFFECT_SIZE="-0.887698257737893" MODIFIED="2013-05-02 16:52:43 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;p&gt;0 and 4 are the reported hospital admissions for asthma exacerbation.&lt;/p&gt;" NOTES_MODIFIED="2013-05-02 16:52:43 +0100" NOTES_MODIFIED_BY="Christopher J Cates" ORDER="251" O_E="-2.0350877192982457" SE="1.0021874531906976" STUDY_ID="STD-Brown-2012" TOTAL_1="377" TOTAL_2="364" VAR="0.9956394067197393" WEIGHT="8.75572828716428"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.887949311010788" CI_END="4.612494954313806" CI_START="0.48338185615180407" DF="4" EFFECT_SIZE="1.4931833017104892" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="59.546718190132964" ID="CMP-001.04.02" LOG_CI_END="0.6639359040853021" LOG_CI_START="-0.31570965496484893" LOG_EFFECT_SIZE="0.17411312456022657" MODIFIED="2013-02-19 17:10:44 +0000" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="0.04235812515781556" P_Z="0.48599577387455595" STUDIES="7" TAU2="0.0" TOTAL_1="1719" TOTAL_2="1069" WEIGHT="100.0" Z="0.6966916763337475">
<NAME>Children and Adolescents</NAME>
<DICH_DATA CI_END="41.53343371819875" CI_START="1.213346203462934" EFFECT_SIZE="7.098903726545099" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6183978372794217" LOG_CI_START="0.08398473557496194" LOG_EFFECT_SIZE="0.8511912864271919" MODIFIED="2013-02-19 17:10:44 +0000" MODIFIED_BY="Toby J Lasserson" ORDER="65" O_E="2.4125874125874125" SE="0.9013218514085513" STUDY_ID="STD-Tal-2002" TOTAL_1="148" TOTAL_2="138" VAR="1.2309493965732463" WEIGHT="40.76179982852603"/>
<DICH_DATA CI_END="6.7201477639548415" CI_START="0.002645326213221787" EFFECT_SIZE="0.13333035302103385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8273788225128552" LOG_CI_START="-2.577520764511034" LOG_EFFECT_SIZE="-0.8750709709990894" MODIFIED="2008-11-14 15:20:40 +0000" MODIFIED_BY="Christopher J Cates" ORDER="77" O_E="-0.5037037037037037" SE="2.0000548719426146" STUDY_ID="STD-SD_x002d_039_x002d_0714" TOTAL_1="136" TOTAL_2="134" VAR="0.24998628257887515" WEIGHT="8.27807449983271"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86" O_E="0.0" SE="0.0" STUDY_ID="STD-SD_x002d_039_x002d_0718" TOTAL_1="128" TOTAL_2="145" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.481715166917478" CI_START="0.1723777725904264" EFFECT_SIZE="1.406837761076575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.0600067688884762" LOG_CI_START="-0.7635187354003494" LOG_EFFECT_SIZE="0.1482440167440633" MODIFIED="2008-11-17 09:44:28 +0000" MODIFIED_BY="Christopher J Cates" ORDER="92" O_E="0.2975047984644914" SE="1.0711479078160815" STUDY_ID="STD-SD_x002d_039_x002d_0725" TOTAL_1="352" TOTAL_2="169" VAR="0.8715676703224642" WEIGHT="28.861192030800982"/>
<DICH_DATA CI_END="285.2909520468372" CI_START="0.07214196970237054" EFFECT_SIZE="4.536678434595444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.455287998301164" LOG_CI_START="-1.1418120042523046" LOG_EFFECT_SIZE="0.6567379970244297" MODIFIED="2008-12-01 15:14:04 +0000" MODIFIED_BY="Christopher J Cates" ORDER="91" O_E="0.33870967741935487" SE="2.1129543474320904" STUDY_ID="STD-SD_x002d_039_x002d_0719" TOTAL_1="123" TOTAL_2="63" VAR="0.22398543184183142" WEIGHT="7.417079339458793"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="55" O_E="0.0" SE="0.0" STUDY_ID="STD-Pohunek-2006" TOTAL_1="417" TOTAL_2="213" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9359658823066719" CI_START="0.002597570782780071" EFFECT_SIZE="0.049307581866877045" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="-0.028739981813177096" LOG_CI_START="-2.5854326092560744" LOG_EFFECT_SIZE="-1.3070862955346256" MODIFIED="2008-11-24 15:11:24 +0000" MODIFIED_BY="Toby J Lasserson" ORDER="50" O_E="-1.3344051446945338" SE="1.5018139051925743" STUDY_ID="STD-Morice-2008" TOTAL_1="415" TOTAL_2="207" VAR="0.44337148430365003" WEIGHT="14.681854301381481"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-05-24 14:28:17 +0100" MODIFIED_BY="Christopher J Cates">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-05-24 14:28:17 +0100" MODIFIED_BY="Christopher J Cates" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASsAAASrCAIAAABFTgmcAAA5DklEQVR42u3dvY4cR5aG4QYICDRo
0NAV8BpoEYQsytI9USaNATim7oLQJSw4u+ZoLHoEl92LZRtj8MfbXRG51epdoVhdlRWZlXEiT9Rz
UBCoYvfXwex468Tv+S4uhBBtYxBCtAgECoFAIRAohECgEAgUQiBQCAQKIRAoBAKFEAgUnfa/Mz6b
hUDRsueVvIlAIZbvdrP/FoFCCASKvpKheaAQLfE7w/EnAgUCESgQiEAEirb972zxQ6AQCBQCgR6E
aNn/zvhgGgJFy863/QfzQCFaEjhYCxUCgQgUZwqhUagQAoFCIFCIgMEnCxMECoFAIRDoQYiW/U+l
Jl1BtJoNjr+DQCEQiEBxBhAahQrRZvpnNwKBQiBQCAQKIRAoBAKFEAgUZ9H/rIXqCqJJ5/MQECgQ
iEABQgQK0XwSaB4ohECgEAgUIn4gikAhQjvf0XcQKAQCESgQiEAhzAMRKHCCQHE2vXlvI/UZBCZ+
1ol683jDTmm2qvUI7Kc3CwSKc/n4WLa3WAtFYD+9OabBS3GiWiEC++nNedus4yEQgX22GYGiq968
3UmWbbCq9Qjspzfn/Tw6ZwgRKBCIQJGil1RYsXTeDYH99OaYuavegsAexl2JerO1UAR2S+Bw9rsR
2wMBo1CBwOPNrnEq7ZyzKwI76c0+jxAoBAIRKJYmpOr5absRCOynNwsECjFnFDryDgKFWH6s6H4g
AvvpzXkzlY6HQOMuY0UEIjBVsxe/H+hMDAI76c21B8yLD57tByKwn96c+sMIgQgUCESgOPuhgXmg
EAKBQiBQiENjRTWzEag3hzY4Rtw8UOTuzena7LQNAhHYstkIRCAIZ87ZKokbhYrEvVkgUIgFBgJn
1SERKNqMFfdKnWFvRGAPvTk4X5kHIrCf0Zcbumf+SYdAvbm3Nuca3yLQiK6rsWK6NR4EWtUQCBTn
9Kkf/FjMA0XuThx5JuYMK9AgsKvenGv8GXDmG4GiwaBr2T6XsWIvAkWz3rxgnwu4R1sVwhQFoBAY
+6AT1t6sDYk78gjsYeaT6FNfIFDM/+DI0luyZFcE6s3N5q5DtdM2O2MB80DRoDdnXAu1HyiyElj1
Uz9sIRSBInp+UmncNZz9rQun0kSb3pxrOdQNXQT2CSGfTQSKTnpzruwacP4WgcaK6ducjhMEIrBZ
b+aziUAErmXknGU3YlCpSWTvGZEPIdEpAgSKfjIVVyYEdji+XbDPpfbZzHL+FoHGXc0y1cCdF4G9
psGMO43OxAjZ9ciPGKod3Uz0wYHAToAZzv5MDAIR2E9vTtrmdBUWh6XXnBGIQJlqGi0lbyJQb17v
p36r6fFSv7sZf4tAvTnBR1KKMqTmgSLuUz/viKD2HuaCnxoI7C2ZVEU60a2LSr168TYj0LhrmniK
/cBEnxoI7GTcFfCpXwnCdItSCERgm0/9jOsc9ebbSz0KBPaTA2v3udS7EWtvJzaSfoJ28Cjc0EVg
nx067wAhxdx1qUeNwFV0rxonNs4ZwkTuAAhsM/4cfxOBqx0RWAs1VuyHwNTFLxAoqrOduk5MDIRG
oSJ6cLjy3qJqvegZv9qzNXfkRVZCUldhq1eBZsE2V3rOCBQNZpiVVjUG1QpFq3FX0rXQxQnM8m9H
4FrmVDWQTrq4r1KTSElgwKd+IrbTzYoR2A+EGtzkaSAw9ySw0gKg2/dZ2oxAn83NOnSuNleabyMQ
gc3ydsY21xoW6cGtBqIplDM+jWT9ARgdjBVFxueMQD1jzqAuUVONQkXc2kOAy186C2ujUBEx88nl
8le7ywWv8fBOEikJTHpGb+9+IO8kBCbz2YxxpAjLrgjMQUiM23u6Y9kdzOQRKMSRHFv1kw6BuT9B
cVJ1XUrVelFxhSDv/cCw+heDHXkh43VDoJPZohkqiaoMZ3FKRWCHKwRDEqfbwfotAhsmkyGPI3SW
OdVQ3yFn8X8+AlsSmIKTdK6jtR1yzAMR2GasmAK/dONbBHayqjG47Zp6XcCDEGuYs51hHUQErmid
IMuI7pxPEciBIIwe30b6q5xh3kZg42RiLTT1784oVOQmMOwGw2pvHiIQge3Ht7WfhlNpYs9n81Dn
dEWigWIYgWuGEIH9ZKrUDyTRmNw8EIETOvGJZbyGyqtHAfWUnIkR1T+bq56EFAjscx7oVFrk4Ha1
N6r8tsQqPjWWHQ7w0BXySeP1kixPA4GN84l6SkOqlWEE9pZP0jU7af0L80CRbHQ0RHkwqBeKwNwQ
uumTenyLwMaTwPWvPSDQKFSc0UdSDQjXXOMUgXpzh7PiyDYjMCsng/vmVoYR2M38pOovseqNqoCZ
doDxKPcyKwT5bvrEzAMHuxEiJgfmrUCz/tkaArtdLzFyTkfgsmNyBIqWnxpVIQw4bTNYCxUB6yUx
kOTaQUFgD8lkwW6nAg0CxeRxV41qMbVXWfUWp9I6wW/7nTUTmNFrOh/P2MhOYMDaw+IE9nFDF4E9
jGFSuNKuf11xb5uHdZ/jQaDoZ1UjRlnFXlHaObK0uer0cuWjDAR2O8M8Z7YT1SZHIAJbsp1r7lqj
NjkCQdg4uy7Sj/OyjcBmv7+h0qpayIbEuc3WzAN7S1O57hmku/eUaO6KQAR6GghE4BlDeOaPAoG5
5/EBY8Uh7U4jAkWHeTvpimXtSk0IFFlHzulqNy57vwyBLUdHuTwrc53eDBvcnvjxgcDGk5N0xZoS
3Y1AoOiEwHTj23jHNQRm6na1PdnT3Y04Z7s1BPaZT7CNQNHPiM5Yo97nEQIb94xzXlcc8rj81Xsa
CGyTqRL15iHh3QgEip5HdBnz9mr3ORAIwmYNTuT2PvJhZB6YO5k44XXmZfYR2Ftqde8JgaIrAjM6
HA11zt8ahXY1EB3OtULmoWan2I2QA2WqBmsPGfN2pX/F4soI7IfAmBHd2X4eVboFhkAENpsH8k5C
YPsOvea1h7CnUSMBho1CESiSrT3EZ+w1T4wRiMCWeftQPlznxHWwG9HlJ/TKOamdXc/8ziECu5rW
J8qu9fwzhlSnCBAIwgYE7ijUfghVb+giEIEHP/jXPL6tmgPrPWc78r3NA9ecS2M6RswoEYEi32g2
uEx91dryqx2TIxCEk5c0zrzDmAd2NQpd+BdZ8+yYqNglPIgmmYoNWJZMhcBuB4ruRtT4QYlOCCGw
HwITeYOG+T2tn20EdjI6yphd4z3GECiMb9PPA5edySMQgRN683D2njCLj58R2OxXOKz7vOJdknnC
VOwPHkRwpspYlwGBCERgb23O2PeWHcUgsM/enGV8m3EeuOxvEIGNp/L1kom10BSVkRHYW3ZFYMzc
FYEiKLvGKA95avg7ldbPx/M514nJlamqf24CI/voCIGt5tsIRGAohPyeVOxFYMvpZVU7lBR5W8Xe
HtZLEn3kZ3y86oWKVXS+qsOtlV88T/Zb0327Gd/Wy9jjb/adqRAoWn7qZ3RcC64IjECRb1aZdJ8D
gaJ0XIfAqjuNg7sRfaDiaWS8VexcqIGi6IFtBPZDoNQa+RtEIAjj5lRVC3um++BwN8I8MJTA4cCe
Qe0d/2U/L6yFirqj0PgateskMAYYBCKwwdrD4gQO+W1hEAjCZjOfNTuuDVHrUu5GpJ8Eevi5xuRy
oBgOjQmxHTMrNg8U7VN3jWSS5cx3lWerk7WdU638U792pqpxdmzxPYlKYw0Eph8dxbthrp/AfJ/I
2OhgfhLZ7LMlkIMnAttPAlPsGWRx3kZgJ/PAwb2n2JGzUagYG9G5dmgeKFoSOCx3bjPvKDQAb3cj
sg4+661YqodfdUxuJaarAVKlT32eMInuoCCwn0/9dHl7qO9IEfBYjEIRmDVv13akyDQ9wUarxJKC
k3Sd2x150fOcylaHeqEilJN0LtYBz1mttE5Goeluha+5Nwc8DQT2lqk8jaFmZet6Y3IEIjB93s5I
4GA3AoStxl2p22wtVOxPJonGXakf9drbiY3+UmuWNJj609P9QBGRA7Pcdk0Mth6cfVVjyOmdFHBO
fVArTdztCu7RDmnP8TgT0w+B6/94HnpZPbIfKGoRmHpOFVY1Z7W/QQS2hNCT9xmKQNFnds2Stz1Q
nKyr8etXrvIE9OPI3lZjhSD1iC6RMgJ76G3ba4xVf6/LfmokOnFar8z+zjTeKDQrgVW7SI01/XQl
lWoUt67xNBDYLAdWAi+gkNmaz7vVU0YgAos+7BMR2MdvEIFyYNYciEAEhv7+AvYMAsZyK78bUbsG
6d3FGCsx4uDv1XNI89HsQQiBQCEQKIRAoBAIFEIgMN2jFGLKXggClySQMuWpygjUMygjEIGUESj0
DMoIRCBlBAo9gzIC+yPw4/98fHH54uk/nj7814cX/3Lx4G8PHv/98c///vM///ufZ6j8Px8/Xr54
8Y+nT//14cN/ubj424MHf3/8+N9//vm//3mq8tevHz99enF9/fTq6uH79xeXlw8+fHj88ePPX7+u
URmBQQT+8p+/fP9v32868d3XpnP/9T/+elbK//nLL//2/ff7hC82QP7HX+crf/nyy9XV9xs87r42
2Hz+vDplBEYQuEkae/vx9mvzNWeivEl0x4QvNl8zQ3mTjvYSsv3afM2qlBFYncBNJjnalW9fh7JK
T8qb7FcmfHEoEx5S3uSoo5Dcvg7lq3jllgQ2qaZ6qGLn3jbsfWektXvf38yjDg3k9g7trv/rumPl
zdzv0OBz73D0v65LlTcztO0h4uvXFz/8cHH//s3rp58ufvttd9D4++/tldsTGLMMtfdH7C36P15Q
8GhpkL1vvrh8UdiVR8Z13ShfvngxRXj/WHSv8qdPL7ZJePTo5tf3668Xr17d/OHJk6IRY7DySgnc
KTd0tzLHCBLllXDHBY+WPCon8Ok/nu7pWbexr9M9/vvjjpX/8fTpJAL//rhU+fr66d5h4du3N63+
7rvd9z98aK+8XgJH8DhKYKGjzVGklyLwdhG/vDc/+NuDjpVvNx7KX397UKp8uz2w83rz5uLZs5tW
v3y5+1eXl+2VVzoPPPrnnXRXiFPJeLKQwEnv7+/H23Gn33WsfJex748IlyrvTVM//nij+fz5/lWT
5sqrHoV2Q6Ac2DAH3rt30+R37/ZAcmIOXET5TAksX18pH2qaB652Hnjodfo88HTlrATO+PP4BkM5
gYVzS2uhzddCb1+3Ub57HqycYB44FHjulRM48hNL9gOPbmDaD1zPfuA4J6fsBy6o3JjA/sKZmBJl
Z2IQGE3g4Fzot+FcKAKjCbzNKvvXGP8YyP3l6i9npbzJhIfWRTfvX/1lvvIfNxgeHr7BsDplBAYR
OBy+a7d3HtW98qH7gXvnfpOUD93i2ztDa66MwDgCKVNGIAIpIxCBlCkjUM+gjEAEUkYgAvUMygjs
g0AheCfJgZTlQARSpoxABFJGIAIpU0YgAikjEIGUKSOwJYG5PH1uI6N3Ui4nKQQGEZjO02fI6Z2U
zkkKgREEZry7nfGOfMaKAQisTmDG+iUZ68RkrJqzXgInOSuVVy4r906a5LI08hMzevpkrJWWsXLc
2gksH6CfUhr0xDePNiOjp0/GeqEZq6emJHC8inZh1fpKsHXj6ZOxZnbGCuJdEXj3C1ZCYEZPn4y+
ERldNFLOA+cNGkuGo0OxpdmkeWBGT5+M3kkZnaR6G4XGELhIDly5p48cKAdWJLDEgiJgHrhmTx/z
QPPA4wQetbaOWSCdumKZwtPHWqi10LH9wD/fmUrgJO+kSvuBKTx97AfaD0wZzsSUKDsTg8BoAgfn
Qr8N50IRGE3gkNDTZ8jpnZTOSQqBQQQO2Tx9/pwFpfNOyuUkhcA4AilTRiACKSMQgZQpI1DPoIxA
BFJGIAL1DMoI7INAIXgnyYGU5UAEUqaMQARSRiACKVNGIAIpIxCBlCkjsCWBvJO2g3cSAkMJ5J20
HbyTEBhKoDvy2+GOPAJDCVQnZif7qROzJIGHaooFzIYLC9SXtJZ30s5sR620AOUFCDxafDqGwFNa
yzvp7pvqhcYon0rgSPXbo2ZGd8t17vxVSf455NYyyXKQd9LdN9XMjlFensC9UBX29XIjpKnf25ZA
3knbwTcijsAZfX1q7y8EdcbgeVyHdxLvpFV4JwUTePeqVQoCeSfJgc3mgQsSWD4KncrJDP/ASR9J
vJPMAxuvhU6d6S3+vYWfGiU6M+zseSdZC228H7h32fPoWmjJ904l8ETvpKNFB3gn2Q/kndQynIkp
UXYmBoHRBA7OhX4bzoUiMJrAgXfSnUzIOwmBoQQOvJPuzAl5JyEwlEDKlBGIQMoIRCBlygjUMygj
EIGUEYhAPYMyAvsgUAjeSXIgZTkQgZQpIxCBlBGIQMqUEYhAyghEIGXKCGxJYD1PH95JMW3mnZSY
wHqePryTYtrMOykxgfVuWLsjH9Nmd+QTE1ivyog6MTFt7rBOzNGjOpE/t2qttHqVtngnxbS5w1pp
S7ksLfJza/tG1Ks2yTspps1rrxd6+lBtvHTndo3Qu/VCC32XRppRu2p9vYrLvJNi2rzqmtmLb4zs
heGoNVKkd9LUqvX1XAd4J8W0eb2+EWEEHh2+Rjq3TCWwnvMO76SYNq/XO6k5gSNuSushMDgH8k6S
A+fPA083UantnTTDuSV+Hsg7yTxw5lpowCg03jspbC2Ud5K10AX2A0fM4vemr/IvHk72TppHYNh+
IO8k+4HnHs7ElCg7E4PABotMzoVuh3OhCIwmcKjp6cM7KabNvJNyEzjU9PThnRTTZt5JuQmkTBmB
CKSMQARSpoxAPYMyAhFIGYEI1DMoI7APAoXgnSQHUpYDEUiZMgIRSBmBCKRMGYEIpIxABFKmjMCW
BNZzOOKdFNPmGs8ZgUEE1nM44p0U0+ZKzxmBEQTWu8nujnxMm+s9ZwRWJ7BeNRd1YmLaXO85L0zg
+DGc0+uUFZZXW0R5RHYSgfUcjngnxbS53nOuQmD5/w5LmBmdXk10RqHuSQTWczjinRTT5nrPuTqB
h/r0iZxM/XHLvjmVwHoOR7yTYtpc7zlHE1hYYHe895/iDLGIf+BUAus5HPFOimlzvefcLAeWGAYO
Bb5lKQis53DEOymmzfWecyiBM7CcNzRNkQMXcTjindQwBy7ynNdL4OzJYdV54DwC6zkc8U5qOw88
/TmHroXWW5yM/HEzCKzncMQ7qcla6ILPudl+4OIbdIn2Axd0OOKd1GQ/cMHnvDyBZx7OxJQoOxOD
wGgCB+dCvw3nQhEYTeBQ0+GId1JMmys9ZwQGETjUdDjinRTT5hrPGYFxBFKmjEAEUkYgAilTRqCe
QRmBCKSMQATqGZQR2AeBQvBOkgMpy4EIpEwZgQikjEAEUqaMQARSRiACKVNGYEsC63n6ZFTO6J1U
QxmBQQTW8/TJqJzRO6mSMgIjCKx3dzujcsY78vWUEVidwHr1SzIqZ6wTU085lMAZP2VSqbJCwRoF
1EbaVq+GV0bljLXS6imnJHCpBixbRHTkzXp1LDMqZ6wXWk+5JYGH7CKOWruMe7kcTVNLEVj+eVGv
lnNG5Yw1s+spNyOwxKel5A/jXi7j/6hT3MsmjULr+RlkVM7oG1FPeXUEjnT6pdLUOKgzPiOOPuV6
nj4ZlTN6J9VTbkng3XtTI51+hs1tYQIMmAfKgXJgSwLnGeJOGo5O4mEos5dZkEDzQPPAVRNY+GYh
gTMgsRZqLbTztdDCjbXCTn/KKPRQ1QD7gfYDz2I/sPtwJqZE2ZkYBEYTODgX+m04F4rAaAKHmp4+
GZUzeidVUkZgEIFDTU+fjMoZvZNqKCMwjkDKlBGIQMoIRCBlygjUMygjEIGUEYhAPYMyAvsgUAje
SXIgZTkQgZQpIxCBlBGIQMqUEYhAyghEIGXKCGxJ4NevHz99enF9/fTq6uH79xeXlw8+fHj88ePP
X7/+c7XKvJNqKyMwiMAvX365uvp+g8fd1wabz5//ukJl3kkBygiMIHCTjvYSsv3afM2qlN2Rj1FG
YHUCNznqKCS3r0P5Kl5ZnZgY5XURuLhT0sF/baB30maGtj1EfP364ocfLu7fv3n99NPFb7/tDhp/
//26ubJaaTHKayewBn53/1y7XuinTy+2SXj06OZp//rrxatXN3948qRoxBisrF5ojPKqCSwsJbp+
76Tr66d7h4Vv39408rvvdt//8OFxc2U1s2OU10tgYWH5FN5Jt9sDO683by6ePbvRefly968uLx80
V+YbEaO8UgJPKSxf/m+eNzSd4Z20N039+OON1PPn+1dNmivzTopRXiOBeyGc551Ug8AZzO/NVPfu
3TTv3bs9kJyYAxdRlgPPOgdWhWQI9046NFs79Dp9Hni6snnguc8DD3X9Er/Bu19ZvuERsBZ6+7qN
8t3zYGVrodZCD87BCkehh9TivZN2du3GOTllP3BBZfuBZ7ofmD2ciSlRdiYGgdEEDs6FfhvOhSIw
msDh/24wPDx8g+EvK1TmnRSgjMAgAofDt/j2ztBWosw7qbYyAuMIpEwZgQikjEAEUqaMQD2DMgIR
SBmBCNQzKCOwDwKF4J0kB1KWAxFImTICEUgZgQikTBmBCKSMQARSpozAlgTyTtqOet5JuZ4GAoMI
5J20HfW8k9I9DQRGEOiO/HbUuyOf8WkgsDqB6sTsZL9KdWIyPo0GBE41SCq3bSj86eUV0EaqrZU/
Zd5JO3O/SrXSMj6NZgTuLS4YQOCM2ttHv/3oU+adtB316oVmfBprJHBvMc/h8KHno981Cey7Ji2T
Bpy8k44q16uZnfFptByF3v3vUFAGexJCp3gnlTy1wjd5J21HPd+IjE+jcwKnDkfLCZz0Pu+k7ajn
nZTxaayRwL0jzJIJ26Hvak4g76SGOXDlT2PVOXBGMpw3gJxK4NShKe+ktvPANT+NxrsRhVluEoFH
c2Chd9KJGycja3S8k2LWQlM8jdUROLKqeWg59Oh37d3NK/FO2gvkeNEB3knr2Q9M8TTaENhxOBNT
ouxMDAKjCRycC/02nAtFYDSBA++kO5mwkndSuqeBwCACB95Jd+aElbyTcj0NBMYRSJkyAhFIGYEI
pEwZgXoGZQQikDICEahnUEZgHwQKwTtJDqQsByKQMmUEIpAyAhFImTICEUgZgQikTBmBLQms50OU
Ubmed1Kup4HAIALr+RBlVK7nnZTuaSAwgsB6N6wzKte7I5/xaSCwOoH1qoxkVK5XJybj02hG4NRC
gEtNl8u9k0ZKqk2qlVav0lZG5Xq10jI+jcYETnJQWhz78qL35bAFV5vMqFyvXmjGp7FeAse9kI56
jJX8i04hcFLV+noVlzMq16uZnfFptB+FTvJvKamifTR3nU7g1Kr19VwHMirX843I+DSSETj+5iQC
jzq3LGlpVs15J6NyPe+kjE+jTwILb2SFESgHyoFnmgMLOZlqbT11kdY80Dxw1bsRUx2UTpwHFg5c
FyTQWqi10GQEDse8kGavhU7yTjr05lQC7QfaDxyciQn+WNkJZ2K2w5kYBEYTODgX+m04F4rAaAKH
mj5EGZXreSelexoIDCJwqOlDlFG5nndSrqeBwDgCKVNGIAIpIxCBlCkjUM+gjEAEUkYgAvUMygjs
g0AheCfJgZTlQARSpoxABFJGIAIpU0YgAikjEIGUKSOwJYH1PH2+fv346dOL6+unV1cP37+/uLx8
8OHD448ff/76lXcS7yQE/hH1PH2+fPnl6ur7DXh3XxsgP3/mncQ76ewJrHfDepPo9rK3/dp8zara
7I48AkMJrFdlZJP9juJ3+zqUCdWJaas88E46/c3xhtWrtLWZ+20PPl+/vvjhh4v7929eP/108dtv
u8PR339XK02ttG9/6qH/DcD+xALBa/BO+vTpxTZjjx7dPMNff7149ermD0+eFI1F1QttqLxeAtfp
nTSPwHoVl6+vn+4dcL59e6P93Xe773/4oGa2mtmHiVq/d9I8Auu5DtxuPOy83ry5ePbsRvvly92/
urzkG8E34gQCx9+cROBs55YZ88B6zjt7E+CPP95IPn++fz2meZt5J/VPYD3vpBQ58N69G+F37/bg
JwfKgaE5sHAptb954KGXeaB54Ng0bP3eSStfC7193Ub5vry10PNdCx3v36v1TlrtfuA4gfYD7Qf2
H87ElCg7E4PAaAIH50K/DedCERhN4FDT0+ePuxEPD9+N4J3EOwmB/z+jqOTpc+h+4N6530razDsJ
gdEEUqaMQARSRiACKVNGoJ5BGYEIpIxABOoZlBHYB4FC8E6SAynLgQikTBmBCKSMQARSpoxABFJG
IAIpU0ZgSwLrORzxToppM++kxATWczjinRTTZt5JiQmsd5PdHfmYNrsjn5jAetVc1ImJaXMndWKm
lvccqQt6ShvKK6CNVAQuf8r1HI54J8W0uZ9aaXu7fiSBMwrUH/32o/+ceg5HvJNi2txPvdC9zkeH
0sv2//7536O569BXFuK98+YiBNZzOOKdFNPmfmpmjxB4tCR2eWntwsxZUgl7EQLrORzxToppcz++
EeMUFX5Z4bcMp3knLUhgPYcj3kkxbe7HO+mQI+fOkLKcwJFvWQ+B9RyOeCfJgYsRWGjMMpxsrjKJ
q6rzwNMdjngnmQeetBtxKN1NJXBSDpxk+lljLXRBhyPeSdZCl9wP3Fn53PtOybeU7OaVeCdV2g9c
0OGId5L9QFH0lJ2J2Q5nYhAYTeDgXOi34VwoAqMJHGo6HPFOimkz76TcBA41HY54J8W0mXdSbgIp
U0YgAikjEIGUKSNQz6CMQARSRiAC9QzKCOyDQCF4J8mBlOVABFKmjEAEUkYgAilTRiACKSMQgZQp
I7Algbk8fWor805CYCiB6Tx9Bt5JIcoIjCAw491td+RjlBFYncCM9UvUiYlRrk7gVL+kAEgKvZMm
uSyN/NMy1vBSKy1GOYjASX5JYTmqRjngbupYqhcaoxyXAwv9kg692co7aeTN8hyYsZazmtkxyo0J
nPRmsHfSuKXZpFFoRj8DvhExyqHzwKpuEIs7t8zDuxtPH95JMcrRKzGT3FqGpt5JC84D5UA5sE8C
q3onLUigeaB54Ip2I47mq6UcdofTvJOshVoL7WotdKTHl69wHvr2oY53kv1A+4E97AeeVTgTU6Ls
TAwCowkcnAv9NpwLRWA0gUNCT5+Bd1KIMgKDCByyefrUVuadhMBoAilTRiACKSMQgZQpI1DPoIxA
BFJGIAL1DMoI7INAIXgnyYGU5UAEUqaMQARSRiACKVNGIAIpIxCBlCkjsCWBvJO2g3cSAkMJ5J20
HbyTEBhKoDvy2+GOPAJDCVQnZif7qRPThsBD1ceGw1XMwtpQXhatsBDw9sxBrbTtuZ9aaW0IHK8+
GOOvtFSV7kkEqhe6HeqFtiFwJJOMEHgI1J3/TirpeQqBe5t69Cmrmb0damavjsCR/x23JSs3VFqK
wHmjUL4R28E3Yr0EHqpmXTg4nETgKTpTCeSdtB28kzLlwHkEFt7ICiNQDpQDz4vAqY2pTaB5oHng
qtdCy6lYZBR6infSPAKthVoLXfV+4NHR4wwap/4U+4H2A/vfD1xwBJuuqc7EbIczMZkIzHVczrnQ
QmXnQjPlwD4IHHgn3cmEvJMQGJ2xeSftzAl5JyEwx5iZcsfKCNQzKCMQgZQRKPQMyghEIGUECj2D
MgIzEigE7yQ5kLIciEDKlBGIQMoIRCBlyghEIGUEIpAyZQS2JJB30nbwTkJgKIG8k7aDdxICQwl0
R3473JFHYCiB6sTsZD91YqoT2L1NUvlTVittZ+6nVlp1As/BJqmcQPVCt0O90OoE9m2TNP4T1cw+
qqxmdksCR/43hU3SjILcA9+Ib4NvxCoI7NYmiXfSMWXeSSvNgUMSm6TxnygHyoE5cuBSBE5tTJNR
qHmgeeBa1kIndesV2iTtnZdaC7UWukbvpF5tkv78snIC7QfaDxyynInJfjTHmZgSZWdiVkpgByfj
nAstVHYudKU5sGMCB95JdzIh7yQERqdx3kk7c0LeSQjMMZCm3LEyAvUMyghEIGUECj2DMgIRSBmB
Qs+gjMCMBArBO0kOpCwHIpAyZQQikDICEUiZMgIRSBmBCKRMGYEtCeSdtB28kxAYSiDvpO3gnYTA
UALdkd8Od+QRGEqgOjE72U+dmLoEhrkjzZtAF7pBjNRZm1StUK20nbmfWmkRBMasL834EYUlEucV
51Uv9KiyeqGNCTxkF7H95/J69YU/YkR/HoG8k9TMTlMze5huXTSDz0l2LsuWsj/6V3wjtoNvxFrm
geX2fSV+EouYSRzySDvVUIl30lbwTmqQAw/BOZvAoyLlbko7mO310JUD5cB8OfDo+4vkwBnrIsNp
roCFVqHmgeaBqyawZLw3z0ep9jxwBoHWQq2Frm4UWjLeG18LmbcWeuJ+4DwC7QfaDxyciYkJZ2JK
lJ2JQWA0gYNzod+Gc6EIjCZw4J10JxPyTkJgKIED76Q7c0LeSQgMJZAyZQQikDICEUiZMgL1DMoI
RCBlBCJQz6CMwD4IFIJ3khxIWQ5EIGXKCEQgZQQikDJlBCKQMgIRSJkyAlsSyDtpO3gnITCUQN5J
28E7CYGhBLojvx3uyCMwlEB1YnaynzoxixF4tjZJ5W1TK21n7qdW2sIExiwlzfgRVW2SytumXuh2
qBcaR2CXNkmFZhjboWb2dqiZHURglzZJ87Il34jt4BvRYB54RjZJvJOOKfNOqpsDD8E5m8C12STN
cLGWA+XABgR2aZM0bxRqHmge2JLAnmySRsar1kKtha5iLXTeeC+RTdKh8ar9QPuBvJPahzMxJcrO
xCAwmsDBudBvw7lQBEYTOPBOupMJeSchMJTAgXfSnTkh7yQEhhJImTICEUgZgQikTBmBegZlBCKQ
MgIRqGdQRmAfBArBO0kOpCwHIpAyZQQikDICEUiZMgIRSBmBCKRMGYEtCazn6fP168dPn15cXz+9
unr4/v3F5eWDDx8ef/z489evvJN4JyHwj6jn6fPlyy9XV99vwLv72gD5+TPvJN5JZ09gvRvWm0S3
l73t1+ZrVtVmd+QRGEpgvSojm+x3FL/b16FMqE5MW+VmBE4yJ1qweZNqpRW+Od7OepW2NnO/7cHn
69cXP/xwcf/+zeunny5++213OPr772qlqZV2oEHjDViqeVPrCJe8ebSd9apNfvr0YpuxR49ufo+/
/nrx6tXNH548KRqLqhfaUHmlBN4tUz/yv8PhWveFDahNYL2Ky9fXT/cOON++vdH+7rvd9z98UDO7
u5rZixM4o072UWuKtgTWcx243XjYeb15c/Hs2Y32y5e7f3V5yTeiO9+IxeeB8wicOl4t/4nDlCrd
wc47exPgjz/eSD5/vn89pnmbeSetNAeOk1nuplQ4Cp1HYIoceO/ejfC7d3vwkwPlwCICC0eM86SG
E+xcsswDD73MA80Dp+Fx4ii0EJJu1kJvX7dRvi9vLdRa6PEtu5K10JJR6Mjks4P9wHEC7QfaD+w/
nIkpUXYmBoENErtzodvhXCgCowkcanr6/HE34uHhuxG8k3gnIfD/ZxSVPH0O3Q/cO/dbSZt5JyEw
mkDKlBGIQMoIRCBlygjUMygjEIGUEYhAPYMyAvsgUAjeSXIgZTkQgZQpIxCBlBGIQMqUEYhAyghE
IGXKCGxJYD2HI95JMW3mnZSYwHoOR7yTYtrMOykxgfVusrsjH9Nmd+QTE1ivmos6MTFtzlQnppUp
UqFmvHdSPYcj3kkxbU5WK62JKVL5P/Xun2vXC63ncMQ7KabNyeqFlpsiDVu2R4Vl5EuSUqGNxIkE
lsNfz+GId1JMm5PVzJ5qinSKQVJ5ge0FCZw6Cq3ncMQ7KabNyXwj5pkiLf5mJeeWGQ4W9RyOeCfF
tDmZd9I8Q4jZb+61UlqVd1I9hyPeSXJgewILh5flM9XFCazncMQ7yTywLoFHzXFnzAPjvZPqORzx
TrIWOmvnsWDd8s8vm2FqW2KrFOmdVM/hiHeS/UBR9JSdidkOZ2IQGE3g4Fzot+FcKAKjCRxqOhzx
ToppM++k3AQONR2OeCfFtJl3Um4CKVNGIAIpIxCBlCkjUM+gjEAEUkYgAvUMygjsg0AheCfJgZTl
QARSpoxABFJGIAIpU0YgAikjEIGUKSOwJYG5PH1qK/NOQmAogek8fQbeSSHKCIwgMOPdbXfkY5QR
WJ3AjPVL1ImJUV4dgSUHeU5pbbx3UsYaXmqlxSivlMB6a1NNvJMy1rFULzRGOROB2+VD91YWLUxT
VWHrppazmtkxyskIHKmKXU5OPIEZ/Qz4RsQoZ5oHFvpGTDUPnEfgpHlgRk8f3kkxygly4AwCC29k
hREoB8qB50XgKYs9JQQWgm0eaB54RgSeMn+bRGC5LaG1UGuh/RM4dS30RO+ko0Nc+4H2A3knrfHj
w5mY7XAmBoHRBA7OhX4bzoUiMJrAIaGnz8A7KUQZgUEEDtk8fWor805CYDSBlCkjEIGUEYhAypQR
qGdQRiACKSMQgXoGZQT2QaAQvJPkQMpyIAIpU0YgAikjEIGUKSMQgZQRiEDKlBHYksCvXz9++vTi
+vrp1dXD9+8vLi8ffPjw+OPHn79+/edqlXkn1VZGYBCBX778cnX1/QaPu68NNp8//3WFyryTApQR
GEHgJh3tJWT7tfmaVSm7Ix+jjMDqBG5y1FFIbl+H8lW8sjoxMcpBBI5XKDvagKW8jYaJFdCmmjft
fX8zQ9seIr5+ffHDDxf379+8fvrp4rffdgeNv/9+3VxZrbQY5SACx81YJnXrBc0eSr5gpORhOYGf
Pr3YJuHRo5tv//XXi1evbv7w5EnRiDFYWb3QGOV1EXg6NicSePdvFyHw+vrp3mHh27c3Ot99t/v+
hw+PmyurmR2j3IbAQgaCCZxUYHsSgbfbAzuvN28unj27eewvX+7+1eXlg+bKfCNilNvPA08k8JBg
SU3rMAL3pqkff7xp4fPn+1dNmivzTopRbrMWenQUusPqvMnbVKkSAkdaPjVT3bt306p37/ZAcmIO
XERZDuwqB4bNA2dLFRI1zzfi0Gzt0Ov0eeDpyuaBPc8DV7gWusiuQ+GK5e3rNsp3z4OVrYV2tRa6
8v3A2gTu7NqNc3LKfuCCyvYDu9oPPJ9wJqZE2ZkYBEYTODgX+m04F4rAaAKH/7vB8PDwDYa/rFCZ
d1KAMgKDCBwO3+LbO0NbiTLvpNrKCIwjkDJlBCKQMgIRSJkyAvUMyghEIGUEIlDPoIzAPggUgneS
HEhZDkQgZcoIRCBlBCKQMmUEIpAyAhFImTICWxJYz9OHd1JMm3knJSawnqcP76SYNvNOSkxgvRvW
7sjHtNkd+cQE1qsyok5MTJt5J63FO2lcP7jSFu+kmDbzTlqLd9K82sH1qk3yToppM++ktXgnzSOw
XsVl3kkxbeadtBbvpHkE1nMd4J0U02beSevyTpo6D6znvMM7KabNvJNW55205hzIO0kObDYPnC1V
7p2UYh7IO8k8MNlaaFUCw9ZCeSdZC025Hzh1rWi1+4G8k+wHnns4E1Oi7EwMAqMJHJwL/TacC0Vg
NIFDTU8f3kkxbeadlJvAoaanD++kmDbzTspNIGXKCEQgZQQikDJlBOoZlBGIQMoIRKCeQRmBfRAo
BO8kOZCyHIhAypQRiEDKCEQgZcoIRCBlBCKQMmUEtiSwnsNRPeV6Dke8kxAYSmA9h6N6yvUcjngn
ITCUwHo32esp17vJ7o48AkMJrFfNpZ5yvWou6sQ0IPCcvZPqORzVU65X0UyttAYEnrl3Uj2Ho3rK
9ap6qhe6XgKHTr2T6jkc1VOuV9lazez2BBYyEExgPd+Ieg5H9ZTruTvwjVjXPPBEAoO9kybp/xn1
HI7qKddzOOKd1H4tNK930l392ZlqEYejespyYFc5sBvvpHk/tJ7DUT1l88Ce54Hn5p1Uz+GonrK1
0K7WQofz9k6q53BUT9l+YFf7gecTzsS0VXYmBoHOhTZWdi4UgQejnsNRPeV6Dke8kxAYTeBQ0+Go
nnI9hyPeSQiMJpAyZQQikDICEUiZMgL1DMoIRCBlBCJQz6CMwD4IFIJ3khxIWQ5EIGXKCEQgZQQi
kDJlBCKQMgIRSJkyAlsSmNE7qZ4PEe8kBIYSmNE7qZ4PEe8kBIYSmPGOfL1b4e7IIzCUwIx1YupV
RlEnpgGBGb2TxvXLqxVm9E6qVx1MrbQGBGb0TppaWXTkbzN6J9WrkKle6HoJHNbknVTY4BKFjN5J
9apEq5ndnsCpDDT0TrqrP6Nib0bvpHpOCXwj1jUPPJHA2t5JU4ej3Xgn1XML4p3Ufi00kXfS1Pe7
8U6SA7vKgbyT0nknmQf2PA/M4p1UYnM9Y8UyhXeStdCu1kKHhN5JkzYJJ+3apfBOsh/Y1X7g+YQz
MSXKzsQgMJrAwbnQb8O5UARGEzjk9E6q50PEOwmB0QQOOb2T6vkQ8U5CYDSBlCkjEIGUEYhAypQR
qGdQRiACKSMQgXoGZQT2QaAQvJPkQMpyIAIpU0YgAikjEIGUKSMQgZQRiEDKlBHYkkDeSdvBOwmB
oQTyTtoO3kkIDCXQHfntcEcegaEEqhOzk/3UiYkmsD/vpPKnzDtpZ+6nVlo0gd14Jy1SL5R3knqh
KyVw4J3EO0nN7MjZUUbvpOGwLczAO6lAmW/EuuaBJxIY7500ng95Jx1V5p3Ufi00r3fSvHkg7yQ5
cOCdNAOncUp5J5kH8k5abB7IO8laaM9roQPvJN5J9gOdiYmc4u6EMzHb4UwMAqMJHJwL/TacC0Vg
NIED76Q7mZB3EgJDCRx4J92ZE/JOQmAogZQpIxCBlBGIQMqUEahnUEYgAikjEIF6BmUE9kGgELyT
5EDKciACKVNGIAIpIxCBlCkjEIGUEYhAypQR2JLAXJ4+tZXreSflcmVCYBCB6Tx9hpzeSelcmRAY
QWDGu9sZ78hnvH2PwOoEZqxfkrFOTMYKNHEEFpZFqz1pnlRhbaSGWnmTMtbwylgrLWMVtjgCy00a
qhI4qcroeFHD8nqhGetYZqwXmrESaXsCD3mhjGSqvV9wyJSi3I/lUMMm8d9NLeeMNbMzVuNuRuAh
qEoyVfnXH60CfDSzLUJgRj+DjL4RGR0p2s8D51Wkn/f1JePJGYX0j2OZ0NMno3dSRlemZmuhJelr
xPYoF4FyoBy49nlgCTwLEli+vlI+1DQPNA/MNA/cO1tbfB5YCMkkAstTq7VQa6Fp5oEz1kLHl0ZH
0tckR6RDrSrx6LUfaD9wvfPAZTcG1xPOxJQoOxODwAb/HOdCt8O50LUQ2Fl05ukz5PROSufKhMC4
lJ7L06e2cj3vpFyuTAhMMKim3LEyAvUMyghEIGUECj2DMgIRSBmBQs+gjMCMBArBO0kOpCwHIpAy
ZQQikDICEUiZMgIRSBmBCKRMGYEtCaznQ/T168dPn15cXz+9unr4/v3F5eWDDx8ef/z489ev5+id
lMtJCoFBBNbzIfry5Zerq+834N19bYD8/Pm8vJPSOUkhMILAejesN4luL3vbr83XrKrNGW+yuyOf
mMB6VUY22e8ofrevQ5mwpzoxGavmJCNw6mGfEYUF3xz/ifUqbW3mftuDz9evL3744eL+/ZvXTz9d
/Pbb7nD09997rpWWsXJc4hxY0uDC0qAnvnm0VfWqTX769GKbsUePbn6Pv/568erVzR+ePCkai3ZT
LzRj9dSuCCwsGVoVtuCKy9fXT/cOON++vdH+7rvd9z986LlmdsYK4v0QeIp1RG0C67kO3G487Lze
vLl49uxG++XL3b+6vOzZNyKji0afo9Cp1hEzCFyJd9LeBPjjjzeSz5/vX49p3uaMDkcdeidVHYWu
jcDgHHjv3o3wu3d78JMD5cBVjEKnfu+Jtp7x88BDL/NA88DqBB7NgacskA4r807aWQu9fd1G+b68
tVBroUuOQodjtrvl3kkjX7YS76Sd/cBxAu0H2g/sP5yJKVF2JgaBDVZonQvdDudCERhN4FDTh+iP
uxEPD9+NOC/vpHROUggMInCo6UN06H7g3rnfStqcy+GonjIC4wikTBmBCKSMQARSpoxAPYMyAhFI
GYEI1DMoI7APAoXgnSQHUpYDEUiZMgIRSBmBCKRMGYEIpIxABFKmjMCWBPJO2g7eSQgMJZB30nbw
TkJgKIHuyG+HO/IIDCVQnZid7KdOzDIEjhfSnFpX85QBXrngJEekEneKo83gnbQz91MrrQqBO5UC
F19WWkRtamnQktq+RxvJO2k71AsNInC8GufOlx1NSuP/WyI40vhxndMJ5J20HWpmLzwPPNRlC52J
9pa4PvotUwVnEHj0f3kn8Y1YhW/EocHnIjhNTVnlw+DCovSLEMg7aTt4JzUgcMTVaHwOdgi2GYIN
CeSdJAeuJQdOGgGWZLkZgpO4SjoP5J10Xt5JhW5E80ahi8wS57V2KQJ5J1kLbUlgydJl4Si0fC30
6G5eiXdSuv1A3km8k849nIkpUXYmBoHRBA7OhX4bzoUiMJrAgXfSnUzIOwmBoQQOvJPuzAl5JyEw
lEDKlBGIQMoIRCBlygjUMygjEIGUEYhAPYMyAvsgUAjeSXIgZTkQgZQpIxCBlBGIQMqUEYhAyghE
IGXKCGxJIO+k7eCdhMBQAnknbQfvJASGEuiO/Ha4I4/AUALVidnJfurExBFYfjbnxE5fXln0FO+k
YbonFO+knbmfWmnNcmDVn1JiF3Gid9JwzBOGd9JRZfVCmxFYWET0UIIaDrjETM2BhQSOeCdNJZB3
0naomb0KAkcMIUZwKv/K0wlccBTKO2k7+Ea0IbCk186oYD+bwHnOLfMI5J20HbyTGhA4viLSPYG8
k+TA1RG4FGzzCJztnTSPQN5J5oGNdyPGR54nmuPO2I0ozIdLEcg7yVpoMwJH7uofWuEc2RU4ncDT
vZPWvB/IO8l+YOLtxKotdCZmO5yJyURgvcM0wZ8RzoVuh3OhKXNg9izNO2knE/JOQmD0OJl30s6c
kHcSAnPMVCl3rIxAPYMyAhFIGYFCz6CMQARSRqDQMygjMCOBQvBOkgMpy4EIpEwZgQikjEAEUqaM
QARSRiACKVNGYEsCc3n61FbmnYTAUALTefoMvJNClBEYQWDGu9vuyMcoI7A6gRnrl6gTE6NcSuCk
IzaLTGprl2+b9+awplppGZXVSlsgB87wY1gJgScWBR5W5p2UUVm90FMJHE8U49VB9zoljesc/cph
n+lSYVafh+V6amZnVFYze0kCZ1TOrVQt++gXL0LgvFFoRj8DvhExypMJLHFcKCdwvHElA8LCLzjl
c+R0AjN6+vBOilGeRmBhEfhDSWzEKWlkbNkBgXKgHFiRwJLcNcl9oTCFnkLgpEx+OoHmgeaBy+xG
TF1anL3YWJXAU6zU5hFoLdRa6KkEHrVAOmR1dHQBc3wUesjMfURqnMBJ3kn2A+0HrnQ/UEzdw3Qm
ZjuciUFgNIGDc6HfhnOhCIwmcEjo6TPwTgpRRmAQgUM2T5/ayryTEBhNIGXKCEQgZQQikDJlBOoZ
lBGIQMoIRKCeQRmBfRAoBO8kIRJ+cHsQQiBQCAQKIRAoBAKFEAgUAoFCiLoECiFaxf8CNABvm1xw
wBQAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-03-15 07:56:37 +0000" MODIFIED_BY="Christopher J Cates" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.1 All-cause mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2wAAALgCAMAAADftwR0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-03-15 07:57:20 +0000" MODIFIED_BY="Christopher J Cates" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.2 All-cause non-fatal serious adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2wAAALgCAMAAADftwR0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-03-15 07:57:57 +0000" MODIFIED_BY="Christopher J Cates" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.3 Asthma mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzoAAAJgCAMAAAB1DeajAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-03-15 07:58:22 +0000" MODIFIED_BY="Christopher J Cates" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.4 Asthma-related non-fatal serious adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2wAAALQCAMAAADbzQPZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-03-15 07:57:20 +0000" MODIFIED_BY="Christopher J Cates" NO="6" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.2 All-cause non-fatal serious adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="RevisedFigure14withouttotals.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>All-cause serious adverse events in children given regular formoterol (with or without ICS).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArQAAAHQCAMAAABnbQk5AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-05-24 14:27:27 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;/h1&gt;&lt;p&gt;Final amendments following discussion with MJC.&lt;/p&gt;&lt;p&gt;CJC nov 9&lt;br&gt;Further amendments made following discussion with TL. SIT and AMD are included but not BDF for relief use only in randomisation. ICS remains the control arm for this review (so SIT v AMD would not be included for example).&lt;br&gt;Back to TL for checking.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;br&gt;CJC Nov 5&lt;br&gt;Thanks for amending this Toby. I am happy to publish the current version&lt;br&gt;~~~~~~~~~~~~~~~~~~~~~~&lt;br&gt;Will varying the exposure to LABA in intermittent/AMD studies confound the risk in control group? Given the emphasis on regular LABA use in the protocol we may need to give some thought as to whether control groups where there is exposure to LABAs are estimating a different treatment effect to something other than studies like FACET. I have restructured the Criteria for intervention section to reflect this.&lt;/p&gt;&lt;p&gt;----------------------------&lt;br&gt;Key differences in Red from the other Formoterol protocol. FACET may get left out in the cold here but the main focus is on REGULAR LABA use, so this is where I have drawn the line.&lt;br&gt;What do you think?&lt;br&gt;Chris&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f19792&quot;&gt;&lt;span coll_flag=&quot;f19792&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Title&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3710&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Review information&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3713&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3761&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cates, Christopher&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3763&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lasserson, Toby&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3765&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cates, Matthew&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3711&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contact person&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3716&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dates&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3720&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;What's new&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3767&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Amended, 30 June 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3721&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;History&lt;/h2&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3759&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abstract&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f19999&quot;&gt;&lt;span coll_flag=&quot;f19999&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20001&quot;&gt;&lt;span coll_flag=&quot;f20001&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20003&quot;&gt;&lt;span coll_flag=&quot;f20003&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20005&quot;&gt;&lt;span coll_flag=&quot;f20005&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection criteria&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20007&quot;&gt;&lt;span coll_flag=&quot;f20007&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20009&quot;&gt;&lt;span coll_flag=&quot;f20009&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20011&quot;&gt;&lt;span coll_flag=&quot;f20011&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3758&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language summary&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f19994&quot;&gt;&lt;span coll_flag=&quot;f19994&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language title&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f19996&quot;&gt;&lt;span coll_flag=&quot;f19996&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary text&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20024&quot;&gt;&lt;span coll_flag=&quot;f20024&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20034&quot;&gt;&lt;span coll_flag=&quot;f20034&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20036&quot;&gt;&lt;span coll_flag=&quot;f20036&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Methods&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20038&quot;&gt;&lt;span coll_flag=&quot;f20038&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Criteria for considering studies for this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20040&quot;&gt;&lt;span coll_flag=&quot;f20040&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20042&quot;&gt;&lt;span coll_flag=&quot;f20042&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of participants&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20044&quot;&gt;&lt;span coll_flag=&quot;f20044&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of interventions&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20046&quot;&gt;&lt;span coll_flag=&quot;f20046&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of outcome measures&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20048&quot;&gt;&lt;span coll_flag=&quot;f20048&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Primary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20050&quot;&gt;&lt;span coll_flag=&quot;f20050&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Secondary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20052&quot;&gt;&lt;span coll_flag=&quot;f20052&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods for identification of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20054&quot;&gt;&lt;span coll_flag=&quot;f20054&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Electronic searches&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20056&quot;&gt;&lt;span coll_flag=&quot;f20056&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Searching other resources&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20058&quot;&gt;&lt;span coll_flag=&quot;f20058&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20060&quot;&gt;&lt;span coll_flag=&quot;f20060&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20062&quot;&gt;&lt;span coll_flag=&quot;f20062&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data extraction and management&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20064&quot;&gt;&lt;span coll_flag=&quot;f20064&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Assessment of risk of bias in included studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20076&quot;&gt;&lt;span coll_flag=&quot;f20076&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data synthesis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20078&quot;&gt;&lt;span coll_flag=&quot;f20078&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Subgroup analysis and investigation of heterogeneity&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20080&quot;&gt;&lt;span coll_flag=&quot;f20080&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sensitivity analysis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20082&quot;&gt;&lt;span coll_flag=&quot;f20082&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20084&quot;&gt;&lt;span coll_flag=&quot;f20084&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20092&quot;&gt;&lt;span coll_flag=&quot;f20092&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias in included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20104&quot;&gt;&lt;span coll_flag=&quot;f20104&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Effects of interventions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20106&quot;&gt;&lt;span coll_flag=&quot;f20106&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Discussion&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20118&quot;&gt;&lt;span coll_flag=&quot;f20118&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20120&quot;&gt;&lt;span coll_flag=&quot;f20120&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for practice&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20122&quot;&gt;&lt;span coll_flag=&quot;f20122&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for research&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20013&quot;&gt;&lt;span coll_flag=&quot;f20013&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Acknowledgements&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20017&quot;&gt;&lt;span coll_flag=&quot;f20017&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contributions of authors&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20015&quot;&gt;&lt;span coll_flag=&quot;f20015&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Declarations of interest&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20019&quot;&gt;&lt;span coll_flag=&quot;f20019&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Differences between protocol and review&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f20021&quot;&gt;&lt;span coll_flag=&quot;f20021&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Published notes&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3729&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3730&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4076&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f22201&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22201&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f22203&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22203&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f22205&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22205&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f22207&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22207&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f22209&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22209&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4082&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4078&quot; id=&quot;s4078&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19949&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f22214&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22214&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4081&quot; id=&quot;s4081&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19954&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f22223&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22223&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4080&quot; id=&quot;s4080&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19959&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f22220&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22220&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4077&quot; id=&quot;s4077&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19964&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f22211&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22211&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4079&quot; id=&quot;s4079&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19969&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f22217&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22217&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7747&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chuchalin 2002&lt;/h3&gt;&lt;p&gt;Why does Roman report 3 SAE or admissions in Budesonide group?&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f41952&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41952&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f41954&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41954&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f41956&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41956&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f41958&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41958&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f41960&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41960&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7753&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s7749&quot; id=&quot;s7749&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19949&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f41965&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41965&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s7752&quot; id=&quot;s7752&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19954&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f41974&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41974&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s7751&quot; id=&quot;s7751&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19959&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f41971&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41971&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s7748&quot; id=&quot;s7748&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19964&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f41962&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41962&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s7750&quot; id=&quot;s7750&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19969&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f41968&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f41968&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4061&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Corren 2007&lt;/h3&gt;&lt;p&gt;Jaeschke says 2/2 SAE for Corren and this is not correct according to the web report. Need to check.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f22130&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22130&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f22132&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22132&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f22134&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22134&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f22136&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22136&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f22138&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22138&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4067&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4063&quot; id=&quot;s4063&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19949&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f22143&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22143&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4066&quot; id=&quot;s4066&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19954&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f22152&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22152&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4065&quot; id=&quot;s4065&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19959&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f22149&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22149&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4062&quot; id=&quot;s4062&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19964&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f22140&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22140&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s4064&quot; id=&quot;s4064&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19969&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f22146&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f22146&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9592&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jenkins 2006&lt;/h3&gt;&lt;p&gt;Was LABA withdrawn during run-in I wonder? Roman states 7/3 for SAE but these are events not patients with one or more events I notice.....&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f55712&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55712&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f55714&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55714&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f55716&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55716&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f55718&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55718&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f55720&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55720&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9598&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9594&quot; id=&quot;s9594&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19949&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f55725&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55725&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9597&quot; id=&quot;s9597&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19954&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f55734&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55734&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9596&quot; id=&quot;s9596&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19959&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f55731&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55731&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9593&quot; id=&quot;s9593&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19964&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f55722&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55722&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9595&quot; id=&quot;s9595&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19969&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f55728&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55728&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3830&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Noonan 2006&lt;/h3&gt;&lt;p&gt;Interventions to Add:&lt;/p&gt;&lt;p&gt;1. Budesonide 160 mcg twice daily&lt;/p&gt;&lt;p&gt;2. Budesonide and Formoterol 160/9 mcg twice daily (results from separate and combined inhalers both used)&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f20855&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20855&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f20857&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20857&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f20859&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20859&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f20861&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20861&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f20863&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20863&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3832&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s3837&quot; id=&quot;s3837&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19949&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f20929&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20929&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s3831&quot; id=&quot;s3831&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19954&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f20865&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20865&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s3839&quot; id=&quot;s3839&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19959&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f20935&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20935&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s3840&quot; id=&quot;s3840&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19964&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f20938&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20938&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s3841&quot; id=&quot;s3841&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19969&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f20941&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f20941&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9569&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oppenheimer 2008&lt;/h3&gt;&lt;p&gt;No asthma SAE data found. Roman does not seem to have data on this one!&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f55547&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55547&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f55549&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55549&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f55551&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55551&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f55553&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55553&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f55555&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55555&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9575&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9571&quot; id=&quot;s9571&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19949&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f55560&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55560&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9574&quot; id=&quot;s9574&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19954&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f55569&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55569&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9573&quot; id=&quot;s9573&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19959&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f55566&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55566&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9570&quot; id=&quot;s9570&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19964&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f55557&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55557&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s9572&quot; id=&quot;s9572&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f19969&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f55563&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f55563&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3731&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7857&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ankerst 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43438&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43438&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7861&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43448&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43448&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7865&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43458&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43458&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7869&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43468&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43468&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7873&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005c&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43478&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43478&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7877&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005d&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43488&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43488&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7881&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43498&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43498&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7885&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43508&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43508&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7889&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43518&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43518&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7893&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Balanag 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43528&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43528&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7897&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43538&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43538&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7901&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43548&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43548&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7905&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bouros 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43558&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43558&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7913&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43578&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43578&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7917&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burgess 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43588&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43588&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7921&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Canonica 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43598&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43598&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7925&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ceylan 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43608&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43608&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7929&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dhillon 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43618&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43618&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7941&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43648&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43648&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7945&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43658&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43658&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7953&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haahtela 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43678&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43678&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7957&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ind 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43688&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43688&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7961&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kozlik-Feldmann 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43698&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43698&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7965&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lalloo 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43708&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43708&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7969&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leuppi 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43718&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43718&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8073&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lotvall&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f44028&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f44028&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7977&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lundborg 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43738&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43738&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7981&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mitchell 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43748&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43748&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7985&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Molimard 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43758&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43758&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7989&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43768&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43768&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7993&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Novartis 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43778&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43778&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7997&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43788&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43788&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8001&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papi 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43798&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43798&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8005&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pleskow 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43808&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43808&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8009&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rabe 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43818&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43818&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8021&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43848&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43848&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8013&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43828&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43828&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8017&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2003a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43838&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43838&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8025&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scicchitano 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43858&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43858&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8029&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Villa, 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43868&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43868&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8033&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Von Berg 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43878&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43878&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8037&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worth 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43888&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43888&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8041&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43898&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43898&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8045&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstr&amp;#246;m 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f43908&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f43908&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3732&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3733&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3741&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of findings tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3742&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3744&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;References to studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3745&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4073&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4070&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 2003;97(4):323-30.&lt;/h4&gt;Buhl, R&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7740&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chuchalin 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7743&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chuchalin AG, Ovcharenko SI, Goriachkina LA, Sidorenko IV, Tsoi AN, Epoch Study G. The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: A comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia. International Journal of Clinical Practice 2002;56(1):15-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4051&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Corren 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4057&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SD-039-0716. A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trialof SYMBICORT&amp;#174; pMDI (80/4.5 &amp;#956;g) versus its Monoproducts (budesonide andformoterol) in Children (&amp;#8805;6 Years of Age) and Adults with Asthma &amp;#8211; SPRUCE 80/4.5. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0716.pdf accessed november 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4054&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics 2007;29(5):823-43.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9589&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jenkins 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9587&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W, et al. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 2006;11(3):276-86.&lt;/h4&gt;Record Number: 606710&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3823&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Noonan 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3826&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: A randomised clinical trial. Drugs 2006;66(17):2235-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9566&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oppenheimer 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9576&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. A randomized, double-blind, active-controlled, parallel-group, singledummy,multicenter, 12 week study to assess the efficacy and safety ofSYMBICORT&amp;#174; pMDI 160/4.5 &amp;#956;g x 2 actuations once-daily (qd) comparedto SYMBICORT pMDI 80/4.5 &amp;#956;g x 2 actuations qd, SYMBICORT pMDI80/4.5 &amp;#956;g x 2 actuations twice-daily (bid) and to budesonide pMDI 160 &amp;#956;gx 2 actuations qd in asthmatic subjects 12 years of age and older. [D5896C00001]. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/D5896C00001.pdf Accessed November 11th 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9564&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oppenheimer JJ, Kerwin EM, LaForce C, Miller CJ, O'Dowd L, Goldman M. Asthma Control with Once-Daily (qd) Budesonide/Formoterol Pressurized Metered-Dose Inhaler (pMDI) in Adults and Adolescents with Asthma Previously Stable with Twice-Daily (bid) Budesonide/Formoterol pMDI. 2008;121(2, Supplement 1):S8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3746&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7854&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ankerst 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7758&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulmonary Pharmacology &amp;amp; Therapeutics 2003;16(3):147-51.&lt;/h4&gt;Record Number: 11450&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7858&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7760&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. Efficacy &amp;amp; safety of Symbicort Turbuhaler 160/4.5 &amp;#181;g twice daily &amp;amp; Pulmicort Turbuhaler 200 &amp;#181;g twice daily + Theolong tablet 200 mg twice daily in Japanese asthmatic patients. clinicaltrials.gov 2005.&lt;/h4&gt;Record Number: 600840&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7862&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7762&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SHARE - symbicort and health economics in a real life evaluation. clinicaltrials.gov 2005.&lt;/h4&gt;Record Number: 622650&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7866&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7764&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SOLO-symbicort in the treatment of persistent asthma in adolescents &amp;amp; adults. clinicaltrials.gov 2005.&lt;/h4&gt;Record Number: 601830&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7870&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005c&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7766&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. STYLE - symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. clinicaltrials.gov 2005.&lt;/h4&gt;Record Number: 622620&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7874&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005d&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7768&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SYMPHONIE -a comparison of symbicort single inhaler and conventional best practice for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov 2005.&lt;/h4&gt;Record Number: 622660&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7878&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7770&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. A comparison of the control of asthma inflammation provided by Symbicort turbuhaler 160/4.5 mcg/inhalation bid plus as-needed versus symbicort turbuhaler 320/9 ug/inhalation bid plus pulmicort turbuhaler 400mcg/dose bid plus terbutaline turbuhaler 0.4mg/inhalation as-needed. clinicaltrials.gov 2006.&lt;/h4&gt;Record Number: 622600&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7882&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7772&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov 2006.&lt;/h4&gt;Record Number: 622590&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7886&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7774&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SALTO - symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. clinicaltrials.gov 2006.&lt;/h4&gt;Record Number: 622800&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7890&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Balanag 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7776&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulmonary Pharmacology &amp;amp; Therapeutics 2006;19(2):139-47.&lt;/h4&gt;Record Number: 582680&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7894&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7778&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman ED, Bantje TA, Gomes MJ, Toumbis MG, Huber RM, Naya I, et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. American Journal of Respiratory Medicine 2003;2(3):275-81.&lt;/h4&gt;Record Number: 124160&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7898&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7780&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman ED, Fairall L, Lombardi DM, English R. Budenoside/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respiratory Research. 2006;7:13.&lt;/h4&gt;Record Number: 591060&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7902&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bouros 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7782&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bouros D, Bachlitzanakis N, Kottakis J, Pfister P, Polychronopoulos V, Papadakis E, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. European Respiratory Journal 1999;14(3):627-32.&lt;/h4&gt;Record Number: 17926&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7910&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7786&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Bruggenjurgen B, Willich SN, et al. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Current Medical Research &amp;amp; Opinion 2004;20(8):1209-20.&lt;/h4&gt;Record Number: 267950&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7914&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burgess 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7788&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. European Journal of Clinical Pharmacology 1998;54(2):141-7.&lt;/h4&gt;Record Number: 181270&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7918&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Canonica 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7790&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Canonica GW, Castellani P, Cazzola M, Fabbri LM, Fogliani V, Mangrella M, et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulmonary Pharmacology &amp;amp; Therapeutics 2004;17(4):239-47.&lt;/h4&gt;Record Number: 213270&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7922&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ceylan 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7792&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ceylan E, Mehmet G, Sahin A. Addition of formoterol or montelukast to low-dose budesonide: An efficacy comparison in short- and long-term asthma control. Respiration 2004;71(6):594-601.&lt;/h4&gt;Record Number: 308270&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7926&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dhillon 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7794&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dhillon S, Keating GM. Beclometasone dipropionate/formoterol: In an HFA-propelled pressurised metered-dose inhaler. Drugs 2006;66(11):1475-83.&lt;/h4&gt;Record Number: 14970&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7938&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7800&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. Journal of Allergy &amp;amp; Clinical Immunology 1999;103(3 I):427-35.&lt;/h4&gt;Record Number: 3360&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7942&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7802&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald JM, Sears MR, Boulet LP, Becker AB, McIvor AR, Ernst P, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five-month multicentre Canadian study. Canadian Respiratory Journal 2003;10(8):427-34.&lt;/h4&gt;Record Number: 157330&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7950&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haahtela 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7806&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haahtela T, Tamminen K, Malmberg LP, Zetterstrom O, Karjalainen J, Yla-Outinen H, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. European Respiratory Journal 2006;28(4):748-55.&lt;/h4&gt;Record Number: 3730&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7954&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ind 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7808&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ind PW, Haughney J, Price D, Rosen JP, Kennelly J. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: The ASSURE study. Respiratory Medicine 2004;98(5):464-75.&lt;/h4&gt;Record Number: 76920&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7958&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kozlik-Feldmann 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7810&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kozlik-Feldmann R, von Berg A, Berdel D, Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. European Journal of Medical Research 1996;1(10):465-70.&lt;/h4&gt;Record Number: 16118&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7962&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lalloo 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7812&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003;123(5):1480-7.&lt;/h4&gt;Record Number: 159170&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7966&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leuppi 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7814&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leuppi FD, Salzberg M, Meyer L, Bucher SE, Nief M, Brutsche MH, et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Medical Weekly 2003;133(21-22):302-9.&lt;/h4&gt;Record Number: 121940&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8060&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lotvall&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8063&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lotvall J, Langley S, Woodcock A. Inhaled steroid/long-acting beta2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Respiratory Research. Vol. 7, 2006. Article Number: 110. Date of Publication: 18 AUG 2006..&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7974&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lundborg 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7818&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: An efficacy and cost-effectiveness study. Current Medical Research &amp;amp; Opinion 2006;22(5):809-21.&lt;/h4&gt;Record Number: 633480&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7978&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mitchell 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7820&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mitchell C, Jenkins C, Scicchitano R, Rubinfeld A, Kottakis J. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulmonary Pharmacology &amp;amp; Therapeutics 2003;16(5):299-306.&lt;/h4&gt;Record Number: 123290&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7982&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Molimard 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7822&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P, et al. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respiratory Medicine 2001;95(1):64-70.&lt;/h4&gt;Record Number: 7760&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7986&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7824&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice AH, Hochmuth L, Puterman A, Artheden L, Beckman O. Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy &amp;amp; Clinical Immunology 2005;115(2 Suppl):S3.&lt;/h4&gt;Record Number: 40&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7990&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Novartis 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7826&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Novartis. A 12-month multicenter, randomized, double-blind, double-dummy trial to examine the long-term tolerability of fomoterol 10&amp;#181;g via the multiple dose dry powder inhaler (MDDPI), both as twice daily maintenance therapy and as on-demand use in addition to maintenance in patients with persistent asthma. http://pharma.us.novartis.com/ 2005.&lt;/h4&gt;Record Number: 575290&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7994&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7828&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.[see comment]. American Journal of Respiratory &amp;amp; Critical Care Medicine 2005;171(2):129-36.&lt;/h4&gt;Record Number: 355870&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7998&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papi 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7830&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM, Zarkovic J, et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. European Respiratory Journal 2007;29(4):682-9.&lt;/h4&gt;Record Number: 6620&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8002&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pleskow 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7832&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma 2003;40(5):505-14.&lt;/h4&gt;Record Number: 100740&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8006&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rabe 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7834&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomized, double-blind trial. Chest 2006;129(2):246-56.&lt;/h4&gt;Record Number: 592460&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8018&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7840&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall L, Heinig JH, Lindqvist A, Leegaard J, Stahl E, Bergqvist PB. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. International Journal of Clinical Practice. 2002;56(6):427-33.&lt;/h4&gt;Record Number: 620&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8010&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7836&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall L, Borg S, Andersson HF, Ericsson K. Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. International Journal of Clinical Practice 2003;57(8):662-7.&lt;/h4&gt;Record Number: 147240&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8014&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2003a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7838&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Stahl E, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respiratory Medicine 2003;97(6):702-8.&lt;/h4&gt;Record Number: 161100&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8022&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scicchitano 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7842&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centann S, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research &amp;amp; Opinion 2004;20(9):1403-18.&lt;/h4&gt;Record Number: 254780&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8026&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Villa, 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7844&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Villa, Kuna, Egner, and B. A 6-month comparison of the safety profiles of formoterol (Oxis&amp;#174;) turbuhaler&amp;#174; as needed and terbutaline (Bricanyl&amp;#174;) turbuhaler&amp;#174; as needed in asthmatic children on anti-inflammaotry medication [abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165(8 Suppl):A746.&lt;/h4&gt;Record Number: 161910&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8030&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Von Berg 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7846&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbuhaler in children. International Journal of Clinical Practice 2003;57(10):852-6.&lt;/h4&gt;Record Number: 34530&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8034&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worth 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7848&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worth H. DESOLO - SiT Peri-Launch: a comparison of symbicort single inhaler therapy and conventional best practice for the treatment of persistent asthma in adults. clinicaltrials.gov 2005.&lt;/h4&gt;Record Number: 622630&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8038&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7850&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom O, Buhl R, Mellem H. Efficacy and safety of symbicort&amp;#174; budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; San Francisco CA ,May 18-23 2001.&lt;/h4&gt;Record Number: 1320&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s8042&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstr&amp;#246;m 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s7852&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstr&amp;#246;m O, Buhl R, Mellem H, Perpi&amp;#241;&amp;#225; M, Hedman J, O'Neill S, et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal 2000;16(Suppl 31):455s Abstract P3198.&lt;/h4&gt;Record Number: 2040&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3747&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3748&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3749&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other references&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3750&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional references&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3769&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Altman 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3771&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Beach 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9064&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cates 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s9068&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cates 2008a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3773&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ducharme 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3775&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giembycz 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3777&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Greenstone 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3779&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lipworth 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3781&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ni Chroinin 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3783&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ni Chroinin 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3785&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pearce 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3788&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Salpeter 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3790&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sears 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3792&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SMART 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3794&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Walters 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3796&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Walters 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3751&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other published versions of this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3752&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Classification pending references&lt;/h2&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3756&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data and analyses&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4025&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Formoterol and ICS versus same dose ICS&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4026&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1 All-cause Mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4035&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.1 Adults and Adolescents&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4039&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.2 Children&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4028&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2 All-cause non-fatal Serious Adverse Events&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4038&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.1 Adults and Adolescents&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4040&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.2 Children&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4087&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3 Asthma Mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4088&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3.1 Adults and Adolescents&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4092&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3.2 Children&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4041&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4 Asthma-related non-fatal Serious Adverse Events&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4042&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4.1 Adults and Adolescents&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4044&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4.2 Children&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s4027&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.5 New Outcome&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3753&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figures&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3722&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sources of support&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3723&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Internal sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3768&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;NHS R&amp;amp;D, UK&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3724&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;External sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3754&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feedback&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3727&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendices&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-05-24 14:27:27 +0100" NOTES_MODIFIED_BY="Christopher J Cates">
<APPENDIX ID="APP-01" MODIFIED="2013-05-24 14:27:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE MODIFIED="2008-11-18 12:56:15 +0000" MODIFIED_BY="Christopher J Cates">Pharmacology of beta<SUB>2</SUB>-agonists</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-24 14:27:27 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Beta-agonists are thought to cause bronchodilatation primarily through binding of beta<SUB>2</SUB>-adrenoceptors on airways smooth muscle (ASM), with subsequent activation of both membrane-bound potassium channels and a signalling cascade involving enzyme activation and changes in intracellular calcium levels following a rise in cyclic adenosine monophosphate (cAMP) (<LINK REF="REF-Barnes-1993" TYPE="REFERENCE">Barnes 1993</LINK>).However, beta<SUB>2</SUB>-adrenoceptors are also expressed on a wide range of cell types where beta<SUB>2</SUB>-agonists may have a clinically significant effect, including airway epithelium (<LINK REF="REF-Morrison-1993" TYPE="REFERENCE">Morrison 1993</LINK>), mast cells, postcapillary venules, sensory and cholinergic nerves and dendritic cells (<LINK REF="REF-Anderson-2006" TYPE="REFERENCE">Anderson 2006</LINK>).Beta<SUB>2</SUB>-agonists will also cross-react to some extent with other beta-adrenoceptors, including beta<SUB>1</SUB>-adrenoceptors on the heart.</P>
<P>The in vivo<I> </I>effect of any beta<SUB>2</SUB>-agonist will depend on a number of factors related to both the drug and the patient.The degree to which a drug binds to one receptor over another is known as <I>selectivity, </I>which can be defined as absolute binding ratios to different receptors in vitro, whilst <I>functional selectivity</I> is measured from downstream effects of drugs in different tissue types in vitro<I> </I>or in vivo<I>.</I>All of the beta<SUB>2</SUB>-agonists described thus far are more beta<SUB>2</SUB> selective than their predecessor isoprenaline in vitro. However, because attempts to differentiate selectivity between the newer agents are confounded by so many factors, it is difficult to draw conclusions about in vitro<I> </I>selectivity studies and is probably best to concentrate on specific adverse effects in human participants at doses that cause the same degree of bronchodilatation.The <I>potency</I> of a drug refers to the concentration that achieves half the maximal receptor activation of which that drug is capable. but it is not very important clinically, as for each drug, manufacturers will alter the dose to try to achieve a therapeutic ratio of desired to undesired effects.In contrast, <I>efficacy</I> refers to the ability of a drug to activate its receptor independent of drug concentration. Drugs that fully activate a receptor are known as <I>full agonists.</I> and those that partially activate a receptor are known as <I>partial agonists</I>.Efficacy also is very much dependent on the system in which it is being tested and is affected by factors such as the number of receptors available and the presence of other agonists and antagonists. Thus whilst salmeterol acts as a partial agonist in vitro,<I> </I>it causes a similar degree of bronchodilatation to the strong agonist formoterol in stable asthmatic patients (<LINK REF="REF-vanNoord-1996" TYPE="REFERENCE">vanNoord 1996</LINK>), presumably because an abundance of well-coupled beta<SUB>2</SUB>-adrenoceptors are available with few downstream antagonising signals.In contrast, with repetitive dosing, formoterol is significantly better than salmeterol at preventing methacholine-induced bronchoconstriction (<LINK REF="REF-Palmqvist-1999" TYPE="REFERENCE">Palmqvist 1999</LINK>). These differences have led to attempts to define the &#8220;intrinsic efficacy&#8221; of a drug independent of tissue conditions (<LINK REF="REF-Hanania-2002" TYPE="REFERENCE">Hanania 2002</LINK>), as shown in Table 1.The clinical significance of intrinsic efficacy remains unclear.</P>
<SUBSECTION>
<HEADING LEVEL="2"/>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="2">
<TITLE MODIFIED="2008-11-18 13:00:05 +0000" MODIFIED_BY="Christopher J Cates">Possible mechanisms of increased asthma mortality with beta-agonists</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates">
<SUBSECTION>
<HEADING LEVEL="4">Direct toxicity</HEADING>
<P>This hypothesis states that direct adverse effects of beta<SUB>2</SUB>-agonists are responsible for an associated increase in mortality, and most research in the area has concentrated on effects detrimental to the heart. Whilst it is often assumed that cardiac side effects of beta<SUB>2</SUB>-agonists are due to cross-reactivity with beta<SUB>1</SUB>-adrenoceptors (i.e. poor selectivity), it is worth noting that human myocardium also contains an abundance of beta<SUB>2</SUB>-adrenoceptors capable of triggering positive chronotropic and inotropic responses (<LINK REF="REF-Lipworth-1992" TYPE="REFERENCE">Lipworth 1992</LINK>).Indeed, good evidence suggests that cardiovascular side effects of isoprenaline (<LINK REF="REF-Arnold-1985" TYPE="REFERENCE">Arnold 1985</LINK>) and of beta<SUB>2</SUB>-agonists including salbutamol (<LINK REF="REF-Hall-1989" TYPE="REFERENCE">Hall 1989</LINK>) are mediated predominantly via cardiac beta<SUB>2</SUB>-adrenoceptors, thus making the concept of in vitro<I> </I>selectivity less relevant. Generalised beta<SUB>2</SUB>-adrenoceptor activation can also cause hypokalaemia (<LINK REF="REF-Brown-1983" TYPE="REFERENCE">Brown 1983</LINK>), and it has been proposed that, through these and other actions, beta<SUB>2</SUB>-agonists may predispose to life-threatening dysrhythmias or may cause other adverse cardiac effects.</P>
<P>During the 1960s epidemic, most deaths occurred in patients with severe asthma, and it was originally assumed that asthma and its sequelae, including hypoxia, were the primary cause of death.However, mucus plugging and hypoxia do not preclude a cardiac event as the final cause of death, and one might expect those with severe asthma to take additional doses of a prescribed inhaler. As noted by Speizer and Doll, most deaths in the 1960s were in the 10- to 19-year age group, and &#8220;at these ages children have begun to act independently and may be particularly prone to misuse a self-administered form of treatment&#8221; (<LINK REF="REF-Speizer-1968" TYPE="REFERENCE">Speizer 1968</LINK>).If toxicity were related to increasing doses of beta<SUB>2</SUB>-agonists, one might expect most deaths to occur in hospital, where high doses are typically used, but this was not the case.One possible explanation for this anomaly was provided by animal experiments in which large doses of isoprenaline caused little ill effect in anaesthetised dogs with normal arterial oxygenation, whereas much smaller doses caused fatal cardiac depression and asystole (although no obvious dysrhythmia) when hypoxic (<LINK REF="REF-Collins-1969" TYPE="REFERENCE">Collins 1969</LINK>; <LINK REF="REF-McDevitt-1974" TYPE="REFERENCE">McDevitt 1974</LINK>).It has been hypothesised therefore that such events would be less likely in hospital, where supplemental oxygen is routinely given.The clinical relevance of these studies remains unclear, although some evidence suggests a synergistic effect between hypoxia and salbutamol use in asthmatic patients in reducing total peripheral vascular resistance (<LINK REF="REF-Burggraaf-2001" TYPE="REFERENCE">Burggraaf 2001</LINK>)&#65293;another beta<SUB>2-</SUB>mediated effect that could be detrimental to the heart during an acute asthma attack through a reduction in diastolic blood pressure.Other potential mechanisms of isoprenaline toxicity include a potential increase in mucus plugging and worsening of ventilation-perfusion mismatch despite bronchodilatation (<LINK REF="REF-Pearce-1990" TYPE="REFERENCE">Pearce 1990</LINK>).</P>
<P>Additional concerns about a possible toxic effect of beta<SUB>2</SUB>-agonists were raised during the New Zealand epidemic in the 1970s.In 1981, Wilson et al, who first reported the epidemic, reviewed 22 fatal cases of asthma and noted, &#8220;In 16 patients, death was seen to be sudden and unexpected.Although all were experiencing respiratory distress, most were not cyanosed, and the precipitate nature of their death suggested a cardiac event, such as an arrest, inappropriate to the severity of their respiratory problem&#8221; (<LINK REF="REF-Wilson-1981" TYPE="REFERENCE">Wilson 1981</LINK>). In humans, fenoterol causes significantly greater chronotropic, inotropic and electrocardiographic side effects than are produced by salbutamol in asthmatic patients (<LINK REF="REF-Wong-1990" TYPE="REFERENCE">Wong 1990</LINK>).It is interesting to note that across the same parameters, fenoterol also causes more side effects than are produced by isoprenaline (<LINK REF="REF-Burgess-1991" TYPE="REFERENCE">Burgess 1991</LINK>).</P>
<P>In patients with mild asthma and without a bronchoconstrictor challenge, salmeterol and salbutamol cause a similar degree of near-maximal bronchodilation at low doses (<LINK REF="REF-Bennett-1994" TYPE="REFERENCE">Bennett 1994</LINK>). However, whilst as a one-off dose salbutamol is typically used at 2 to 4 times the concentration of salmeterol, the dose equivalences for salmeterol versus salbutamol in increasing heart rate and decreasing potassium concentration and diastolic blood pressure were 17.7, 7.8 and 7.6, respectively (i.e. salmeterol had a greater effect across all parameters).Given the lower intrinsic efficacy of salmeterol (Table 2), these results highlight the importance of in vivo<I> </I>factors; one possible explanation for the difference is the increased lipophilicity of salmeterol compared with salbutamol, contributing to higher systemic absorption (<LINK REF="REF-Bennett-1994" TYPE="REFERENCE">Bennett 1994</LINK>). </P>
<P>When increasing actuations of standard doses of formoterol and salmeterol inhalers are compared in stable asthmatic patients, relatively similar cardiovascular effects are seen at lower doses (<LINK REF="REF-Guhan-2000" TYPE="REFERENCE">Guhan 2000</LINK>).However, at highest doses (above those recommended by the manufacturers), trends towards an increase in systolic blood pressure were noted with formoterol; in comparison, a trend towards a decrease in diastolic blood pressure and an increase in QTc interval was seen with salmeterol, although no statistical analysis of the difference was performed. In contrast, in asthmatic patients with methacholine-induced bronchoconstriction, no significant difference was noted between salmeterol and formoterol in causing increased heart rate and QTc interval, although formoterol caused significantly greater bronchodilatation and hypokalaemia (<LINK REF="REF-Palmqvist-1999" TYPE="REFERENCE">Palmqvist 1999</LINK>). Whilst good evidence of cardiovascular and metabolic side effects has been observed with increasing doses of beta<SUB>2</SUB>-agonists, it is a little difficult to envisage serious adverse effects of this nature when LABAs are used at manufacturer-recommended preventative doses.However, it is possible that some patients choose to use repeated doses of LABAs during exacerbations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tolerance</HEADING>
<P>In this setting, the term <I>tolerance </I>refers to an impaired response to beta<SUB>2</SUB>-agonists in patients who have been using regular beta<SUB>2</SUB>-agonist treatment previously (<LINK REF="REF-Haney-2006" TYPE="REFERENCE">Haney 2006</LINK>).Tolerance is likely to result from a combination of reduced receptor numbers secondary to receptor internalisation and reduced production and also uncoupling of receptors from downstream signalling pathways following repeated activation (<LINK REF="REF-Barnes-1995" TYPE="REFERENCE">Barnes 1995</LINK>). This phenomenon is likely to explain the beneficial reduction in systemic side effects seen with regular use of beta<SUB>2</SUB>-agonists including salbutamol after 1 to 2 weeks (<LINK REF="REF-Lipworth-1989" TYPE="REFERENCE">Lipworth 1989</LINK>).However, the same effect on beta<SUB>2</SUB>-adrenoceptors in the lung might be expected to produce a diminished response to the bronchodilating activity of beta<SUB>2</SUB>-agonists following regular use.In patients with stable asthma, whilst some evidence shows tolerance to both salbutamol (<LINK REF="REF-Nelson-1977" TYPE="REFERENCE">Nelson 1977</LINK>) and terbutaline (<LINK REF="REF-Weber-1982" TYPE="REFERENCE">Weber 1982</LINK>), other studies have been less conclusive (<LINK REF="REF-Harvey-1982" TYPE="REFERENCE">Harvey 1982</LINK>; <LINK REF="REF-Lipworth-1989" TYPE="REFERENCE">Lipworth 1989</LINK>).However, evidence of tolerance to short- and long-acting beta<SUB>2</SUB>-agonists in both protecting against and reducing bronchoconstriction is much stronger in the setting of an acute bronchoconstrictor challenge with chemical, allergen and 'natural' stimuli (<LINK REF="REF-Haney-2006" TYPE="REFERENCE">Haney 2006</LINK>; <LINK REF="REF-Lipworth-1997" TYPE="REFERENCE">Lipworth 1997</LINK>).</P>
<P>Studies comparing salmeterol and formoterol have shown that both cause tolerance compared with placebo, but no significant difference was noted between the drugs (<LINK REF="REF-van-der-Woude-2001" TYPE="REFERENCE">van der Woude 2001</LINK>). There also appears to be little difference in the tolerance induced by regular formoterol and regular salbutamol treatment (<LINK REF="REF-Hancox-1999" TYPE="REFERENCE">Hancox 1999</LINK>; <LINK REF="REF-Jones-2001" TYPE="REFERENCE">Jones 2001</LINK>).To the review authors' knowledge, no studies have looked specifically at the degree of tolerance caused by isoprenaline and fenoterol in the setting of acute bronchoconstriction.Tolerance to bronchodilatation has clearly been shown to occur with addition of inhaled corticosteroids to salmeterol and formoterol (<LINK REF="REF-Lee-2003" TYPE="REFERENCE">Lee 2003</LINK>) and terbutaline (<LINK REF="REF-Yates-1996" TYPE="REFERENCE">Yates 1996</LINK>). Evidence as to whether high-dose steroids can reverse tolerance in the acute setting is conflicting (<LINK REF="REF-Lipworth-2000" TYPE="REFERENCE">Lipworth 2000</LINK>; <LINK REF="REF-Jones-2001" TYPE="REFERENCE">Jones 2001</LINK>).</P>
<P>At first glance, the toxicity and tolerance hypotheses might appear incompatible, as systemic and cardiovascular tolerance ought to protect against toxicity in the acute setting, and good evidence suggests that such tolerance occurs in stable asthmatic patients (<LINK REF="REF-Lipworth-1989" TYPE="REFERENCE">Lipworth 1989</LINK>).However, whilst this study showed that changes in heart rate and potassium levels were blunted by previous beta<SUB>2</SUB>-agonist use, they were not abolished; furthermore, at the doses studied, these side effects appear to follow an exponential pattern (<LINK REF="REF-Lipworth-1989" TYPE="REFERENCE">Lipworth 1989</LINK>).In contrast, in the presence of bronchoconstrictor stimuli, the bronchodilator response to beta<SUB>2</SUB>-agonists follows a flatter curve (<LINK REF="REF-Wong-1990" TYPE="REFERENCE">Wong 1990</LINK>; <LINK REF="REF-Hancox-1999" TYPE="REFERENCE">Hancox 1999</LINK>), and as was previously discussed, this curve is shifted downwards by previous beta<SUB>2</SUB>-agonist exposure (<LINK REF="REF-Hancox-1999" TYPE="REFERENCE">Hancox 1999</LINK>). Thus, it is theoretically possible that in the setting of an acute asthmatic attack and strong bronchoconstricting stimuli, bronchodilator tolerance could lead to repetitive beta<SUB>2</SUB>-agonist use and ultimately to more systemic side effects than would otherwise have occurred.Of course, other sequelae of inadequate bronchodilation including airway obstruction will be detrimental in this setting.</P>
<P>Whilst the tolerance hypothesis is often cited as contributing towards the asthma mortality epidemics, it is difficult to argue that reduced efficacy of a drug can cause increased mortality relative to a time when that drug was not used at all. However, tolerance to the bronchodilating effect of endogenous circulating adrenaline is theoretically possible, and evidence has revealed rebound bronchoconstriction when fenoterol is stopped (<LINK REF="REF-Sears-1990" TYPE="REFERENCE">Sears 1990</LINK>), which may be detrimental.Furthermore, it appears that regular salbutamol treatment can actually increase airway responsiveness to allergen (<LINK REF="REF-Cockcroft-1993" TYPE="REFERENCE">Cockcroft 1993</LINK>)&#65293;a potentially important effect that could produce a variant of the toxicity hypothesis. Differences between beta<SUB>2</SUB>-agonists in this regard are unclear, but the combination of rebound hyperresponsiveness and tolerance of the bronchodilator effect with regular beta<SUB>2</SUB>-agonist exposure has been recently advocated as a possible mechanism to explain the association between beta<SUB>2</SUB>-agonists and asthma mortality (<LINK REF="REF-Hancox-2006" TYPE="REFERENCE">Hancox 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other explanations</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Confounding by severity</HEADING>
<P>Historically, this hypothesis has been used extensively to try to explain the association between mortality and the use of fenoterol during the 1970s New Zealand epidemic (see <LINK REF="REF-Pearce-2007" TYPE="REFERENCE">Pearce 2007</LINK>), and it is still quoted today.The hypothesis essentially relies on the supposition that patients with more severe asthma are more likely to take higher doses of beta<SUB>2</SUB>-agonists or a particular beta<SUB>2</SUB>-agonist (such as fenoterol), thereby explaining the association.This hypothesis was carefully ruled out in the three case-control studies by comparison of the association between fenoterol and mortality in patients with varying severity of disease (<LINK REF="REF-Crane-1989" TYPE="REFERENCE">Crane 1989</LINK>; <LINK REF="REF-Pearce-1990" TYPE="REFERENCE">Pearce 1990</LINK>; <LINK REF="REF-Grainger-1991" TYPE="REFERENCE">Grainger 1991</LINK>). Furthermore, the hypothesis cannot explain the overall increase in mortality in the 1960s and 1970s, nor can it explain any significant increase in mortality (whether or not inhaled steroids are taken) based on randomised controlled trial data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">The delay hypothesis</HEADING>
<P>This hypothesis accepts that beta<SUB>2</SUB>-agonists or a particular beta<SUB>2</SUB>-agonist can cause increased risk of mortality, but indirectly, by causing patients to delay before getting medical help and further treatments, including high-dose steroids and oxygen.Evidence indicates that both salmeterol and formoterol can reduce awareness of worsening underlying inflammation (Bijl-Hofland 2001; McIvor 1998).It is difficult to rule out the delay hypothesis in explaining or contributing towards both the asthma mortality epidemics and an association with regular use of LABAs.Evidence shows that beta<SUB>2</SUB>-agonists with higher intrinsic efficacy are more effective in relieving bronchoconstriction in the acute setting (<LINK REF="REF-Hanania-2007" TYPE="REFERENCE">Hanania 2007</LINK>) and could paradoxically cause patients to further delay seeking medical help.For the delay hypothesis to explain the increase in mortality during the 1960s and 1970s, one has to imply that hospital treatment of asthma when mortality rates were low during the earlier years of the 20<SUP>th</SUP> century was effective.It is difficult to say exactly how effective such treatment is likely to have been. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reduced corticosteroid treatment</HEADING>
<P>A slight but significant variation of the delay hypothesis suggests that patients who have separate beta<SUB>2</SUB>-agonists and corticosteroid inhalers may choose to take less corticosteroid because of better symptom control from the inhaled beta<SUB>2</SUB>-agonists, and it is reduced corticosteroid treatment that contributes to a rise in mortality.It is rather difficult to see how this hypothesis explains the epidemics of asthma deaths in the 1960s and 1970s relative to the 1920s and 1930s (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), given that corticosteroids were not used for the treatment of asthma in the earlier decades.If this hypothesis were to explain increased mortality based on more recent randomised controlled trial data, one would not expect to see an increase in mortality in those taking LABAs alone.</P>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-01-24 13:37:34 +0000" MODIFIED_BY="[Empty name]">Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches: core databases</HEADING>
<TABLE COLS="2" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P>
<B>Database</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Frequency of search</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL (<I>T</I>
<I>he Cochrane Library</I>)</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE (Ovid)</P>
</TD>
<TD VALIGN="TOP">
<P>Weekly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE (Ovid)</P>
</TD>
<TD VALIGN="TOP">
<P>Weekly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>PsycINFO (Ovid)</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CINAHL (EBSCO)</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>AMED (EBSCO)</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
</TR>
</TABLE>
<P></P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Handsearches: core respiratory conference abstracts</HEADING>
<TABLE COLS="2" ROWS="9">
<TR>
<TD VALIGN="TOP">
<P>
<B>Conference</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Years searched</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>American Academy of Allergy, Asthma and Immunology (AAAAI)</P>
</TD>
<TD VALIGN="TOP">
<P>2001 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>American Thoracic Society (ATS)</P>
</TD>
<TD VALIGN="TOP">
<P>2001 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Asia Pacific Society of Respirology (APSR)</P>
</TD>
<TD VALIGN="TOP">
<P>2004 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>British Thoracic Society Winter Meeting (BTS)</P>
</TD>
<TD VALIGN="TOP">
<P>2000 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Chest Meeting</P>
</TD>
<TD VALIGN="TOP">
<P>2003 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>European Respiratory Society (ERS)</P>
</TD>
<TD VALIGN="TOP">
<P>1992, 1994, 2000 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>International Primary Care Respiratory Group Congress (IPCRG)</P>
</TD>
<TD VALIGN="TOP">
<P>2002 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Thoracic Society of Australia and New Zealand (TSANZ)</P>
</TD>
<TD VALIGN="TOP">
<P>1999 onwards</P>
</TD>
</TR>
</TABLE>
<P></P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE search strategy used to identify trials for the CAGR</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Asthma search</HEADING>
<P>1. exp Asthma/</P>
<P>2. asthma$.mp.</P>
<P>3. (antiasthma$ or anti-asthma$).mp.</P>
<P>4. Respiratory Sounds/</P>
<P>5. wheez$.mp.</P>
<P>6. Bronchial Spasm/</P>
<P>7. bronchospas$.mp.</P>
<P>8. (bronch$ adj3 spasm$).mp.</P>
<P>9. bronchoconstrict$.mp.</P>
<P>10. exp Bronchoconstriction/</P>
<P>11. (bronch$ adj3 constrict$).mp.</P>
<P>12. Bronchial Hyperreactivity/</P>
<P>13. Respiratory Hypersensitivity/</P>
<P>14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.</P>
<P>15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.</P>
<P>16. or/1-15</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Filter to identify RCTs</HEADING>
<P>1. exp "clinical trial [publication type]"/</P>
<P>2. (randomised or randomised).ab,ti.</P>
<P>3. placebo.ab,ti.</P>
<P>4. dt.fs.</P>
<P>5. randomly.ab,ti.</P>
<P>6. trial.ab,ti.</P>
<P>7. groups.ab,ti.</P>
<P>8. or/1-7</P>
<P>9. Animals/</P>
<P>10. Humans/</P>
<P>11. 9 not (9 and 10)</P>
<P>12. 8 not 11</P>
<P>The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NO="4">
<TITLE MODIFIED="2008-11-18 13:08:23 +0000" MODIFIED_BY="Christopher J Cates">Definition of Serious Adverse Events</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-23 11:05:34 +0100" MODIFIED_BY="Christopher J Cates" NOTES="&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;/h1&gt;&lt;p&gt;Nov 26th: I need Joe or Roman to indicate where the death was in FACET and what the cause was? Also was suicide on combined or separate inhalers in Zetterstrom&lt;/p&gt;&lt;p&gt;Nov 24th rogue version repaired by Jacob. This one has the table restored and is fine for Susan to add data. I have tidied up the sensitivity and subgroup analyses.&lt;/p&gt;&lt;p&gt;Nov 21st. Double data checking with Roman has revealed a mistake by Joe in the FACET asthma SAEs in the Bud 400 arm. It should have been five patients. Data checking with Toby fine and text modifications made.&lt;/p&gt;&lt;p&gt;#~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;Nov 17th&lt;/p&gt;&lt;p&gt;Will still need to ask Susan to enter all the additional references to included studies. I have described the included studies. Ready for risk of bias.&lt;/p&gt;&lt;p&gt;&amp;quot;A total of 7 patients in the budesonide/formoterol group had a serious adverse event requiring admission to hospital (asthma (5), larynx edema (1), pneumonia (1).&amp;quot; Deaths are not mentioned nor are any events in the budesonide group. Further clarification is being sought from the sponsors, but we have currently assumed no serious adverse events in the budesonide group (as none are recorded in the paper). Tal 2002&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;Nov 11 2009&lt;/p&gt;&lt;p&gt;First six included studies entered into RevMan and data checked against Roman's paper. Also complete set of excluded studies entered too.&lt;/p&gt;&lt;p&gt;Peto results and Mantel-Haenszel method given quite different looking results for all-cause mortality. What about exact methods?&lt;/p&gt;&lt;p&gt;Doses are widely variable here and may need some thought I guess.&lt;/p&gt;&lt;p&gt;TAL data needs to be referred back to Joe urgently. Done&lt;/p&gt;&lt;p&gt;Check that SAE non-fatal does not include the deaths......&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;CJC nov 9&lt;br&gt;Further amendments made following discussion with TL. SIT and AMD are included but not BDF for relief use only in randomisation. ICS remains the control arm for this review (so SIT v AMD would not be included for example).&lt;br&gt;Back to TL for checking.&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;br&gt;CJC Nov 5&lt;br&gt;Thanks for amending this Toby. I am happy to publish the current version&lt;br&gt;~~~~~~~~~~~~~~~~~~~~~~&lt;br&gt;Will varying the exposure to LABA in intermittent/AMD studies confound the risk in control group? Given the emphasis on regular LABA use in the protocol we may need to give some thought as to whether control groups where there is exposure to LABAs are estimating a different treatment effect to something other than studies like FACET. I have restructured the Criteria for intervention section to reflect this.&lt;/p&gt;&lt;p&gt;----------------------------&lt;br&gt;Key differences in Red from the other Formoterol protocol. FACET may get left out in the cold here but the main focus is on REGULAR LABA use, so this is where I have drawn the line.&lt;br&gt;What do you think?&lt;br&gt;Chris&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6653&quot;&gt;&lt;span coll_flag=&quot;f6653&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Title&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1040&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Review information&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1043&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1091&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cates, Christopher&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1093&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lasserson, Toby&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1095&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cates, Matthew&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1097&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jaeschke, Roman&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1041&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contact person&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1046&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dates&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1050&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;What's new&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1051&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;History&lt;/h2&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1089&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abstract&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6860&quot;&gt;&lt;span coll_flag=&quot;f6860&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6862&quot;&gt;&lt;span coll_flag=&quot;f6862&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6864&quot;&gt;&lt;span coll_flag=&quot;f6864&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6866&quot;&gt;&lt;span coll_flag=&quot;f6866&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection criteria&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6868&quot;&gt;&lt;span coll_flag=&quot;f6868&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6870&quot;&gt;&lt;span coll_flag=&quot;f6870&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6872&quot;&gt;&lt;span coll_flag=&quot;f6872&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1088&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language summary&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6855&quot;&gt;&lt;span coll_flag=&quot;f6855&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language title&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6857&quot;&gt;&lt;span coll_flag=&quot;f6857&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary text&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6885&quot;&gt;&lt;span coll_flag=&quot;f6885&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6895&quot;&gt;&lt;span coll_flag=&quot;f6895&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6897&quot;&gt;&lt;span coll_flag=&quot;f6897&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Methods&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6899&quot;&gt;&lt;span coll_flag=&quot;f6899&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Criteria for considering studies for this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6901&quot;&gt;&lt;span coll_flag=&quot;f6901&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6903&quot;&gt;&lt;span coll_flag=&quot;f6903&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of participants&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6905&quot;&gt;&lt;span coll_flag=&quot;f6905&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of interventions&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6907&quot;&gt;&lt;span coll_flag=&quot;f6907&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of outcome measures&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6909&quot;&gt;&lt;span coll_flag=&quot;f6909&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Primary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6911&quot;&gt;&lt;span coll_flag=&quot;f6911&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Secondary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6913&quot;&gt;&lt;span coll_flag=&quot;f6913&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods for identification of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6915&quot;&gt;&lt;span coll_flag=&quot;f6915&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Electronic searches&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6917&quot;&gt;&lt;span coll_flag=&quot;f6917&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Searching other resources&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6919&quot;&gt;&lt;span coll_flag=&quot;f6919&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6921&quot;&gt;&lt;span coll_flag=&quot;f6921&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6923&quot;&gt;&lt;span coll_flag=&quot;f6923&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data extraction and management&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6925&quot;&gt;&lt;span coll_flag=&quot;f6925&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Assessment of risk of bias in included studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6937&quot;&gt;&lt;span coll_flag=&quot;f6937&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data synthesis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6939&quot;&gt;&lt;span coll_flag=&quot;f6939&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Subgroup analysis and investigation of heterogeneity&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6941&quot;&gt;&lt;span coll_flag=&quot;f6941&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sensitivity analysis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6943&quot;&gt;&lt;span coll_flag=&quot;f6943&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6945&quot;&gt;&lt;span coll_flag=&quot;f6945&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Description of studies&lt;/h2&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6953&quot;&gt;&lt;span coll_flag=&quot;f6953&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Risk of bias in included studies&lt;/h2&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6965&quot;&gt;&lt;span coll_flag=&quot;f6965&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Effects of interventions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6967&quot;&gt;&lt;span coll_flag=&quot;f6967&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Discussion&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6969&quot;&gt;&lt;span coll_flag=&quot;f6969&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of main results&lt;/h2&gt;&lt;p&gt;I am a bit concerned that this draws on the results from the RD, when the Peto is used in the review as well. Is there a way of conveying the subtle distinction between these two models somewhere in the Discussion section? &lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6971&quot;&gt;&lt;span coll_flag=&quot;f6971&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Overall completeness and applicability of evidence&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6973&quot;&gt;&lt;span coll_flag=&quot;f6973&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Quality of the evidence&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6975&quot;&gt;&lt;span coll_flag=&quot;f6975&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Potential biases in the review process&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6977&quot;&gt;&lt;span coll_flag=&quot;f6977&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Agreements and disagreements with other studies or reviews&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6979&quot;&gt;&lt;span coll_flag=&quot;f6979&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6981&quot;&gt;&lt;span coll_flag=&quot;f6981&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for practice&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6983&quot;&gt;&lt;span coll_flag=&quot;f6983&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for research&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6874&quot;&gt;&lt;span coll_flag=&quot;f6874&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Acknowledgements&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6878&quot;&gt;&lt;span coll_flag=&quot;f6878&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contributions of authors&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6876&quot;&gt;&lt;span coll_flag=&quot;f6876&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Declarations of interest&lt;/h1&gt;&lt;p&gt;Add RJ conflict of interest&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6880&quot;&gt;&lt;span coll_flag=&quot;f6880&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Differences between protocol and review&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f6882&quot;&gt;&lt;span coll_flag=&quot;f6882&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Published notes&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1059&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1060&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1613&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl 2003&lt;/h3&gt;&lt;p&gt;I have used the data from Roman's paper here. 2 SAE on BDF and 2 SAE on bud and one death on BDF. One SAE on BDF was entered as asthma related.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11601&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11601&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11603&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11603&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11605&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11605&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11607&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11607&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11609&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11609&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1107&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1945&quot; id=&quot;s1945&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12864&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12864&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1968&quot; id=&quot;s1968&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12933&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12933&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1992&quot; id=&quot;s1992&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13005&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13005&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2016&quot; id=&quot;s2016&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13077&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13077&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2039&quot; id=&quot;s2039&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13146&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13146&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1614&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chuchalin 2002&lt;/h3&gt;&lt;p&gt;Why does Roman report 3 SAE or admissions in Budesonide group? Error on his part agreed. 0/2 entered.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11612&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11612&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11614&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11614&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11616&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11616&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11618&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11618&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11620&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11620&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1113&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1946&quot; id=&quot;s1946&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12867&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12867&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1969&quot; id=&quot;s1969&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12936&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12936&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1993&quot; id=&quot;s1993&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13008&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13008&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2017&quot; id=&quot;s2017&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13080&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13080&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2040&quot; id=&quot;s2040&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13149&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13149&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1615&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Corren 2007&lt;/h3&gt;&lt;p&gt;Jaeschke says 2/2 SAE for Corren and this is not correct according to the web report. Need to check. 2/0 is correct, this was an error in Roman's table.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11623&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11623&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11625&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11625&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11627&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11627&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11629&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11629&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11631&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11631&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1121&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1947&quot; id=&quot;s1947&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12870&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12870&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1970&quot; id=&quot;s1970&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12939&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12939&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1994&quot; id=&quot;s1994&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13011&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13011&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2018&quot; id=&quot;s2018&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13083&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13083&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2041&quot; id=&quot;s2041&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13152&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13152&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1616&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D5896C00001&lt;/h3&gt;&lt;p&gt;No asthma SAE data found. Roman does not seem to have data on this one!&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11634&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11634&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11636&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11636&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11638&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11638&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11640&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11640&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11642&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11642&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1129&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1948&quot; id=&quot;s1948&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12873&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12873&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1971&quot; id=&quot;s1971&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12942&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12942&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1995&quot; id=&quot;s1995&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13014&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13014&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2019&quot; id=&quot;s2019&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13086&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13086&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2042&quot; id=&quot;s2042&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13155&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13155&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1617&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jenkins 2006&lt;/h3&gt;&lt;p&gt;Was LABA withdrawn during run-in I wonder? Roman states 7/3 for SAE so asked to recheck this.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11645&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11645&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11647&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11647&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11649&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11649&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11651&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11651&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11653&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11653&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1135&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1949&quot; id=&quot;s1949&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12876&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12876&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1972&quot; id=&quot;s1972&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12945&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12945&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1996&quot; id=&quot;s1996&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13017&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13017&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2020&quot; id=&quot;s2020&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13089&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13089&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2043&quot; id=&quot;s2043&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13158&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13158&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1618&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuna 2006&lt;/h3&gt;&lt;p&gt;Check with Roman whether he has data on patients rather than events for 1/2 in asthma and 3/4 total SAEs&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11656&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11656&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11658&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11658&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11660&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11660&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11662&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11662&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11664&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11664&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1141&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1950&quot; id=&quot;s1950&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12879&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12879&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1973&quot; id=&quot;s1973&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12948&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12948&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1997&quot; id=&quot;s1997&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13020&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13020&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2021&quot; id=&quot;s2021&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13092&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13092&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2044&quot; id=&quot;s2044&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13161&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13161&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1619&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice 2007&lt;/h3&gt;&lt;p&gt;This study was excluded on its abstract but included from full paper and AZ trial register.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11667&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11667&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11669&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11669&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11671&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11671&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11673&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11673&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11675&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11675&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1150&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1951&quot; id=&quot;s1951&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12882&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12882&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1974&quot; id=&quot;s1974&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12951&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12951&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1998&quot; id=&quot;s1998&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13023&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13023&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2022&quot; id=&quot;s2022&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13095&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13095&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2045&quot; id=&quot;s2045&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13164&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13164&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1620&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice 2008&lt;/h3&gt;&lt;p&gt;Children's data so not included by Roman. Dose 200 per day.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11678&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11678&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11680&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11680&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11682&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11682&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11684&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11684&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11686&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11686&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1157&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1952&quot; id=&quot;s1952&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12885&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12885&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1975&quot; id=&quot;s1975&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12954&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12954&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1999&quot; id=&quot;s1999&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13026&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13026&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2023&quot; id=&quot;s2023&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13098&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13098&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2046&quot; id=&quot;s2046&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13167&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13167&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1621&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Noonan 2006&lt;/h3&gt;&lt;p&gt;This one appears to be missing from Roman's review.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11689&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11689&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11691&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11691&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11693&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11693&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11695&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11695&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11697&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11697&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1163&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1953&quot; id=&quot;s1953&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12888&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12888&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1976&quot; id=&quot;s1976&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12957&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12957&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2000&quot; id=&quot;s2000&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13029&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13029&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2024&quot; id=&quot;s2024&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13101&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13101&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2047&quot; id=&quot;s2047&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13170&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13170&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1622&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne 2001&lt;/h3&gt;&lt;p&gt;OPTIMA but data entered as from Susan's sheet. Roman to check this and the group and cause of death in the single patient. &lt;a link_type=&quot;REFERENCE&quot; href=&quot;Sears 2008&quot; protected=&quot;true&quot;&gt;Sears 2008&lt;/a&gt; indicates that the death was also related to status asthmaticus and was in a patient taking budesonide/formoterol combination treatment.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11700&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11700&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11702&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11702&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11704&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11704&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11706&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11706&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11708&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11708&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1169&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1954&quot; id=&quot;s1954&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12891&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12891&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1977&quot; id=&quot;s1977&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12960&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12960&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2001&quot; id=&quot;s2001&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13032&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13032&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2025&quot; id=&quot;s2025&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13104&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13104&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2048&quot; id=&quot;s2048&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13173&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13173&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1623&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne 2001a&lt;/h3&gt;&lt;p&gt;Use this for the 200 mcg ICS data from Optima.&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;Group A&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Group A&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Group A&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Placebo&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Budesonide 100?g bid&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;Budesonide 100?g bid&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;+ formoterol 4.5?g bid&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;(n=239)&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;(n=228)&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;(n=231)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;Number of patients &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&lt;b&gt;with one or more &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;8&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;SAEs of any cause &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;Number of patients &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&lt;b&gt;with one or more &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;asthma SAEs &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&amp;#160;Group B Budesonide 100?g bid (n=322)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Group B Budesonide 100?g bid + formoterol 4.5?g bid (n=323)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Group B Budesonide 200?g bid (n=312)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Group B Budesonide 200?g bid + formoterol 4.5?g bid (n=315)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&lt;b&gt;Number of patients with one or more SAEs of any cause &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;12&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;p&gt;&lt;b&gt;Number of patients with one or more asthma SAEs &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;6&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11711&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11711&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11713&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11713&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11715&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11715&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11717&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11717&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11719&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11719&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1175&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1955&quot; id=&quot;s1955&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12894&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12894&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1978&quot; id=&quot;s1978&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12963&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12963&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2002&quot; id=&quot;s2002&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13035&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13035&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2026&quot; id=&quot;s2026&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13107&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13107&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2049&quot; id=&quot;s2049&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13176&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13176&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1624&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11722&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11722&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11724&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11724&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11726&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11726&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11728&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11728&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11730&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11730&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1182&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1956&quot; id=&quot;s1956&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12897&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12897&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1979&quot; id=&quot;s1979&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12966&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12966&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2003&quot; id=&quot;s2003&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13038&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13038&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2027&quot; id=&quot;s2027&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13110&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13110&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2050&quot; id=&quot;s2050&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13179&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13179&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1625&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels 1997a&lt;/h3&gt;&lt;p&gt;Check 4 or 5 and where is the single death. IT was FIVE - mistake by Joe GRAY. Joe also confirms that the single death was on the higher dose Budesonide plus formoterol. Cause awaited. The table now reads 15 and 10 for all cause SAE on BD and F.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11733&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11733&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11735&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11735&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11737&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11737&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11739&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11739&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11741&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11741&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1189&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1957&quot; id=&quot;s1957&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12900&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12900&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1980&quot; id=&quot;s1980&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12969&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12969&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2004&quot; id=&quot;s2004&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13041&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13041&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2028&quot; id=&quot;s2028&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13113&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13113&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2051&quot; id=&quot;s2051&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13182&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13182&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1626&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peters 2008&lt;/h3&gt;&lt;p&gt;Zero Asthma SAE on Bud also needs to be run by Joe! Too recent for Roman's paper.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11744&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11744&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11746&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11746&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11748&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11748&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11750&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11750&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11752&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11752&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1195&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1958&quot; id=&quot;s1958&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12903&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12903&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1981&quot; id=&quot;s1981&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12972&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12972&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2005&quot; id=&quot;s2005&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13044&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13044&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2029&quot; id=&quot;s2029&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13116&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13116&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2052&quot; id=&quot;s2052&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13185&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13185&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1627&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pohunek 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11755&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11755&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11757&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11757&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11759&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11759&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11761&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11761&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11763&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11763&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1201&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1959&quot; id=&quot;s1959&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12906&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12906&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1982&quot; id=&quot;s1982&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12975&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12975&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2006&quot; id=&quot;s2006&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13047&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13047&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2030&quot; id=&quot;s2030&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13119&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13119&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2053&quot; id=&quot;s2053&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13188&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13188&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1628&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Price 2002&lt;/h3&gt;&lt;p&gt;Data from Roman's paper: 2/3 SAE and 0/2 asthma SAE. No deaths. 250/255&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11766&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11766&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11768&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11768&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11770&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11770&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11772&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11772&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11774&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11774&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1208&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1960&quot; id=&quot;s1960&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12909&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12909&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1983&quot; id=&quot;s1983&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12978&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12978&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2007&quot; id=&quot;s2007&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13050&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13050&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2031&quot; id=&quot;s2031&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13122&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13122&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2054&quot; id=&quot;s2054&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13191&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13191&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1629&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0714&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11777&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11777&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11779&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11779&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11781&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11781&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11783&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11783&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11785&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11785&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1214&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1961&quot; id=&quot;s1961&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12912&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12912&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1984&quot; id=&quot;s1984&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12981&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12981&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2008&quot; id=&quot;s2008&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13053&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13053&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2032&quot; id=&quot;s2032&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13125&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13125&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2055&quot; id=&quot;s2055&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13194&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13194&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1630&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0718&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11788&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11788&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11790&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11790&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11792&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11792&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11794&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11794&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11796&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11796&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1220&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1962&quot; id=&quot;s1962&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12915&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12915&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1985&quot; id=&quot;s1985&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12984&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12984&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2009&quot; id=&quot;s2009&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13056&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13056&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2033&quot; id=&quot;s2033&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13128&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13128&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2056&quot; id=&quot;s2056&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13197&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13197&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1631&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0719&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11799&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11799&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11801&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11801&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11803&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11803&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11805&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11805&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11807&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11807&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1963&quot; id=&quot;s1963&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12918&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12918&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1986&quot; id=&quot;s1986&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12987&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12987&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2010&quot; id=&quot;s2010&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13059&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13059&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2034&quot; id=&quot;s2034&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13131&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13131&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2057&quot; id=&quot;s2057&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13200&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13200&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1632&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0725&lt;/h3&gt;&lt;p&gt;Only SAEs that occured during the double blind treatment period are included here. See table.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11810&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11810&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11812&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11812&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11814&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11814&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11816&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11816&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11818&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11818&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1232&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1964&quot; id=&quot;s1964&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12921&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12921&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1987&quot; id=&quot;s1987&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12990&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12990&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2011&quot; id=&quot;s2011&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13062&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13062&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2035&quot; id=&quot;s2035&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13134&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13134&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2058&quot; id=&quot;s2058&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13203&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13203&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1633&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0726&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11821&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11821&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11823&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11823&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11825&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11825&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11827&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11827&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11829&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11829&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1238&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1965&quot; id=&quot;s1965&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12924&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12924&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1988&quot; id=&quot;s1988&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12993&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12993&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2012&quot; id=&quot;s2012&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13065&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13065&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2036&quot; id=&quot;s2036&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13137&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13137&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2059&quot; id=&quot;s2059&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13206&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13206&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1634&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tal 2002&lt;/h3&gt;&lt;p&gt;Data entered as described with zero entries for Budesonide group This has now been confirmed by Joe.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11832&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11832&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11834&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11834&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11836&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11836&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11838&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11838&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11840&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11840&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1244&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1966&quot; id=&quot;s1966&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12927&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12927&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1989&quot; id=&quot;s1989&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12996&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12996&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2013&quot; id=&quot;s2013&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13068&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13068&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2037&quot; id=&quot;s2037&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13140&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13140&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2060&quot; id=&quot;s2060&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13209&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13209&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1635&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom 2001&lt;/h3&gt;&lt;p&gt;Data confirmed by Roman's paper/ 1 to zero deaths, 3/1 SAE and none related to asthma. 238/124 totals Care needed not to include deaths in non-fatal arm.&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f11843&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11843&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f11845&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11845&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f11847&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11847&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11849&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11849&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f11851&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11851&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1250&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1967&quot; id=&quot;s1967&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6810&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12930&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12930&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1990&quot; id=&quot;s1990&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6815&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f12999&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f12999&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2014&quot; id=&quot;s2014&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6820&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13071&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13071&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2038&quot; id=&quot;s2038&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6825&quot;&gt;Incomplete outcome data addressed? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f13143&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13143&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s2061&quot; id=&quot;s2061&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6830&quot;&gt;Free of selective reporting?&lt;/td&gt;&lt;td doc_fld_id=&quot;f13212&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f13212&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1061&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1636&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ankerst 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11854&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11854&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1637&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11857&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11857&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1638&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11860&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11860&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1639&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11863&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11863&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1640&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005c&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11866&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11866&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1641&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005d&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11869&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11869&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1642&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11872&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11872&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1643&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11875&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11875&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1644&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11878&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11878&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1645&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Balanag 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11881&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11881&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1646&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11884&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11884&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1647&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11887&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11887&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1648&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bouros 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11890&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11890&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1649&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11893&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11893&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1650&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burgess 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11896&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11896&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1651&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Canonica 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11899&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11899&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1652&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ceylan 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11902&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11902&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1653&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dhillon 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11905&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11905&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1654&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11908&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11908&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1655&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11911&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11911&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1656&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haahtela 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11914&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11914&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1657&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ind 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11917&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11917&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1658&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kozlik-Feldmann 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11920&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11920&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1659&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lalloo 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11923&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11923&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1660&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leuppi 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11926&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11926&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1661&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lotvall&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11929&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11929&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1662&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lundborg 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11932&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11932&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1663&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mitchell 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11935&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11935&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1664&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Molimard 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11938&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11938&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1665&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Novartis 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11941&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11941&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1666&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11944&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11944&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1667&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Overbeek 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11947&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11947&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1668&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papi 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11950&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11950&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1669&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11953&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11953&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1670&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pleskow 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11956&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11956&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1671&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pohl 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11959&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11959&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1672&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rabe 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11962&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11962&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1673&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11965&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11965&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1674&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11968&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11968&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1675&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2003a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11971&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11971&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1676&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scicchitano 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11974&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11974&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1677&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stelmach 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11977&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11977&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1678&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van der Molen 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11980&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11980&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1679&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Villa, 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11983&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11983&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1680&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Von Berg 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11986&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11986&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1681&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worth 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11989&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11989&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1682&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom 2001a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11992&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11992&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1683&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstr&amp;#246;m 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f11995&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f11995&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1062&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1063&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1071&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of findings tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1072&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1684&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Dose and delivery of budesonide and formoterol&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1074&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;References to studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1075&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1101&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1104&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine 2003;97(4):323-30.&lt;/h4&gt;Buhl, R&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1108&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chuchalin 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1111&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chuchalin AG, Ovcharenko SI, Goriachkina LA, Sidorenko IV, Tsoi AN, Epoch Study G. The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: A comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia. International Journal of Clinical Practice 2002;56(1):15-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1114&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Corren 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1117&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SD-039-0716. A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trialof SYMBICORT&amp;#174; pMDI (80/4.5 &amp;#956;g) versus its Monoproducts (budesonide andformoterol) in Children (&amp;#8805;6 Years of Age) and Adults with Asthma &amp;#8211; SPRUCE 80/4.5. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0716.pdf accessed november 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1119&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics 2007;29(5):823-43.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1122&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D5896C00001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1125&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. A randomized, double-blind, active-controlled, parallel-group, singledummy,multicenter, 12 week study to assess the efficacy and safety ofSYMBICORT&amp;#174; pMDI 160/4.5 &amp;#956;g x 2 actuations once-daily (qd) comparedto SYMBICORT pMDI 80/4.5 &amp;#956;g x 2 actuations qd, SYMBICORT pMDI80/4.5 &amp;#956;g x 2 actuations twice-daily (bid) and to budesonide pMDI 160 &amp;#956;gx 2 actuations qd in asthmatic subjects 12 years of age and older. [D5896C00001]. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/D5896C00001.pdf Accessed November 11th 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1127&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oppenheimer JJ, Kerwin EM, LaForce C, Miller CJ, O'Dowd L, Goldman M. Asthma Control with Once-Daily (qd) Budesonide/Formoterol Pressurized Metered-Dose Inhaler (pMDI) in Adults and Adolescents with Asthma Previously Stable with Twice-Daily (bid) Budesonide/Formoterol pMDI. Journal of Allergy and Clinical Immunology 2008;121(2, Supplement 1):S8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1130&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jenkins 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1133&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W, et al. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 2006;11(3):276-86.&lt;/h4&gt;Record Number: 606710&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1136&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuna 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1139&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuna P, Creemers J, Vondra V, Black PN, Lindqvist A, Nihlen U, et al. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respiratory Medicine 2006;100(12):2151-9.&lt;/h4&gt;Record Number: 12840&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1142&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1145&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice AH, Hochmuth L, Puterman A, Artheden L, Beckman O. Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy &amp;amp; Clinical Immunology 2005;115(2 Suppl):S3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1147&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. International Journal of Clinical Practice 2007;61(11):1874-83.&lt;/h4&gt;Morice, A H&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1151&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1154&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary Pharmacology and Therapeutics 2008;21(1):152-9.&lt;/h4&gt;Morice, Alyn H&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1158&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Noonan 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1161&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: A randomised clinical trial. Drugs 2006;66(17):2235-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1164&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1167&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom EVA, Sandstrom T, Svensson K, et al. Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma . The OPTIMA Randomized Trial. American Journal of Respiratory and Critical Care Medicine 2001;164(8):1392-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1170&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne 2001a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1173&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom EVA, Sandstrom T, Svensson K, et al. Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma . The OPTIMA Randomized Trial. American Journal of Respiratory and Critical Care Medicine 2001;164(8):1392-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1176&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1179&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine 1997;337(20):1405-11.&lt;/h4&gt;Pauwels, R A&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1183&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels 1997a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1186&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [New England Journal of Medicine]. N Engl J Med 1997;337(20):1405-11.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1190&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peters 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1193&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peters SP, Prenner BM, Mezzanotte WS, Martin P, O'Brien CD. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurised metered-dose inhaler in asthma. Alllergy and Asthma Proceedings 2008;29:1-18.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1196&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pohunek 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1199&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pohunek P, Kuna P, Jorup C, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy &amp;amp; Immunology 2006;17(6):458-65.&lt;/h4&gt;Record Number: 13390&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1202&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Price 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1205&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Price D, Dutchman D, Mawson A, Bodalia B, Duggan S, Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 2002;57(9):791-8.&lt;/h4&gt;Price, D&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1209&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0714&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1212&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. Efficacy and safety of budesonide/formoterol Turbuhaler&amp;#174; (160/4.5 mg b.i.d.delivered dose) compared to budesonide Turbuhaler&amp;#174; (200 mg b.i.d. metereddose) in steroid-using asthmatic adolescent patients. A double-blind, doubledummy,randomised, parallel group, phase III, multicentre study. (ATTAINSTUDY). http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0714.pdf Accessed November 14 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1215&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0718&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1218&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. A Twelve-Week, Randomized, Double-Blind, Double-Dummy Trial ofSymbicort&amp;#174; (40/4.5 mcg) versus its Mono-Products (budesonide and formoterol) in Asthmatic Children Aged Six to Fifteen Years.. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0718.pdf Accessed November 14 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1221&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0719&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1224&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. A Six-Month, Randomized, Open-Label Safety Study of SYMBICORT&amp;#174;(160/4.5 &amp;#956;g) Compared to PULMICORT Turbuhaler&amp;#174; in AsthmaticChildren Aged 6 to 11 Years.. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0719.pdf Accessed November 14 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1227&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0725&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1230&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. A Twelve-Week, Randomized, Double-blind, Double-Dummy, Active-Controlled Study ofSYMBICORT&amp;#174; pMDI Administered Once Daily in Children and Adolescents 6 to 15Years of Age with Asthma. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD_039_0725.pdf Accessed November 18 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1233&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SD-039-0726&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1236&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Study of SYMBICORT&amp;#174; pMDI Administered Once Daily in Adults andAdolescents with Asthma.. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0726.pdf Accessed November 14 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1239&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tal 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1242&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology 2002;34(5):342-50.&lt;/h4&gt;Record Number: 570&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1248&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal 2001;18(2):262-8.&lt;/h4&gt;Record Number: 2050&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1076&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1251&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ankerst 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1254&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulmonary Pharmacology &amp;amp; Therapeutics 2003;16(3):147-51.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1256&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1259&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. Efficacy &amp;amp; safety of Symbicort Turbuhaler 160/4.5 &amp;#181;g twice daily &amp;amp; Pulmicort Turbuhaler 200 &amp;#181;g twice daily + Theolong tablet 200 mg twice daily in Japanese asthmatic patients. clinicaltrials.gov 2005.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1261&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1264&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SHARE - symbicort and health economics in a real life evaluation. clinicaltrials.gov 2005.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1266&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SOLO-symbicort in the treatment of persistent asthma in adolescents &amp;amp; adults. clinicaltrials.gov 2005.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1271&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005c&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1274&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. STYLE - symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. clinicaltrials.gov 2005.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1276&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2005d&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1279&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SYMPHONIE -a comparison of symbicort single inhaler and conventional best practice for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov 2005.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1281&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1284&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. A comparison of the control of asthma inflammation provided by Symbicort turbuhaler 160/4.5 mcg/inhalation bid plus as-needed versus symbicort turbuhaler 320/9 ug/inhalation bid plus pulmicort turbuhaler 400mcg/dose bid plus terbutaline turbuhaler 0.4mg/inhalation as-needed. clinicaltrials.gov 2006.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1286&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1289&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov 2006.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1291&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca 2006b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1294&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;AstraZeneca. SALTO - symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. clinicaltrials.gov 2006.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1296&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Balanag 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1299&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulmonary Pharmacology &amp;amp; Therapeutics 2006;19(2):139-47.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1301&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1304&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman ED, Bantje TA, Gomes MJ, Toumbis MG, Huber RM, Naya I, et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. American Journal of Respiratory Medicine 2003;2(3):275-81.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1306&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1309&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bateman ED, Fairall L, Lombardi DM, English R. Budenoside/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respiratory Research. 2006;7:13.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1311&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bouros 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1314&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bouros D, Bachlitzanakis N, Kottakis J, Pfister P, Polychronopoulos V, Papadakis E, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. European Respiratory Journal 1999;14(3):627-32.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1316&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1319&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Bruggenjurgen B, Willich SN, et al. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Current Medical Research &amp;amp; Opinion 2004;20(8):1209-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1321&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burgess 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1324&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. European Journal of Clinical Pharmacology 1998;54(2):141-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1326&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Canonica 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1329&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Canonica GW, Castellani P, Cazzola M, Fabbri LM, Fogliani V, Mangrella M, et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulmonary Pharmacology &amp;amp; Therapeutics 2004;17(4):239-47.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1331&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ceylan 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1334&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ceylan E, Mehmet G, Sahin A. Addition of formoterol or montelukast to low-dose budesonide: An efficacy comparison in short- and long-term asthma control. Respiration 2004;71(6):594-601.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1336&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dhillon 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1339&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dhillon S, Keating GM. Beclometasone dipropionate/formoterol: In an HFA-propelled pressurised metered-dose inhaler. Drugs 2006;66(11):1475-83.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1341&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1344&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. Journal of Allergy &amp;amp; Clinical Immunology 1999;103(3 I):427-35.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1346&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1349&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;FitzGerald JM, Sears MR, Boulet LP, Becker AB, McIvor AR, Ernst P, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five-month multicentre Canadian study. Canadian Respiratory Journal 2003;10(8):427-34.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1351&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haahtela 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1354&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haahtela T, Tamminen K, Malmberg LP, Zetterstrom O, Karjalainen J, Yla-Outinen H, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. European Respiratory Journal 2006;28(4):748-55.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1356&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ind 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1359&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ind PW, Haughney J, Price D, Rosen JP, Kennelly J. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: The ASSURE study. Respiratory Medicine 2004;98(5):464-75.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1361&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kozlik-Feldmann 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1364&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kozlik-Feldmann R, von Berg A, Berdel D, Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. European Journal of Medical Research 1996;1(10):465-70.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1366&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lalloo 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1369&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003;123(5):1480-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1371&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leuppi 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1374&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leuppi FD, Salzberg M, Meyer L, Bucher SE, Nief M, Brutsche MH, et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Medical Weekly 2003;133(21-22):302-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1376&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lotvall&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1379&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lotvall J, Langley S, Woodcock A. Inhaled steroid/long-acting beta2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Respiratory Research. Vol. 7, 2006. Article Number: 110. Date of Publication: 18 AUG 2006..&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1381&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lundborg 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1384&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: An efficacy and cost-effectiveness study. Current Medical Research &amp;amp; Opinion 2006;22(5):809-21.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1386&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mitchell 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1389&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mitchell C, Jenkins C, Scicchitano R, Rubinfeld A, Kottakis J. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulmonary Pharmacology &amp;amp; Therapeutics 2003;16(5):299-306.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1391&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Molimard 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1394&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P, et al. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respiratory Medicine 2001;95(1):64-70.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1396&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Novartis 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1399&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Novartis. A 12-month multicenter, randomized, double-blind, double-dummy trial to examine the long-term tolerability of fomoterol 10&amp;#181;g via the multiple dose dry powder inhaler (MDDPI), both as twice daily maintenance therapy and as on-demand use in addition to maintenance in patients with persistent asthma. http://pharma.us.novartis.com/ 2005.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1401&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1404&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.[see comment]. American Journal of Respiratory &amp;amp; Critical Care Medicine 2005;171(2):129-36.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1406&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Overbeek 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1409&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Overbeek SE, Mulder PG, Baelemans SM et al. Formoterol added to low dose budesonide has no additional anti-inflammatory effect in asthmatic patients. Chest 2005;128:1121-27.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1411&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papi 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1414&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM, Zarkovic J, et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. European Respiratory Journal 2007;29(4):682-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1416&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1419&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. European Respiratory Journal 2003;22(5):787-94.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1421&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pleskow 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1424&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma 2003;40(5):505-14.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1426&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pohl 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1429&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pohl WR, Vetter N, Zwick H, Hrubos W. Adjustable maintenance dosing with budesonide/formoterol or budesonide: Double-blind study. Respiratory Medicine 2006;100(3):551-60.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1431&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rabe 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1434&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomized, double-blind trial. Chest 2006;129(2):246-56.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1436&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1439&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall L, Heinig JH, Lindqvist A, Leegaard J, Stahl E, Bergqvist PB. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. International Journal of Clinical Practice. 2002;56(6):427-33.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1441&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1444&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall L, Borg S, Andersson HF, Ericsson K. Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. International Journal of Clinical Practice 2003;57(8):662-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1446&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall 2003a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1449&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Stahl E, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respiratory Medicine 2003;97(6):702-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1451&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scicchitano 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1454&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centann S, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research &amp;amp; Opinion 2004;20(9):1403-18.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1456&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stelmach 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1459&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulm Pharmacol Ther 2007;20(6):691-700.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1462&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van der Molen 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1465&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van der Molen T, Postma DS, Turner MO, Jong BM, Malo JL, Chapman K, et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 1997;52(6):535-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1467&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Villa, 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1470&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Villa, Kuna, Egner, and B. A 6-month comparison of the safety profiles of formoterol (Oxis&amp;#174;) turbuhaler&amp;#174; as needed and terbutaline (Bricanyl&amp;#174;) turbuhaler&amp;#174; as needed in asthmatic children on anti-inflammaotry medication [abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165(8 Suppl):A746.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1472&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Von Berg 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1475&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbuhaler in children. International Journal of Clinical Practice 2003;57(10):852-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1477&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worth 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1480&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worth H. DESOLO - SiT Peri-Launch: a comparison of symbicort single inhaler therapy and conventional best practice for the treatment of persistent asthma in adults. clinicaltrials.gov 2005.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1482&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom 2001a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1485&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstrom O, Buhl R, Mellem H. Efficacy and safety of symbicort&amp;#174; budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; San Francisco CA ,May 18-23 2001.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1487&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstr&amp;#246;m 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1490&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zetterstr&amp;#246;m O, Buhl R, Mellem H, Perpi&amp;#241;&amp;#225; M, Hedman J, O'Neill S, et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal 2000;16(Suppl 31):455s Abstract P3198.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1077&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1078&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1079&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other references&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1080&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional references&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1492&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Altman 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1494&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Anderson 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1496&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Arnold 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1498&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barnes 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1500&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barnes 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1502&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Beach 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1504&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bennett 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1506&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brown 1983&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1508&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burgess 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1510&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burggraaf 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1512&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cates 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1515&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cates 2008a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1518&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cockcroft 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1520&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Collins 1969&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1522&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crane 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1524&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ducharme 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1527&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giembycz 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1529&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Grainger 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1531&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Greenstone 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1534&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Guhan 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1536&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hall 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1538&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanania 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1540&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanania 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1542&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hancox 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1544&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hancox 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1547&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haney 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1549&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Harvey 1982&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1551&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;ICHE2a 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3276&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jaeschke 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1553&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jones 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1555&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lee 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1557&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lipworth 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1559&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lipworth 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1561&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lipworth 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1563&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lipworth 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1565&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McDevitt 1974&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1567&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Morrison 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1569&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nelson 1977&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1571&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ni Chroinin 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1574&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ni Chroinin 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1578&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Palmqvist 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1580&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pearce 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1582&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pearce 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1585&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sears 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1587&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sears 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1589&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sears 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1591&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SMART 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1593&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Speizer 1968&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3341&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sweeting 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1595&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van der Woude 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1597&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;vanNoord 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1599&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Walters 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1602&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Walters 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1605&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Weber 1982&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1607&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wilson 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1609&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wong 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1611&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yates 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1081&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other published versions of this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1082&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Classification pending references&lt;/h2&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1086&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data and analyses&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1685&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Formoterol and ICS versus same dose ICS&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1686&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1 All-cause Mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1687&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.1 Adults and Adolescents&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1704&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1.2 Children and Adolescents&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1712&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2 All-cause non-fatal Serious Adverse Events&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1713&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.1 Adults and Adolescents&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1730&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2.2 Children and Adolescents&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1738&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3 Asthma Mortality&lt;/h3&gt;" NOTES_MODIFIED="2013-05-23 11:05:34 +0100" NOTES_MODIFIED_BY="Christopher J Cates">
<P>The Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) defines serious adverse events as follows (<LINK REF="REF-ICHE2a-1995" TYPE="REFERENCE">ICHE2a 1995</LINK>):</P>
<P>"A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:</P>
<UL>
<LI>Results in death.</LI>
<LI>Is life threatening.</LI>
<LI>Requires inpatient hospitalisation or prolongation of existing hospitalisation.</LI>
<LI>Results in persistent or significant disability/incapacity.</LI>
<LI>Is a congenital anomaly/birth defect.</LI>
</UL>
<P>NOTE: The term 'life threatening' in the definition of 'serious' refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe."</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>